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MicroRNAs (miRNAs) are regulatory RNA molecules of 22 nucleotides that (in part) control up 
to 60% of all genes in humans. They act by binding to the 3' untranslated regions of target 
messenger RNAs, leading either to translational repression or mRNA degradation. In addition to 
being involved in the regulation of several fundamental cellular processes, the misregulation of 
miRNAs has been linked to a wide range of diseases including cancer. Particularly, miR-21 is 
significantly upregulated in nearly all types of human cancers, and its overexpression is often 
associated with poor prognosis. The downregulation of miR-122 is found in more than 70% of 
hepatocellular carcinoma cases and miR-122 is a required factor for the replication of the HCV 
virus. The modulation of miRNA function is commonly achieved using oligonucleotide agents. 
However, compared to oligonucleotides, small molecules have several advantages, such as fast 
activity, systemic delivery, and excellent cell permeability. Taking advantage of luciferase-based 
reporters, two separate high-throughput screens of >300,000 compounds each, were conducted to 
discover new small molecule inhibitors of miR-21 or miR-122. Several hit compounds were re-
synthesized, their ability to inhibit miR-21 was validated, and the most promising compounds 
were investigated by SAR studies, which revealed two additional, structurally diverse classes of 
miR-21 inhibitors. Similarly, extensive SAR studies of previously discovered miR-122 inhibitors 
were performed in order to better understand the molecular requirements for the miR-122 
inhibitory activity. The hit compounds identified in the HTS were analyzed through secondary 
assays that led to the identification of two new promising miR-122 inhibitors. Furthermore, the 
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 v 
knowledge gained during the SAR studies was further used to synthesize several small molecule 
miR-21/miR-122 inhibitors as probes to explore their mechanisms of action. MicroRNAs 
represent promising, novel drug targets, and small molecule miRNA inhibitors provide tools to 
study the molecular mechanisms of miRNA biogenesis and have the potential to be new 
therapeutic agents for the treatment of cancers and viral infections. 
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 1 
1.0  INTRODUCTION TO MICRORNAS  
It was recently discovered that 80% of the human genome is transcribed mostly 
generating a vast amount of non-coding RNA transcripts, as only about 2% is being subsequently 
translated.
1
 Non-coding RNAs used to be considered as non-functional “junk” until recent 
studies revealed their importance in the regulation of many biological processes, creating a 
significant interest in non-coding RNA biology. MicroRNAs (miRNAs) are single stranded 
endogenous RNA molecules of 21-25 nucleotides and constitute the most established class of 
non-coding RNAs.
1
 Over 2,500 human miRNAs have been registered in miRbase
2
 and they 
represent one of the most abundant classes of gene regulatory molecules as they are estimated to 
control up to 60% of genes in humans.
3
 Lee, Feinbaum, and Ambros discovered the first 
miRNA, lin-4, in 1993.
4
 They found that instead of coding for a protein, the gene lin-4, which is 
responsible for the larval development of Caenorhabditis elegans (C. elegans), produces a pair 
of small RNAs that have antisense complementarity to several sites in the 3′ untranslated region 
(3′-UTR) of lin-14 messenger RNA (mRNA). It was later demonstrated that the regulation of lin-
14 by lin-4 resides in the complementarity of this small RNA for the 3′-UTR of the lin-14 
mRNA and that the binding of the small RNA significantly reduces the amount of LIN-14 
protein.
4
 A second miRNA, let-7, which is also responsible for the developmental timing of C. 
elegans, was discovered seven years later. Similar to lin-4, let-7 encodes a small 21-nucleotide 
RNA which shows complementarity to multiple regions of the 3′-UTRs of the heterochronic 
 2 
genes lin-14, lin-28, lin-41, lin-42, and daf-12.
5
 More importantly, the discovery that miRNAs 
are generally conserved in evolution, let-7 was detected in human, Drosophila, and several other 
animals,
6
 highlighted the importance of miRNAs as a new class of gene regulatory molecules 
and spurred research efforts to understand their biogenesis, mechanism of regulation, and 
function.
7
 
1.1 MIRNA BIOGENESIS AND FUNCTION 
miRNA genes are transcribed by RNA polymerase II into transcripts ranging from hundreds to 
thousands of nucleotides in length, called primary miRNAs (pri-miRNAs).
2
 In most cases, 
precursor miRNAs (pre-miRNAs), hairpin intermediates of 70-100 nucleotides, are obtained 
after processing of the pri-miRNAs in the nucleus by the RNase III enzyme Drosha and DGCR8 
(DiGeorge syndrome critical region gene 8). However, some pre-miRNAs have also been found 
to be generated by mRNA splicing via an alternative pathway, bypassing Drosha processing.
2
 
Pre-miRNAs are then exported to the cytoplasm by the nuclear export protein Exportin 5 (Figure 
1.1). In the cytoplasm another RNase III enzyme, Dicer, aided by the proteins dsRBD and TAR 
RNA binding protein (TRBP) cleaves the pre-miRNA to release the miRNA double-stranded 
RNA duplex.
8
 After unwinding of the duplex the mature miRNA strand, which is selected based 
on its relatively unstable 5' terminus, is loaded into the RNA-induced silencing complex (RISC), 
and the passenger strand is degraded.
9
 RISC along with the Argonaute protein, facilitate binding 
of the miRNA to its single stranded target mRNA (Figure 1.1). 
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Figure 1.1: The canonical pathway of miRNA processing. 
The endogenous miRNA gene is transcribed into a mature microRNA which is then loaded into RISC and matched with its target 
mRNA to lead to translational repression or mRNA cleavage. Adapted by permission from Macmillan Publishers Ltd: Nat. Cell 
Biology, 2009, 11, 3, 228, copyright (2009). 
 
In general, miRNAs regulate gene expression in a sequence-specific fashion by binding 
to specific regions in the 3'-UTR of target mRNAs. The nucleotides 2-8 located at the 5-end of 
the miRNA, called the seed region, is particularly important in mediating the binding of the 
miRNA to its target mRNA.
10
 Recent studies showed that miRNAs can bind to mRNA within 
their 5′-UTR or their open reading frame, and can interact with promoter regions at the DNA 
level too.
11
 More surprisingly, it was recently discovered that miRNAs can also upregulate 
protein translation; either by recruiting protein complexes to AU-rich elements of target mRNA, 
by directly interacting with proteins blocking the translation of the target genes, or by enhancing 
ribosome biogenesis which stimulates global protein synthesis.
11
 These additional miRNA-
 4 
regulatory mechanisms have only been observed in a few instances, thus it is not clear whether 
they represent a new general phenomenon or are only exceptions.
11
  
The outcome of miRNA/mRNA interaction is dictated by the degree of base-pairing 
complementarity between the miRNA and its target mRNA.
2
 miRNA binding can induce mRNA 
degradation when perfect complementarity is observed; this is mostly found in plants. Most 
commonly in humans, miRNA and its target mRNA bind with imperfect complementarity, 
leading to the inhibition of translation or inducing the destabilization or de-adenylation of the 
mRNA.
8, 12
 Translational repression can occur through blocking of the initiation of translation, or 
by sequestering the mRNA in P-bodies away from translational machinery.
13
 As there is no need 
for perfect sequence matching between the miRNA nucleotide sequence and the 3′-UTR target 
site of the mRNA, a single miRNA can interact with numerous mRNAs, and thus can regulate 
hundreds of different genes with different strengths,
9
 adding an additional layer of complexity. 
Though the origin of miRNAs remains poorly understood, one hypothesis is that expansion of 
the miRNA repertoire may be associated with evolution in complex organisms and major body-
plan innovations. Indeed, the temporal and spatial expression of distinct sets of tissue-specific 
miRNAs is critical for the regulation of tissue development and differentiation.
14
 Additionally, 
miRNAs are thought to play essential roles in regulatory networks, conferring them robustness 
and “fine-tunability”, and reducing the developmental noise in these networks by regulating the 
amounts of proteins resulting from an imprecise number of transcripts.
15
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1.2 MIRNAS AS POTENTIAL DRUG TARGETS 
miRNAs are involved in many cellular pathways, notably in fundamental cell processes, 
such as development, differentiation, proliferation, survival, and death.
16
 The misregulation of 
microRNAs has been linked to a wide range of diseases including viral infections, cardiovascular 
diseases, and various cancers.
2
 miRNAs can be universally expressed throughout an organism or 
their expression can be limited to a specific developmental stage, a specific tissue, a specific cell 
type or their expression can follow a disease-specific pattern.
17
 
The first evidence of miRNAs involvement in cancer derived from a study of the 
chromosome 13q14 frequently deleted in chronic lymphocitic leukemia (CLL). The loss of 
chromosome 13q14 occurs in 69% of CLLs as well as other cancers, such as myelomas and 
prostate cancer. This region was instinctively expected to contain a tumor suppressor gene but 
instead this study revealed that it contains the two miRNA genes miR-15a and miR-16-1.
18
 It 
was later established that a downregulation of miR-15a and miR-16-1 induces an increased 
expression of the anti-apoptotic gene BCL2.
19
 Subsequent experiments performed in mice, that 
developed CLL after being engineered to lack the miR-15/16 cluster, demonstrated that the 
deregulation of these miRNAs alone can be responsible for cells becoming neoplastic.
20
 In a 
follow-up study it was discovered that many miRNA genes are located in fragile loci or loci 
prone to amplification in human cancers.
21
 Upon cancer development the amplification of a 
chromosomal region encompassing for an oncogenic miRNA results in the increased expression 
of this miRNA, and ultimately in the silencing of the targeted tumor suppressor genes. Such 
miRNAs are commonly named ‘oncomirs’.8 On the contrary, tumor suppressor miRNAs, which 
target oncogenes, are often located in regions prone to deletion or mutation. Such events result in 
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the downregulation of the miRNA and consequently to an increased expression of the target 
oncogenes.
8
 
To maintain homeostasis in cells, miRNAs are organized in precise networks. Similarly, 
the development and proliferation of cancers are governed by specific networks of miRNAs. For 
example, 64 aberrantly expressed miRNAs are involved in lung cancer.
22
 Studies of 540 patient 
samples including lung, breast, stomach, prostate, colon, and pancreatic tumors showed a strong 
correlation between aberrant expression of certain miRNAs and the type of cancer studied.
23
 In 
addition, it was demonstrated through genome-wide profiling that it is possible to distinguish 
between normal healthy cells, and cancerous cells by investigating the miRNA expression 
signatures, since a specific pattern in miRNA misregulation and the type of cancer has been 
observed in several cases.
22
 miRNA expression signatures not only allow for the differentiation 
of healthy and cancerous cells, but can also predict with high accuracy the type of cancer 
presented as well as the primary origin of the malignant tissue.
8, 19, 23
 This observation is highly 
significant and highlights the potential of using miRNAs for diagnostic purposes.
24
  
In addition, it was recently established that circulating miRNAs represent novel, 
predictable, and non-invasive biomarkers.
25
 Quantitative real-time PCR (qRT-PCR) 
measurements of eight miRNAs expressed in the liver of twenty patients chronically infected 
with the hepatitis B virus (HBV) and fifteen healthy individuals showed that levels of miR-122 
were significantly higher in HBV infected subjects than in the control group. A high plasma 
concentration of miR-122 coincided specifically with viral-, alcohol-, and chemical-induced liver 
diseases.
26
 Although very appealing, the clinical use of circulating miRNAs as diagnostic and 
prognostic tools remains a great challenge as there is currently limited overlap between the 
findings of similar studies of the same disease.
27
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Supported by the initial demonstration of specific miRNAs playing key roles in 
carcinogenesis, several groups investigated the mechanistic involvement of miRNAs in cancer 
(Error! Reference source not found.).
11
 For example, it was reported that miR-17 and miR-21 
are consistently upregulated in colon, lung, stomach, prostate, and pancreatic tumors; while miR-
155 is upregulated in breast, lung, and colon cancers.
16
 In addition to well-known functions of 
miRNAs as oncogenes or tumor suppressors, it was recently demonstrated that some miRNAs 
can promote metastasis by regulating cell invasion and migration. An example of these would be 
miR-10a, whose overexpression in non-metastatic breast cancer cells initiated invasion and 
metastasis.
28
  
The concept of generating potential therapies for human diseases by specifically 
regulating miRNA activity is rapidly gaining attention. Particularly in the development of cancer 
therapeutics, where targeting specific miRNAs that regulate entire gene networks rather than 
targeting a single gene or protein may be highly beneficial.
11
 Indeed only a subset of miRNAs is 
misregulated in cancer, compared to a large number of genes and proteins involved in 
malignancies.
8
 It was reported that 192 miRNAs are deregulated in cancer cells and among them 
168 are overexpressed.
29
 Over 60% of mRNAs possess at least one conserved miRNA-binding 
site. In addition, bioinformatics predictions and subsequent experimental confirmations revealed 
that the 3′-UTRs of single genes can also be targeted through non-conserved binding sites, 
suggesting that most protein-coding genes may be under the control (at least partial) of 
miRNAs.
16
 
Thus, miRNAs have potential as new, highly promising drug targets, since the specific 
control of misregulated miRNAs offers the possibility of reversing disease phenotypes. 
Furthermore, since miRNAs are capable of specifically controlling multiple genes, therapies 
 8 
targeting one single misregulated miRNA offer the great possibility of regulating entire gene 
networks.
30
 
 
Table 1.1: Selected miRNAs misregulated in different cancers. 
Reprinted by permission from Macmillan Publishers Ltd: Nat. Rev. Drug Discov. 2013, 12, 847. copyright (2013). 
1.3 ENDOGENOUS REGULATION OF MIRNAS         
Since miRNAs play critical regulatory functions in almost all biological processes and 
are deregulated in many human disorders, Nature has evolved many means to tightly regulate 
each and every step of miRNA biogenesis.
31
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Transcription of miRNA genes delivers the pri-miRNAs, which similarly as mRNAs, 
bear a 5′ 7-methylguanylate cap and have a poly-A tail at their 3′ end.9 It was shown that miRNA 
gene promoters share many characteristics with protein-coding gene promoters, including the 
frequencies of CpG islands, a TATA box, and DNA-binding factors, suggesting that miRNA 
genes are also subjected to epigenetic regulation.
32
 For example the transcription factor c-Myc 
regulates approximately 15% of all human genes along with some miRNA genes, such as the 
miR-17-miR-92 cluster. c-Myc controls important genes associated with cell growth and 
apoptosis and is frequently overexpressed in cancer. Consistently the miR-17-miR-92 is often 
upregulated in a broad range of cancers.
11
 One major hallmark in carcinogenesis lies in 
epigenetic alterations such as changes in DNA methylation status and chromatin modifications.
33
 
It is then not surprising that the promoters of several miRNAs have been found to be 
hypermethylated in multiple cancers. For example, promoter hypermethylation of miR-127 is 
responsible for aberrantly low levels of miR-127 in bladder cancer.
32
 miRNA genes are also 
regulated by histone modifications. For instance, it was demonstrated that high HDACs 
expression in CLL causes epigenetic silencing of miR-15a, miR-16, and miR-29b. Treatment 
with SAHA (an FDA approved HDACs inhibitor) restored the expression of miR-15a, miR-16, 
and miR-29b and triggered apoptosis.
34
 
The processing step of pri-miRs to pre-miRs is carried out by a large complex known as 
‘Microprocessor’ composed of Drosha, its binding partner DGCR8, and other cofactors.32 
Multiple mechanisms exist to control the expression level, the activity, and specificity of Drosha. 
The homeostatic maintenance of the Microprocessor is controlled by a feedback loop involving 
Drosha and DGCR8. Drosha can specifically cleave a hairpin in the second exon of DGCR8 
mRNA, resulting in the destabilization of DGCR8; whereas DGCR8 stabilizes Drosha through 
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protein-protein interactions.
35
 Additionally, the activity, the nuclear localization, and stability of 
the Microprocessor are tightly regulated by post-translational modifications.
9
 The 
phosphorylation of Drosha at Ser300 or Ser302 by the glycogen synthase kinase 3 (GSK3) is 
ensuring its nuclear localization.
36
 An unidentified protein can acetylate Drosha which protects it 
from degradation.
9
 DGCR8 is also subjected to modifications, for example HDAC1 was found to 
deacetylate critical lysine residues in the RNA-binding domains of DGCR8, increasing the 
affinity of DGCR8 to pri-miR transcripts and causing an increased miRNA processing.
37
 
Phosphorylation of DGCR8 by the protein kinase ERK promotes its stability.
38
 The DEAD-Box 
RNA helicases p68 and p72 have been reported to associate with DGCR8 and promote the 
processing of a subset of miRNAs.
32
 The maturation of certain miRNAs can also be induced 
upon interaction of p68 with different proteins such as the signal transducers SMADs, the tumor 
suppressor protein p53, and the estrogen receptor .32 The interaction of two specific SMAD 
signal transducers with p68 within the Microprocessor was shown to promote a rapid increase in 
the expression of mature miR-21.
39
 Furthermore, the terminal loops of pri-miRNAs are enriched 
with cis-elements that promote the binding of regulatory proteins. For example, Drosha-
processing of pri-miR-18a and pri-let-7 is stimulated by the heterogeneous nuclear 
ribonucleoprotein A1 (HNRNPA1) and KSRP binding to the terminal loops, respectively.
9
 
LIN28 can specifically bind to the terminal loops of pri-let-7 and pre-let-7, preventing both 
Drosha- and Dicer-mediated processing.
40
 Interestingly, let-7 in turn inhibits LIN28. Few 
miRNAs are similarly regulated via negative feedback loop mechanisms. 
The Dicer mediated-processing of the pre-miRs is also tightly regulated, particularly via 
the interaction of Dicer and various RNA-binding proteins. For example, Dicer association with 
TRBP and protein kinase R-activating protein promotes its stability and processing activity.
41
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The homeostatic regulation of Dicer activity is thought to be controlled by a negative feedback 
loop involving Dicer and the miRNA let-7, as several let-7 binding sites are contained within 
Dicer mRNA.
42
 The stability of the Dicer processing complex is also influenced by diverse 
signaling pathways. For example, the phosphorylation of TRBP by the mitogen activated protein 
kinase (MAPK) Erk stabilizes the Dicer-TRBP processing complex, which results in an 
increased production of growth-promoting miRNAs, such as miR-17, miR-20a, and miR-92a, as 
well as in the downregulation of the let-7a tumor-suppressor miRNA.
43
 
Similarly to Drosha and Dicer, AGO proteins are subject to numerous modifications.
9
 For 
instance, AGO2 phosphorylation at Tyr529 reduces its small RNA binding properties.
44
 The 
maturation and turnover of miRNAs can be affected by alterations in the structure or sequence of 
the RNA.
9
 miRNA biogenesis or target specificity can be altered by single nucleotide 
polymorphisms. For example, the single substitution of a C to T nucleotide in the pri-miR-16 
negatively affects Drosha processing and results in low expression of miR-16.
45
 The association 
of the miRNA-AGO complex to target mRNA not only negatively regulates gene expression, as 
discussed above, but can also affect the stability of the miRNA itself. When bound to an RNA 
target, miRNAs are prone to degradation via the addition of adenosine or uracil to the miRNA 
(‘tailing’) followed by the ‘trimming’ or 3′ to 5′-exonucleolytic degradation of the miRNAs.46 
All miRNAs may be susceptible to target RNA-mediated tailing and trimming, but the 
probability of miRNAs to be degraded via this pathway increases as the complementarity 
between miRNA and mRNA becomes greater. Highly complementary RNAs have a slower 
dissociation rate, which facilitates the modification and degradation of miRNAs.
46
 For example, 
the protein LIN-28 has been shown to recruit some terminal uridylyl transferases promoting 3′ 
uridylation of pre-let-7 and resulting in the degradation of pre-let-7.
47
 In the contrary, mass 
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spectrometry analyses of miR-122 isolated from human hepatocytes and mouse livers, revealed 
that the 3′ adenylation of miR-122 mediated by the poly (A) polymerase GLD-2 promotes the 
selective stabilization of miR-122 in the liver.
48
 These observations suggest that the 
consequences of miRNA tailing might be context-dependent and the causes for these differences 
remain to be elucidated. Other modifications affecting the miRNA sequences have been 
identified, such as RNA editing and RNA methylation. Adenosine deaminases (ADARs) 
promote the conversion of adenosine to inosine within the stem region of some pri-miRs, making 
them poor substrate for Drosha.
9
 Drosha and Dicer-mediated processing of miRNAs leave them 
with a 5′ monophosphate group. The efficient miRNA processing and the stability of the RISC 
complex are critically driven by the specific interaction of the negatively charged 
monophosphate at the 5′-end of miRNAs and positively charged pockets in Dicer and AGO2 
proteins.
49
 It was recently found that the enzyme BCDIN3D can O-methylate the 5′ 
monophosphate group of pre-miR-145, therefore annihilating the negative charge of the 
transcript and diminishing Dicer-mediated processing.
49
 Upon loading into RISC, miRNAs are 
highly stable since AGO proteins protect both ends. Although miRNA turnover has been 
investigated in various systems and several nucleases have been proposed to degrade miRNAs, a 
lot of questions remain unanswered about their selectivity and whether there is a conserved 
machinery regulating miRNA decay.
9
 
All considering, it is evident that Nature has evolved many regulatory mechanisms to 
tightly control the expression levels of specific miRNAs, and a more precise understanding of 
these mechanisms will provide exciting opportunities for the development of tools to manipulate 
the miRNA machinery for therapeutic applications.
50
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1.4 MODULATING MIRNA FUNCTION WITH OLIGONUCLEOTIDES 
With the realization of the potential therapeutic significance of miRNAs, substantial 
efforts have been made to build tools to better understand the mechanisms of action of miRNAs 
and to enable the control of miRNA function. Based on the finding that several miRNAs are 
overexpressed in cancer,
19
 strategies have been developed in order to inhibit these specific 
miRNAs. The most commonly employed method is the specific inhibition of miRNA by anti-
miRNA oligonucleotides (AMOs).
51
 AMOs are synthetic, chemically modified oligonucleotides 
that possess the exact complementary sequence of the miRNA of interest.
52
 They act as 
competitive inhibitors as they can bind to the mature miRNA guide strand thereby blocking the 
interaction between the miRNA and its target mRNA. Unlike antisense oligonucleotides, which 
have been used to repress mRNA expression for over thirty years, unmodified DNA 
oligonucleotides were not efficient in silencing miRNAs, presumably due to rapid endogenous 
degradation by exo- and endonucleases.
52
 The use of oligonucleotides to repress miRNA 
function is straightforward in the design of the probes, but can display disadvantages such as 
limited reagent stability, poor cellular uptake, and low hybridization affinity.
52
 These limitations 
have partially been overcome by installing different chemical modifications on the 
oligonucleotides (Figure 1.2).
53
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Figure 1.2: Common chemical modifications of AMOs 
Include a phosphorothioate linkage (PS DNA), a 2′ methoxy group (2′-OMe), a 2′ methoxyethyl group (2′-MOE), a 
2′ fluoro atom (2′-F), a methylene bridge connecting the 2′-O and 4′-C of the ribose ring (LNA), and also 
replacement of the ribose-backbone with morpholinos (PMO) and peptide nucleic acids (PNA). Base is either a 
purine motif (adenine or guanine) or a pyrimidine motif (cytosine, uracil, thymine). 
 
The first reports of successful miRNA inhibition using AMO technology appeared in 
2004, and employed 2′-O-methyl (2′-OMe) AMOs (Figure 1.2).54 The introduction of 2′- O-
methyl groups in the ribose ring induces a North conformation in the sugar, similar to RNA, thus 
2′-OMe AMOs exhibit an increased binding affinity for RNA targets, as well as an increased 
nuclease stability.
52
 Other substitutions, such as 2′-O-methoxyethyl (2′- MOE), and 2′-fluorine 
(2′-F), similarly resulted in an increased binding affinity and nuclease resistance.55 These analogs 
demonstrated more effective miR-21 inhibition than 2′-OMe AMOs (Figure 1.2). Another 
modification applied to improve oligonucleotide stability consists of replacing a non-bridging 
oxygen in the phosphate backbone by a sulfur atom, thus preventing nucleases from cleaving the 
phosphate bonds in between nucleotides (Figure 1.2).
56
 Although, the phosphorothioate (PS) 
motif can be introduced throughout the sequence of the AMO, since the introduction of a sulfur 
atom in the phosphate backbone decreases the hybridization affinity, phosphodiester and PS 
linkages have been used in mixed compositions.
56
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Krutzfeldt et al. developed a new class of AMOs, called antagomirs. Antagomirs are 
similar to AMOs but combine complete 2′-OMe modification with PS backbones, and are 
conjugated at their 3′-end with a cholesterol moiety.57 Conjugation with a cholesterol motif 
facilitates AMO delivery into cells (see Chapter 5 for a more in-depth discussion). MicroRNA 
miR-122 levels were significantly reduced in mice treated with an antagomir bearing six PS 
modifications; this was the first example of the successful utilization of the AMO technology in 
vivo.
57
 Similar rules were established regarding the potency and the specificity of antagomirs. 
For example they need to consist of >19-nucleotides in length and are sensitive to single base-
pair mismatched at certain positions.
57
  
AMOs were also generated through addition of a methylene bridge connecting the 2′-O 
and 4′-C of the ribose ring, and are known as locked nucleic acids (LNAs) (Figure 1.2). This 
additional bond locks the sugars of the nucleosides into a North conformation, favorably pre-
organizing them for Watson-Crick interactions with target miRNAs.
58
 Among all the 2′ 
modifications developed so far, the introduction of LNA motifs results in the highest increase in 
binding affinity, adding 1.5-6 °C stabilization per nucleotide.
56
 In some cases, it can be beneficial 
to combine multiple modifications into an AMO. For instance, Fabani et al. constructed a miR-
122 LNA/2′-OMe mixmer which displayed better potency in miR-122 inhibition than a 2′-OMe 
AMO.
59
 The fate of the miRNAs upon inhibition with an AMO has been unclear and largely 
debated in the literature.
60
 A recent study revealed that the binding of the AMO to the miRNA 
prevents the miRNA to be properly recovered during the RNA isolation step using common 
guanidinium-thiocyanate-phenol-choloroform RNA extraction protocols, and could possibly 
explain the discrepancies observed in different publications. Using an improved RNA isolation 
method, the authors demonstrated that high affinity-AMOs such as LNA, LNA/OMe mixmers, 
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and PNA anti-miRs act by sequestering the miRNA, whereas 2′-OMe AMOs seem to promote 
the degradation of the targeted miRNA.
60
 
Taken together, these modifications enable fine-tuning the properties of the AMOs and 
can dramatically affect the binding affinity to their miRNA targets. Increased binding affinity 
allowed for shorter oligonucleotides, when the truncations are performed in the 5′-end of the 
AMO, in order to not disrupt the critical interactions with the seed region of the miRNA (bases 
2-8 from the 5′-end).56 An unconjugated, fully PS modified, 16-mer alternating between two-
DNA and one-LNA units resulted in substantial miR-122 knockdown in mice.
61
 “Tiny LNAs” 
correspond to the shortest AMOs that have been successfully used to either repress an entire 
family of miRNAs (miR-221/222) or an individual miRNA (miR-21).
62
 Tiny LNAs are 8-mer, 
fully LNA and PS modified AMOs that target the seed region of the desired miRNA with a high 
level of specificity and no undesired off-target effects.  
Another class of miRNA inhibitors, miRNA sponges, consists of RNA transcripts 
containing multiple binding sites for a specific miRNA and can be transiently or stably expressed 
in cells. The targeted miRNA is sequestered by the multiple binding sites present in the decoys, 
effectively outcompeting endogenous mRNA targets.
63
 Modified oligonucleotides, so called 
miR-masks, compete with endogenous miRNAs in the binding of the target mRNAs, thereby 
hiding the miRNA binding site and inhibiting miRNA repression.
64
 Unlike AMOs, which 
prevent miRNA:mRNA interaction by creating AMO:miRNA complex, miR-masks induce gene-
specific repression via oligo:mRNA binding, leaving intact the function of the miRNA towards 
other gene targets.
64
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Likewise, methods have emerged to increase the levels of specific miRNAs. These 
include the use of miRNA overexpression vectors
65
 and miRNA mimics.
66
 MicroRNA mimics 
are small, double-stranded, chemically modified oligonucleotides that function the same way as 
an endogenously expressed miRNA and are expected to silence the same target genes.  
Although chemical modifications allowed for improvements in the stability, the 
specificity, and the affinity of the oligonucleotides, resulting in a specific, efficient, and long-
lasting regulation of miRNA function, this regulation approach still suffers from several 
limitations (Table 1.2). The main consideration for the development of miRNA therapeutics is to 
be able to achieve specific delivery of the oligonucleotides (AMOs or miRNA mimics) at a 
concentration high enough to induce the desired biological effect.
16
 Introduction of 
phosphorothioate linkages, cholesterol conjugation, and 2′-O-alkyl groups resulted in an 
enhanced lipophilicity and greater cell membrane permeability. However, the intestinal 
absorption of AMOs remains limited, and even though they are broadly distributed, they have a 
tendency to accumulate in the liver and in the kidneys.
67
 In addition, oligonucleotides are rapidly 
cleared from the bloodstream but are stable in cells, where they have a slow clearance rate and 
half-lives of several weeks. Since AMOs rapidly disappear from plasma, the nature and the 
duration of their pharmacological effects are challenging to evaluate.
67
 Another obstacle in 
developing oligonucleotide-based drugs stems from the size and the negative charge of the 
oligonucleotides. Since these oligos have molecular weights of 2-6 kDa and low intestinal 
membrane permeability, they are more conveniently formulated as an intravenous injection than 
as an orally available drug to ensure their bioavailability. 
An additional strategy aimed at enhancing the biodistribution and the cellular uptake of 
oligonucleotides consist of replacing their highly negatively charged backbone with a neutral 
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backbone. To this end, peptide nucleic acid (PNA) and phosphorodiamidate morpholino 
oligomers provide effective miRNA inhibitors (Figure 1.2).
59, 68
 In addition, high thermal 
stability of the PNA:target complex is observed. A PNA analog targeting mature miR-122 
coupled with four lysine residues, induced miR-122 knockdown after being efficiently taken up 
by Huh7 cells without requiring any transfection reagent.
59
 Morpholino oligonucleotides 
designed to target the Drosha and Dicer cleavage sites of pre-miR-205 were successfully used to 
silence miR-205 in zebrafish.
69
 Another method aimed at interfering with the processing of 
precursor miRNAs consists of using DNAzymes.
70
 These 30-mer oligonucleotides contain a 
DNA catalytic domain and two LNA-modified regions that are complementary to the pre-
miRNA of interest. Exposure to DNAzymes targeting the precursors of hsa-miR-372 and hsa-
miR-373 – at high concentrations – resulted in the specific cleavage of these miRNAs, thus 
inhibiting their silencing function.  
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 Advantages Disadvantages Modifications Improvements 
Anti-miRNA 
oligonucleotides 
easy design/optimization 
based on miRNA sequences 
specific and efficient 
miRNA inhibitors 
long-lasting effect 
delivery 
poor cellular-uptake 
off-target effects 
toxicity 
limited stability 
low hybridization 
affinity 
possible stimulation 
of immune-responses 
limited 
biodistribution 
PC/PK properties 
difficult to study 
phosphorothioate 
increased resistance to 
nuclease degradation and 
cellular uptake 
2′-O-alkyl 
increased stability, 
affinity toward RNA 
targets, and cellular 
uptake 
LNA 
highly enhanced 
hybridization affinity 
lower doses required 
low toxicity 
cholesterol 
conjugation 
good bioavailability 
facilitate delivery 
miR-masks 
gene-specific effects 
no off-target effects 
delivery 
limited scope (one 
target) 
- - 
miRNA sponges 
suitable to silence an 
individual or an entire  
family of miRNAs 
delivery 
off-target effects 
- - 
PNAs/PMOs 
neutral backbone 
resistant to degradation 
high stability of the probe-
target duplex 
delivery addition of 4-K 
residues (PNAs) good cellular-uptake 
miRNA mimics 
easy design/optimization 
based on miRNA sequences 
global up-regulation 
off-target effects 
delivery 
same as for AMOs  
same as for AMOs 
Specific small 
molecules 
good bioavailability 
fast and reversible effect 
specific inhibitors/activators 
systemic delivery 
good drug-like profile 
easy delivery 
regulation possible at 
different steps of miRNA 
processing 
 
 
 
 
difficult to identify 
extensive SAR often 
required for 
optimization 
 
- - 
Table 1.2: Limitations and advantages of miRNA regulatory tools. 
Adapted with permission from Macmillan Publishers Ltd: Nat. Rev. 2010, 9, 775. Copyright (2010). 
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1.4.1 Clinical Development of miRNA Therapeutics 
Oligonucleotide chemistry and delivery technologies have greatly advanced within the 
last decade, allowing for the development of highly promising anti-miRNA targeted drugs. The 
concept of generating potential therapies for human diseases by specifically regulating miRNA 
activity is rapidly gaining attention and several pharmaceutical companies are actively 
developing some anti-miR agents for a variety of indications. There is a high number of such 
anti-miR therapeutics currently in preclinical studies and some examples are shown in Table 
1.3.
2
  
Santaris Pharma has developed Miravirsen, a new fully PS modified 15-mer comprised of 
seven DNA and eight LNA nucleotides specific to miR-122, and its successful preclinical studies 
are paving the way for the application of miRNA-targeted therapies.
71
 miR-122 is essential for 
the replication of the hepatitis C virus (HCV), so specific inhibition of miR-122 by Miravirsen 
could provide a potential new treatment for HCV.
71
 Phase I clinical studies demonstrated that 
Miravirsen was well tolerated and was not associated with any toxicity issues. Results of the 
Phase II studies were very promising as four out of the nine patients who received the drug for 4 
weeks exhibited a complete reduction in HCV levels.
72
 Another candidate, RG-101, is being 
pursued by Regulus Therapeutics to specifically inhibit miR-122. To improve the biological 
properties of their anti-miR-122 oligonucleotide, they conjugated the oligonucleotide with N-
acetylgalactosamine (GalNAc) a highly efficient ligand for the asialoglycoprotein receptor. This 
receptor is highly expressed on hepatocytes and facilitates liver accumulation as well as the 
cellular uptake of the GalNAc-conjugated-oligonucleotides via endocytosis.
73
 RG-101 has just 
entered into Phase II clinical studies after an encouraging Phase I completed recently, as no 
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toxicity or adverse effects were observed, and treatment with a single subcutaneous dose of RG-
101 elicited a significant and sustained reduction of viral load in all HCV treated patients.  
Using the same strategy, Regulus Therapeutics is developing, RG-125, a GalNAc-
conjugated anti-miR targeting miR-103/107 for the treatment of non-alcoholic steatohepatitis in 
patients with type 2 diabetes. miR-103 and miR-107 directly target a critical regulator of the 
insulin receptor, the voltage-gated calcium channel Cav1. The silencing of miR-103 and miR-
107 has been shown to improve glucose homeostasis and insulin sensitivity.
2
 The new insulin 
sensitizer, RG-125, is expected to enter Phase I studies by the end of 2015. This company is also 
developing some anti-miR targeted drugs to inhibit miR-21, miR-221, and miR-10b as new 
anticancer therapies, in particular to treat hepatocellular carcinoma (HCC) and glioblastoma. 
Mirna Therapeutics is tackling liver cancer using the opposite approach, which consists 
of delivering a miRNA mimic of miR-34, MRX34, to reinstate the normal regulation of this 
miRNA and its target genes.
2
 miR-34 is frequently lost or downregulated in a variety of cancers 
and is estimated to regulate at least 24 known oncogenes involved in proliferation, anti-
apoptosis, metastasis, and chemoresistance.
74
 MRX34 is delivered by a new liposome-based 
technology, which enhances the uptake of the mimic into tumor cells and accumulation in the 
liver. Administration of the miR-34 mimic in mice models induced a reduction in tumor growth 
and increased overall survival. MRX34 represents the first miRNA mimic to enter clinical trials 
and is currently being tested in Phase I in patients with primary liver cancers or metastatic 
cancers with liver involvement.
2
 
 
 22 
 
Table 1.3: Selected examples of miRNA-targeted therapies under development.  
Adapted with permission from Macmillan Publishers Ltd: Nat. Rev. Drug Discov. 2014, 13, 622. Copyright (2014). 
1.5 MODULATING MIRNA FUNCTION WITH SMALL MOLECULES 
Although the recent advances in oligonucleotide-based miRNA therapeutics are very 
exciting and promising, several challenges still remain to be tackled, particularly due to their less 
than ideal pharmacodynamic and pharmacokinetic properties.
3
 Small molecules capable of 
specifically modifying the activity of miRNAs provide excellent new alternative therapeutic 
approaches, as they possess several advantages over oligonucleotides (Table 1.2). For example, 
they are typically cell permeable, enabling systemic delivery, they induce fast and reversible 
regulation, and their biological effect is directly linked to their concentration, facilitating a dose-
dependent modulation of biological activity.
75
 Small molecules generally have a molecular 
weight <800 Da and can be modified with functional groups that provide good solubility, good 
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bioavailability, and good pharmacokinetic properties.
29
 However, it is important to note that 
specific small molecule regulators of miRNA activity are challenging to discover. Their 
discovery often requires the screening of large size libraries to identify a hit compound, followed 
by several confirmatory assays and extensive structure-activity relationship (SAR) studies to 
optimize their activities and properties. In contrast the binding affinity and the specificity of 
AMOs are inherent to their sequence and backbone modifications are more readily introduced 
than the SAR investigations of small molecules. While nucleic acid-based inhibitors typically 
interact with mature miRNAs, small molecules have the potential to control miRNA function on 
multiple levels of the miRNA pathway, including pre-transcription, transcription, and post-
transcription.
3
 Small molecules are easier to deliver into humans and animals than 
oligonucleotides, they are cheaper to manufacture, resistant to nucleases and typically exhibit 
lower toxicity. Therefore small molecules possess a better drug-like profile and are more 
amenable for drug discovery than oligonucleotides.  
Recently, several small molecules that can modulate miRNA activity, either in a general 
or specific fashion have been discovered (Figure 1.3 and Figure 1.5).  
1.5.1 Small Molecule General Modulators of the siRNA and miRNA Pathways 
Although RNA molecules have had a long reputation of being “undruggable” because of 
their highly negatively charged surfaces, their flexibility, and the paucity of information 
regarding the interaction of RNA/small molecules, as well as the lack of structural information 
(X-ray or NMR), the discovery of ligands that can successfully bind with ribosome RNAs or 
viral transactivation response RNAs, have encouraged efforts involving the design of small 
molecules to directly target miRNAs.
29
 The secondary structure of miRNAs, especially the stem-
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loops found in pre-miRNAs and the bulges found in mature miRNAs, represent attractive target 
sites for small molecule ligands. A screen of different classes of small molecules, including 
approved drugs, antibacterial agents, anticancer therapeutics, and DNA/RNA intercalating 
agents, against pre-miR-155 and Dicer-catalyzed miRNA maturation, revealed that some 
aminoglycoside antibiotics and some anticancer agents can bind to the precursor pre-miR-155 
with good affinity.
76
 This study represented a proof-of-principle for the promising concept of 
directly targeting miRNAs. However, the aminoglycosides framycetin and kanamycin B, which 
exhibited the strongest binding to pre-miR-155 lacked specificity and were ineffective in 
repressing miRNA maturation.
76
 A small series of aminoalkoxy-substituted thioxanthones was 
synthesized and the binding of the derivatives to RNA bulges and loops was subsequently 
investigated using pre-miR-29a as a model. Although it was demonstrated that the thioxanthone 
analog 1 is able to bind the pre-miR-29a proximal to a processing site, thereby preventing Dicer 
processing, the selectivity of 1 was not addressed.
77
 Given pre-miRNAs display a high degree of 
structural similarity, it can be envisioned that targeting pre-miRNAs with small molecules might 
result in a lack of selectivity. A series of multimodal ligands composed of two RNA binding 
motifs, an artificial nucleobase and the aminoglycoside neomycin, was designed to target the 
oncogenic pre-miR-372 and pre-miR-373.
78
 The best analog (2) was found to efficiently inhibit 
Dicer processing of pre-miR-372 and -373 with an IC50 of 2.4 M, and more importantly it was 
shown to inhibit the cell growth of AGS gastric cancer cells, which express high levels of miR-
372 and -373. Following qRT-PCR experiments highlighted a lack of specificity for 2 since at 
least three other miRNAs (miR-17-5p, miR-21, and miR-200b) were downregulated upon 
treatment with the ligand 2.
78
 A set of 1,990 compounds from the NCI Diversity Set was 
screened in a computational screening approach based on the 3D structure of the Dicer binding 
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site on the pre-miR-21.
79
 Out of the 5 hit compounds, having the highest docking scores, the 
carbonitrile AC1MMYR2 (3) was found to reduce the levels of miR-21 by 50% after 6 h 
treatment at a dose of 30 M. This inhibitor blocked miR-21 maturation in 4 cancer cell lines 
and induced a decrease in tumor growth, invasiveness, and metastasis by upregulating known 
tumor-suppressor genes targeted by miR-21. Unfortunately 3 did not appear to be specific for 
miR-21, as 5 randomly tested miRNAs (out of 11) were also downregulated after 24 h 
treatment.
79
 
The fluoroquinolone antibacterial agent enoxacin (4), which acts an RNA interference 
(RNAi) enhancer, was identified via a screen of 2,000 FDA-approved drugs in a cell-based assay 
monitoring RNAi activity. The majority of the miRNAs altered by enoxacin exhibited decreased 
levels of pri- and pre-miRNAs, and inversely they displayed up to 2-fold increased levels of 
mature miRNAs. It was shown that the presence of 4 improved the binding affinity of the trans-
activation-responsive region RNA-binding protein (TRBP) for pre-miRNAs, thereby promoting 
the processing and loading of miRNAs into the RISC.
80
 Similarly, a general activator of miRNA 
function (5) was identified after screening of eight products obtained from the photoreaction of 
naphthalene-1,4-dione and acetylenes in cellular assays using a luciferase reporter under the 
control of several mature miRNAs.
81
 The exact mode of action for the anthracene derivative 5 
has not been fully elucidated, but preliminary results suggest that it generally up-regulates 
mature miRNA levels by promoting the maturation of miRNAs.  
An in vitro assay measuring the interaction between miR-21 and the Argonaute 2 (Ago2) 
protein was used to screen 1,280 compounds from the LOPAC collection and 1,040 compounds 
from the National Institute of Neurological Disorders and Stroke. The Argonaute proteins 
constitute the catalytic components of the RISC assembly and are therefore indispensable to the 
 26 
loading of miRNAs into RISC.
82
 The inhibitors suramin (6), aurintricarboxylic acid (7), and 
oxidopamine (8) were identified, however only 7 was effective in repressing the loading of small 
RNAs to Ago2 in a cell-based assay (Figure 1.3). The triphenylene compound 7 does not disturb 
the catalytic activity of Ago2 but rather prevents its binding with small RNAs in a non sequence-
specific fashion.
83
 A new inhibitor of Ago2 (9) was recently identified via an in silico HTS based 
on the crystallographic structure of Ago2 bound to miR-20a. The inhibitor 9 was found to 
efficiently bind to Ago2, and to impair Ago2 loading of miRNA, non-specifically.
84
 Two 
additional suppressors of miRNA function, poly-L-lysine (10) and tripaflavine (11), were 
discovered from a library of 530 compounds by screening for the inhibition of the RNAi 
pathway using a firefly luciferase reporter system and a simultaneously expressed shRNA 
targeting the firefly gene in HEK293T cells. Since shRNAs and miRNAs follow a similar 
processing pathway in cells, 10 and 11 were tested for their ability to inhibit miRNA function. 
Each compound exhibits a different inhibitory mechanism, as 10 interferes with the association 
of pre-miRNAs and Dicer, and 11 prevents the formation of Ago2/RNA (siRNAs or miRNAs) 
complexes.
85
 Additional inhibitors (12, 13) of the siRNA pathway were discovered via screening 
of a small library of ATP analogs in HeLa cells co-transfected with a plasmid harboring the red- 
and green-fluorescent proteins and an siRNA targeting EGFP.
86
 These two RNAi inhibitors (12, 
13) were found to affect an early ATP-dependent step of the RNAi pathway, specifically they 
prevent the unwinding of the siRNA.
86
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Figure 1.3: Reported small molecule general modifiers of the miRNA or siRNA pathway. 
The year of their discovery is indicated. 
 
Overall, these small molecules constitute good tools to investigate miRNA biogenesis in 
a general fashion; however, they are not suitable for studying the effects and regulation of 
individual miRNAs. 
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1.5.2 Regulation of miRNA Function with Approved Drugs 
Since it was established that the deregulation of miRNA function is closely associated 
with many disease-states, the opposite approach consisting in evaluating the effects on miRNA 
expression after treatment revealed that some of the beneficial effects provided by some 
approved drugs, were due in part to the drugs’ ability to modify the expression levels of a few 
miRNAs. The reference drug against colorectal malignancies, 5-fluorouracil (5-FU, 14), was 
shown to significantly alter the expression levels of 22 miRNAs (over 153 were tested) in colon 
carcinoma cell lines, and most of those are known to target genes involved in cell proliferation 
and carcinogenesis.
87
 Although the combination treatment of 5-FU and oxaliplatin (15) is widely 
used against colorectal cancer, notably in patients who present metastasis, the molecular 
mechanisms for the anti-tumor effects remained unknown.
88
 It was demonstrated that some 
miRNAs were significantly up- or downregulated upon co-treatment of 5-FU and oxaliplatin in 
colon cancer cells. Out of the 15 downregulated miRNAs, the 6 miRNAs (miR-191, miR-93, 
miR-92a, miR-222, miR-197, miR-1826) most strongly affected by the drugs are overexpressed 
in various cancers. The pharmacodynamic mechanisms of these anticancer agents could in part 
be due to their influence on miRNA gene expression.
88
 A recent study aimed at investigating the 
miRNA expression profile following treatment with the chemotherapeutic agent doxorubicin 
(16), showed that miRNA expression was altered differently depending on the breast cancer cell 
subtypes luminal-A or triple negative. Upon exposure to doxorubicin thirteen miRNAs were 
found to be generally modified in all subtypes tested, whereas the expression levels of twenty-
five miRNAs were specifically modified in the triple negative cells and sixty-nine only changed 
in the luminal-A cell line. As previously observed, cancer-associated miRNAs were the most 
strongly perturbed by treatment with doxorubicin.
89
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Similarly, some natural products currently used in therapies or in the diet have been 
found to possess anticancer properties due to their involvement in the regulation of multiple 
signaling pathways. Since a hallmark of miRNAs is the targeting of multiple genes, miRNAs 
were hypothesized to be key intermediates in the regulation of the broad range of gene networks 
targeted by natural agents.
90
 A natural product derived from turmeric, curcumin (17), exhibits 
potent anticancer properties in cell culture as it was shown to inhibit cell proliferation, 
angiogenesis, migration, and to promote apoptosis in a wide range of cancers. Some insights into 
the pharmacodynamic mechanisms of curcumin revealed that it causes the upregulation of 
several tumor suppressor miRNAs, for example miR-181b, miR-15a, miR-16, miR-203, miR-22, 
and/or the downregulation of diverse oncomiRs, such as miR-21.
90
 The isoflavone derivative 
genistein (18) exhibits antioxidant and anticancer activities and causes cell cycle arrest, apoptosis 
and inhibits angiogenesis and metastasis in various cancers. In a similar fashion as curcumin, 
genistein exerts its anticancer properties via the upregulation of three tumor suppressor miRNAs, 
including miR-34a, and the inhibition of at least seven miRNAs whose overexpression is 
strongly associated with cancer phenotypes, such as miR-221 and -222.
90
 A few additional 
examples encompass the phytoalexin resveratrol (19), the major polyphenol component of green 
tea epigallocatechin-3-gallate (20), the vegetable glucosinolates indole-3-carbinol (21) and 3,3'-
diindolylmethane (22), which all up- or downregulate several miRNAs to counteract with the 
deregulation of principal pathways involved in the development of cancer (Figure 1.4).
90
 Based 
on these observations, there has been a rising interest in studying naturally occurring substances 
as new lead compounds to treat human diseases.
91
 A recent study reported that a combination of 
plant-derived polyphenols could limit fatty liver diseases by slightly upregulating miR-103 and 
miR-107 expression levels and downregulating miR-122.
92
 The fungal metabolite diaporine A 
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(23) was identified in a recent screen of endophyte-derived products, and was found to 
efficiently inhibit the viability, the proliferation, and the colony formation of non-small cell lung 
cancer cells. Further analysis into the mode of action of diaporine A revealed that its anticancer 
effects rely in part on the regulation of the mTor signaling pathway via the upregulation of miR-
99a, in a non-highly specific fashion since at least four other miRNAs were also found 
upregulated, albeit less strongly than miR-99a.
91
  
 
Figure 1.4: Structures of selected approved drugs (14, 15, and 16) and natural products (17-23) known to exert 
anticancer properties via the regulation of miRNA expression. 
 31 
1.5.3 Specific Small Molecule Modifiers of miRNA Function 
In 2008 the first small molecule inhibitor of a specific miRNA, the oncogenic miR-21, 
was discovered by the Deiters and Huang labs.
93
 A primary screen of the LOPAC collection and 
additional custom synthesized compounds against a luciferase sensor of miR-21 expression in 
HeLa cells revealed a diazobenzene hit compound, which was further structurally modified to 
discover the potent inhibitor 24. Its selectivity for miR-21 inhibition was confirmed in a counter 
screen with a miR-30a reporter and by qRT-PCR. A combinatorial library composed of 14,024 
peptoid analogs were screened for ligands able to bind to the apical loop of pri-miR-21. The hit 
compound 25 was shown to specifically interfere with the proper processing of the pri-miR-21, 
at a high concentration (150 M).94 Based on the known interactions of aminoglycosides with 
stem-loops and bulges in RNA molecules, fifteen aminoglycosides were tested as potential 
inhibitors of pre-miR-21.
95
 Here, MCF-7 cells transfected with a construct expressing firefly 
luciferase under control of mature miR-21 revealed that streptomycin (26) is able to inhibit miR-
21 function by directly interacting with its precursor pre-miR-21, thereby preventing processing 
by Dicer. The expression levels of nine oncomiRs were measured following exposure to 
streptomycin, as eight miRNAs were unaffected streptomycin was reported to be mostly a miR-
21 inhibitor.
95
 Although quite appealing, the idea of designing ligands to directly bind with 
specific miRNAs appears highly challenging as numerous miRNAs have similar stem-loop 
hairpin structures. As the understanding of the rules for RNA-small molecules binding expands, 
it might become conceivable to predict and fine-tune the selectivity of the ligands to specifically 
target one desired miRNA.  
Some computational-based methods have recently been implemented which allow for a 
“bottom-up” or rationale design of small molecules targeting RNA. One such strategy, named 
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Inforna, analyzes the targetable motifs present in the RNA transcripts of interest and generates a 
list with corresponding molecules previously shown to bind to those motifs.
96
 The Inforna 
screening platform was used to identify small molecules interfering with the Dicer processing of 
a subset of pre-miRNAs. To assess the validity of these newly predicted lead compounds, three 
small molecule/pre-miRNA pairs were further investigated. Very interestingly, the compound 27 
efficiently blocked the maturation of its target pre-miR-96 as it reduced the expression level of 
miR-96 by 90%, and was found to be more selective towards miR-96 than an LNA 
oligonucleotide targeting the miR-96’s seed region.96 Following a similar approach, wherein a 
library of aminoglycoside analogs was screened against an RNA library containing discrete 
secondary structural elements to identify favored small molecule/RNA internal loops 
interactions, the specific miR-10b inhibitor 28 was discovered. Since it was recognized that one 
of the internal loop motif presents in the library corresponds to the Drosha processing site of pri-
miR-10b, the associated binding partner, guanidinylated neomycin (28), was tested for miR-10b 
inhibition. As expected, 28 was found to inhibit the biogenesis of the metastasis-associated miR-
10b.
97
 
A dual luciferase-based reporter system for miR-122 in Huh7 cells was used to identify 
the two specific inhibitors 29 and 30, and the specific activator 31 from a screen of 1,364 
compounds (NCI Diversity Set II).
98
 MicroRNA-122 was targeted because of its involvement in 
several liver disorders, including Hepatitis C virus infection and hepatocellular carcinoma (the 
potential therapeutic of these compounds will be discussed in chapter 3). A similar screening 
approach was employed to identify a small molecule specific activator of miR-34a. The plant 
chalcone derivative, rubone (32), was found to specifically upregulate miR-34a in a p53-
dependent pathway and to potently inhibit tumor growth in HCC cell lines, even more efficiently 
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than the reference anti-HCC drug sorafenib.
99
 Aza-flavanone compounds display a broad 
spectrum of biological activities, and it was discovered that they can act as specific inhibitors of 
miR-4644 and its fly homologue miR-14. Aza-flavanones that showed cytotoxicity against 
MCF7 cells were tested in a cell-based assay against the anti-apoptotic miR-14 
(Drosophila)/miR-4644 (human). The aza-flavanone analogs 33 and 34 were identified as highly 
effective small molecule inhibitors of miR-4644, promoting cell death in breast tumors.
100
 The 
small molecule miR-1 inhibitor 35 was recently discovered after screening of 10 products 
derived from the [2+2] photocycloaddition of diverse aryl acetylenes with 2-methoxy-1,4-
naphthalenequinone. The selectivity of 35 was assessed by qRT-PCR and using a subset of 
reporter constructs having the luciferase gene under the control of different miRNAs. The 
quinoline derivative efficiently and selectively inhibits miR-1, whose dysregulation has been 
reported in coronary artery diseases.
101
 
A new class of specific miR-122 inhibitor has been reported that combines an Ago2 
active site binder with a small PNA targeting a short specific sequence within the seed region of 
miR-122.
102
 627,000 compounds were screened in silico to find privileged scaffolds that can 
interact with Ago2 binding site. A small series of Ago2 binders were synthesized and further 
derivatized with a PNA tetramer specific for miR-122. Two mixed-inhibitors, including 36, were 
found to inhibit the Ago2 RNA cleavage activity with an IC50 of 100 nM. Although these mixed 
inhibitors provide a quick and interesting approach to the inhibition of virtually any miRNA - the 
general Ago2 binder can be coupled to any short PNA sequence of interest - these inhibitors have 
a high molecular weight (<1500 Da) and might suffer from delivery issues similar to AMOs. 
Further insights into the activity in cell-based assays and the selectivity of these mixed inhibitors 
are needed to fully evaluate this new inhibition strategy. 
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Figure 1.5: Reported small molecule specific modifiers of the miRNA function. 
Specific miRNA inhibitors include (14-20, 23-26) and specific miRNA activators include (21 and 22). The year of their 
discovery is indicated. 
 
The research presented here attempts to expand on the existing tools to specifically 
regulate the activity of miR-21 and miR-122. The precise regulation of specific miRNAs is 
highly sought after as a mechanistic tool to study miRNA biogenesis and function as well as new 
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therapeutic avenues. Extensive investigations of the previously discovered miR-21 and miR-122 
inhibitors (Figure 1.5) were conducted through high-throughput screening, hit validation, and 
structure-activity relationship studies. Also discussed here is the development of chemical probes 
and assays to study the mechanism of action of the presented small molecule miR-21 and miR-
122 inhibitors. The discovery of specific miRNA/small molecule pairs provides a novel way to 
study miRNA biogenesis as well as to investigate the development of different diseases, such as 
cancer, and offers new therapeutic approaches to specifically target different stages of the disease 
for a better treatment efficacy. 
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2.0  SYNTHESIS OF SMALL MOLECULE INHIBITORS OF MIR-21 
2.1 INTRODUCTION TO MIR-21 
miR-21 is derived from a gene located on chromosome 17q23.2, and though the miR-21 
coding gene overlaps with the TMEM49 protein coding gene, miR-21 contains its own dedicated 
promoter.
103
 miR-21 is arguably the most studied miRNA due to its implication in many human 
disorders, such as cardiovascular and pulmonary diseases, and more notably in cancers.
103
 miR-
21 is significantly up-regulated in nearly all types of human cancer; for instance, miR-21 
overexpression has been established in breast, colon, lung, pancreas, prostate, stomach, and 
leukaemic cancers.
104
 These observations spurred investigations into miR-21 regulation and the 
development of chemical tools as specific miR-21 inhibitors. The genes targeted by miR-21 are 
similarly involved at various stages in the development of human carcinomas. The principal 
target of miR-21, programmed cell death 4 (PDCD4), is a potent tumor suppressor. As a result of 
miR-21 ectopic expression, PDCD4 is downregulated in various cancers and loss of PDCD4 
expression in lung and colorectal cancers is often associated with a poor patient prognosis.
105
 
Other miR-21 targets include the reversion inducing cysteine-rich protein with kazal motifs 
(RECK), a membrane protein whose inactivation seems to promote invasion and metastasis of 
various cancers,
106
 tropomyosin 1 (TPM1), whose expression potentially slows down cell growth 
and invasiveness of breast carcinomas, and the protein Sprouty2 (SPRY2) whose downregulation 
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affects cellular outgrowths, branching, and migration.
107
 Another notable miR-21 target is the 
well-known tumor suppressor phosphatase and tensin (PTEN) homologue.
108
 It was 
demonstrated that direct repression of PDCD4 by miR-21 promotes chemoresistance to the 
chemotherapeutic agent docetaxel. Treatment of docetaxel-resistant cells PC3R with a 2′-OMe-
modified AMO to selectively inhibit miR-21 restored both PDCD4 expression and sensitivity to 
docetaxel.
109
 The first in vivo demonstration of the importance of miR-21 in cancers was 
established by the Slack group.
110
 They developed a mouse model based on Cre and Tet-off 
technologies where miR-21 expression can be easily turned on/off by doxycycline 
induction/withdrawal. Expression of miR-21 was normal in mice fed with doxycycline, whereas 
in mice fed with standard food (without the drug) miR-21 was highly overexpressed. Mice taken 
off doxycycline showed a tenfold increase in miR-21 expression levels, which is comparable 
with the miR-21 overexpression commonly observed in several human malignancies. Three 
months after doxycycline withdrawal, serious signs of lymphoma started to appear, whereas mice 
continually fed the drug were healthy. These results suggested that miR-21 up-regulation is 
necessary for the initiation of the cancer phenotype.
110
 After the mice showed unambiguous signs 
of lymphoma, they were fed doxycycline; miR-21 expression levels were returned to normal 
within a week and, importantly, full tumor regression was observed in all mice. Taken together, 
this data demonstrated that overexpression of miR-21 not only largely increases the risks of 
initiation of tumors but is also necessary for the maintenance of malignancies.
110
 Small molecule 
regulators of miR-21 activity represent unique and novel tools to investigate the molecular 
mechanisms of chemoresistance and provide fundamentally new therapeutic agents for the 
treatment of cancer. 
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2.2 PREVIOUS WORK: DEVELOPMENT OF A REPORTER ASSAY FOR MIR-21 
FUNCTION AND ITS APPLICATION TO THE DISCOVERY OF THE FIRST SMALL 
MOLECULE INHIBITORS OF MIR-21 
The first small molecule inhibitor of miRNA, miR-21, was identified by the Deiters lab in 
collaboration with Dr. Qihong Huang at the Wistar Institute.
93
 They developed a lentiviral 
reporter assay to identify small molecules that specifically modulate miR-21 activity. Since 
mature miRNAs bind to the 3′-UTR of their target mRNAs to negatively affect gene expression, 
plasmids containing a luciferase gene with a miRNA target sequence located in the 3′-UTR can 
be used as sensors. A reduction in the luminescence signal indicates the presence of the miRNA, 
whereas restoration of the signal indicates any interference with the function of the miRNA of 
interest, for example its inhibition with a small molecule. A lentiviral reporter construct for miR-
21 (Luc-miR-21) was created by introducing the complementary sequence of mature miR-21 
downstream of the firefly luciferase reporter gene (Figure 2.1). A similar lentiviral construct 
containing the target sequence for miR-30a was also constructed as a selectivity control.  
 
Figure 2.1: Assay for small molecules interfering with miR-21 function. 
A miR-21 target site was introduced in the 3′-UTR of a firefly luciferase gene. The presence of mature miR-21 in cells 
transfected with the reporter construct leads to a decrease in luciferase expression. The presence of a small molecule that inhibits 
miR-21 prevents the interaction of miR-21 with its target site, leading to an increase in luciferase signal. 
 
The reporter construct was transfected into the human cervical cancer HeLa cell line, 
selected based on its high expression levels of miR-21 but relatively low levels of miR-30a.
111
 A 
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90% decrease in the luciferase signal was observed when the cells were transfected with the Luc-
miR-21 reporter compared to the control luciferase-linker construct that does not possess any 
known miRNA target sequence, indicating the ability of the sensor to detect endogenous miR-
21.
93
 When the cells were transfected with the Luc-miR-30a construct, only a slight decrease in 
the luciferase signal was observed due the low level of endogenous miR-30a. These results 
demonstrated the feasibility to use the reporter system to accurately and selectively detect 
endogenous miRNAs, as the reporter is sensitive enough to distinguish between different 
miRNAs. A pilot screen of 1,000 small molecules (Library of Pharmacologically Active 
Compounds and in-house set of compounds) was then performed in HeLa cells stably transfected 
with the Luc-miR-21 reporter assay. This primary screen revealed the initial hit compound 37, 
which produced a 251% increase in the luciferase signal, in comparison with DMSO (dimethyl 
sulfoxide) treated cells that did not have any effect on the signal intensity. This hit compound 
was then submitted to structural modifications and additional screening rounds that led to the 
identification of the structurally similar diazobenzene 24. Compound 24 is the most potent miR-
21 inhibitor discovered so far. At a concentration of 10 M, it induces a 485% increase in 
luciferase signal in the miR-21 assay.
93
 Chemical modifications were performed on compounds 
24 and 37 to understand which functional groups are responsible for their high activity in the 
miR-21 assay and to further improve their activity (Figure 2.2). 
 
Figure 2.2: Preliminary structure-activity relationship data for compounds 37 (left) and 24 (right). 
Adapted from Angew. Chem. Int. Ed. 2008, 47, 7482. 
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Dose-response studies for compound 24 were carried out at concentrations ranging from 
0-10 M and revealed a dose-dependent response, as well as an EC50 value of 2 M for 24.
93
 To 
assess the specificity of the inhibitor, HeLa cells stably transfected with either the luciferase 
linker construct or with the Luc-miR-30a reporter were treated with 24 at 10 M for 48 h. The 
diazobenzene inhibitor had no effect on the luciferase signal of the linker construct (without any 
known miRNA target site), nor did it affect the signal intensity of the Luc-miR-30a reporter. 
These results confirmed that 24 is not a general inhibitor of the miRNA pathway and displays 
some selectivity for miR-21. qRT-PCR experiments were performed to measure the intracellular 
level of miRNAs. In accordance to what was observed in the luciferase reporter assay, treatment 
of HeLa cells with 24 at 10 M did not affect the expression of miR-30a, nor miR-93, as the 
levels of mature endogenous miR-30a and miR-93 were not diminished. In comparison, 
treatment with 24 led to a reduction of 78% in miR-21 expression in HeLa cells relative to 
DMSO treatment. Likewise, qRT-PCR measurement of the intracellular levels of pri-miR-21 
after treatment with compound 24 revealed an 87% reduction in pri-miR-21 levels in HeLa cells. 
These results suggested that the diazobenzene 24 might inhibit transcription of the miR-21 gene 
into pri-miR-21, rather than the downstream maturation processes.
93
 
2.2.1 Structure Activity Relationship Studies of the Previously Discovered miR-21 
Inhibitor 24 
The previously discovered miR-21 inhibitor represents the first example of specific 
regulation of miRNA with small molecules, but even though 24 is quite active and selective 
towards miR-21 downregulation, this compound suffers from poor solubility in water and 
presents a metabolically susceptible diazo-bond, thus preventing its application in animal studies. 
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Indeed, azo linkages are rapidly reduced and metabolized by azo-reductase enzymes. Actually, 
the introduction of an azo bond into an active compound is a well-established prodrug strategy, 
particularly in agents used to treat localized diseases of the colon.
112
 These azo derivatives pass 
unaffected through the intestine where they are poorly absorbed, which allows them to be site-
specifically released in the colon where there is a high level of azo-reductases secreted by 
colonic bacteria.
113
 For that reason it seemed desirable to replace the azo-bond of 24 with a more 
stable motif. The preliminary SAR study revealed that an alkene bond instead of the nitrogen 
double bond negatively affected the activity, so it was decided to introduce an amide linkage 
instead (Figure 2.3). The exact analog of 24 substituted with an amide bond in place of the diazo-
bond (38) displayed a 20% reduced activity in comparison with 24 (Figure 2.3). Modification of 
the propargyl group with a bulkier benzyl group (39) further reduced the activity. Since the 
inhibitor possesses an alkyne bond, which can be used in a click reaction to modify the 
compound with various tags, for example with a fluorophore, the benzophenone 40 was designed 
to assess its potential application in target identification experiments (as will be discussed later). 
The benzophenone group is a good photoprobe and is commonly used to map small 
molecule/protein interactions.
114
 Unfortunately modification in the para position of the amide 
bond was not tolerated as 40 and 41 exhibited a 40% reduction in activity compared to 24. 
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Figure 2.3: Analogs of 24 designed to replace the azo-bond with an amide group. 
The numbers represent the activity relative to 24 within the same luciferase assay. Experiments were performed in triplicate and 
the standard deviations of three independent assays were calculated. Cell-based assays were performed by Colleen Connelly.  
 
The amide derivatives 38 and 39 were synthesized in 3 steps (Scheme 2.1), starting with 
the amide coupling of terephthalic acid monomethyl ester chloride (42) and aniline, followed by 
hydrolysis of the methyl ester 43 with KOH (potassium hydroxide). The carboxylic acid 44 was 
obtained in 97% yield and subsequently treated with the corresponding amines and the amide 
coupling reagents EDCI (1-ethyl-3-(3- dimethylaminopropyl) carbodiimide) and HOBt 
(hydroxybenzotriazole). The analogs 40 and 41 were also obtained in 3 steps under similar 
conditions (Scheme 2.1). The acyl chloride 42 was coupled with propargyl amine to deliver the 
methyl ester 45, which was then hydrolyzed with KOH. The acid 46 was stirred in DMF 
(dimethylformamide) in the presence of HATU (2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyl uranium hexafluorophosphate), DIPEA (diisopropylethylamine), and the 
corresponding anilines to afford the compounds 40 and 41. Although pretty disappointing yields 
were observed in the last coupling steps, the conditions were not optimized as it was decided not 
to pursue this series of analogs further based on their low activity in the miR-21 luciferase assay 
(Figure 2.3). 
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Scheme 2.1: Synthesis scheme of the amide analogs (38-41) of the previously discovered miR-21 inhibitor. 
2.3 DISCOVERY OF SMALL MOLECULE MIR-21 INHIBITORS THROUGH 
HIGH-THROUGHPUT SCREENING 
In order to identify additional small molecule miR-21 inhibitors, a high-throughput 
screen of 333,519 compounds was performed by the National Institute of Health (NIH) Chemical 
Genomic Center using the luciferase assay for miR-21 (pubchem AID 2289). The 3,282 small 
molecules identified in the primary screen were subsequently tested in a cell-based assay 
expressing the miR-30a reporter construct to evaluate their selectivity. The derivatives found 
active in both the miR-21 and miR-30a assays were disregarded as they were not considered 
selective for miR-21, but rather may be general miRNA modulators or non-specifically target 
firefly luciferase. The remaining compounds were re-tested in the miR-21 assay in dose-response 
experiments, and only the small molecules exhibiting satisfactory EC50 values were selected to 
deliver about 60 additional hit miR-21 inhibitors. These hits were then tested by qRT-PCR and 
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ranked according to their ability to downregulate miR-21 expression levels. The most promising 
compounds from the HTS included the ether-amides, N-acylhydrazones, oxadiazoles, and aryl-
amides (Figure 2.4); therefore, several of these compounds were re-synthesized to further assess 
their activity and selectivity for miR-21 inhibition.  
 
 
Figure 2.4: Structure of potential new miR-21 inhibitors identified from the HTS. 
The EC50 values determined in the HTS are indicated in blue. 
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2.3.1 Validation of Potential Ether-amide miR-21 Inhibitors  
The investigation started with the validation of the ether-amide hit compound 47 (Figure 
2.5), which was re-synthesized, characterized, and tested in the miR-21 luciferase assay. First, a 
route was envisioned to access the 2-(2-iodophenoxy)acetic acid intermediate 58 in only one step 
(Scheme 2.2). 2-Iodophenol was treated with 2-bromoacetic acid and NaOH (sodium hydroxide) 
in H2O and heated to reflux for 24 h. The expected carboxylic acid 58 was obtained once in 38% 
yield, but efforts to reproduce and increase the yield were unsuccessful. A different route was 
then opted to synthesize 2-(2-iodophenoxy)acetyl chloride (59), which was one step longer but 
high yielding and reproducible and was therefore more amenable for large scale syntheses of 
various analogs (Scheme 2.2). A mixture of 2-iodophenol (56) and tert-butylbromoacetate was 
stirred at 65 °C for 2 h in acetone in the presence of Cs2CO3 (cesium carbonate),
115
 the tert-butyl 
57 was subsequently deprotected by addition of TFA (trifluoroacetic acid) (Scheme 2.2). The 
deprotected carboxylic acid 58 was converted into the acyl chloride 59 with oxalyl chloride. 
Then, 2-aminothiophenol (60) and 4-nitrobenzoyl chloride (61) were heated to reflux in pyridine 
to yield the nitrobenzothiazole intermediate 62.
116
 The nitro group was reduced with SnCl2 (tin 
chloride) in refluxing EtOH (ethanol).
116
 Finally, 4-(benzothiazol-2-yl)aniline (63) and 2-(2-
iodophenoxy)acetyl chloride (59) were coupled to give compound 47 as a yellow solid in 50% 
yield (Scheme 2.2). 
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Scheme 2.2: Synthetic route to benzothiazole derivatives. 
 R = 2-Iodo for compound 47, R = 4-OMe for 64, and R = H for 65. 
 
Starting with the commercially available 4-methoxyphenol and phenol, the previous route 
was used to synthesize the analogs 64 and 65 (Scheme 2.2). Following the synthesis these three 
small molecules were tested in the miR-21 luciferase assay in Hela cells by Colleen Connelly 
(Figure 2.5). The HeLa-miR21-Luc cells were exposed to the small molecules at 10 M in 
triplicate for 48 h and then assayed using a Bright Glo Luciferase Assay Kit (Promega). The 
luminescence data was normalized to a 1% DMSO control, and the previously identified miR-21 
inhibitor 24 was used as a positive control. Unfortunately the ether-amide 47, which was active 
in the HTS, showed a very low activity compared to the positive control 24 (Figure 2.5). A few 
structural modifications were made on 47 as a preliminary SAR investigation. Since the second 
ether-amide (48) identified as a hit in the HTS has a methoxy substituted in the para position 
(Figure 2.4), 64 was synthesized with a para-methoxy instead of an ortho-iodo group. This 
substitution did not affect the activity since 47 and 64 induced a similar increase in the luciferase 
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signal (Figure 2.5). Absence of any ring substituent seemed to be beneficial since 65 was about 
10% more active than the parent compound 47. 
 
 
Figure 2.5: Preliminary SAR investigation of the ether-amide hit compound 47. 
The analogs were synthesized and tested in the miR-21 luciferase assay. The activities are relative to 24 within the same 
luciferase assay. Experiments were performed in triplicate and the standard deviations of the three independent assays were 
calculated. Cell-based assays were performed by Colleen Connelly. 
 
Since the activity of the re-synthesized hit 47 was 43% less than that of compound 24, it 
was decided to not investigate in more details the effects of different substitutions on the phenyl 
ring (shown in orange in Figure 2.5). Instead, benzoxazole analogs were synthesized (Figure 
2.6). The 4-(benzoxazol-2-yl)aniline intermediate 69 was assembled according to a procedure 
developed by Laura Gardner. 2-Aminophenol (66) and 4-nitrobenzoyl chloride (61) were stirred 
in THF in the presence of TEA (triethylamine).
117
 The resulting amide 67 was condensed in 
refluxing xylene in presence of PTSA (para-toluenesulfonic acid) to yield the 4-
nitrobenzoxazole precursor 68.
118
 The nitro group was quantitatively reduced to the amine upon 
reduction with tin chloride in refluxing EtOH (Scheme 2.3).
116
 Compound 69 was finally 
coupled with the three different acetyl chlorides (Scheme 2.3) to yield the final derivatives 70-72 
(Figure 2.6). 
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Scheme 2.3: Synthetic route to the benzoxazole derivatives 70-72. 
 R = 2-I (70), R = 4-OMe (71), and R = H (72). 
 
The benzoxazole analogs were tested in the previously described miR-21 assay by 
Colleen Connelly (Figure 2.1).
93
 Replacement of the sulfur atom with an oxygen did not 
dramatically modify the potency of these additional miR-21 inhibitors. Both compounds 70 and 
72 showed an activity equivalent to that of their respective benzothiazole analogs 47 and 65. As 
previously observed, removal of the iodine functionality led to a slightly more active molecule 
72 compared to its parent compound 70. Unlike the o-iodo and p-methoxy derivatives, the 
benzoxazole 71 was 20% less active than its counterpart benzothiazole 64 (Figure 2.5 and Figure 
2.6). Since all of the small molecules synthesized in this series were less active than the 
previously developed miR-21 inhibitor 24, it was decided not to study the hit compounds ether-
amides 47 and 48 more thoroughly, but instead to investigate another class of compounds. 
 
 
Figure 2.6: Investigation of the benzoxazole derivatives 70-72 for miR-21 inhibition. 
The analogs were synthesized and tested in the miR-21 luciferase assay. The numbers represent the activity relative to 24 within 
the same luciferase assay. Experiments were performed in triplicate and the standard deviations of the three independent assays 
were calculated. Cell-based assays were performed by Colleen Connelly. 
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2.3.2 Validation of Potential N-Acylhydrazone miR-21 Inhibitors 
Next, the hit N-acylhydrazones 49 and 50 were re-synthesized to verify their activity in 
the miR-21 assay. The commercially available ethyl picolinate (73) was heated to reflux in 
hydrazine hydrate to yield the corresponding hydrazide 74.
119
 The hydrazide was then refluxed in 
a mixture of EtOH/MeOH (1:1) in the presence of o-acetoacetaniside (75) to give the final 
compound 50 as an off-white solid in 81% yield (Scheme 2.4).
120
 
 
 
Scheme 2.4: Synthetic route to the N-Acylhydrazone hit compound 50. 
 
 
The same conditions were unsuccessful in delivering hit compound 49. Specifically, the 
final product was not recovered when the hydrazide intermediate 83 and the N-(4-
acetylphenyl)nicotinamide (81) were refluxed in a 1:1 mixture of EtOH/MeOH. In order to 
determine better conditions, a few test reactions were run with the commercially available 2-
furoic acid hydrazide (77) and 4-methylacetophenone (76). First, these reagents were heated to 
reflux in MeOH and one drop of glacial acetic acid was added to catalyze the reaction.
121
 The 
expected hydrazone 78 was obtained in 52% yield (Scheme 2.5). Another test reaction was 
performed, where the furoic hydrazide 77 and 66 were heated to reflux in EtOH.
122
 The expected 
product was obtained in 70% yield. These conditions were then applied to the synthesis of 49 
and the other analogs 84-93 (Scheme 2.5). Methyl-2-methyl-3-furancarboxylate was heated to 
reflux in MeOH in presence of hydrazine to form the hydrazide intermediate 82,
123
 which was 
subsequently heated to reflux in EtOH in the presence of N-(4-acetylphenyl)nicotinamide (81). 
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The amide 81 resulted from the coupling of 4-aminoacetophenone (80) and 3-nicotinoyl chloride 
(79). The hydrazone 49 was finally obtained in 62% yield as a yellow solid (Scheme 2.5).  
 
Scheme 2.5: Synthetic route to the hit compound 49 and other N-Acylhydrazone analogs. 
.  
Compounds 49 and 50 were then tested in the miR-21 luciferase assay by Colleen 
Connelly to measure their efficiency as miR-21 inhibitors (Figure 2.7). Unfortunately, both 
compounds showed activities that were about 50% lower than the reference inhibitor 24. The 
structurally similar compound 78, which was obtained during the test reactions, was also tested 
in the miR-21 assay (Figure 2.7). Interestingly, this analog was quite potent as it displayed an 
activity of 95% relative to 24.  
 
Figure 2.7: Activities of the N-acylhydrazones 49 and 50 identified from the NIH HTS as potential miR-21 
inhibitors and the test compound 78. 
The numbers represent the activity relative to 24 within the same luciferase assay. Experiments were performed in 
triplicate and the standard deviations of the three independent assays were calculated. Cell-based assays were 
performed by Colleen Connelly. 
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Encouraged by the high activity of compound 78, it was decided to make some structural 
modifications on 78 for preliminary SAR studies (Figure 2.8). First the importance of the two 
methyl groups, on the benzene ring (shown in blue in Figure 2.8) and on the hydrazone linkage 
(shown in red in Figure 2.9), was evaluated. Removal of both methyl groups was well tolerated 
as the analog 84 exhibited the same activity as the parent compound 78. The p-phenyl group was 
modified with various functional groups, such as pyridine (84), o-acetoacetaniside (85), butyl 
(86), p-diphenyl (87), and naphthalene (88) (Figure 2.8). Replacement of the p-phenyl group 
with a pyridine, a butyl, and a bulky p-diphenyl functionality led to a significant loss in activity. 
However, introduction of the o-acetoacetaniside group (85), similar to the hit compound 50, 
maintained the activity; as did the introduction of the naphthalene motif (88). The furan group 
was then substituted with 2-methyl furan (89) as in hit compound 49, which slightly improved 
the activity. Replacement of the furan motif with a benzene ring had no effect on the activity 
since 83 and 90 displayed a similar potency. Introduction of an additional aromatic ring was 
beneficial as the benzofuran analog 91 exhibited a 22% increase in activity, compared to 83. 
Lastly, substitution of the acylhydrazone motif with a more stable amide bond led to a more 
potent inhibitor 92, which was 16% more active than the reference inhibitor 24 (Figure 2.8). 
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Figure 2.8: Preliminary SAR investigation of the N-acylhydrazone inhibitor 78. 
The numbers represent the activity relative to 24 within the same luciferase assay. Experiments were performed in triplicate and 
the standard deviations of the three independent assays were calculated. Cell-based assays were performed by Colleen Connelly. 
 
To investigate each inhibitor’s selectivity for miR-21, inhibitors 49, 50, and 83-92 were 
tested at 10 μM in the miR-122 luciferase assay (Figure 2.9). This construct is similar to the 
miR-21 reporter, except the reporter assay for miR-122 was further improved by inserting the 
miR-122 binding site downstream of the Renilla luciferase gene of the plasmid psiCHECK-2. 
This plasmid also contains the firefly luciferase gene, which serves as an internal control. Huh7-
psiCHECK-miR122 cells, which stably express the miR-122 reporter,
124
 were exposed to each 
inhibitor at 10 μM (0.1% final DMSO concentration) for 48 h. The cells were then assayed with 
a Dual Luciferase Kit (Promega), which allows to simultaneously measure the luminescence 
signals of both Renilla and firefly luciferases. The Renilla luciferase readings were normalized to 
the firefly luciferase readings to give relative luciferase units (RLUs). In that case, an increase in 
the Renilla signal would indicate that the compounds show some degree of miR-122 inhibition, 
whereas an increase in the firefly signal would suggest a non-miRNA specific effect on the 
reporter.  
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Figure 2.9: Evaluation of the selectivity of the N-acylhydrazone inhibitors in the miR-122 assay. 
Dual Luciferase Assay of Huh7-psiCHECK-miR-122 cells treated with the hit compounds 49 and 50 and the 
analogs 83-92 at 10 μM. The luciferase signal was normalized to a DMSO control. Experiments were performed in 
triplicate and the standard deviations of the three independent assays were calculated. 
 
None of the inhibitor showed any effect on the Renilla luciferase (Figure 2.9), implying 
that these compounds might be selective towards miR-21 inhibition. A few analogs, 83, and 88-
92, induced a large increase in the firefly luminescence (Figure 2.9), which indicates that the 
high activity previously observed in the miR-21 assay for these compounds (Figure 2.8) might be 
due to a non-specific stabilization of the firefly enzyme, rather than true miR-21 downregulation. 
It has recently been reported that the firefly luciferase enzyme is sensitive to ligand-based 
stabilization by small molecule inhibitors, which leads to protein stabilization and 
accumulation.
125
 In a cell-based assay, treatment with an inhibitor can lead to an increase in 
luciferase signal, whereas in vitro evaluation of the direct interaction between the enzyme and 
these same inhibitors causes a significant decrease in luciferase signal. Certain chemotypes of 
small molecules were presented as apparent inhibitors of the enzyme and can lead to false 
positive hits in screening events relying on firefly luciferase-based assays.
126
 One of the 
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identified FLuc inhibitors, the compound 93, was synthesized by Laura Gardner to provide a 
positive control (Figure 2.10A). In order to further test the effect of the N-acylhydrazone 
inhibitors on firefly luciferase, an in vitro luciferase (FLuc) assay was performed (Figure 2.10B). 
The positive control 93 displayed a 90% FLuc inhibition. The analogs 78, 83, 84, 87-90, and 92 
showed a non-specific modulation of the firefly enzyme as they exhibited 30-65% FLuc 
inhibition. These data indicate that these analogs might inhibit the firefly luciferase rather than 
miR-21. 
 
Figure 2.10: Specifity study of the N-acylhydrazone inhibitors. 
A. Structure of the reported FLuc inhibitor. B. In vitro FLuc assay of the miR-21 inhibitors 49, 50, 78 and 83-92. 
The luciferase signal was normalized to a 1% DMSO control. The error bars indicate the standard deviations 
determined from three independent measurements.  
 
Based on this data, additional experiments were performed by Colleen Connelly to 
investigate the selectivity of the N-acylhydrazone derivatives (Figure 2.11). HeLa cells 
containing the luciferase reporter constructs for miR-21 or miR-30a were exposed for 48 h to 10 
M of each of the small molecules 78, 89, 83, and 84 (Figure 2.11A). The four analogs tested 
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displayed the same level of activity in both the miR-21 and the miR-30a assays, which was 
expected since both of these reporters are based on the firefly luciferase enzyme. In addition, the 
levels of mature miR-21, miR-20a, miR-24, and miR-27b in HeLa cells treated with the 
inhibitors 78 and 83 at 10 M were measured by qRT-PCR. Both 78 and 83 induced a reduction 
in the expression levels of the three miRNAs tested (Figure 2.11B). Although the compounds did 
not interfere with the expression of miR-122, as determined in the luciferase assay (Figure 2.9), 
the levels of mature miR-122 could not be measured in HeLa cells by qRT-PCR because of the 
very low endogenous levels of miR-122 in that cell line. Taken together, all these data suggest 
that the N-acylhydrazone analogs do not inhibit miR-21 selectively, as at least four other 
miRNAs are being similarly reduced upon treatment with these inhibitors (Figure 2.11). 
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Figure 2.11: Assessment of the selectivity of the N-acylhydrazone inhibitors. 
A. Bright Glo Luciferase Assays of HeLa-miR21-Luc and HeLa-miR30A-Luc cells treated with the hydrazones at 
10 μM. The luciferase signal was normalized to a DMSO control. B. qRT-PCR measurements of mature miR-21, 
miR-20a, miR-24, and miR-27b levels in HeLa cells treated with the hydrazones 78 and 83 (10 μM). The expression 
of each miRNA for small molecule treated cells was normalized to a DMSO control (100% expression) and RNU19 
expression. The error bars indicate the standard deviation determined from three independent measurements. Cell-
based assays were performed by Colleen Connelly.  
2.3.3 Validation of Potential Ether-amide miR-21 Inhibitors  
Next, the two oxadiazole hit compounds 51 and 52 identified from the HTS were 
validated through synthesis and SAR investigation (Figure 2.4). The oxadiazole derivatives were 
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synthesized in four steps following a procedure established by Laura Gardner. The commercially 
available anilines were converted to the corresponding arylazides (95) by treatment sequentially 
with excess of concentrated H2SO4 (sulfuric acid), NaNO2 (sodium nitrite) and NaN3 (sodium 
azide) in water at 0 °C; the mixture was slowly allowed to warm up to rt and stirred overnight.
127
 
2-Thiophenecarbonitrile (96) was dissolved in a mixture of 15% EtOH in H2O and a solution of 
Na2CO3 (sodium carbonate) and H2NOHHCl (hydroxylamine hydrochloride) in H2O was 
added.
128
 The hydroxamide 97 was then heated to reflux in dioxane in the presence of 98.
129
 The 
oxadiazole precursor 99 was stirred overnight with the arylazide 95 in presence of NaOMe 
(sodium methylate) in MeOH at 60 °C to deliver the final compounds (Scheme 2.6).
130
 
 
Scheme 2.6: Synthesis scheme for oxadiazole hit compound 51 and analogs. 
Definitions 51: R = 3-OMe, 100: R = 3,5-OMe, 101: R = H, 102: R = 3-Et, 103: R = 3-NMe2, 104: R = 3-iPr, 105: R 
= 3-CF3, 106: R = 3-OCF3 107: R = 3-F, 108: R = 6-OMe, 109: R = 4-OMe, 110: R = C4H4, 111: R = 3-C6H5, 112: 
R = 3-OH. 
 
The two re-synthesized hit compounds were tested in the miR-21 luciferase assay by 
Colleen Connelly (Figure 2.12). Gratifyingly, 52 displayed the same level of miR-21 inhibition 
as the reference miR-21 inhibitor 24, and 51 showed a 40% increase in activity compared to 24 
(Figure 2.12), and an improved EC50 value of 0.15 μM. Encouraged by these results, diverse 
chemical modifications were performed on these structures to better understand the molecular 
requirements for the activity of the miR-21 inhibitors 51 and 52.  
 57 
 
Figure 2.12: Activities of the oxadiazole hit compounds 51 and 52 identified in the HTS. 
The numbers represent the activity relative to 24 within the same luciferase assay. Experiments were performed in 
triplicate and the standard deviations of the three independent assays were calculated. Compound 52 was 
synthesized by Laura Gardner and cell-based assays were performed by Colleen Connelly. 
 
The main oxadiazole-triazole core of compounds 51 and 52 was kept constant. Several 
analogs were designed that contained structural modifications either on the phenyl ring (shown 
in red in Figure 2.13), on the thiophene motif (shown in blue in Figure 2.14) or in place of the 
amino group (shown in magenta in Figure 2.15). This SAR investigation was aimed at 
understanding which functionalities on the molecule are necessary for its miR-21 inhibitory 
activity as well as to identify compounds with increased potency. First, the importance of the 
methoxy group in the meta position of the phenyl ring was investigated (Figure 2.13). All of 
these analogs were synthesized according to the procedure previously described (Scheme 2.6). 
As the parent compound 51 is meta substituted with a methoxy group, compound 100 was 
synthesized with two methoxy groups in the meta positions to see if it would further enhance the 
activity, but the introduction of a second methoxy group led to a 20% loss in activity (Figure 
2.13). The oxadiazole 101 was designed to reveal the importance of having a substituent on the 
phenyl ring, and see if a smaller analog would fit better in the putative binding pocket of the 
target protein, resulting in a more potent inhibitor. The absence of any substituent dramatically 
affected the activity since 101 only showed 32% residual activity (Figure 2.13). In order to 
understand the necessity of having a hydrogen-bond acceptor in the meta position, 102, 103, and 
104 were synthesized. Replacement of the methoxy group with an ethyl substituent (102) or a 
more basic dimethylamino functionality (103) slightly improved the activity. Substitution of the 
 58 
dimethylamino group with an isopropyl functionality (104) abolished the formation of any 
putative hydrogen-bond, and led to a 13% loss of activity (Figure 2.13). A deactivating group 
was then installed in the meta position (105) which yielded a 39% reduction in the activity. To 
understand whether the beneficial effect of the meta substituent was due to a steric or an 
electronic effect, analogs 106 and 107 were synthesized. Replacement of the meta methyl group 
with the more electron-withdrawing group trifluoromethyl (106) caused a 28% reduction in the 
activity. However, the activity was maintained when the small highly electronegative fluoro 
motif was introduced (107). These results and the data collected from compounds 102, 103, and 
104 suggested that a subtle balance needs to be established between the size and the 
electronegativity of the functionalities introduced in the meta position in order to maintain the 
activity of the miR-21 inhibitors (Figure 2.13). The methoxy group was then installed in the 
ortho or para positions. Substitution in ortho (108) dramatically reduced the activity, whereas 
para substitution (109) led to a 16% increase in activity (Figure 2.13). Modification of the 
aromatic ring with the bulkier naphtalene (110) motif yielded a 16% decrease in activity, 
however, the m-diphenyl (111) group was well tolerated. The methoxy group was then removed 
to give compound 112, which now contains a potential hydrogen-bond donor group in the meta 
position (Figure 2.13). The introduction of a hydroxy group (112) caused a 23% loss of activity.  
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Figure 2.13: Structure-activity relationship studies of the miR-21 inhibitor 51 through modification of the phenyl 
ring (variations to the original structure are shown in red). 
The numbers represent the activity relative to 51 within the same miR-21 luciferase assay. Experiments were 
performed in triplicate and the standard deviations of the three independent assays were calculated. Cell-based 
assays were performed by Colleen Connelly. 
 
 
The conditions used to synthesize the previous analogs were unsuccessful in delivering 
the hydroxy derivative 112. When o-azidophenol was heated in the presence of the nitrile-
oxadiazole intermediate 99 and sodium methylate, the expected product could not be isolated. 
Indeed, the other analogs were isolated by filtration after addition of water to the reaction 
mixture, which caused the products to precipitate out of solution. The introduction of the 
hydroxy group might have enhanced the water solubility of 112, which made it difficult to 
recover it under these conditions. The product 112 was successfully obtained in 78% yield after 
deprotection of the methoxy group of compound 51 with three equivalents of BBr3 (boron 
tribromide) (Scheme 2.7).
131
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Scheme 2.7: Synthesis of the alcohol derivative 112. 
 
Next, the importance of the amino group (shown in magenta in Figure 2.14) was 
assessed. Analog 115 was synthesized as a direct derivative of the lead compound 51, where the 
amino group was removed from the triazole moiety. In a first attempt to introduce the triazole 
ring via the well-known “click-reaction”,132 1-azido-3-methoxybenzene (95) and propiolic acid 
were treated with CuSO45H2O (copper sulfate pentahydrated) and sodium ascorbate in a 
mixture of THF/H2O (1:1).
133
 Although some product 114 was obtained using these conditions, it 
was contaminated with some impurities that could not be eliminated through additional acid/base 
extraction or column chromatography. Instead, the arylazide 95 was treated with propargylic 
alcohol, CuSO45H2O and sodium ascorbate to afford the alcohol 113, which was easier to 
purify than the acid 114 since it was less polar. The alcohol derivative 113 was oxidized with 
Jones’ reagent to give the carboxylic acid intermediate 114 in 60-71% yield depending on the 
ring substituent.
134
 The precursor 114 was heated at 120 °C overnight in acetonitrile, in presence 
of hydroxythiophene-2-carboximidamide (97) and EDCI to deliver the final product (Scheme 
2.8). Although this last reaction was pretty low yielding, only 20-30% products were obtained 
due to some loss of material on the column, no optimization was performed as the analogs 
synthesized displayed a rather low activity (Figure 2.14). 
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Scheme 2.8: Synthetic route to oxadiazole analogs 115-117. 
Definitions 115: R = 3-OMe, 116: R = H, and 117: R = 3-F.  
 
Removal of the free amino group on the triazole ring generally led to a loss of activity 
(Figure 2.14). The analog 115 displayed a 13% reduced activity in comparison with the parent 
compound 51. Similarly, 117 was approximately 10% less active than its direct amino-
counterpart 107. As expected, the analog 116 without any substituent on the phenyl ring 
exhibited a reduced activity in comparison to 115. However, unlike 115 and 117, the activity of 
116 was about 30% higher than its direct amino-derivative 101 (Figure 2.14). Overall, comparing 
the hit compound 51 and the triazole 115 it seems that the amino group has a slightly positive 
effect on the miR-21 inhibitory activity. 
 
Figure 2.14: Structure-activity studies of the miR-21 inhibitor 51 through removal of the amino group (variations to 
the original structure are shown in magenta and red). 
The numbers represent the activity relative to 51 within the same luciferase assay. Experiments were performed in 
triplicate and the standard deviations of the three independent assays were calculated. Cell-based assays were 
performed by Colleen Connelly. 
 
Next, acylation of the primary amine in 51 was attempted, through reaction with acetic 
anhydride and DIPEA in DCM; however even after several days the TLC showed only unreacted 
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starting material. In an attempt to optimize the reaction conditions, different small-scale test 
reactions were performed: with/without DMAP (4-dimethylaminopyridine), with different 
equivalents of base and anhydride, or heating to reflux for 48 h.
135
 As none of these conditions 
delivered the acetylated product, 51 was treated with the more reactive acetyl chloride (AcOCl). 
These reagents were stirred under reflux in DCM in presence of TEA and catalytic amount of 
DMAP but no reaction was observed even after a few days. 
Lastly, the replacement of the thiophene ring with different heterocycles was investigated 
(Figure 2.15). Compound 118 was synthesized by Colleen Connelly according to the procedure 
previously described (Scheme 2.6) and possesses a furan ring in place of the thiophene. The 
activity of the furan derivative 118 was improved by 20% in comparison with the hit compound 
51 (Figure 2.15). The analogs 119, 120, and 121 were also synthesized with the conditions 
previously discussed (Scheme 2.6). Replacement of the thiophene ring with a slightly larger 
benzene ring (119) was tolerated, as this modification only caused a 2% loss of potency. 
Substitution with the more basic pyridine ring (120) led to a slight increase in the activity. To 
verify whether the introduction of a pyridine ring would consistently lead to a more potent 
inhibitor, compound 121 was synthesized with a m-fluoro group instead of the m-methoxy 
(shown in red in Figure 2.15) since it was previously observed that this modification is well 
tolerated (Figure 2.13). Substitution of the thiophene with a pyridine ring did not improve the 
activity as expected, since 107 and 121 were equipotent. The compound 122 was designed to 
investigate whether an aromatic ring was necessary to maintain the activity or if an aliphatic 
group would be tolerated (Figure 2.15). Reaction of 1-cyanoacetyl-3,5-dimethylpyrazole (98) 
and hydroxypentanimidamide in dioxane failed to deliver the product, therefore the alkane 
derivative 122 was synthesized without the amino group using the conditions described in 
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Scheme 2.8. Introduction of the butyl group in place of the thiophene motif did not significantly 
affect the activity as 115 and 122 showed similar potency. The same conditions were used to 
synthesize the analog 124. Substitution with the sterically more demanding benzothiophene 
functionality (123) slightly improved the activity (Figure 2.15) relative to the triazole anolog 
115. 
 
Figure 2.15: Structure-activity relationship investigation of the miR-21 inhibitor 51 through modifications of the 
thiophene motif (variations to the original structure are shown in color). 
The numbers represent the activity relative to 51 within the same luciferase assay. Experiments were performed in 
triplicate and the standard deviations of the three independent assays were calculated. Cell-based assays were 
performed by Colleen Connelly. 
 
The SAR study of the lead compound 51 was encouraging given a few analogs with 
activities comparable to 51 (102, 103, 107, and 119) or even slightly higher (109, 111, 118, and 
120) were identified. A 20% and 16% increases in the potency were achieved with the inhibitors 
118 and 109, respectively. Next, the selectivity of the oxadiazole inhibitors was investigated 
based on the study of the hit compound 51. The oxadiazole 51 was tested at 10 μM in the miR-
122 assay. This compound did not show any effect on neither the Renilla nor the firefly signal 
(Figure 2.16A). The luminescence reads out were slightly lower for 51 than for the DMSO 
control due to some toxicity. These data indicated that 51 did not inhibit miR-122, and therefore 
is not a general inhibitor of the miRNA pathway. These data also suggested that the inhibitor 51 
does not stabilize the firefly enzyme, as no increase in FLuc was observed in the miR-122 assay 
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(Figure 2.16A). Given some oxadiazole containing compounds have been previously identified 
as FLuc inhibitors,
126
 the hit compound 51 and the most potent analogs of this series were tested 
in the in vitro FLuc assay to determine whether they affect the FLuc enzyme (Figure 2.16B). The 
analogs 103, 107, 118, 120, and 121 showed a moderate inhibition of the firefly luciferase 
enzyme as they reduced luminescence by 33-52%. The hit compound 51 only slightly modified 
the luciferase signal in the in vitro assay (Figure 2.16B). Since the furan and pyridine derivatives 
118 and 120 showed 33% FLuc inhibition, their high activity in the miR-21 luciferase assay 
might be due to stabilization of the firefly luciferase rather than true miR-21 downregulation. 
This also validates the decision to maintain the thiophene group on the majority of the analogs, 
as this motif seems less prone to induce FLuc stabilization. The selectivity of these derivatives 
for miR-21 inhibition should be further investigated. For example, the treatment of HeLa cells 
with the most promising oxadiazole inhibitors, followed by qRT-PCR measurement of the 
expression levels of several miRNAs will bring important knowledge regarding the selectivity 
profile of these compounds. 
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Figure 2.16: Evaluation of the selectivity of the oxadiazole miR-21 inhibitors. 
A. Dual Luciferase Assay of Huh7-psiCHECK-miR-122 cells treated with the hit compound 51 at 10 μM. The 
luciferase signal was normalized to a DMSO control. B. In vitro FLuc assay. The compounds (10 μM) were 
incubated for 30 min with the recombinant firefly luciferase enzyme and the luminescence was measured using a 
Bright glo assay (Promega). The data are relative to the DMSO control. Experiments were performed in triplicate 
and the standard deviations of the three independent assays were calculated. 
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2.3.4 Validation of Potential Aryl-amide miR-21 Inhibitors (53 & 54) 
The aryl-amide chemotype was found in several compounds identified in the HTS 
(Figure 2.4). The hit compounds 53 and 54 were re-synthesized to confirm their activity as miR-
21 inhibitors. They were both synthesized in three steps from commercially available starting 
materials (Scheme 2.9).  
 
Scheme 2.9: Synthetic route to the aryl-amide hit compounds 53 and 54. 
. 
For the synthesis of hit compound 53, the aminobenzofuran 124 was treated with 2-
methoxyacetyl chloride and pyridine in DCM,
136
 followed by hydrolysis of the ethyl ester (125). 
Treatment of the ester 125 with 2 equivalents of 2 M LiOH (lithium hydroxide) at rt in dioxane, 
with 2 M KOH in EtOH,
137
 or with 2 M LiOH at 60 °C in a mixture of THF/H2O were 
unsuccessful in delivering the expected acid 126. In fact, the heat caused the decomposition of 
the intermediate 125. The ester was successfully converted to the carboxylic acid 126 using 10 
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equivalents of NaOH in a mixture of MeOH/H2O at rt for 2 h (Scheme 2.9). Several different 
conditions were screened in order to perform the amide coupling reaction in the final step. Only 
starting material was recovered when the carboxylic acid intermediate 126 was treated with 1,4-
benzodioxan-6-amine in the presence of different peptide coupling reagents such as EDCI, 
DMAP, and TEA in DCM
138
 or HATU, DIPEA, and with/without HOBt in DMF. The coupling 
was also unsuccessful when the carboxylic acid 126 was heated to reflux with SOCl2 (thionyl 
chloride) for 1 h, followed by evaporation of the excess SOCl2 and subsequent reaction of the 
resulting acyl chloride with the amine in DCM. Finally, compound 53 was successfully obtained 
upon activation of 126 with phosphorus pentachloride at 0 °C, followed by treatment with 1,4-
benzodioxan-6-amine and pyridine in DCM (Scheme 2.9).
139
 
The synthesis of 54 started with the treatment of 5-(4-bromophenyl)-2-furoic acid (127) 
with SOCl2 at reflux for 1 h, followed by the reaction of the corresponding acyl chloride with 
methyl anthranilate and TEA in DCM. The resulting methyl-ester 128 was then converted to the 
carboxylic acid 129 after treatment with 10 equivalents of NaOH in a 1:1 mixture of MeOH/H2O 
at 40 °C for 1 h. The first failed attempt to compound 54 consisted in treating the acid 129 with 
oxalyl chloride in DCM and a catalytic amount of DMF, the resulting acyl chloride was taken up 
into CHCl3 (chloroform) and stirred in presence of a solution of aqueous ammonia.
140
 The next 
attempt relied in stirring the precursor 129 with TEA, EDCI, HOBt, and a solution of ammonium 
chloride in THF,
141
 and successfully delivered 54 in 75% yield (Scheme 2.9).  
Both re-synthesized hit compounds 53 and 54, as well as the precursors 128 and 129 were 
tested in the miR-21 luciferase assay by Colleen Connelly. Unfortunately the two aryl-amides 
identified in the HTS, 53 and 54, did not look very promising (Figure 2.17). Compound 53 
exhibited an activity 32% lower than the reference miR-21 inhibitor 24. Similarly, 54 showed a 
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38% reduced activity in comparison with 24. The methyl ester and carboxylic acid precursors 
(129 and 130) were completely inactive (Figure 2.17). Given the low activity of these small 
molecules in the miR-21 assay, it was chosen not to investigate them more thoroughly and 
moved on to the study of another aryl-amide hit compound identified in the HTS (Figure 2.4). 
 
Figure 2.17: Activities of re-synthesized hit compounds 53, 54, and intermediates 128 and 129 in the miR-21 assay. 
The numbers represent the activity relative to 24 within the same assay. Experiments were performed in triplicate 
and the standard deviations of the three independent assays were calculated. Cell-based assays were performed by 
Colleen Connelly. 
2.3.5 Validation of the Potential Aryl-amide miR-21 Inhibitor 55  
The additional aryl-amide hit compound 55 identified in the HTS was re-synthesized by 
Matt Stephens and tested in the miR-21 luciferase assay by Yuta Naro. Even though this 
inhibitor showed a 20% reduced activity compared to 24, it promoted a 36% increase in 
luciferase expression compared to DMSO (Figure 2.18), thus showing some potential miR-21 
inhibition. A structure-activity relationship investigation was conducted to try to improve the 
potency (modifications from the parent compound shown in green, blue, or red in Figure 2.18). 
Replacement of the bulky piperidine group with a smaller acetyl (130) or methoxy (131) group 
resulted in ~47% and ~65% increase in activity compared to the parent compound 55. Further 
modification of the meta position to a hydroxyl group (132) showed a more modest ~27% 
increase in activity, while complete removal of the meta substitution (133) completely abolished 
the activity. Very little change in activity was observed when an hydroxy group was introduced 
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in meta (134) or para (135) positions or upon removal of both substitutions (136). Interestingly, 
the 1,3-dihydroxy derivative (137) displayed a significant ~86% increase in activity. 
Replacement of a cyclohexene motif (132) with a cyclohexane (138) resulted in an ~57% 
increase in activity relative to 55, while replacement with a benzene ring (139) or loss of the ring 
entirely (140) abolished the activity. Surprisingly, removal of the meta-hydroxy associated with 
substitution of the p-methoxy to an ethyl ether (141), propyl ether (142), benzyl ether (143), or to 
a free amine (144) rescued the activity (Figure 2.18).  
Based on these observations, the p-methoxy was kept constant and modifications of the 
benzene motif were investigated. Increasing the size of the aliphatic linker by adding a carbon 
(145) resulted in a ~58% increase in activity compared to the parent compound 55, while further 
extending or shortening the linker by an additional carbon (146, 147) resulted in complete loss in 
activity. The introduction of 2-pyridine (148) resulted in a loss in activity, while modification 
with a naphthalene (149) or benzyl (150) groups partially recovered some activity. Completely 
removing the aliphatic linker (151) resulted in a gratifying ~103% increase in activity compared 
to 55 (Figure 2.18). Replacement of the benzene ring with a naphthalene (152), allyl (153) or 
free amino groups (154), led to reduced activities. Removal of the p-methoxy (155) from 151 
resulted in a loss in inhibition, while having a p-methoxy group on both benzene rings (156) 
induced an important ~152% increase in activity over the original hit compound 55. This SAR 
investigation led to the identification of four potent aryl amides miR-21 inhibitors (131, 137, 
151, and 156 (Figure 2.18). 
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Figure 2.18: Activity of re-synthesized hit compound 55 in the miR-21 assay and SAR investigation. 
Values represent percent change in luciferase signal normalized to cell viability and relative to DMSO control. Error 
calculated from the standard deviation of three independent measurements. Cell-based assays were performed by 
Yuta Naro and analogs were synthesized by Matt Stephens. 
 
The four most promising aryl-amide analogs were further investigated to assess their 
potency and selectivity towards miR-21 inhibition. Yuta Naro tested the four inhibitors in dose-
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response experiments using the miR-21 luciferase assay to calculate their EC50 values. 
Gratifyingly, 151 and 156, which promoted the largest increase in firefly luminescence (Figure 
2.18) were found to have EC50 values of 2.3 μM and 0.86 μM, respectively, which was 
comparable and even improved over the reference miR-21 inhibitor 24 (EC50 value of 2 μM). 
These inhibitors were tested in the miR-122 luciferase assay to determine their level of 
selectivity. Huh7-psiCHECK-miR122 cells were treated with the aryl-amide derivatives at 10 
μM for 48 h and the Renilla luciferase expression was measured using a Dual Luciferase Assay 
(Promega). None of these inhibitors affected the expression of Renilla luciferase, suggesting 
some degree of selectively for miR-21 regulation (Figure 2.19). 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
DMSO 55 131 137 151 156 
R
e
n
ill
a
 l
u
c
if
e
ra
s
e
 
 
Figure 2.19: Evaluation of the selectivity of the aryl-amide inhibitors 55, 131, 137, 151, and 156 in the miR-122 
assay. 
Dual Luciferase Assay of Huh7-psiCHECK-miR-122 cells treated with the hit compound 55 and the most promising 
analogs at 10 μM. The luciferase signal was normalized to a DMSO control. Experiments were performed in 
triplicate and the standard deviations of the three independent assays were calculated. 
 
To look more deeply into the selectivity of the aryl-amide inhibitors, the endogenous 
levels of three different miRNAs, in addition to miR-21, were measured by qRT-PCR after 
exposure to the compounds (Figure 2.20). HeLa cells were treated with the aryl-amide analogs 
131, 151, and 156 at 10 μM for 48 h. The total RNA for each sample was isolated using the 
miRNeasy kit (qiagen), the concentration was measured on a Nanodrop, and all the samples were 
diluted to the same concentration (8 ng/μL) before being reverse transcribed using the TaqMan 
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microRNA Reverse Transcription Kit (Life Technologies) in combination with the 
corresponding TaqMan RT primers for RNU19 (endogenous control), miR-21, miR-125b, miR-
17-5p, and miR-222 (Life Technologies). Quantitative Real Time PCR was conducted in 
triplicate for each RT reaction with the TaqMan 2x Universal PCR Master Mix and the TaqMan 
primers for RNU19 or the corresponding miRNAs on a CFX96 RT-PCR detection system 
(BioRad). Although, the derivative 131 did not show much inhibition, the aryl-amide 151 and 
156 significantly reduced the miR-21 levels by 43 and 61%, respectively (Figure 2.20A). In 
contrast, the expression levels of miR-125b, miR-17-5p, and miR-222 were barely affected by 
the exposure to the inhibitors (Figure 2.20A). These data and the luciferase data (Figure 2.19) 
suggest that these compounds may be selective miR-21 inhibitors and not general inhibitors of 
the miRNA pathway. 
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Figure 2.20: qRT-PCR measurements of miRNA expression levels after treatment with the potent aryl-amide miR-
21 inhibitors 131, 151, and 156. 
HeLa cells were exposed to the inhibitors at 10 M for 48 h. A. qRT-PCR of the intracellular levels of miRNAs 
miR-21, -125b, -17-5p, and -222. B. qRT-PCR of intracellular levels of pri-miR-21 after treatment with compounds 
at 10 M for 48 h. The data were normalized to a DMSO control and the error bars indicate the standard deviation 
determined from three independent measurements. 
 
The levels of primary pri-miR-21 were also measured by qRT-PCR after treatment with 
the compounds 131, 137, 151, and 156. In a similar way, HeLa cells were treated with the four 
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most potent aryl-amides at 10 μM for 48 h. The total RNA for each sample was isolated using 
the miRNeasy kit (qiagen), the concentration was measured on a Nanodrop, and all the samples 
were diluted to the same concentration (10 ng/μL) before being reverse transcribed using the 
iScript cDNA Synthesis kit (BioRad). Quantitative Real Time PCR was conducted in triplicate 
for each RT reaction with the TaqMan 2x Universal PCR Master Mix and the TaqMan primers 
for pri-miR-21 and the endogenous GAPDH control on a CFX96 RT-PCR detection system 
(BioRad). The levels of pri-miR-21 were normalized to the GAPDH control and the  
method was used to determine the pri-miR-21 expression change in the treated samples relative 
to the DMSO control. In contrast to compound 24, the aryl-amide inhibitors did not significantly 
modify the expression levels of pri-miR-21 (Figure 2.20B). These preliminary data suggest that 
the mechanism of action of these new inhibitors is fundamentally different from the mechanism 
of the previously discovered miR-21 inhibitor 24. The aryl-amide inhibitors 151 and 156 do not 
target miR-21 at the transcriptional level, but rather may target some downstream processes 
involved in the maturation of miR-21. Further studies into their mechanism will be performed. 
2.4 INVESTIGATION INTO THE MODE OF ACTION OF MIRNA INHIBITOR 51 
2.4.1 Recovery of Inhibition by Transfection of Precursor miR-21 
After studying a subset of the different chemotypes identified from the HTS (Figure 2.4), 
at least two new classes of inhibitors, the oxadiazole and the aryl-amide series based on 51 and 
156, respectively, delivered additional miR-21 inhibitors. The small molecule miR-21 inhibitors 
are therapeutically relevant as they can provide new lead structures for anticancer therapies, as 
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well as new probes to study the implication of miR-21 in the development of cancer. There are 
still a lot of unknowns to be discovered within the miRNA pathway and their participation in 
various diseases. Although there are some pieces of evidence showing that the oxadiazole 51 is a 
potent inhibitor of miR-21, nothing is known regarding its mechanism of action. Identifying the 
protein(s) specifically targeted by the small molecule miR-21 inhibitor 51 would not only 
increase the current knowledge but could also lead to potential new drug targets.  
As discussed in Chapter 1.5, the small molecule inhibitors can potentially interfere with 
different steps of the biogenesis of miRNA. First, the effect of inhibitor 51 on miR-21 maturation 
was evaluated. Colleen Connelly transfected HeLa-miR-21-Luc cells, which were engineered to 
stably express the miR-21 reporter construct, with precursor pre-miR-21 (Figure 2.21). If the 
small molecule 51 interferes with the mature miR-21, either at the unwinding step, at the RISC 
loading step, or with the association of the miR-21 with the mRNA, or if 51 prevents the 
processing of pre-miR-21 into miR-21, introduction of exogenous pre-miR-21 should alleviate 
the inhibitory effect of 51. Conversely, if the small molecule 51 acts at the transcriptional step, or 
blocks the processing of pri-miR-21, the exogenous pre-miR-21 should be processed properly 
through the miRNA pathway to produce mature miR-21. Transfection of HeLa-miR-21-Luc cells 
with xtremeGENE or precursor pre-miR-122 (used as a selectivity control) followed by exposure 
to DMSO did not have any effect on the luciferase expression; in comparison transfection with 
pre-miR-21 induced a 50% decrease in the firefly signal (Figure 2.21). This was due to the 
presence of additional mature miR-21, which further inhibited the translation of the firefly 
luciferase mRNA through binding to its target sequence. In the cells transfected with 
xtremeGENE (no precursor) or the control precursor pre-miR-122, treatment with the inhibitors 
24 and 51 led to 50% increase in firefly expression, due to the inhibition of miR-21 by the small 
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molecules. However, in the cells transfected with the precursor pre-miR-21, treatment with 24 
and 51 had virtually no effect on the luciferase expression compared to the DMSO control 
(Figure 2.21). This demonstrated that the precursor pre-miR-21 was correctly processed into 
mature miR-21, even in the presence of the small molecules 24 and 51, and suggested that the 
inhibitors act at the transcriptional or the pre-transcriptional step. If the compounds would inhibit 
the miR pathway post-transcriptionally, an increase in firefly expression would be expected, 
because the processing of the precursor into mature miR-21 would be blocked by the inhibitors.  
 
 
Figure 2.21: Recovery of the inhibitory activity of the miR-21 inhibitors 24 and 51 through transfection of a pre-
miR-21 precursor. 
A. Structure of the inhibitors 24 and 51. B. Bright Glo Luciferase assay of HeLa-miR-21-Luc cells transfected with 
the precursors pre-miR-21 or pre-miR-122 and treated with DMSO, 24, or 51 for 48 h. All experiments were 
conducted in triplicate and the data was normalized to the vehicle (xtremeGENE transfection reagent) control. The 
error bars indicate standard deviations determined from three independent experiments. Cell-based assays were 
performed by Colleen Connelly. 
2.4.2 Target Identification Experiments for the Oxadiazole Inhibitor 51 
Although the SAR studies of the hit compound 51 did not lead to the identification of a 
significantly more potent inhibitor, the knowledge collected during this investigation was very 
helpful in locating suitable positions where modifications were tolerated. In order to identify the 
cellular target of the inhibitor 51, it was first opted to isolate the target protein via affinity-
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purification  (Figure 2.22).
142
 This method relies on the attachment of the inhibitor “active pull-
down probe” to a resin support. The cells are lysed and the cellular extract is incubated with the 
functionalized resin. This step is followed by a series of washes, elution of the target protein with 
free inhibitor, analysis by SDS-PAGE, and after excision from the gel, the protein is digested and 
analyzed by mass spectrometry to identify its identity (Figure 2.22). Some proteins might 
interact with the resin or the linker non-specifically and contrary to the unbound proteins, they 
might not be totally removed during the washing steps. That’s why in addition to functionalizing 
the resin with an active ligand, the resin is also commonly modified with an inactive but 
structurally similar analog. That way the non-specific proteins appear on both “active” and 
“inactive” lanes on the gel, while the target protein is only visible on the active lane (Figure 
2.22).
143
  
 
Figure 2.22: Representation of the affinity chromatography approach to target identification. 
The active ligand (L) or a structurally similar inactive analog (A) are immobilized on a resin (shown in gray). The 
resin is incubated with cell lysate containing the target protein (T) and non-specific proteins (shown in green and 
yellow). Unbound proteins (shown in blue) are removed through a series of washes. The target protein is eluted by 
incubation of the resin with an excess of the unmodified active compound and separated by SDS-PAGE. The target 
protein is excised from the gel, digested, and finally analyzed by mass spectroscopy. Adapted from Chem. Biol. 17, 
Sato, S.; Murata, A.; Shirakawa, T.; Uesugi, M.; Biochemical Target Isolation for Novices: Affinity-Based 
Strategies, 616. Copyright (2010), with permission from Elsevier.  
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In order to isolate the target protein of 51 via affinity-purification, a nucleophilic handle 
needed to be introduced in the molecule to allow further attachment to a resin. Modification of 
the para position (158) with the hydroxymethylene group was well tolerated, while 
modifications of the meta (157) or ortho (159) positions led to 67% and 38% reduction in 
activity, respectively (Figure 2.23). To efficiently pull-down the target protein, it is important 
that the protein retains its affinity for the modified probe.
143
 For example, attachment to the resin 
might block the approach of the protein or display the ligand in a conformation not anymore 
recognized by the protein. To address this concern, 160 was synthesized that contains a short 
PEG-linker (Figure 2.23). The introduction of a small linker was not tolerated as 160 suffered a 
53% loss in activity. 
 
 
Figure 2.23: Structural modifications of the miR-21 inhibitor 51 aimed at identifying a probe suitable for affinity 
purification (variations to the original structure are shown in red). 
The numbers represent the activity relative to 51 within the same miR-21 luciferase assay. All assays were 
conducted in triplicate and the error represents the standard deviation from the three independent experiments. Cell-
based assays were performed by Colleen Connelly. 
 
To synthesize the analog 160, the aniline 161 was protected with a Boc protective group. 
The phenol 162 was alkylated with the short PEG linker after being heated to 60 °C in the 
presence of Cs2CO3 and 163 in DMA (dimethylacetamide). The corresponding product 164 was 
treated with 4 M HCl (hydrochloric acid) in dioxane to remove the protective group, and 
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subsequently treated with NaNO2 and NaN3 to afford the azide 166 (Scheme 2.10). 
Unfortunately, coupling of 166 with the nitrile derivative 99 failed to deliver the expected 
product. It was then decided to introduce the PEG linker directly on compound 112 using similar 
alkylation conditions with Cs2CO3 and DMA (Scheme 2.10).  
 
 
Scheme 2.10: Conditions tested to synthesize the pegylated-oxadiazole 160. 
 
Since 160 displayed a low activity, it did not seem that the affinity-purification would be 
successful in isolating the target protein. A different strategy, based on the photo-crosslinking 
method, was therefore envisioned. In this method a slight decrease in potency is more tolerated 
than in a pull-down experiment due to the formation of a covalent bond between the inhibitor 
and its target (Figure 2.24). To apply this strategy the inhibitor must be functionalized with two 
orthogonal motifs: 1) It must bear one photo-crosslinking group such as a diazirine, an aryl-
azide, or a benzophenone group, which is capable of forming a covalent bond with the nearby 
target protein after a brief UV irradiation.
144
 2) An alkyne functionality is often introduced in 
order to add a fluorescent tag to the small molecule/protein complex via click reaction. Once 
such a modified compound is available, it is important to verify that these modifications do not 
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abolish the activity of the inhibitor. The cells (or cell lysate) are incubated with the inhibitor for a 
few hours, then exposed to UV light for a few minutes. After lysis of the cells, a click reaction is 
carried out to introduce a fluorophore or biotin tag to the probe/protein complex, in order to 
facilitate the subsequent analysis of the protein. After the click reaction, the cell lysate is 
analyzed by SDS-PAGE, from where the band corresponding to the target protein can be excised 
and further analyzed by mass spectrometry (Figure 2.24). 
 
 
Figure 2.24: Schematic of the photo-crosslinking strategy to identify the target protein of 51. 
The inhibitor (I) is functionalized with an alkyne and a photo-probe (P). It is then incubated with live cells, and 
covalently linked to its target protein(s) upon UV irradiation. Following click reaction with an azido-fluorophore 
(F), the lysate is analyzed by SDS-PAGE and the target protein(s) can be easily detected when imaging for 
fluorescence. Adapted with permission from J. Am. Chem. Soc. 2012, 134, 3001. Copyright 2012 American 
Chemical Society. 
 
The inhibitor 51 was then modified with an alkyne or a benzophenone functionality to 
determine the feasibility of the photo-crosslinking method. Replacement of the m-methoxy (51) 
with m-propargyl (167) led to a slight increase in activity, whereas modification with a 
benzophenone in meta (168) or ortho (170) positions resulted in a 20% decrease in activity 
(Figure 2.25). Surprisingly, para substitution (169) could be well accommodated as very little 
change in activity was observed. Keeping the benzophenone in meta (171) or para (172) 
positions, an alkyne motif was introduced in place of the thiophene ring (Figure 2.25). 
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Gratifyingly these two photo-crosslinking probes still showed a good inhibition of miR-21, their 
activity was increased by 24% and 5%, respectively for 171 and 172, compared to the parent 
compound 51. Extension of the alkyne linker by four additional carbons (173) negatively 
affected the activity. 
 
 
 
Figure 2.25: Structural modifications of the miR-21 inhibitor 51 aimed at identifying a probe suitable for photo-
crosslinking (variations to the original structure are shown in red and blue). 
The numbers represent the activity relative to 51 within the same miR-21 luciferase assay. All assays were 
conducted in triplicate and the error represents the standard deviation from the three independent experiments. Cell-
based assays were performed by Colleen Connelly. 
 
The analogs 167-170 were synthesized following the protocol described in Scheme 2.6 
from the corresponding azides (95) and the intermediate 99. The derivatives 171 and 172 were 
obtained using very similar conditions (Scheme 2.11). The alkylation of 4-hydroxybenzonitrile 
(174) with propargyl bromide and Cs2CO3 at 50 °C in acetone quantitatively delivered 175. The 
nitrile 175 was then treated with Na2CO3 and H2NOHHCl to provide the hydroxamine 176 in 
94% yield. This intermediate was condensed with 98 to form the oxadiazole precursor 177, 
which was treated with the corresponding azides (178) to yield the probes 171 and 172 (Scheme 
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2.11). Similarly, 173 was obtained upon reaction of the azido-benzophenone 178 and the 
precursor 182. The oxadiazole intermediate 182 was synthesized in three steps, starting from a 
Mitsunobu reaction between 4-hydroxybenzonitrile and the alcohol 179, followed by treatment 
with Na2CO3 and H2NOHHCl to form the hydroxamine 181. The precursor 181 was then heated 
to reflux with 98 to deliver 182 in moderate yield (Scheme 2.11). 
 
Scheme 2.11: Synthetic route to photo-crosslinking probes 171-173. 
 
Since the analogs 167, 169, and 171 showed satisfactory activity in the miR-21 luciferase 
assay, being comparable or slightly more potent than 51, they were further tested in the in vitro 
FLuc assay. The less potent photoprobe 173 was also evaluated. None of these compounds 
inhibited the enzyme (Figure 2.26), which suggested that they display miRNA inhibition activity, 
and confirmed that they represent promising probes to investigate the mode of action of 51. 
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Figure 2.26: In vitro FLuc assay of the oxadiazole photoprobes. 
The compounds 167, 169, 171, and 173 (10 μM) were incubated for 30 min with the recombinant firefly luciferase enzyme and 
the luminescence was measured using a Bright glo assay (Promega). The data are relative to the DMSO control (1%). Three 
independent assays were averaged and error bars represent standard deviations. 
 
The synthesis of the aryl-azide probe 188 was also undertaken. 4-Aminobenzonitrile was 
treated with NaNO2 and NaN3 to form the azide 184. Different conditions were tested to 
synthesize 185 because the treatment with Na2CO3 and H2NOHHCl, which was previously 
employed to obtain hydroxamine intermediates, failed to deliver the expected product. Instead, 
the nitrile 184 was heated to 50 °C in the presence of H2NOHHCl and a large excess of NMP 
(N-methylmorpholine). The intermediate 185 was then condensed with 98 to give the oxadiazole 
186 in 79% yield. Although some of the expected azide 188 could be obtained after the cyclic 
addition of 186 and 187 (Scheme 2.13), it was contaminated with some impurities. In order to 
test and use the probe 188 in cell-based experiments different purification methods, such as 
trituration in DCM or hexanes and column chromatography, were tried to improve the purity of 
188 but did not afford any pure compound. Given three interesting photo-crosslinking probes 
(171-173) were obtained, it was decided to test those in target identification experiments and to 
consider a different approach to the azide 188 only if the benzophenone probes failed to 
selectively react with the target protein. 
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Scheme 2.12: Attempted synthesis of the azide photo-crosslinking probe 188. 
 
In the aim of facilitating the detection of the target protein(s), a fluorescein-azide was 
synthesized that could be introduced into the probe/protein complex via click reaction (Figure 
2.24). 1,6-Dibromohexane was treated with NaN3 to form 1,6-diazidohexane (189), and then a 
Staudinger reaction was carried out to reduce one azido group to the corresponding free amine 
190.
145
 Fluorescein isothiocyanate was stirred overnight with DIPEA and 190 in DMF to deliver 
the azide 191 in 71% yield (Scheme 2.13). 
 
 
Scheme 2.13: Synthesis of the fluorescein-azide 191. 
 
 
Following the synthesis, the photo-crosslinking probes 171 and 173 were tested in live 
cell experiments by adapting a similar approach previously reported.
146
 HeLa cells were treated 
with the inhibitors 171 and 173 (10 M, 0.5% DMSO) or with DMSO (0.5%) for 16 h. The 
media was removed and the cells were quickly washed with 1 mL of PBS. The cells were 
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irradiated at 365 nm for 10 min, trypsinized, and pelleted by centrifugation. The proteins were 
extracted with 50 L mammalian protein extraction buffer (GE healthcare) followed by 20 min 
incubation on ice, 5 min vortex, and 30 min centrifugation at 4 °C. The supernatant was 
extracted and the amount of proteins was determined using a Bradford assay. After dilution of 
each sample to the same concentration in PBS, the click reaction was performed with the 
fluorescein-azide (191), TCEP (tris(2-carboxyethyl)phosphine), copper (II) sulfate, and TBTA 
(tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) for 2 h at room temperature. The final 
concentration of the fluorescein-azide was optimized to achieve successful labeling. After the 
click reaction an acetone precipitation was performed to remove the excess click reaction 
reagents, the proteins were re-suspended in PBS and analyzed by SDS-PAGE (Figure 2.27). 
Unfortunately, these experiments were not successful as the same fluorescently-labeled proteins 
were observed in lanes 3, 4, and 5 (Figure 2.27). In lane 3, the cells were only treated with 
DMSO (no alkyne-containing probe), therefore no fluorescently-tagged proteins were expected. 
These data suggest that the fluorescein-azide might non-specifically react with cellular 
components. In the future, to successfully detect the target protein the experimental design will 
need to be optimized, for example different UV irradiation times could be tested, the click 
reaction might be performed under denaturing conditions, and a different fluorophore probe 
could be synthesized. 
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Figure 2.27: Example of a 12% SDS-PAGE of protein samples isolated from HeLa cells treated with the 
photoprobes 171 and 173 or the negative control DMSO, and labeled with the fluorescein-azide. 
Lanes 1 & 2: Ladder, Lane 3: DMSO (0.5%), Lane 4: 171 (10 M, 0.5% DMSO), Lane 5: 173 (10 M, 0.5% 
DMSO). A. The gel was imaged on a ChemiDoc using the filter for FITC. B. The gel was non-specifically stained 
with coomassie blue. 
 
2.5 THERAPEUTIC EVALUATION OF THE SMALL MOLECULE MIR-21 
INHIBITORS IN LIVER CANCER CELLS 
Hepatocellular carcinoma (HCC) is a primary cancer of the liver and is the third leading 
cause of cancer-related death worldwide.
147
 Major risk factors include obesity, diabetes, and in 
80% of cases infection with hepatitis B or C virus.
148
 HCC is largely insensitive to most 
chemotherapeutics, only a few kinase inhibitors, such as sorafenib, help improving patients 
overall survival and reducing disease recurrence after surgery. However, metastasis and 
recurrence are still very common in 30-40% of cases.
147
 The majority of patients are diagnosed at 
late stages of the diseases due to a lack of reliable biomarkers.
147
 The molecular mechanisms 
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responsible for the pathogenesis of HCC have not been elucidated yet but would be of 
tremendous value in order to improve the diagnosis of HCC and find more effective treatments.  
Some studies have recently linked miRNA misregulation with HCC. For example, the 
liver specific miR-122 is greatly downregulated in HCC cells; where it was shown to target 
Cyclin G1 (CCNG1) and the Bcl-2-family member Bcl-w, which results in chromosomal 
instability and enhanced anti-apoptotic activity.
149
 Not surprisingly, miR-21 was found to be 
highly overexpressed in HCC cell lines compared to normal liver cells.
148
 miR-21 was 
demonstrated to participate in the development of HCC, in part by repressing the tumor 
suppressor PDCD4,
150
 and by suppressing both PTEN and human sulfatase-1 (hSulf-1), which 
leads to the activation of the AKT/ERK pathway.
151
 Constitutive activation of the AKT pathway, 
reported in more than 40% cases of HCC, plays a critical role in the formation of metastasis and 
in drug-resistance.
152
 Transfection with an AMO anti-miR-21 in various HCC cell lines was 
shown to promote significant reductions in cell viability.
148, 151
 Interestingly, a recent study 
showed that the naturally occurring indole-3-carbinol (21, Figure 1.4) reduces the growth and 
clonogenic survival of HCC cell lines, via direct inhibition of miR-21, miR-221, and miR-222. 
Treatment of SNU-449 HCC cell lines with 200 M indole-3-carbinol for 48 h elicited a 50% 
reduction in cell viability.
152
 These results suggest that inhibiting miR-21 alone, or in 
combination with known drugs, represent a potentially attractive avenue to new HCC therapies. 
Based on these observations, the ability of the miR-21 inhibitors 24 and 51 at promoting 
the death of HepG2 HCC cells was tested. HepG2 cells were treated with increasing 
concentrations of the compounds and incubated for 48 h, followed by measurement of cell 
viability using a CellTiter Glo assay (Promega). This luminescent assay measures the reduction 
in ATP levels, which correlates with the presence of metabolically active live cells. A dose-
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dependent reduction of the cell viability was observed after treatment with either inhibitor 
(Figure 2.28). It is noteworthy that at a concentration of 50 M, the inhibitors 24 and 51 
displayed a 50% and 66% decrease in cell viability, respectively. This compares favorably with 
what was found with the natural product indole-3-carbinol and suggests that miR-21 inhibitors 
are effective at inducing apoptosis in HCC cells. 
 
Figure 2.28: Cell viability assay of HepG2 cells treated with the miR-21 inhibitors 24 and 51. 
HepG2 cells were exposed to increasing concentrations of the inhibitors for 48 h and the cell viability was measured 
with a CellTiter Glo assay (Promega). The data were normalized to a non-treated control, and some cells were 
treated with 1 M HCl for 1 h as a positive control for cell death. All assays were conducted in triplicate and the error 
represents the standard deviation from the three independent experiments. 
 
HepG2 cells that were transfected with a miR-122 overexpressing vector and treated with 
the anti-HCC reference drug sorafenib exhibited a significant reduction in cell viability, as well 
as a 35% increase in apoptosis, compared to sorafenib only exposed cells.
153
 Given the scarcity 
of therapeutic agents for HCC and the poor efficacy of the available ones due to intrinsic drug-
resistance,
154
 there is an urgent need to identify new therapeutic approaches or combination 
therapies to improve patient outcome. In the future, it will be interesting to investigate the 
therapeutic potential associated with the co-treatment of HCC cells with the small molecule miR-
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122 activator (31) and sorafenib, a small molecule miR-21 inhibitor (24 or 51) and the miR-122 
activator 31, or sorafenib with a small molecule miR-21 inhibitor (24 or 51). 
2.6 SUMMARY AND OUTLOOK 
Analogs of the previously identified miR-21 inhibitor 24 were synthesized to further 
improve its potency and replace the diazo linkage with more stable bonds. To that aim, four 
analogs were synthesized which introduced an amide bond in place of the diazo motif, but none 
of them showed noticeable improvements in activity.  
Several hit compounds from a miR-21 high-throughput screen were re-synthesized and 
investigated through the synthesis and testing of analogs. Some of these re-synthesized hits did 
not show any activity in the miR-21 luciferase assay; as it was the case with the aryl-amides 53 
and 54 and the ether-amides 47 and 48. Five analogs of 47 were quickly synthesized in the hope 
to rescue some activity but since none of them showed any promising increase in luciferase 
expression in the miR-21 assay, this series was not pursued any further.  
Even though the re-synthesized N-acylhydrazone hit compounds 49 and 50 were not very 
active, a few promising analogs were identified through preliminary SAR investigation (thirteen 
analogs total were synthesized). The best hydrazone derivatives 78 and 84 were subjected to 
secondary assays to investigate their selectivity. Although they had no effect on the expression of 
miR-122, they downregulated miR-21, -20a, -24, and -27b to the same extent, suggesting they 
are not selective towards miR-21 inhibition. Their selectivity profile would need to be further 
investigated via large scale profiling of miRNAs. 
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The re-synthesized oxadiazole hit compound 51 showed an encouraging 40% increase in 
activity compared to the reference inhibitor 24. An SAR study was conducted via the synthesis 
of 34 analogs, where a few compounds were identified that displayed a comparable or slightly 
improved activity over 51. Preliminary data indicated that the oxadiazole 51 targets miR-21 at a 
transcriptional or pre-transcriptional step. Different strategies have been attempted to identify the 
cellular target of 51. Some efforts went into the synthesis of several photo-crosslinking probes, 
which exhibited the same level of activity as 51, and will be used to isolate the target protein(s). 
The last series of compounds studied was based on the hit aryl-amide 55. In total, 28 
analogs were synthesized (by Matt Stephens) that led to the identification of four promising 
inhibitors (131, 137, 151, and 156). These compounds displayed a high level of selectivity for 
miR-21, and in contrast to the other miR-21 inhibitors discovered 24 and 51, they seem to target 
downstream processes of miR-21 maturation. A more thorough investigation of their mode of 
action should be performed in the future. 
miR-21 is a known oncomiR, which is highly expressed in almost all types of cancer. 
miR-21 inhibition has been shown to help inducing apoptosis, decreasing cell proliferation, and 
increasing the sensitivity of common chemotherapeutic agents.
104
 The small molecule miR-21 
inhibitors 24 and 51 induced a >50% decrease in cell viability of HepG2 cells at 20 M. Further 
studies will investigate the therapeutic potential of the combination treatment of small molecule 
miR-21 inhibitors with either the small molecule miR-122 activator 31, or known anticancer 
agents, specifically with sorafenib in HCC cells. 
In conclusion, new small molecule miR-21 inhibitors were developed, which represent 
powerful tools to investigate miR-21 biogenesis, as well as miR-21 participation in 
carcinogenesis. More importantly, these small molecule miR-21 inhibitors provide new agents to 
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study the benefit of combination therapies and could aid in the development of new anticancer 
therapeutics. 
2.7 EXPERIMENTALS 
Cell culture. Experiments were performed using the HeLa cell line cultured in Dulbecco’s 
Modified Eagle Medium (DMEM; Hyclone) supplemented with 10% Fetal Bovine Serum (FBS; 
Seradigm premium grade, Lot #093B13) and 2% penicillin/streptomycin (VWR) and maintained 
at 37 °C in a 5% CO2 atmosphere. Huh7-psiCHECK-miR122 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM; Hyclone) supplemented with 10% fetal bovine serum (FBS; 
Seradigm premium grade, Lot #093B13), 500 μg/mL of G418 (Sigma Aldrich), and 2% 
penicillin/streptomycin (VWR) and maintained at 37 °C in a 5% CO2 atmosphere. HepG2 cells 
were cultured in Eagle’s Minimum Essential Medium (Hyclone) supplemented with 10% FBS 
(VWR), 2% streptomycin/ampicillin (VWR), and 0.5 mM sodium pyruvate and maintained at 37 
°C in a 5% CO2 atmosphere.  
 
Assessment of the selectivity of the small molecule miR-21 inhibitors. Huh7-psiCHECK-
miR122 cells (a stably transfected line harboring a miR-122 binding sequence in the 3 UTR of a 
Renilla luciferase gene)
124
 were seeded at a density of 5,000 cells per well in white, clear-bottom, 
384-well plates (Greiner). After an overnight incubation in media (DMEM, 10% FBS, free of 
antibiotics and free of G418, 45 L), the cells were treated with compounds at a concentration of 
10 M (addition of 5 L of a 0.1 mM solution stock in 1% DMSO) or a DMSO control (0.1% 
DMSO final concentration) in triplicate. The cells were incubated for 48 h followed by analysis 
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with a Dual Luciferase Reporter Assay Kit (Promega) using 20 L passive lysis buffer and 25 
L of each luciferase reagent. The luminescence was measured on a Tecan M1000 platereader 
with a measurement time of 1 s and a delay time of 2 s. All experiments were performed in 
triplicate, for each well the Renilla luciferase read out was normalized to the firefly luciferase 
read out, and the average for each sample was further normalized to the DMSO control. 
 
Quantitative real time PCR analysis. Hela cells were seeded at a density of 100,000 cells per 
well in 6-well plates, grown overnight, and treated with compounds at 10 μM (20 μL of a 1 mM 
DMSO stock in 1980 μL media) or with DMSO (1% final DMSO concentration). The cells were 
incubated at 37 °C for 48 h (DMEM, antibiotics-free, 5% CO2). The media was removed, and 
cells were washed with PBS buffer (1 mL, pH 7.4) followed by RNA isolation with the 
miRNeasy mini kit (Qiagen) according to the procedure described in the appendix 6.2. The RNA 
was quantified using a Nanodrop ND-1000 spectrophotometer, and 40 ng of each RNA sample 
were reverse transcribed using the TaqMan microRNA Reverse Transcription Kit (Life 
Technologies) in conjunction with the RNU19 (control) or one of the miR-21, miR-125b, miR-
222, miR-17-5p TaqMan RT primer (16 °C, 30 min; 42 °C, 30 min; 85 °C, 5 min, 5 μL RNA per 
15 μL reaction). Quantitative real time PCR was carried out with a TaqMan 2x Universal PCR 
Master Mix and the appropriate TaqMan miRNA assay (Life Technologies) on a BioRad CFX96 
RT-PCR thermocycler (1.3 μL RT PCR product; 95 °C, 10 min; followed by 40 cycles of 95 °C, 
15 s; 60 °C, 60 s). The triplicate threshold cycles (Ct) obtained for each small molecule treatment 
were used to determine the relative levels of miR-21 in small molecule treated cells relative to 
the DMSO control using the  method.
155
 The samples were also analyzed by qRT-PCR to 
measure the expression levels of pri-miR-21. After RNA isolation, 50 ng of each RNA sample 
were reverse transcribed using the iScript cDNA synthesis kit (BioRad) (25 °C, 5 min; 42 °C, 30 
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min; 85 °C, 5 min, 20 μL reaction). Quantitative real time PCR was conducted with a TaqMan 
2x Universal PCR Master Mix and the appropriate TaqMan primers for hsa-pri-miR-21 or the 
endogenous control GAPDH (Life Technologies) on a BioRad CFX96 RT-PCR thermocycler (2 
μL RT PCR product; 95 °C, 10 min; followed by 40 cycles of 95 °C, 15 s; 60 °C, 60 s). The 
triplicate threshold cycles (Ct) obtained for each small molecule treatment were used to 
determine the relative levels of pri-miR-21 in small molecule treated cells relative to the DMSO 
control and normalized to the GAPDH control using the  method. 
 
Cell viability assay. HepG2 cells were passaged into a 96-well plate at 15,000 cells/well in 98 
L media, and were grown overnight. The cells were treated with DMSO or the small molecules 
at a range of concentrations (0.5-50 μM) (1% final DMSO concentration, by addition of 2 L 
compound dilution in 50% DMSO) in triplicate. The cells were incubated at 37 °C for 48 h and 
were then assayed for viability using a Cell Titer Glo assay (Promega). An equal volume of Cell 
Titer Glo reagent (100 μL) was added to the media, the plate was shaken for 2 min to lyse the 
cells, and incubated in the dark at rt for 10 min. The luminescence was recorded on a microplate 
reader (Tecan M200). The percent cell viability relative to the DMSO control, where DMSO 
represents 100% viability, was calculated for each of the triplicates, the data was averaged, and 
standard deviations were calculated. 
 
Target identification experiments for the miR-21 inhibitor 51. HeLa cells were passaged into 
10 cm plates and were grown to 80% confluency. The media was removed and the cells (in 9.95 
mL DMEM media, antibiotics-free) were treated with either DMSO (50 L; 0.5% DMSO final 
concentration), or the small molecule probes 171 and 173 (10 M, 50 μL of 2 mM DMSO stock) 
and incubated overnight at 37 °C. After an overnight incubation at 37 °C, the media was 
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removed, the cells were washed with PBS (1 mL), and irradiated in PBS (5 mL) on a 
transilluminator (365 nm, 25 W, UVP TFML-20) for 10 min. The PBS was removed, 
mammalian protein extraction buffer (1 mL, GE Healthcare) was added, the plates were shaken 
while kept on ice for 10 min, the cells were detached by pipetting them up and down, transferred 
to a microcentrifuge tube, and pelleted by centrifugation at 12,000 x g for 20 min at 4 °C. The 
supernatants were collected, the protein concentrations were determined with a Bradford assay 
(absorbance measured at 595 nm on a Tecan M1000), and an equal amount of proteins (100 μg) 
for each sample was treated with 33 μL of freshly prepared “click reaction cocktail”146 
containing the fluorescein-azide 191 (see the appendix 6.3.1 for the recipe of cocktail). The click 
reaction was performed at room temperature for 2 h. The proteins were subsequently isolated via 
acetone precipitation, 600 L of prechilled acetone was added into the click reaction mixtures, 
which were then incubated for 60 min at −20 °C. The proteins were pelleted by centrifugation 
(13,000 x g for 10 min at 4 °C), the supernatants were discarded and the pellets were washed 
twice with prechilled MeOH (200 μL, 4 min centrifugation at 10,000 x g) and finally air dried at 
rt for 10 min. The pellets were re-suspended in PBS (40 μL), denaturing loading dye (5x) was 
added (10 μL) and the samples were heated to 95 °C for 5 min. The samples (40 μL) were then 
analyzed by a 12% SDS-PAGE (4% stacking gel) at 60 V for 30 min followed by 150 V for 90 
min. The fluorescence was detected on a ChemiDoc (BioRad, setting: Filter 4: 530/28 nm, light: 
blue epi illumination).  
 
Synthetic protocol 
All reactions were performed in flame-dried glassware under a nitrogen atmosphere and stirred 
magnetically. Reactions were followed by thin layer chromatography (TLC) using glass-backed 
silica gel plates (Sorbent technologies, 250 µm thickness). Tetrahydrofuran and DCM were 
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obtained from a dry solvent delivery system. MeCN, EtOH, MeOH and pyridine were distilled 
from calcium hydride and stored over 4 Ǻ molecular sieves. Other reagents and solvents were 
obtained from commercial sources (Sigma, VWR, Fisher, Accros), stored under nitrogen and 
used directly without further purification. Yields refer to pure compounds unless otherwise 
stated. Flash chromatography was performed on silica gel (60 Å, 40-63 μm (230 × 400 mesh), 
Sorbtech) as a stationary phase. High resolution mass spectral analysis (HRMS) was performed 
at the University of Pittsburgh. The 
1
H NMR and 
13
C NMR spectra were recorded on a 300 MHz 
or a 400 MHz Varian or Brucker NMR spectrometers. Chemical shifts are given in δ units (ppm) 
for NMR spectra. 
Synthesis of analogs 38-41 
Methyl 4-(phenylcarbamoyl)benzoate (43). TEA (2.8 ml, 20.12 mmol) was added to a solution 
of aniline (0.55 ml, 6.04 mmol) in DCM (10 ml) at 0 °C. The reaction mixture was stirred at 0 °C 
for 10 min and terephthalic acid monomethyl ester chloride (42) (1 g, 5.03 mmol) was added. 
The resulting mixture was slowly allowed to warm up to rt and stirred for 4 h. The solution was 
slowly neutralized with 1 M HCl (2 mL) and H2O (20 mL) was added. The aqueous layer was 
extracted with DCM (2 x 15 mL). The combined organic layers were washed with H2O (3 x 12 
mL) and brine (8 mL). The organic layers were combined, dried with Na2SO4, filtered, and 
concentrated delivering 43 as a white solid (990 mg, 77%) that was used without further 
purification. 
1
H NMR (300 MHz, chloroform-d)  8.15 (d, J = 8.5 Hz, 2H), 7.91 (d, J = 8.6 Hz, 
2H), 7.89 (s, 1H), 7.64 (d, J = 7.6 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.20 (t, J = 7.5 Hz, 1H), 3.95 
(s, 3H). The analytical data matched literature reports.
156
 
 
4-(Phenylcarbamoyl)benzoic acid (44). A solution of the ester 43 (50 mg, 0.19 mmol) in 
MeOH (0.5 ml) was added to a solution of potassium hydroxide (33 mg, 0.59 mmol) in H2O (0.2 
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ml). The resulting mixture was stirred under reflux for 1 h. After allowing the mixture to cool to 
room temperature, H2O (5 ml) was added and the aqueous solution was washed with EtOAc (4 
ml). The aqueous layer was acidified with 1 M HCl until pH  3 and extracted with Et2O (3 x 6 
mL). The organic layers were combined, dried with Na2SO4, filtered, and concentrated to deliver 
44 as a white solid (44 mg, 97%) that was used without further purification. 
1
H NMR (300 MHz, 
DMSO-d6)  10.37 (s, 1H), 8.03 (t, J = 2.4 Hz, 4H), 7.75 (d, J = 7.5 Hz, 2H), 7.34 (t, J = 7.5 Hz, 
2H), 7.15 (t, J = 7.5 Hz, 1H). 
 
N
1
-Phenyl-N
4
-(prop-2-yn-1-yl)terephthalamide (38). EDCI (66 mg, 0.34 mmol) and HOBt (28 
mg, 0.21 mmol) were added to a solution of 44 (45 mg, 0.19 mmol) in DCM (0.6 mL). The 
mixture was stirred at rt for 40 min, propargylamine (0.026 ml, 0.38 mmol) was added, and 
stirring was continued at rt overnight (ON). The reaction mixture was poured into H2O (4 ml) 
and extracted with DCM (3 x 5 mL). The combined organic layers were washed with saturated 
NaHCO3, brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with 5% MeOH:DCM to give 38 as a brown solid (8 mg, 
19%). 
1
H NMR (300 MHz, DMSO-d6)  10.34 (s, 1H), 9.09 (s, 1H), 8.04 - 7.98 (m, 4H), 7.76 
(d, J = 7.5 Hz, 2H), 7.35 (t, J = 7.2 Hz, 2H), 7.10 (t, J = 7.5 Hz, 1H), 4.08 - 4.05 (m, 2H), 3.15 - 
3.13 (m, 1H). HRMS (ESI
+
) calcd for C17H14N2O2 (M+Na)
+
 301.2950, found 301.0956. 
 
N-Benzyl-N-phenylterephthalamide (39). Same procedure as 38 using benzylamine (39 mg, 
0.37 mmol) as the starting material. The residue was purified by flash chromatography on silica 
gel, eluting with 5% MeOH:DCM to give 39 as a white solid (11 mg, 19%). 
1
H NMR (300 MHz, 
DMSO-d6)  10.34 (s, 1H), 9.19 - 9.17 (m, 1H), 8.02 - 7.98 (m, 3H), 7.76 (d, J = 7.5 Hz, 2H), 
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7.37 - 7.22 (m, 7H), 7.10 (t, J = 7.5 Hz, 1H), 4.48 - 4.41 (m, 2H). HRMS (ESI
+
) calcd for 
C21H18N2O2 (M+Na)
+
 353.3696, found 353.1269. 
 
Methyl 4-(prop-2-yn-1-ylcarbamoyl)benzoate (45). Same procedure as 43 using terephthalic 
monomethyl ester chloride (500 mg, 2.5 mmol) and propargyl amine (0.194 ml, 3.02 mmol) as 
the starting materials. The compound 45 was obtained as a yellow solid (517 mg, 95%) that was 
used without further purification. 
1
H NMR (300 MHz, DMSO-d6)  9.18 (s, 1H), 8.02 (d, J = 6.6 
Hz, 2H), 7.96 (d, J = 6.5 Hz, 2H), 4.06 - 4.02 (m, 2H), 3.86 (s, 3H), 3.14 (s, 1H). 
 
4-(Prop-2-yn-1-ylcarbamoyl)benzoic acid (46). Same procedure as 44 using 45 (50 mg, 0.23 
mmol) as the starting material. The compound 46 was obtained as a white solid (38 mg, 84%) 
that was used without further purification. 
1
H NMR (300 MHz, DMSO-d6)  9.18 (s, 1H), 7.98 
(d, J = 6.6 Hz, 2H), 7.93 (d, J = 6.5 Hz, 2H), 4.06 - 4.02 (m, 2H), 3.14 (s, 1H). 
 
N-(4-Iodophenyl)-N-(prop-2-yn-1-yl)terephthalamide (41). HATU (273 mg, 0.72 mmol) and 
4-iodoaniline (65 mg, 0.29 mmol) were added to a solution of 46 (50 mg, 0.24 mmol) and 
DIPEA (0.25 ml, 1.44 mmol) in DMF (0.3 ml). The resulting mixture was stirred overnight at rt. 
The reaction mixture was poured into H2O (4 ml) and extracted with Et2O (3 x 5 mL). The 
combined organic layers were washed with brine (5 mL), dried over Na2SO4, filtered, and 
concentrated. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (1:1) to give 41 as a white-off solid (7 mg, 10%). 
1
H NMR (300 MHz, 
chloroform-d)  8.01 (d, J = 9 Hz, 2H), 7.95 (d, J = 8.7 Hz, 2H), 7.80 (s, 1H), 7.67 (d, J = 9 Hz, 
2H), 7.44 (d, J = 8.7 Hz, 2H), 6.89 (s, 1H), 2, 42 (s, 2H), 1.58 (s, 1H). HRMS (ESI
+
) calcd for 
C17H14IN2O2 (M+H)
+
 405.2097, found 405.2651. 
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N-(4-Benzoylphenyl)-N-(prop-2-yn-1-yl)terephthalamide (40). Same procedure as 41 using 
46 (37 mg, 0.18 mmol) and 3-aminobenzophenone (71 mg, 0.36 mmol) as the starting materials. 
The residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc 
(2:1) to give 40 as a yellow solid (5 mg, 8%). 
1
H NMR (300 MHz, DMSO-d6)  9.98 (s, 1H), 
8.30 - 8.21 (m, 3H), 8.12 - 7.85 (m, 3H), 7.84 - 7.81 (m, 2H), 7.60 - 7.55 (m, 5H), 4.23 - 4.20 (m, 
2H), 2.71 - 2.69 (m, 1H). HRMS (ESI
+
) calcd for C24H18N2O3 (M+H)
+
 383.4193, found 
383.1391. 
Synthesis of ether-amide analogs 
 
2-(4-Nitrophenyl)benzo[d]thiazole (62). 4-Nitrobenzoyl chloride (312 mg, 1.7 mmol) was 
added to a solution of 2-aminothiophenol (0.180 mL, 1.7 mmol) in pyridine (4.2 mL), and the 
reaction mixture was heated to reflux for 3 h. After completion of the reaction, as confirmed by 
TLC, the mixture was poured into H2O (6 mL). The product was isolated by filtration and 
washed with H2O (2 x 3 mL). The crude product was purified by trituration in MeOH to give 62 
as a yellow solid (256 mg, 59%). 
1
H NMR (300 MHz, chloroform-d)  8.37 - 8.26 (m, 4H), 8.13 
(d, J = 8.1 Hz, 2H), 7.96 (d, J = 8.1 Hz, 1H), 7.59 - 7.44 (m, 2H). 
4-(Benzo[d]thiazol-2-yl)aniline (63). Tin(II) chloride (945 mg, 5.0 mmol) was added to a 
solution of 62 (256 mg, 1.0 mmol) in EtOH (3.3 mL). The mixture was stirred at reflux for 2 h, 
and the solvent was removed under vacuum. The residue was suspended in EtOAc (10 mL) and 
washed with 2 M NaOH (3 x 7 mL) and H2O (2 x 7 mL). The organic layer was dried over 
Na2SO4, filtered, and concentrated. Trituration in MeOH afforded 63 as a yellow solid (187 mg, 
83%). 
1
H NMR (300 MHz, DMSO-d6)  8.00 (d, J = 7.9 Hz, 1H), 7.87 (d, J = 6 Hz, 1H), 7.74 
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(d, J = 8.4 Hz, 2H), 7.44 (td, J = 6.1, 2.9 Hz, 1H), 7.32 (td, J = 7.2, 2.9 Hz, 1H), 6.66 (d, J = 8.7 
Hz, 2H), 5.88 (s, 2H). The analytical data matched literature reports.
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tert-Butyl 2-(2-iodophenoxy)acetate (57). Cesium carbonate (150 mg, 0.46 mmol) was added to 
a solution of 2-iodophenol (50 mg, 0.23 mmol) in acetone (4.4 mL). The resulting mixture was 
stirred at 65 °C for 30 min. tert-Butylbromoacetate (0.037 mL, 0.23 mmol) was added and the 
solution was stirred for an additional hour. The reaction mixture was allowed to cool to rt and 
was filtered through a cotton plug. The residue was washed with acetone (2 x 5 mL) and the 
filtrate was concentrated. The residue was purified by flash chromatography on silica gel, eluting 
with hexanes/EtOAc (10:1) to give 57 as a yellow oil (66 mg, 86%). 
1
H NMR (300 MHz, 
chloroform-d)  7.79 (d, J = 7.7 Hz, 1H), 7.26 (t, J = 7.5 Hz, 1H), 6.75 - 6.67 (m, 2H), 4.58 (s, 
2H), 1.50 (s, 12H). The analytical data matched literature reports.
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2-(2-Iodophenoxy)acetic acid (58). TFA (7.9 mL) was added to a solution of 57 (66 mg, 0.20 
mmol) in DCM (7.9 mL). The reaction mixture was stirred at rt for 2 h and concentrated under 
vacuum to give 58 as a yellow solid (49 mg, 90%). 
1
H NMR (300 MHz, chloroform-d)  7.81 (d, 
J = 7.8 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 6.84 - 6.77 (m, 2H), 4.72 (s, 2H). The analytical data 
matched literature reports.
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2-(2-Iodophenoxy)acetyl chloride (59).  Oxalyl chloride (0.3 mL, 3.45 mmol) and 2 drops of 
DMF were added to a solution of 58 (639 mg, 2.30 mmol) in DCM (6 mL) at 0 °C. The resulting 
mixture was slowly allowed to warm up to rt and stirred for 2 h. The solvent was removed under 
vacuum to deliver 59 as a brown solid that was used without further purification (652 mg, 96%). 
1
H NMR (400 MHz, chloroform-d)  7.82 (d, J = 7.8 Hz, 1H), 7.32 - 7.29 (m, 1H), 6.81 (t, J = 
6.0 Hz, 1H), 6.74 (d, J = 6.0 Hz, 1H), 5.01 (s, 2H). 
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N-(4-(Benzo[d]thiazol-2-yl)phenyl)-2-(2-iodophenoxy)acetamide (47). The acyl chloride 59 
(129 mg, 0.44 mmol) was added to a solution of 63 (50 mg, 0.22 mmol) and DIPEA (0.06 mL, 
0.34 mmol) in DCM (3 mL). The resulting mixture was stirred at rt for 1.5 h, and then was 
filtered through a cotton plug. The filtrate was diluted with DCM (6 mL) and washed with 1 M 
HCl (2 x 5 mL), saturated NaHCO3 (2 x 5 mL), brine (4 mL), dried over Na2SO4, filtered, and 
concentrated. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (2:1) to give 47 as a yellow solid (58 mg, 39%). 
1
H NMR (300 MHz, 
chloroform-d)  9.04 (s, 1H), 8.12 - 8.05 (dd, J = 8.7, 7.5 Hz, 3H), 7.94 - 7.80 (m, 4H), 7.56 (t, J 
= 7.5 Hz, 1H), 7.41 (t, J = 7.8 Hz, 2H), 6.88 - 6.84 (m, 2H), 4.68 (s, 2H). HRMS (ESI
+
) calcd for 
C21H15IN2O2S (M+H)
+
 486.9972, found 487.0098. 
 
The acyl chlorides used to synthesize the analogs 64 and 65 were prepared from the 
corresponding phenols following the same protocol described for 59: 
 
2-(4-Methoxyphenoxy)acetyl chloride. Same procedure as 59 using 2-(4-
methoxyphenoxy)acetic acid (586 mg, 3.22 mmol) as the starting material. The compound was 
obtained as a brown oil (64 mg, 99%) and was used without further purification. 
1
H NMR (400 
MHz, chloroform-d)  6.85 (m, 4H), 4.90 (s, 2H), 3.78 (s, 3H). 
2-Phenoxyacetyl chloride. Same procedure as 59 using 2-phenoxyacetic acid (728 mg, 4.79 
mmol) as the starting material. The compound was obtained as a brown oil (80 mg, 98%) and 
was used without further purification. 
1
H NMR (400 MHz, chloroform-d)  7.28 (t, J = 7.2 Hz, 
2H), 7.01 (t, J = 6.8 Hz, 1H), 6.84 (d, J = 8.0 Hz, 2H), 4.91 (s, 2H). The analytical data matched 
literature reports.
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Analogs 64 and 65 were prepared from 63 and the corresponding acyl chlorides using the 
procedure described for 47: 
 
N-(4-(Benzo[d]thiazol-2-yl)phenyl)-2-(4-methoxyphenoxy)acetamide (64). Same procedure 
as 47 using 63 (40 mg, 0.18 mmol) and 2-(4-methoxyphenoxy)acetyl chloride (72 mg, 0.36 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with DCM/EtOAc (7:1) to afford 64 as a yellow solid (35 mg, 50%). 
1
H NMR (300 MHz, 
chloroform-d)  8.46 (s, 1H), 8.11 (dd, J = 8.7, 7.8 Hz, 3H), 7.91 (d, J = 7.5 Hz, 1H), 7.76 (d, J = 
8.7 Hz, 2H), 7.49 (t, J = 8.3 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.00 - 6.88 (m, 4H), 4.60 (s, 2H), 
3.80 (s, 3H). HRMS (ESI
+
) calcd for C21H16N2O2S (M+H)
+
 361.1005, found 361.1029. 
 
N-(4-(Benzo[d]thiazol-2-yl)phenyl)-2-phenoxyacetamide (65). Same procedure as 47 using 63 
(40 mg, 0.18 mmol) and 2-phenoxyacetyl chloride (61 mg, 0.36 mmol) as the starting materials. 
The residue was purified by flash chromatography on silica gel, eluting with DCM/EtOAc (2:1) 
to afford 65 as a yellow solid (40 mg, 62%). 
1
H NMR (300 MHz, chloroform-d)  8.45 (s, 1H), 
8.01 (dd, J = 8.4, 7.6 Hz, 3H), 7.91 (d, J = 7.7 Hz, 1H), 7.77 (d, J = 8.6 Hz, 2H), 7.54 (t, J = 7.5 
Hz, 1H), 7.38 (t, J = 7.8 Hz, 2H), 7.11 (t, J = 7.5 Hz, 1H), 7.03 (d, J = 8.7 Hz, 3H), 4.66 (s, 2H). 
HRMS (ESI
+
) calcd for C21H16N2O2S (M+H)
+
 361.1005, found 361.1029. 
 
Synthesis of analogs 70-72 
N-(2-Hydroxyphenyl)-4-nitrobenzamide (67). 4-Nitrobenzoylchloride (1.7 g, 9.17 mmol) was 
added to a solution of 2-aminophenol (1.0 g, 9.17 mmol) and TEA (2 mL, 13.5 mmol) in THF 
(11 mL) at 0 °C. The resulting mixture was allowed to warm to rt and stirred for 20 h. After 
completion of the reaction (TLC), the mixture was dissolved in EtOAc (16 mL), washed 
successively with H2O (2 x 8 mL), 1 M HCl (8 mL), brine (6 mL), dried over Na2SO4, filtered, 
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and concentrated to deliver 67 as a light brown solid (2.4 g, 90%) which was used without 
further purification. 
1
H NMR (300 MHz, DMSO-d6)  9.83 (s, 1H), 9.71 (s, 1H), 8.34 (d, J = 7.2 
Hz, 2H), 8.18 (d, J = 9 Hz, 2H), 7.60 (d, J = 7.7 Hz, 1H), 7.06 (dd, J = 8.1, 7.3 Hz, 1H), 6.92 (d, 
J = 8.1 Hz, 1H), 6.83 (t, J = 7.6 Hz, 1H). 
 
2-(4-Nitrophenyl)benzo[d]oxazole (68). Acid para-toluenesulfonic (PTSA) (778 mg, 4.09 
mmol) was added to a solution of 67 (500 mg, 1.95 mmol) in xylene (19 mL). The reaction 
mixture was heated to reflux for 4 h. After cooling down, the solution was diluted with EtOAc 
(15 mL), washed with saturated NaHCO3 (2 x 8 mL), H2O (2 x 8 mL). The combined aqueous 
layer was re-extracted with EtOAc (8 mL). The combined organic layers were washed with brine 
(5 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (4:1) to give 68 as a yellow solid (148 
mg, 32%). 
1
H NMR (300 MHz, DMSO-d6)  8.44 (d, J = 1.7 Hz, 4H), 7.87 (t, J = 8.0 Hz, 2H), 
7.55 - 7.42 (m, 2H).  
 
4-(Benzo[d]oxazol-2-yl)aniline (69). Tin(II) chloride (3.7 g, 19.8 mmol) was added to a solution 
of the nitro 68 (950 mg, 3.9 mmol) in ethanol (20 mL). The mixture was stirred at reflux for 2 h. 
The solvent was removed under vacuum. The residue was diluted in EtOAc (18 mL) and washed 
with H2O (2 x 10 mL) and brine (6 mL). The organic layer was dried over Na2SO4, filtered, and 
concentrated. Trituration in MeOH afforded 69 as a yellow solid (2.2 mg, 100%). 
1
H NMR (300 
MHz, DMSO-d6)  7.83 (d, J = 8.4 Hz, 2H), 7.66 – 7.63 (m, 2H), 7.33 - 7.27 (m, 2H), 6.67 (d, J 
= 8.7 Hz, 2H), 6.00 (s, 2H). The analytical data matched literature reports.
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N-(4-(Benzo[d]oxazol-2-yl)phenyl)-2-(2-iodophenoxy)acetamide (70). The acyl chloride 59 
(140 mg, 0.48 mmol) was added to a solution of 69 (50 mg, 0.24 mmol) and pyridine (0.03 mL, 
0.37 mmol) in DCM (2 mL). The resulting mixture was stirred at rt for 3 h. The reaction mixture 
was diluted with DCM (5 mL), washed with 1 M HCl (4 mL). The aqueous layer was washed 
with DCM (2 x 6 mL). The combined organic layers were washed with brine (5 mL), dried over 
Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography on silica 
gel, eluting with hexanes/EtOAc (3:1) to give 70 as a pink solid (8.1 mg, 20%). 
1
H NMR (300 
MHz, chloroform-d)  9.07 (s, 1H), 8.28 (d, J = 8.8 Hz, 1H), 7.89 - 7.76 (m, 4H), 7.61 - 7.58 (m, 
1H), 7.40 - 7.32 (m, 2H), 6.88 (t, J = 14.4 Hz, 2H), 6.83 - 6.76 (m, 2H), 4.69 (s, 2H). HRMS 
(ESI
+
) calcd for C21H15IN2O3 (M+H)
+
 471.0206, found 471.0226. 
 
Analogs 71 and 72 were prepared from 69 and the corresponding acyl chlorides using the 
procedure described for 70: 
N-(4-(Benzo[d]oxazol-2-yl)phenyl)-2-(4-methoxyphenoxy)acetamide (71). Same procedure as 
70 using 69 (90 mg, 0.43 mmol) and 2-(4-methoxyphenoxy)acetyl chloride (172 mg, 0.86 mmol) 
as the starting materials. The residue was purified by flash chromatography on silica gel, eluting 
with hexanes/EtOAc (1:1) to afford 71 as a white solid (11 mg, 9%). 
1
H NMR (300 MHz, 
chloroform-d)  8.48 (s, 1H), 8.26 (d, J = 8.7 Hz, 2H), 7.82 - 7.76 (m, 3H), 7.61 - 7.55 (m, 1H), 
7.38 - 7.33 (m, 2H), 6.97 - 6.87 (dd, J = 9.6, 6.0 Hz, 4H), 4.60 (s, 2H), 3.80 (s, 3H). HRMS 
(ESI
+
) calcd for C22H18N2O4 (M+H)
+
 375.1345, found 375.1363. 
 
N-(4-(Benzo[d]oxazol-2-yl)phenyl)-2-phenoxyacetamide (72). Same procedure as 70 using 69 
(80 mg, 0.38 mmol) and 2-phenoxyacetyl chloride (129 mg, 0.76 mmol) as the starting materials. 
The residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc 
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(3:1) to afford 72 as a white solid (11.2 mg, 9%) 
1
H NMR (300 MHz, chloroform-d)  8.47 (s, 
1H), 8.26 (d, J = 8.7 Hz, 2H), 7.82 - 7.75 (m, 3H), 7.61 - 7.55 (m, 1H), 7.40 - 7.33 (m, 3H), 7.08 
- 7.00 (dd, J = 15.6, 6.6 Hz, 3H), 4.66 (s, 2H). HRMS (ESI
+
) calcd for C21H16N2O3 (M+H)
+
 
345.1239, found 345.1269. 
Synthesis of N-acylhydrazone hit compounds 49 and 50  
Picolinohydrazide (74). Hydrazine (0.105 mL, 3.31 mmol) was added dropwise to a solution of 
ethyl picolinate (0.223 mL, 1.65 mmol). The resulting mixture was heated to reflux for 18 h. 
After allowing the mixture to cool down, all volatiles were evaporated under vacuum and the 
residue was recrystallized from EtOH to give 74 as a white solid (111 mg, 25%). 
1
H NMR (300 
MHz, DMSO-d6)  9.85 (s, 1H), 8.59 (d, J = 4.7 Hz, 1H), 7.97 - 7.95 (m, 2H), 7.57 - 7.52 (m, 
1H), 4.53 (s, 2H). The analytical data matched literature reports.
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(E)-N-(2-Methoxyphenyl)-3-(2-picolinoylhydrazono)butanamide (50). A solution of 74 (40 
mg, 0.29 mmol) in EtOH (0.7 mL) was added to a solution of acetanilide (60.1 mg, 0.29 mmol) 
in MeOH (0.7 mL). The resulting mixture was heated to reflux for 5 h. The solvents were 
removed under vacuum and the residue was triturated in hexanes to give 50 as a light brown 
solid (76 mg, 81%). 
1
H NMR (300 MHz, chloroform-d)  10.88 (s, 1H), 8.56 (d, J = 4.5 Hz, 1H), 
8.31 (d, J = 8.1 Hz, 3H), 7.90 (t, J = 7.7 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.04 – 6.34 (m, 3H), 
3.86 (s, 3H), 3.59 (s, 2H), 2.24 (s, 3H). HRMS (ESI
+
) calcd for C17H18N4O8 (M+Na)
+
 349.1277, 
found 349.1261. 
 
2-Methylfuran-3-carbohydrazide (82). Hydrazine (0.113 mL, 3.57 mmol) was added to a 
stirred solution of methyl-2-methyl-3-furancarboxylate (0.224 mL, 1.78 mmol) in MeOH (3 mL) 
and heated to reflux overnight. After allowing the mixture to cool down, the solvent was 
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removed under vacuum to give 82 as a yellow solid (274 mg, 100%). 
1
H NMR (300 MHz, 
DMSO-d6)  9.26 (s, 1H), 7.47 (sd, J = 1.8 Hz, 1H), 6.78 (sd, J = 1.8 Hz, 1H), 4.33 (s, 2H), 2.48 
(s, 3H). 
 
N-(4-Acetylphenyl)nicotinamide (81). A solution of nicotinoyl chloride hydrochloride (250 mg, 
1.77 mmol) in THF (1 mL) was added to a solution of 4-aminoacetophenone (286 mg, 2.12 
mmol) and TEA (0.5 mL, 3.54 mmol) in THF (5 mL). The resulting mixture was stirred for 3 h 
at rt. The solvent was removed under vacuum and the residue was purified by flash 
chromatography on silica gel, eluting with 10% MeOH in DCM to give 81 as a pink solid (93 
mg, 23%). 
1
H NMR (300 MHz, chloroform-d)  9.11 (d, J = 2.4, 1H), 8.83 - 8.79 (m, 1H), 8.22 
(d, J = 7.9 Hz, 1H), 8.01 (d, J = 8.7 Hz, 2H), 7.76 (d, J = 8.7, 2H), 7.47 (m, 1H), 2.61 (s, 3H). 
 
(E)-N-(4-(1-(2-(2-Methylfuran-3-carbonyl)hydrazono)ethyl)phenyl)nicotinamide (49). The 
methyl ketone 81 (28 mg, 0.12 mmol) was added to a solution of 83 (16 mg, 0.12 mmol) in 
EtOH (0.3 mL). The reaction mixture was heated to reflux for 4 h. Upon cooling down the 
product precipitated out and was isolated by filtration and washed with cold Et2O (2 x 4 mL) to 
afford 49 as a yellow solid (20 mg, 45%). 
1
H NMR (400 MHz, DMSO-d6)  10.60 (s, 1H), 9.11 
(s, 1H), 8.76 (sd, J = 3.2 Hz, 1H), 8.30 (m, 1H), 8.00 - 7.83 (m, 5H), 7.58 (d, J = 4.8 Hz, 2H), 
6.94 (s, 1H), 2.51 (s, 3H), 2.31 (s, 3H). HRMS (ESI
+
) calcd for C20H18N4O3 (M+Na)
+
 385.1277, 
found 385.1267. 
 
The analogs 78 and 83-91 were prepared from the corresponding starting materials according to 
the procedure described for 49: 
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(E)-N'-(1-(p-Tolyl)ethylidene)furan-2-carbohydrazide (78). Same procedure as 49 using 2-
furoic hydrazide (50 mg, 0.39 mmol) and 4-methylacetophenone (53 mg, 0.39 mmol) as the 
starting materials. The residue was purified via recrystallization in EtOH to provide 78 as a white 
solid (67 mg, 70%). 
1
H NMR (300 MHz, DMSO-d6)  7.92 (s, 1H), 7.71 (d, J = 7.8 Hz, 2H), 
7.34 (s, 1H), 7.24 (d, J = 8.1 Hz, 2H), 6.68 (d, J = 3.5 Hz, 1H), 2.33 (s, 3H), 2.31 (s, 3H). HRMS 
(ESI
+
) calcd for C14H14N2O2 (M+H)
+
 243.2811, found 243.1135. The analytical data matched 
literature reports.
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(E)-N'-Benzylidenefuran-2-carbohydrazide (83). Same procedure as 49 using 2-furoic 
hydrazide (50 mg, 0.39 mmol) and benzaldehyde (0.04 L, 0.40 mmol) as the starting materials. 
The residue was purified via recrystallization in EtOH to provide 83 as a white solid (63 mg, 
74%). 
1
H NMR (300 MHz, DMSO-d6)  11.82 (s, 1H), 8.44 (s, 1H), 7.93 (s, 1H), 7.88 (dd, J = 
6.9, 2.7 Hz, 2H), 7.48 - 7.42 (m, 2H), 7.29 (s, 1H), 6.69 (s, 1H). HRMS (ESI
+
) calcd for 
C12H10N2O2 (M+Na)
+
 237.0640, found 237.0639. The analytical data matched literature 
reports.
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(E)-N'-(1-(Pyridin-2-yl)ethylidene)furan-2-carbohydrazide (84). Same procedure as 49 using 
2-furoic hydrazide (52 mg, 0.41 mmol) and 2-acetylpyridine (0.046 L, 0.41 mmol) as the 
starting materials. The residue was purified via recrystallization in EtOH to provide 84 as a white 
solid (2 mg, 5%) 
1
H NMR (300 MHz, DMSO-d6)  8.60 (s, 1H), 8.08 - 7.80 (m, 3H), 7.42 (s, 
2H), 6.70 (s, 1H), 2.42 (s, 3H). HRMS (ESI
+
) calcd for C12H11N3O2 (M+H)
+
 252.0749, found 
252.0751. The analytical data matched literature reports.
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(E)-3-(2-(Furan-2-carbonyl)hydrazono)-N-(2-methoxyphenyl)butanamide (85). Same 
procedure as 49 using 2-furoic hydrazide (50 mg, 0.39 mmol) and o-acetanisidine (90 mg, 0.44 
mmol) as the starting materials. The residue was purified via recrystallization in Et2O to provide 
85 as a white solid (7.5 mg, 10%). 
1
H NMR (300 MHz, methanol-d)  8.13 (dd, J = 1.6, 7.9 Hz, 
1H), 7.73 (d, J = 1.5 Hz, 1H), 7.24 (d, J = 3.6 Hz, 1H), 7.20 - 6.90 (m, 3H), 6.65 (d, J = 3.5 Hz, 
1H), 4.89 (s, 2H), 3.94 (s, 3H), 3.31 (s, 3H). HRMS (ESI
+
) calcd for C16H17N3O4 (M+Na)
+
 
338.3136, found 338.3432. 
 
(E)-N'-Pentylidenefuran-2-carbohydrazide (86). Same procedure as 49 using 2-furoic 
hydrazide (59 mg, 0.47 mmol) and valeraldehyde (0.05 L, 0.47 mmol) as the starting materials. 
The residue was purified via recrystallization in MeOH to provide 86 as a white solid (28 mg, 
31%) 
1
H NMR (300 MHz, methanol-d)  7.71 - 7.68 (m, 2H), 7.22 (d, J = 3.6 Hz, 1H), 6.61 (dd, 
J = 1.8, 3.6 Hz, 1H), 4.89 (s, 1H), 2.38 - 2.31 (m, 2H), 1.57 - 1.52 (m, 2H), 1.44 - 1.38 (m, 2H), 
0.95 (t, J = 7.5 Hz, 3H). HRMS (ESI
+
) calcd for C10H14N2O2 (M+H)
+
 195.2383, found 195.1126. 
 
(E)-N'-([1,1'-Biphenyl]-4-ylmethylene)furan-2-carbohydrazide (87). Same procedure as 49 
using 2-furoic hydrazide (59 mg, 0.47 mmol) and 4-biphenylcarboxaldehyde (87 mg, 0.47 mmol) 
as the starting materials. The residue was purified via recrystallization in Et2O to provide 87 as a 
yellow solid (40 mg, 29%). 
1
H NMR (400 MHz, DMSO-d6)  11.88 (s, 1H), 8.47 (s, 1H), 7.95 
(s, 1H), 7.78 (d, J = 3.2 Hz, 4H), 7.75 - 7.71 (m, 4H), 7.50 - 7.46 (m, 2H), 7.40 - 7.36 (m, 1H), 
6.70 (s, 1H). HRMS (ESI
+
) calcd for C18H14N2O2 (M+H)
+
 291.3239, found 291.1122. 
 
(E)-N'-(1-(Naphthalen-2-yl)ethylidene)furan-2-carbohydrazide (88). Same procedure as 49 
using 2-furoic hydrazide (59 mg, 0.47 mmol) and 2-acetylnaphtalene (80 mg, 0.47 mmol) as the 
starting materials. The residue was purified via recrystallization in MeOH to provide 88 as a 
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white solid (51 mg, 41%). 
1
H NMR (300 MHz, DMSO-d6)  8.30 (s, 1H), 8.10 - 7.92 (m, 5H), 
7.46 (m, 2H), 7.40 (s, 1H), 6.60 (s, 1H), 3.32 (s, 3H). 
 
 (E)-2-Methyl-N'-(1-(p-tolyl)ethylidene)furan-3-carbohydrazide (89). Same procedure as 49 
using 82 (40 mg, 0.28 mmol) and 4-methylacetophenone (38 mg, 0.28 mmol) as the starting 
materials. The compound 89 was obtained as a white solid (22 mg, 31%) and was used without 
further purification. 
1
H NMR (300 MHz, DMSO-d6)  10.29 (s, 1H), 7.60 (s, 2H), 7.56 (s, 1H), 
7.21 (d, J = 7.9 Hz, 2H), 6.91 (s, 1H), 3.30 (s, 3H), 2.32 (s, 3H), 2.27 (s, 3H). HRMS (ESI
+
) 
calcd for C15H16N2O2 (M+H)
+
 257.1290, found 257.1294. 
 
(E)-N'-Benzylidenebenzohydrazide (90). Same procedure as 49 using phenylhydrazine (60 mg, 
0.44 mmol) and benzaldehyde (0.045 L, 0.44 mmol) as the starting materials. The residue was 
purified via recrystallization in MeOH to provide 90 as a white solid (45 mg, 45%). 
1
H NMR 
(300 MHz, DMSO-d6)  11.80 (s, 1H), 8.44 (s, 1H), 7.90 (d, J = 9.6 Hz, 2H), 7.72 - 7.70 (m, 
2H), 7.56 - 7.7.43 (m, 6H). HRMS (ESI
+
) calcd for C14H12N2O (M+H)
+
 225.2658, found 
225.1024. The analytical data matched literature reports.
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Ethyl benzofuran-2-carboxylate. Oxalyl chloride (0.13 mL, 1.48 mmol) and a catalytic amount 
of DMF were added to a solution of benzofuran-2-carbacid (200 mg, 1.23 mmol) in DCM (0.5 
mL) at 0 °C, and the suspension was stirred overnight at rt. After removal of the solvents under 
vacuum, the residue was dissolved in EtOH (2 mL) and TEA (0.172 mL, 1.23 mmol) was added. 
The resulting mixture was heated under reflux for 4 h, after allowing the solution to cool to rt, 
H2O (6 mL) was added and the product was extracted with DCM (3 x 5 mL). The combined 
organic layers were washed with NaHCO3 (6 mL), brine (6 mL), dried over Na2SO4, filtered, and 
concentrated. The residue was purified by flash chromatography on silica gel, eluting with 
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hexanes/EtOAc (9:1) to deliver a white solid (138 mg, 59%). 
1
H NMR (300 MHz, chloroform-d) 
 7.69 (dd, J = 0.9, 7.5 Hz, 1H), 7.61 (d, J = 7.5 Hz, 1H), 7.53 (d, J = 1.2 Hz, 1H), 7.46 (t, J = 
7.2 Hz, 1H), 7.33 - 7.27 (m, 1H), 4.44 (q, J = 7.2 Hz, 2H), 1.43 (t, J = 7.2 Hz, 3H). The 
analytical data matched literature reports.
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Benzofuran-2-carbohydrazide. Hydrazine hydrate (0.072 mL, 1.45 mmol) was added to a 
solution of ethyl benzofuran-2-carboxylate (55 mg, 0.29 mmol) in EtOH (0.55 mL) and the 
resulting mixture was stirred under reflux for 3 h. After allowing the solution to cool to rt the 
product precipitated out and was collected by filtration. The crude product was recrystallized 
from EtOH to deliver a white solid (35 mg, 70%). 
1
H NMR (300 MHz, methanol-d)  7.70 (d, J 
= 7.5 Hz, 1H), 7.57 (dd, J = 0.9, 8.4 Hz, 1H), 7.47 - 7.41 (m, 2H), 7.30 (t, J = 8.1 Hz, 1H). 
 
(E)-N'-Benzylidenebenzofuran-2-carbohydrazide (91). Same procedure as 49 using 
benzofuran-2-carbohydrazide (26 mg, 0.15 mmol) and benzaldehyde (0.015 L, 0.15 mmol) as 
the starting materials. The residue was purified via recrystallization in MeOH to provide 91 as a 
white solid (8 mg, 23%). 
1
H NMR (300 MHz, methanol-d)  8.44 (s, 1H), 7.88 - 7.84 (m, 2H), 
7.78 (d, J = 7.8 Hz, 1H), 7.69 - 7.64 (m, 2H), 7.53 (dd, J = 1.2, 7.2 Hz, 1H), 7.48 - 7.44 (m, 3H), 
7.35 (t, J = 8.1 Hz, 1H). HRMS (ESI
+
) calcd for C16H12N2O2 (M+H)
+
 265.2866, found 265.0968. 
 
N-Phenethylfuran-2-carboxamide (92). EDCI (171 mg, 0.89 mmol), DMAP (136 mg, 1.11 
mmol), and phenetylamine (0.056 mL, 0.44 mmol) were added to a solution of 2-furoic acid (50 
mg, 0.44 mmol) and TEA (0.186 mL, 1.33 mmol) in DMF (1 mL). The reaction mixture was 
stirred overnight at rt, and then diluted with Et2O (5 mL), washed with H2O (2 x 5 mL), 10% 
HCl (3 mL), NaHCO3 (3 mL), and brine (3 mL). The combined organic layers were dried over 
Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography on silica 
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gel, eluting with hexanes/EtOAc (2:1) to give 92 as a colorless oil (7 mg, 10%). 
1
H NMR (300 
MHz, chloroform-d)  7.42 - 7.38 (m, 1H), 7.36 - 7.32 (m, 2H), 7.28 - 7.22 (m, 3H), 7.10 (dd, J 
= 1.9, J = 5.4 Hz, 1H), 6.50 - 6.48 (m, 1H), 3.68 (q, J = 6.6 Hz, 2H), 2.91 (t, J = 6.4 Hz, 2H). 
HRMS (ESI
+
) calcd for C13H13NO2 (M+H)
+
 216.2528, found 216.1029. The analytical data 
matched literature reports.
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Synthesis of the oxadiazole hit compound 51 
1-Azido-3-methoxybenzene (95). Sulfuric acid (2.25 mL) was slowly added to a stirred solution 
of m-anisidine (1.05 mL, 8.5 mmol) in H2O (6 mL) at 0 °C. A solution of sodium nitrite (762 
mg, 11.0 mmol) in H2O (1.2 mL) was added dropwise, and the resulting mixture was stirred for 
30 min at 0 °C. A solution of sodium azide (884 mg, 13.6 mmol) in H2O (1.6 mL) was added 
slowly. The reaction mixture was slowly allowed to warm to rt and stirred overnight. The 
mixture was poured into NaHCO3 (10 mL) and extracted with DCM (3 x 10 mL). The combined 
organic layers were washed with brine (6 mL), dried over Na2SO4, filtered, and concentrated. 
The residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc 
(9:1) to give 95 as a yellow oil (1.06 g, 84%). 
1
H NMR (300 MHz, chloroform-d)  7.25 (t, J = 
6.1 Hz, 1H), 6.71 – 6.63 (m, 2H), 6.55 (t, J = 2.3 Hz, 1H), 3.81 (s, 3H). The analytical data 
matched literature reports.
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(E)-N'-Hydroxythiophene-2-carboximidamide (97). A solution of hydroxylamine 
hydrochloride (4.5 g, 64.5 mmol) and sodium carbonate (4.5 g, 43 mmol) in H2O (20 mL) was 
slowly added to a solution of 2-thiophenecarbonitrile (2 mL, 21.5 mmol) in a mixture of 
H2O:15% EtOH (40:9 mL).  The reaction mixture was stirred at rt for 24 h. The product was 
extracted with EtOAc (3 x 12 mL). The combined organic layers were washed with saturated 
NaHCO3 (6 mL), brine (6 mL), dried over Na2SO4, filtered, and concentrated to afford 97 as a 
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white solid (12.9 g, 97%), which was used without further purification. 
1
H NMR (300 MHz, 
DMSO-d6)  10.81 (s, 1H), 7.34 - 7.17 (m, 2H), 6.62 - 6.47 (m, 2H), 5.12 (s, 2H). The analytical 
data matched literature reports.
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2-(3-(Thiophen-2-yl)-1,2,4-oxadiazol-5-yl)acetonitrile (99). 1-Cyanoacetyl-3,5-
dimethylpyrazole (1.4 g, 8.45 mmol) was added to a solution of 97 (1.0 g, 7.04 mmol) in dioxane 
and heated to reflux for 24 h. After allowing the mixture to cool to rt, the dioxane was removed 
under vacuum. The residue was dissolved in DCM (16 mL) and washed with saturated NaHCO3 
(2 x 10 mL), brine (6 mL), dried over Na2SO4, filtered, and concentrated. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to give a 
yellow solid (1.8 g, 60%). 
1
H NMR (300 MHz, chloroform-d)  7.83 (d, J = 3.7 Hz, 1H), 7.56 (d, 
J = 4.8 Hz, 1H), 7.18 (t, J = 5.0 Hz, 1H), 4.12 (s, 2H). 
 
1-(3-Methoxyphenyl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine 
(51). A solution of sodium methylate (102 mg, 1.89 mmol) in MeOH (3 mL) was added to 99 
(120 mg, 0.63 mmol) in MeOH (1.5 mL). The resulting mixture was stirred at rt for 15 min, then 
the azide 95 (94 mg, 0.63 mmol) was added and the reaction mixture was stirred at 60 °C 
overnight. After allowing the solution to cool to room temperature, a few drops of H2O were 
added. The precipitate was isolated by filtration and triturated into hexanes to give 51 as a brown 
solid (136 mg, 63%). 
1
H NMR (300 MHz, DMSO-d6)  8.03 (d, J = 3.9 Hz, 1H), 7.91 (d, J = 4.8 
Hz, 1H), 7.57 (t, J = 8.3 Hz, 1H), 7.30 (t, J = 5.2 Hz, 1H), 7.22 - 7.14 (m, 3H), 6.92 (s, 2H), 3.86 
(s, 3H). LRMS calcd for C15H12N6O2S (M+Na)
+
 363.06, found: 363.10.  
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The analogs 100-112 were prepared from 99 and the corresponding arylazides following the 
procedure and purification described for 51 unless otherwise indicated: 
1-Azido-3-ethylbenzene. Same procedure as 95 using ethylaniline (0.26 mL, 2.06 mmol) as the 
starting material. The compound was obtained as an orange oil (250 mg, 80%) and was used 
without further purification. 
1
H NMR (400 MHz, chloroform-d)  7.31 - 7.25 (m, 1H), 6.99 (d, J 
= 7.8 Hz, 1H), 6.87 (d, J = 6.8 Hz, 2H), 2.66 (q, J = 7.6 Hz, 2H), 1.31 (t, J = 8 Hz, 3H). 
1-(3-Ethylphenyl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine (102). 
Same procedure as 51 using 1-azido-3-ethylbenzene (54 mg, 0.37 mmol) and 99 (71 mg, 0.37 
mmol) as the starting materials. The compound 102 was obtained as a brown solid (48 mg, 49%). 
1
H NMR (300 MHz, DMSO-d6)  8.01 (d, J = 3.7 Hz, 1H), 7.89 (dd, J = 5.0, 1.2 Hz, 1H), 7.54 
(t, J = 6.8 Hz, 1H), 7.50 - 7.41 (m, 3H), 7.29 (dd, J = 5.0, 3.7 Hz, 1H), 6.86 (s, 2H), 2.73 (q, J = 
7.6 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H). HRMS (ESI
+
) calcd for C16H14N6OS (M+Na)
+
 361.0847, 
found 361.0829. 
3-Azido-N,N-dimethylaniline. Same procedure as 95 using 3-N,N-dimethyaniline (300 m, 2.2 
mmol) as the starting material. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (9:1) to afford a light red oil (53 mg, 44%). 
1
H NMR (300 MHz, 
chloroform-d)  7.22 (t, J = 8.1 Hz, 1H), 6.50 (d, J = 8.4 Hz, 1H), 6.42 (dd, J = 7.8, 2.1 Hz, 1H), 
6.31 - 6.29 (m, 1H), 2.95 (s, 6H). 
1-(3-(Dimethylamino)phenyl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-
amine (103). Same procedure as 51 using 3-azido-N,N-dimethylaniline (34 mg, 0.21 mmol) and 
99 (40 mg, 0.21 mmol) as the starting materials. The compound 103 was obtained as a brown 
solid (26 mg, 35%). 
1
H NMR (300 MHz, DMSO-d6)  8.0 (d, J = 2.4 Hz, 1H), 7.88 (d, J = 5.1 
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Hz, 1H), 7.42 (t, J = 8.1 Hz, 1H), 7.31 - 7.26 (m, 1H), 6.98 - 6.80 (m, 3H), 6. 79 (s, 2H), 2.97 (s, 
6H). HRMS (ESI
+
) calcd for C16H15N7OS (M+H)
+
 354.1, found 354.1. 
 
1-Azido-3-isopropylbenzene. Same procedure as 95 using 3-isopropylaniline (0.365 mL, 2.59 
mmol) as the starting material. The compound was obtained as a yellow oil (40 mg, 80%) and 
was used without further purification. 
1
H NMR (300 MHz, chloroform-d)  7.26 (q, J = 6.8 Hz, 
1H), 7.01 (d, J = 7.0 Hz, 1H), 6.85 (s, 2H), 2.85 (m, 1H), 1.23 (d, J = 7.5 Hz, 6H). 
 
1-(3-Isopropylphenyl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine 
(104). Same procedure as 51 using 1-azido-3-isopropylbenzene (34 mg, 0.21 mmol) and 99 (40 
mg, 0.21 mmol) as the starting materials. The compound 104 was obtained as a brown solid (24 
mg, 32%).  
1
H NMR (300 MHz, DMSO-d6)  8.01 (d, J = 4.2 Hz, 1H), 7.90 (d, J = 5.0 Hz, 1H), 
7.57 (t, J = 7.8 Hz, 1H), 7.51 - 7.42 (m, 3H), 7.29 (d, J = 5.0 Hz, 1H), 6.88 (s, 2H), 3.28 – 3.24 
(m, 1H), 1.26 (d, J = 6.9 Hz, 6H). HRMS (ESI
+
) calcd for C17H16N6OS (M+H)
+
 353.1, found 
353.1. 
 
1-Azido-3-(trifluoromethyl)benzene. Same procedure as 95 using 3-aminobenzotrifluoride 
(0.27 mL, 2.17 mmol) as the starting material. The residue was purified by flash chromatography 
on silica gel, eluting with pentane/Et2O (8:1) to afford a light green oil (95 mg, 23%). 
1
H NMR 
(300 MHz, chloroform-d)  7.48 (t, J = 8.1 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.22 (m, 2H). 
 
4-(3-(Thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-5-
amine (105). Same procedure as 51 using 1-azido-3-(trifluoromethyl)benzene (51 mg, 0.27 
mmol) and 99 (52 mg, 0.27 mmol) as the starting materials. The compound 105 was obtained as 
a grey solid (37 mg, 36%). 
1
H NMR (300 MHz, DMSO-d6)  8.07 - 8.01 (m, 2H), 7.96 (d, J = 
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8.7 Hz, 2H), 7.88 (d, J = 4.8 Hz, 2H), 7.29 (t, J = 5.1 Hz, 1H), 7.08 (s, 2H). HRMS (ESI
+
) calcd 
for C15H9F3N6OS (M+H)
+
 379.1, found 379.1. 
 
1-Azido-3-(trifluoromethoxy)benzene. Same procedure as 95 using 3-(trifluoromethoxy)aniline 
(0.227 mL, 1.69 mmol) as the starting material. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (8:1) to afford a yellow oil (53 mg, 
44%). 
1
H NMR (300 MHz, chloroform-d)  7.38 (t, J = 8.2 Hz, 1H), 6.99 (t, J = 8.0 Hz, 2H), 
6.92 - 6.85 (m, 1H). 
4-(3-(Thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-
5-amine (106). Same procedure as 51 using 1-azido-3-(trifluoromethoxy)benzene (53 mg, 0.26 
mmol) and 99 (50 mg, 0.26 mmol) as the starting materials. The compound 106 was obtained as 
a grey solid (19 mg, 20%). 
1
H NMR (300 MHz, DMSO-d6)  8.02 (d, J = 3.6 Hz, 1H), 7.89 (d, J 
= 4.9 Hz, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.72 (s, 2H), 7.63 (d, J = 8.5 Hz, 1H), 7.44 – 7.46 (m, 
1H), 7.03 (s, 2H). HRMS (ESI
+
) calcd for C15H9F3N6O2S (M+H)
+
 395.0, found 395.0. 
 
1-Azido-3-fluorobenzene. Same procedure as 95 using 3-fluoroaniline (0.105 mL, 1.08 mmol) 
as the starting material. The residue was purified by flash chromatography on silica gel, eluting 
with hexanes/EtOAc (8:1) to afford a yellow oil (250 mg, 41%). 
1
H NMR (300 MHz, 
chloroform-d)  7.43 - 7.24 (m, 1H), 6.95 - 6.80 (m, 2H), 6.81 - 6.70 (m, 1H). The analytical 
data matched literature reports.
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1-(3-Fluorophenyl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine 
(107). Same procedure as 51 using 1-azido-3-fluorobenzene (36 mg, 0.26 mmol) and 99 (50 mg, 
0.26 mmol) as the starting materials. The compound 107 was obtained as a brown solid (33 mg, 
45%). 
1
H NMR (300 MHz, DMSO-d6)  8.04 (d, J = 3.8 Hz, 1H), 7.89 (d, J = 5.2 Hz, 1H), 7.75 
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- 7.64 (m, 1H), 7.60 (d, J = 9.3 Hz, 1H), 7.56 - 7.41 (m, 3H), 7.01 (s, 2H). HRMS (ESI
+
) calcd 
for C14H9FN6OS (M+Na)
+
 351.0440, found 351.0528. 
1-Azido-2-methoxybenzene. Same procedure as 95 using o-anisidine (0.46 mL, 4.06 mmol) as 
the starting material. The residue was purified by flash chromatography on silica gel, eluting 
with hexanes/EtOAc (5:1) to afford an orange oil (90 mg, 86%). 
1
H NMR (400 MHz, 
chloroform-d)  7.07 (d, J = 7.6 Hz, 1H), 7.02 (d, J = 7.8 Hz, 1H), 6.97 - 6.87 (m, 2H), 3.87 (s, 
3H). The analytical data matched literature reports.
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1-(2-Methoxyphenyl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine 
(108). Same procedure as 51 using 1-azido-2-methoxybenzene (108 mg, 0.72 mmol) and 99 (166 
mg, 0.87 mmol) as the starting materials. The residue was purified by flash chromatography on 
silica gel, eluting with hexanes/acetone (1:2) to afford 108 as a brown solid (41 mg, 18%). 
1
H 
NMR (300 MHz, acetone-d6)  7.96 (d, J = 3.7 Hz, 1H), 7.84 (d, J = 4.8 Hz, 1H), 7.63 (t, J = 8.4 
Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.37 - 7.25 (m, 2H), 7.20 (t, J = 7.7 Hz, 1H), 6.42 (s, 2H), 3.93 
(s, 3H). HRMS (ESI
+
) calcd for C15H12N6O2 (M+H)
+
 341.3677, found 341.0833. 
1-Azido-4-methoxybenzene. Same procedure as 95 using p-anisidine (0.47 mL, 4.06 mmol) as 
the starting material. The compound was obtained as a yellow solid (437 mg, 90%) and was used 
without further purification. 
1
H NMR (300 MHz, chloroform-d)  6.90 (dd, J = 6.6, 12.9 Hz, 
4H), 3.80 (s, 3H). 
 
1-(4-Methoxyphenyl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine 
(109). Same procedure as 51 using 1-azido-4-methoxybenzene (108 mg, 0.72 mmol) and 99 (166 
mg, 0.87 mmol) as the starting materials. The compound 109 was obtained as a brown solid (57 
mg, 73%). 
1
H NMR (300 MHz, DMSO-d6).  8.02 (dd, J = 1.5, 3.9 Hz, 1H), 7.90 (dd, J = 1.5, 
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5.4 Hz, 1H), 7.54 (d, J = 9.0 Hz, 2H), 7.30 - 7.28 (m, 1H), 7.19 (d, J = 9.0 Hz, 2H), 6.81 (s, 2H), 
3.58 (s, 3H). HRMS (ESI
+
) calcd for C15H12N6O2 (M+H)
+
 341.3677, found 341.0828. 
 
2-Azidonaphthalene. Same procedure as 95 using 2-naphthylamine (85 mg, 0.59 mmol) as the 
starting material. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (9:1) to afford an orange solid (35 mg, 35%). 
1
H NMR (300 MHz, chloroform-d) 
 7.85 - 7.76 (m, 3H), 7.54 - 7.45 (m, 3H), 7.17 (dd, J = 2.4, 8.7 Hz, 1H). The analytical data 
matched literature reports.
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1-(Naphthalen-2-yl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine 
(110). Same procedure as 51 using 2-azidonaphthalene (30 mg, 0.17 mmol) and 99 (34 mg, 0.17 
mmol) as the starting materials. The compound 110 was obtained as a red solid (38 mg, 63%). 
1
H 
NMR (300 MHz, DMSO-d6)  8.26 (d, J = 1.5 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.12 - 8.08 (m, 
2H), 8.04 (d, J = 3.6 Hz, 1H), 7.90 (dd, J = 0.6, 4.8 Hz, 1H), 7.75 (dd, J = 1.8, 8.4 Hz, 1H), 7.69 
- 7.66 (m, 2H), 7.31 - 7.29 (m, 1H), 7.01 (s, 2H). HRMS (ESI
+
) calcd for C18H12N6OS (M+H)
+
 
361.4004, found 361.0879. 
 
3-Azido-1,1'-biphenyl. Azidotrimethylsilane (0.19 mL, 1.42 mmol) was added dropwise to a 
solution of 3-aminobiphenyl (200 mg, 1.18 mmol) and tert-butyl nitrite (0.21 mL, 1.77 mmol) in 
ACN (2 mL) at 0 °C. The reaction mixture was then slowly allowed to warm to rt and was stirred 
for 4 h. After completion of the reaction, Et2O (8 mL) and H2O (6 mL) were added, the organic 
layer was separated and further washed with H2O (2 x 5 mL), brine (4 mL), dried over Na2SO4, 
filtered and concentrated. The residue was purified by flash chromatography on silica gel, eluting 
with hexanes/EtOAc (11:1) to deliver a light yellow oil (207 mg, 80%). 
1
H NMR (300 MHz, 
 115 
chloroform-d)  7.58 (d, J = 8.7 Hz, 2H), 7.48 - 7.35 (m, 5H), 7.25 - 7.23 (m, 1H), 7.03 - 7.00 
(m, 1H). The analytical data matched literature reports.
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1-([1,1'-Biphenyl]-3-yl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine 
(111). Same procedure as 51 using 3-azido-1,1’-biphenyl (32 mg, 0.16 mmol) and 99 (31 mg, 
0.16 mmol) as the starting materials. The compound 111 was obtained as an orange solid (28 mg, 
46%). 
1
H NMR (300 MHz, DMSO-d6)  8.00 (dd, J = 0.9, 4.8 Hz, 1H), 7.89 (d, J = 6.9 Hz, 3H), 
7.78 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 7.49 (t, J = 7.2 Hz, 
2H), 7.42 (d, J = 7.5 Hz, 1H), 7.30 - 7.26 (m, 1H), 6.99 (s, 2H). HRMS (ESI
+
) calcd for 
C20H14N6OS (M+H)
+
 387.4377, found 387.1016. 
 
3-(5-Amino-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-yl)phenol (112). 
Boron tribromide (1 M solution in DCM, 0.62 mL, 0.62 mmol) was added dropwise to a solution 
of 51 (84 mg, 0.25 mmol) in DCM (1.3 mL) at 0 °C. The reaction mixture was slowly allowed to 
warm to rt and stirred overnight. H2O was added (1.5 mL) and the product precipitated out, it 
was isolated by filtration, washed with H2O (2 mL) and hexanes (3 x 2 mL), then it was dried 
under vacuum to afford 112 as a brown solid (57 mg, 73%). 
1
H NMR (300 MHz, DMSO-d6).  
10.11 (s, 1H), 8.02 (d, J = 3.6 Hz, 1H), 7.89 (d, J = 5.1 Hz, 1H), 7.43 (t, J = 8.1 Hz, 1H), 7.34 – 
7.25 (m, 1H), 7.08 - 6.92 (m, 3H), 6.87 (s, 2H). 
 
(1-(3-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol (113). Sodium ascorbate (58 mg, 0.29 
mmol) and copper pentahydrate (18 mg, 0.07 mmol) were added to a solution of the azide 95 (56 
mg, 0.37 mmol) and propargyl alcohol (0.024 mL, 0.41 mmol) in a solution of tBuOH:H2O 
(0.2:0.2 mL) at rt. The resulting mixture was stirred overnight. The solvents were removed under 
vacuum. The residue was purified by flash chromatography on silica gel, eluting with 5% MeOH 
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in DCM to deliver 113 as a white solid (34 mg, 64%). 
1
H NMR (300 MHz, DMSO-d6)  8.71 (s, 
1H), 7.46 (d, J = 7.2 Hz, 4H), 7.04 – 6.98 (m, 1H), 5.33 (t, J = 5.5 Hz, 1H), 4.59 (d, J = 5.4 Hz, 
2H), 3.84 (s, 3H). The analytical data matched literature reports.
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1-(3-Methoxyphenyl)-1H-1,2,3-triazole-4-carboxylic acid (114). A solution of 2.7 M Jones’ 
reagent (0.25 mL) was added dropwise to a solution of 113 (34 mg, 0.16 mmol) in acetone (2 
mL) at 0 °C and stirred for 10 min. The reaction mixture was allowed to warm up to rt and 
stirred for 1 h at rt. 2-Propanol was added slowly until the orange color of the excess of Jones’ 
reagent was discharged. The reaction mixture was poured over ice, the product precipitated out, 
it was collected by filtration, washed with H2O (3 mL), and dried under vacuum to give 114 as a 
light blue solid (25 mg, 71%).
 1
H NMR (300 MHz, DMSO-d6)  9.42 (s, 1H), 7.58 – 7.42 (m, 
4H), 7.08 (s, 1H), 3.85 (s, 3H). The analytical data matched literature reports.
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5-(1-(3-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)-3-(thiophen-2-yl)-1,2,4-oxadiazole (115). 
EDCI (19 mg, 0.10 mmol) and 97 (15 mg, 0.10 mmol) were added to a solution of acid 114 (19 
mg, 0.09 mmol) in ACN at rt. The mixture was stirred at rt for 30 min and then was heated to 
120 °C overnight. After allowing the solution to cool to rt, the solvent was removed under 
vacuum. The residue was suspended into EtOAc (5 mL), washed with saturated NaHCO3 (2 x 4 
mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to give 115 as a dark oil (13 mg, 
46%). 
1
H NMR (300 MHz, chloroform-d)  8.71 (s, 1H), 7.93 (d, J = 3.7 Hz, 1H), 7.55 (d, J = 
5.0 Hz, 1H), 7.48 (t, J = 8.1 Hz, 1H), 7.46 – 7.40 (m, 1H), 7.34 (d, J = 8.8 Hz, 1H), 7.20 (t, J = 
4.8 Hz, 1H), 7.06 (d, J = 8.2 Hz, 1H), 3.92 (s, 3H). HRMS (ESI
+
) calcd for C15H11N5O2S 
(M+H)
+
 326, found 326. 
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The analogs 116 and 117 were synthesized from intermediate 97 and the corresponding azides 
following the procedure described for 115: 
Azidobenzene. Same procedure as 95 using aniline (0.34 mL, 3.76 mmol) as the starting 
material. The compound was obtained as an orange oil (39 mg, 82%) and was used without 
further purification. 
1
H NMR (300 MHz, chloroform-d)  7.36 (t, J = 8.1 Hz, 2H), 7.22 (t, J = 7.9 
Hz, 1H), 7.02 (d, J = 7.5 Hz, 2H). The analytical data matched literature reports.
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(1-Phenyl-1H-1,2,3-triazol-4-yl)methanol. Same procedure as 113 using azidobenzene (87 mg, 
0.73 mmol) as the starting material. The residue was purified by flash chromatography on silica 
gel, eluting with 5% MeOH in DCM to deliver a yellow solid (76 mg, 60%) 
1
H NMR (300 MHz, 
DMSO-d6)  8.68 (s, 1H), 7.91 (d, J = 7.5 Hz, 2H), 7.58 (t, J = 8.4 Hz, 2H), 7.45 (d, J = 8.2 Hz, 
1H), 5.33 (t, J = 5.6 Hz, 1H), 4.60 (d, J = 5.5 Hz, 2H). The analytical data matched literature 
reports.
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1-Phenyl-1H-1,2,3-triazole-4-carboxylic acid. Same procedure as 114 using (1phenyl-1H-
1,2,3-triazol-4-yl)methanol (77 mg, 0.44 mmol) as the starting material. The compound was 
obtained as a yellow solid (21 mg, 25%). 
1
H NMR (400 MHz, DMSO-d6)  9.38 (s, 1H), 7.95 
(d, J = 8.4 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.52 (t, J = 8.0 Hz, 1H). The analytical data matched 
literature reports.
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5-(1-Phenyl-1H-1,2,3-triazol-4-yl)-3-(thiophen-2-yl)-1,2,4-oxadiazole (116).  Same procedure 
as 115 using 1-phenyl-1H-1,2,3-triazole-4-carboxylic acid (20 mg, 0.11 mmol) and 97 (18 mg, 
0.13 mmol) as the starting materials. The residue was purified by flash chromatography on silica 
gel, eluting with hexanes/EtOAc (3:1) to afford 116 as a white solid (8 mg, 25%). 
1
H NMR (300 
MHz, chloroform-d)  8.74 (s, 1H), 7.92 (d, J = 3.7 Hz, 1H), 7.82 (d, J = 12 Hz, 2H), 7.65 - 7.51 
 118 
(m, 4H), 7.19 (t, J = 5.1 Hz, 1H). HRMS (ESI
+
) calcd for C14H9N5OS (M+Na)
+
 318.0, found 
318.0. 
(1-(3-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol. Same procedure as 113 using 1-azido-3-
fluorobenzene (74 mg, 0.53 mmol) as the starting material. The residue was purified by flash 
chromatography on silica gel, eluting with 5% MeOH in DCM to deliver a yellow solid (57 mg, 
56%). 
1
H NMR (300 MHz, chloroform-d)  8.01 (s, 1H), 7.63 - 7.40 (m, 3H), 7.15 (m, 1H), 4.90 
(s, 2H). 
1-(3-Fluorophenyl)-1H-1,2,3-triazole-4-carboxylic acid. Same procedure as 114 using (1-(3-
fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (57 mg, 0.29 mmol) as the starting material. The 
compound was obtained as a white solid (44 mg, 73%). 
1
H NMR (300 MHz, DMSO-d6)  9.44 
(s, 1H), 7.93 (t, J = 2.2 Hz, 1H), 7.91 - 7.83 (m, 2H), 7.66 (m, 1H), 7.38 (t, J = 8.4 Hz, 1H). 
5-(1-(3-Fluorophenyl)-1H-1,2,3-triazol-4-yl)-3-(thiophen-2-yl)-1,2,4-oxadiazole (117). Same 
procedure as 115 using 1-(3-fluorophenyl)-1H-1,2,3-triazole-4-carboxylic acid (44 mg, 0.21 
mmol) and 97 (36 mg, 0.25 mmol). The residue was purified by flash chromatography on silica 
gel, eluting with hexanes/EtOAc (3:1) to afford 117 as a yellow solid (19 mg, 28%). 
1
H NMR 
(300 MHz, DMSO-d6)  9.96 (s, 1H), 8.05 - 7.87 (m, 5H), 7.71 (td, J = 8.3, 6.2 Hz, 1H), 7.48 - 
7.39 (m, 1H), 7.31 (dd, J = 5.0, 3.7 Hz, 2H). HRMS (ESI
+
) calcd for C14H8FN5OS (M+H)
+
 
314.05, found 314.05. 
The analogs 119-121 were synthesized from the corresponding azides and hydroximes following 
the procedure and purification described for 51 unless otherwise indicated: 
N-Hydroxybenzimidamide. Same procedure as 97 using benzonitrile (0.55 mL, 5.34 mmol) as 
the starting material. The compound was obtained as a yellow oil (397 mg, 56%). 
1
H NMR (300 
 119 
MHz, chloroform-d)  7.76 - 7.55 (m, 3H), 7.56 - 7.34 (m, 2H), 4.90 (s, 1H). The analytical data 
matched literature reports.
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2-(3-Phenyl-1,2,4-oxadiazol-5-yl)acetonitrile. Same procedure as 99 using N-
hydroxybenzimidamide (152 mg, 1.11 mmol) and 98 (91 mg, 0.56 mmol) as the starting 
materials. The compound was obtained as a white solid (41 mg, 41%). 
1
H NMR (300 MHz, 
chloroform-d)  8.07 (d, J = 8.0 Hz, 2H), 7.67 - 7.43 (m, 3H), 4.12 (s, 2H). The analytical data 
matched literature reports.
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1-(3-Methoxyphenyl)-4-(3-phenyl-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine (119). 
Same procedure as 51 using 95 (33 mg, 0.22 mmol) and 2-(3-phenyl-1,2,4-oxadiazol-5-
yl)acetonitrile (41 mg, 0.22 mmol) as the starting materials. The compound was obtained as a 
brown solid (33 mg, 45%). 
1
H NMR (300 MHz, chloroform-d)  8.15 (d, J = 8.0 Hz, 1H), 7.53 
(d, J = 1.6 Hz, 4H), 7.23 - 7.06 (m, 4H), 5.49 (s, 1H), 3.90 (s, 3H). HRMS (ESI
+
) calcd for 
C17H14N6O2 (M+H)
+
 335.1256, found 335.1342. 
N-Hydroxypicolinimidamide. Same procedure as 97 using 2-cyanopyridine (200 mg, 1.92 
mmol) as the starting material. The compound was obtained as a light yellow solid (66 mg, 
80%). 
1
H NMR (300 MHz, DMSO-d6)  10.38 (s, 1H), 8.62 (d, J = 4.3 Hz, 1H), 7.99 - 7.84 (m, 
2H), 7.57 - 7.43 (m, 1H), 6.85 (s, 2H). The analytical data matched literature reports.
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2-(3-(Pyridin-2-yl)-1,2,4-oxadiazol-5-yl)acetonitrile. Same procedure as 99 using N-
hydroxypicolinimidamide (100 mg, 0.73 mmol) and 98 (143 mg, 0.87 mmol) as the starting 
materials. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (1:1) to afford a yellow solid (67 mg, 50%). 
1
H NMR (300 MHz, DMSO-d6)  
8.77 (d, J = 4.8 Hz, 1H), 8.14 - 7.98 (m, 2H), 7.64 - 7.60 (m, 1H), 4.81 (s, 2H). 
 120 
1-(3-Methoxyphenyl)-4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine 
(120). Same procedure as 51 using 95 (45 mg, 0.30 mmol) and 2-(3-(pyridin-2-yl)-1,2,4-
oxadiazol-5-yl)acetonitrile (57 mg, 0.30 mmol) as the starting materials. The compound was 
obtained as a light brown solid (24 mg, 25%). 
1
H NMR (300 MHz, DMSO-d6)  8.77 (d, J = 4.0 
Hz, 1H), 8.36 (d, J = 7.9 Hz, 1H), 8.04 (t, J = 5.8 Hz, 1H), 7.66 - 7.51 (m, 2H), 7.25 - 7.13 (m, 
3H), 6.95 (s, 2H), 3.85 (s, 3H). HRMS (ESI
+
) calcd for C16H13N7O2 (M+H)
+
 336.0, found 336.0. 
1-(3-Fluorophenyl)-4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-5-amine (121). 
Same procedure as 51 using 1-azido-3-fluorobenzene (25 mg, 0.13 mmol) and 2-(3-(pyridin-2-
yl)-1,2,4-oxadiazol-5-yl)acetonitrile (18 mg, 0.13 mmol) as the starting materials. The compound 
was obtained as a light orange solid (19 mg, 45%). 
1
H NMR (300 MHz, DMSO-d6)  8.78 (d, J 
= 3.9 Hz, 1H), 8.37 (d, J = 7.8 Hz, 1H), 8.04 (t, J = 7.8 Hz, 1H), 7.76 - 7.57 (m, 3H), 7.53 - 7.50 
(m, 2H), 7.04 (s, 2H). HRMS (ESI
+
) calcd for C15H10FN7O (M+Na)
+
 346.2744, found 346.0810. 
The analogs 122 and 123 were obtained following the protocol described for 115: 
N-Hydroxypentanimidamide. Same procedure as 97 using valeronitrile (0.5 mL, 4.81 mmol) as 
the starting material. The compound was obtained as a colorless oil (40 mg, 25%). 
1
H NMR (300 
MHz, chloroform-d)  4.54 (s, 2H), 2.34 (t, J = 7.1 Hz, 2H), 2.13 (t, J = 8.1 Hz, 2H), 1.73 - 1.28 
(m, 2H), 0.93 (t, J = 7.3 Hz, 3H). The analytical data matched literature reports.
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3-Butyl-5-(1-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazole (122). Same 
procedure as 115 using N-hydroxypentanimidamide (60 mg, 0.52 mmol) and 114 (25 mg, 0.11 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (2:1) to afford 122 as a white solid (7 mg, 22%). 
1
H NMR (300 
MHz, chloroform-d)  8.63 (s, 1H), 7.47 (t, J = 8.2 Hz, 1H), 7.39 (t, J = 2.2 Hz, 1H), 7.32 (d, J = 
 121 
7.9 Hz, 1H), 7.05 (dd, J = 8.3, 2.5 Hz, 1H), 3.90 (s, 3H), 2.83 (t, J = 7.5 Hz, 2H), 1.81 (m, 2H), 
1.44 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H). HRMS (ESI
+
) calcd for C15H17N5O2 (M+Na)
+
 322.1280, 
found 322.1258. 
Benzo[b]thiophene-2-carbonitrile. Ammonium hydroxide (0.7 ml) and iodine (370 mg, 1.45 
mmol) were added to a stirred solution of benzothiophene-2-carboxaldehyde (200 mg, 1.23 
mmol) in THF (4 ml). The reaction mixture was stirred overnight under refluxing condition. The 
mixture was then treated with 5% aqueous solution of Na2S2O3 (5 ml) and the product was 
extracted with EtOAc (2 x 6 mL). The combined organic layers were washed with brine, dried 
over Na2SO4, filtered, and concentrated. The product was obtained as a yellow oil (130 mg, 
70%) and used without further purification. 
1
H NMR (300 MHz, chloroform-d).  7.89 (m, 2H), 
7.58 (d, J = 7.5 Hz, 1H), 7.49 (d, J = 7.0 Hz, 1H), 7.44 (m, 1H). The analytical data matched 
literature reports.
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N-Hydroxybenzo[b]thiophene-2-carboximidamide. Same procedure as 97 using 
benzo[b]thiophene-2-carbonitrile (80 mg, 0.5 mmol) as the starting material.  The compound was 
obtained as a white solid (64 mg, 67%). 
1
H NMR (300 MHz, DMSO-d6)  9.93 (s, 1H), 7.87 (m, 
2H), 7.65 - 7.50 (m, 1H), 7.40 - 7.30 (m, 2H), 6.05 (s, 2H). 
3-(Benzo[b]thiophen-2-yl)-5-(1-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazole 
(123). Same procedure as 115 using N-hydroxybenzo[b]thiophene-2-carboximidamide (42 mg, 
0.22 mmol) and 114 (40 mg, 0.18 mmol) as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to afford 123 as a light 
yellow solid (12 mg, 18%). 
1
H NMR (300 MHz, DMSO-d6)  9.96 (s, 1H), 8.29 (s, 1H), 8.15 - 
8.03 (m, 2H), 7.64 (d, J = 6.6 Hz, 1H), 7.61 - 7.47 (m, 3H), 7.13 (d, J = 9.4 Hz, 1H), 3.88 (s, 
3H). 
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Synthesis of hit compounds 53 and 54 
Ethyl-3-(2-methoxyacetamido)benzofuran-2-carboxylate (125). 2-Methoxyacetyl chloride 
(0.267 mL, 2.92 mmol) was added dropwise to a solution of ethyl 3-aminobenzofuran-2-
carboxylate (200 mg, 0.97 mmol) and pyridine (0.236 mL, 2.92 mmol) in DCM (4.9 mL) at 0 
°C. The resulting mixture was allowed to warm to rt and stirred for 2 h. The mixture was diluted 
with DCM (5 mL), and washed with H2O (3 x 4 mL). The organic layer was dried over Na2SO4, 
filtered, and concentrated. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (3:2) to give 125 as a white solid (211 mg, 82%). 
1
H NMR (400 
MHz, chloroform-d)  10.22 (s, 1H), 8.49 - 8.44 (d, J = 12 Hz, 1H), 7.55 - 7.44 (m, 2H), 7.30 (t, 
J = 8 Hz, 1H), 4.50 (q, J = 7.1, 2H), 4.14 (s, 2H), 3.59 (s, 3H), 1.47 (t, J = 7.1, 3H). 
 
3-(2-Methoxyacetamido)benzofuran-2-carboxylic acid (126). A 2 M solution of LiOH (2.94 
mL) was added to the ester 125 (125 mg, 0.47 mmol) in a mixture of THF:MeOH (3 mL:1 mL). 
The reaction mixture was stirred at rt for 1h30. H2O was added (6 mL) and the aqueous layer 
was washed with EtOAc (8 mL). The aqueous layer was acidified with 1 M HCl (pH  3) and 
extracted with EtOAc (3 x 6 mL). The combined organic layers were dried over Na2SO4, filtered, 
and concentrated to give 126 as a light yellow solid (90 mg, 77%). 
1
H NMR (300 MHz, 
chloroform-d)  10.20 (s, 1H), 8.48 (d, J = 8.2 Hz, 1H), 7.49 (s, 2H), 7.30 (m, 1H), 4.14 (s, 2H), 
3.55 (s, 3H). 
N-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-3-(2-methoxyacetamido)benzofuran-2-
carboxamide (53). PCl5 (167 mg, 0.8 mmol) was added portionwise to a suspension of the acid 
126 (40 mg, 0.16 mmol) in DCM (1.2 mL) at 0 °C. After the mixture turned clear, the reaction 
mixture was allowed to warm up to rt and stirred for 2 h. The solvent was removed under 
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vacuum and the residue was suspended in DCM (0.2 mL). This solution was added dropwise to a 
cold solution of 1,4-benzodioxan-6-amine (0.016 mL, 0.13 mmol) in pyridine (0.16 mL). After 
completion of the addition, the reaction mixture was stirred at rt ON. The mixture was diluted 
with DCM (6 mL) and washed with 1 M HCl (2 mL), H2O (2 x 8 mL), 0.1 M NaOH (2 mL), 
brine (3 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (1:1) to give 53 as a white solid (20 
mg, 32%). 
1
H NMR (300 MHz, chloroform-d)  8.16 (d, J = 7.8 Hz, 1H), 7.68 (d, J = 8.4 Hz, 
1H), 7.61 (t, J = 6.9 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.03 (d, J = 8.5 Hz, 1H), 6.85 (sd, J = 2.5 
Hz, 1H), 6.79 (dd, J = 8.5, 2.6 Hz, 1H), 4.39 - 4.29 (m, 4H), 4.24 (s, 2H), 3.38 (s, 3H). 
Methyl-2-(5-(4-bromophenyl)furan-2-carboxamido)benzoate (128). Thionyl chloride (0.142 
mL, 1.96 mmol) was added to a suspension of 5-(4-bromophenyl)-2-furoic acid (150 mg, 0.56 
mmol). The mixture was heated to reflux for 1 h. The excess of thionyl chloride was removed 
under vacuum. The residual liquid was cooled to 0 °C in an ice bath and a solution of methyl-2-
aminobenzoate (0.145 mL, 1.12 mmol) and TEA (0.098 mL, 0.7 mmol) in DCM (1.1 mL) was 
added slowly. The resulting mixture was heated to reflux for 1 h. It was then treated with a 
saturated sodium bicarbonate solution until the aqueous layer was slightly basic (pH  8). The 
phases were separated and the organic layer was washed with H2O (2 x 10 mL), dried over 
Na2SO4, filtered, and concentrated. The crude product was purified by recrystallization in 
refluxing EtOH to give 128 as a white solid (139 mg, 62%). 
1
H NMR (300 MHz, chloroform-d) 
 12.34 (s, 1H), 8.87 (d, J = 8.6 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.83 - 7.73 (m, 2H), 7.60 (m, 
3H), 7.31 (d, J = 10.8 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 6.80 (sd, J = 3.6 Hz, 1H), 4.01 (s, 3H). 
2-(5-(4-Bromophenyl)furan-2-carboxamido)benzoic acid (129). NaOH (295 mg, 7.34 mmol) 
was added to a solution of the ester 128 (295 mg, 0.74 mmol) in MeOH:H2O (2:1.2 mL). The 
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reaction was heated to reflux for 2.5 h. The reaction mixture was diluted with H2O (6 mL) and 
extracted with EtOAc (5 mL). The aqueous layer was acidified to a pH of 3 with 1 M HCl (2.5 
mL) and extracted with EtOAc (3 x 6 mL). The combined organic layers were dried over 
Na2SO4, filtered, and concentrated to give 129 as a white solid (256 mg, 90%). 
1
H NMR (300 
MHz, DMSO-d6)  12.4 (s, 1H), 9.72 (d, J = 8.7 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 
8.7 Hz, 2H), 7.68 (d, J = 8.7 Hz, 3H), 7.38 (sd, J = 3.6 Hz, 1H), 7.29 (sd, J = 3.9 Hz, 1H), 7.21 
(t, J = 6.9 Hz, 1H). 
5-(4-Bromophenyl)-N-(2-carbamoylphenyl)furan-2-carboxamide (54). EDCI (67 mg, 0.35 
mmol), HOBt (49 mg, 0.36 mmol), and ammonium chloride (63 mg, 1.17 mmol) were added to a 
solution of 129 (45 mg, 0.12 mmol) and TEA (0.163 mL, 1.17 mmol) in THF (0.5 mL). The 
reaction mixture was stirred at rt overnight, and poured into H2O (5 mL) and extracted with 
EtOAc (3 x 5 mL). The combined organic layers were washed with saturated NaHCO3 (4 mL), 
brine (4 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to give 54 as a white solid (57 
mg, 75%). 
1
H NMR (300 MHz, DMSO-d6)  8.65 (d, J = 9.0 Hz, 1H), 8.41 (s, 1H), 7.89 (td, J = 
8.1, 1.8 Hz, 3H), 7.70 (dd, J = 8.4, 2.1 Hz, 2H), 7.57 (t, J = 7.2 Hz, 1H), 7.35 – 7.28 (m, 2H), 
7.18 (t, J = 7.5 Hz, 1H). HRMS (ESI
+
) calcd for C18H13BrN2O3 (M+Na)
+
 408.2, found 409.0. 
 
Synthesis of oxadiazole probes for target Identification 
The analogs 157-159 were synthesized from intermediate 99 and the corresponding azides 
following the procedure described for 51: 
(3-Azidophenyl)methanol. Same procedure as 95 using 3-aminobenzylalcohol (200 mg, 1.62 
mmol) as the starting material. The compound was obtained as a brown oil (52 mg, 78%). 
1
H 
 125 
NMR (300 MHz, DMSO-d6)  8.02 (d, J = 3.6 Hz, 1H), 7.89 (d, J = 5.0 Hz, 1H), 7.65 - 7.59 (m, 
1H), 7.29 (d, J = 5.0 Hz, 1H), 5.42 (s, 1H), 4.62 (s, 2H). The analytical data matched literature 
reports.
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(3-(5-Amino-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-
yl)phenyl)methanol (157). Same procedure as 51 using 99 (48 mg, 0.25 mmol) and (3-
azidophenyl)methanol (37 mg, 0.25 mmol) as the starting materials. The compound 157 was 
obtained as a brown solid (54 mg, 63%). 
1
H NMR (300 MHz, DMSO-d6)  8.02 (d, J = 3.6 Hz, 
1H), 7.89 (d, J = 4.8 Hz, 1H), 7.60 - 7.51 (m, 4H), 7.28 (t, J = 4.8 Hz, 1H), 6.89 (s, 2H), 5.48 (s, 
1H), 4.62 (s, 2H). HRMS (ESI
+
) calcd for C15H12N6O2S (M+H)
+
 341.3677, found 341.0789. 
(4-Azidophenyl)methanol. Same procedure as 95 using 4-aminobenzylalcohol (300 mg, 2.44 
mmol) as the starting material. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (4:1) to deliver a brown oil (360 mg, 90%). 
1
H NMR (300 MHz, 
chloroform-d)  7.16 (d, J = 8.6 Hz, 2H), 6.68 (d, J = 8.5 Hz, 2H), 4.55 (s, 2H). The analytical 
data matched literature reports.
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(4-(5-Amino-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-
yl)phenyl)methanol (158). Same procedure as 51 using 99 (50 mg, 0.26 mmol) and (4-
azidophenyl)methanol (39 mg, 0.26 mmol) as the starting materials. The compound 158 was 
obtained as a brown solid (46 mg, 53%). 
1
H NMR (300 MHz, DMSO-d6)  8.03 (s, 1H), 7.90 
(m, 2H), 7.58 (s, 3H), 7.29 (s, 1H), 6.89 (s, 2H), 5.44 (s, 1H), 4.62 (s, 2H). HRMS (ESI
+
) calcd 
for C15H12N6O2S (M+H)
+
 341.3677, found 341.0794. 
(2-Azidophenyl)methanol. Same procedure as 95 using 2-aminobenzylalcohol (200 mg, 1.62 
mmol) as the starting material. The compound was obtained as a brown oil (90 mg, 98%). 
1
H 
 126 
NMR (300 MHz, chloroform-d)  7.34 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 8.5 Hz, 2H), 4.66 (s, 2H). 
The analytical data matched literature reports.
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(2-(5-Amino-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-
yl)phenyl)methanol (159). Same procedure as 51 using 99 (50 mg, 0.26 mmol) and (2-
azidophenyl)methanol (39 mg, 0.26 mmol) as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with hexanes/EtOAc (4:1) to deliver 159 as a brown 
solid (22 mg, 48%). 
1
H NMR (300 MHz, DMSO-d6)  8.01 (d, J = 3.7 Hz, 1H), 7.88 (d, J = 5.0 
Hz, 1H), 7.74 (d, J = 7.6 Hz, 1H), 7.65 (t, J = 6.8 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.45 (d, J = 
7.2 Hz, 1H), 7.29 – 7.26 (m, 1H), 6.79 (s, 2H), 5.37 (t, J = 5.4 Hz, 1H), 4.32 (d, J = 5.3 Hz, 2H). 
HRMS (ESI
+
) calcd for C15H12N6O2S (M+H)
+
 341.3677, found 341.0809. 
tert-Butyl (3-hydroxyphenyl)carbamate (162). di-tert-Butyl-dicarbonate (1.8 g, 8.2 mmol) was 
added to a solution of 3-aminophenol (600 mg, 5.5 mmol) in THF (6 ml). The reaction mixture 
was heated to reflux for 4 h. The mixture was diluted in EtOAc (15 ml) and washed with 1% HCl 
(5 mL) and H2O (2 x 10 mL). The combined organic layers were further washed with brine (5 
mL), dried over MgSO4, filtered, and concentrated to give 162 as a white solid (852 mg, 87%). 
1
H NMR (300 MHz, chloroform-d).  7.12 - 7.07 (m, 1H), 6.73 (d, J = 8.1 Hz, 1H), 6.60 - 6.52 
(m, 2H), 3.54 - 3.50 (m, 1H), 1.51 (m, 9H). The analytical data matched literature reports.
175
 
tert-Butyl (3-(2,5,8,11-tetraoxatridecan-13-yloxy)phenyl)carbamate (164). Cs2CO3 (189 mg, 
0.58 mmol) and triethyleneglycol-2-bromoethylmethylether (0.070 mL, 0.32 mmol) were added 
to a solution of the alcohol 162 (62 mg, 0.29 mmol) in DMA (0.5 mL). The resulting mixture 
was stirred at 60 °C overnight. After allowing the solution to cool to rt, H2O (5 mL) was added 
and the product was extracted with Et2O (2 x 6 mL). The combined organic layers were washed 
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with brine (4 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by 
flash chromatography on silica gel, eluting with hexanes/EtOAc (3/1) to afford 164 as a yellow 
oil (100 mg, 87%). 
1
H NMR (300 MHz, chloroform-d).  7.16 - 7.10 (m, 1H), 6.80 (d, J = 8.6 
Hz, 1H), 6.60 - 6.58 (m, 2H), 4.10 (t, J = 4.2 Hz, 2H), 3.82 (t, J = 5.1 Hz, 2H), 3.70 - 3.62 (m, 
10H), 3.55 - 3.53 (m, 2H), 3.36 (s, 3H), 1.50 (s, 9H). 
3-(2,5,8,11-Tetraoxatridecan-13-yloxy)aniline (165). A solution of 4 M HCl in dioxane (0.19 
mL, 0.08 mmol) was added to a solution of the amine 164 (51 mg, 0.13 mmol) in THF (0.9 mL). 
The reaction mixture was stirred overnight at rt. The solvents were removed under pressure, the 
residue was dissolved in DCM (5 ml) and washed with H2O (2 x 4 ml) and brine (4 mL). The 
organic layer was dried over Na2SO4, filtered, and concentrated to give 165 as an oil (35 mg, 
92%). 
1
H NMR (300 MHz, chloroform-d)  7.10 (t, J = 8.5 Hz, 1H), 6.30 - 6.25 (m, 3H), 4.10 (t, 
J = 4.2 Hz, 2H), 3.82 (t, J = 5.1 Hz, 2H), 3.70 - 3.56 (m, 12H), 3.36 (s, 3H). 
13-(3-Azidophenoxy)-2,5,8,11-tetraoxatridecane (166). Same procedure as 95 using 165 (67 
mg, 0.22 mmol) as the starting material. The residue was purified by flash chromatography on 
silica gel, eluting with DCM/EtOAc (1:1) to afford 166 as a yellow oil (34 mg, 48%). 
1
H NMR 
(400 MHz, chloroform-d)  7.21 (t, J = 8.5 Hz, 1H), 6.68 (d, J = 9 Hz, 1H), 6.64 (d, J = 8.6 Hz, 
1H), 6.55 (s, 1H), 3.84 - 3.81 (m, 2H), 3.71 - 3.61 (m, 12H), 3.60 - 3.56 (m, 2H), 3.36 (s, 3H). 
 
1-(3-(2,5,8,11-Tetraoxatridecan-13-yloxy)phenyl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-
1H-1,2,3-triazol-5-amine (160). Cs2CO3 (70 mg, 0.21 mmol) and triethyleneglycol-2-
bromoethylmethylether (0.022 mL, 0.11 mmol) were added to a solution of the alcohol 112 (35 
mg, 0.11 mmol) in DMA (0.3 mL). The resulting mixture was stirred at 50 °C overnight. After 
allowing the solution to cool to rt, H2O (5 mL) was added and the product was extracted with 
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Et2O (2 x 6 mL). The combined organic layers were washed with brine (4 mL), dried over 
Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography on silica 
gel, eluting with methanol/DCM (5% MeOH) to give 160 as a yellow oil (28 mg, 55%). 
1
H NMR 
(300 MHz, acetone-d6)  7.92 (m, 1H), 7.82 (m, 1H), 7.55 (m, 1H), 7.30 - 7.22 (m, 4H), 4.27 (t, 
J = 6.0 Hz, 2H), 3.87 (t, J = 3.9 Hz, 2H), 3.67 - 3.37 (m, 14H), 3.28 - 3.24 (m, 2H), 2.99 (s, 3H). 
HRMS (ESI
+
) calcd for C23H28N6O6S (M+H)
+
 517.1869, found 517.1908. 
1-(3-(prop-2-yn-1-yloxy)phenyl)-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-
5-amine (167). Same procedure as 160 using 112 (23 mg, 0.07 mmol) and propargyl bromide 
(80% in toluene, 0.08 mL, 0.07 mmol) as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to afford 167 as a white 
solid (5 mg, 20%). 
1
H NMR (300 MHz, acetone-d)  7.95 (dd, J = 0.9, 3.3 Hz, 1H), 7.81 (d, J = 
4.8 Hz, 1H), 7.62 - 7.57 (m, 1H), 7.34 - 7.24 (m, 4H), 6.61 (s, 2H), 4.94 (d, J = 2.4 Hz, 2H), 3.19 
(t, J = 2.4 Hz, 1H). HRMS (ESI
+
) calcd for C17H12N6O2S (M+H)
+
 365.3891, found 365.0829. 
The analogs 168-170 were synthesized from intermediate 99 and the corresponding azides 
following the procedure and purification described for 51: 
(3-Azidophenyl)(phenyl)methanone. Concentrated sulfuric acid (0.1 mL) was added to a 
solution of 3-aminobenzophenone (50 mg, 0.25 mmol) in acetic acid (0.34 mL) at 0 °C, then a 
solution of sodium nitrite (100 mg, 1.45 mmol) in H2O (2 mL) was slowly added over 30 min. 
The resulting mixture was stirred at 0 °C for 2 h and a solution of sodium azide (162 mg, 2.5 
mmol) in H2O (3 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 1 h and 
then it was diluted with H2O (6 mL) and extracted with EtOAc (2 x 6 mL). The combined 
organic layers were further washed with H2O (2 x 5 mL), NaHCO3 (5 mL), brine (4 mL), dried 
over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography on 
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silica gel, eluting with hexanes/EtOAc (9:1) to deliver a yellow solid (52 mg, 95%) 
1
H NMR 
(300 MHz, Chloroform-d)  7.79 (dt, J = 1.5, 81 Hz, 2H), 7.61 (t, J = 1.5, 7.5 Hz, 1H), 7.54 - 
7.44 (m, 5H), 7.25 - 7.22 (m, 1H). 
 
(3-(5-Amino-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-
yl)phenyl)(phenyl)methanone (168). Same procedure as 51 using 99 (25 mg, 0.13 mmol) and 
(3-azidophenyl)(phenyl)methanone (30 mg, 0.13 mmol) as the starting materials. The compound 
168 was obtained as a brown solid (25 mg, 47%). 
1
H NMR (300 MHz, DMSO-d6)  8.02 - 1.98 
(m, 1H), 7.96 - 7.94 (m, 2H), 7.91 - 7.87 (m, 2H), 7.82 (d, J = 7.2 Hz, 3H), 7.70 (t, J = 7.0 Hz, 
1H), 7.58 (t, J = 7.5 Hz, 2H), 7.30 - 7.28 (m, 1H), 7.02 (s, 2H). HRMS (ESI
+
) calcd for 
C21H14N6O2S (M+H)
+
 415.4478, found 415.0990. 
 
(4-Azidophenyl)(phenyl)methanone. A solution of sodium nitrite (17.5 mg, 0.25 mmol) in H2O 
(0.1 mL) was added to a solution of 4-aminobenzophenone (50 mg, 0.25 mmol) in 10% HCl 
(0.37 mL) at 0 °C and the resulting mixture was stirred for 30 min. A solution of sodium azide 
(18 mg, 0.28 mmol) in H2O (0.3 mL) was added and the reaction mixture was stirred at 0 °C for 
another hour, allowed to warm up to rt and stirred for 1 h. The reaction mixture was then diluted 
with H2O (4 mL) and extracted with EtOAc (2 x 5 mL). The combined organic layers were 
further washed with H2O (2 x 4 mL), NaHCO3 (4 mL), brine (4 mL), dried over Na2SO4, filtered, 
and concentrated. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (8:1) to deliver a yellow solid (44 mg, 80%). 
1
H NMR (300 MHz, Chloroform-
d)  7.87 - 7.75 (m, 4H), 7.59 (t, J = 7.5 Hz, 1H), 7.50 (t, J = 7.8 Hz, 2H), 7.12 (dt, J = 2.1, 4.2 
Hz, 2H). 
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(4-(5-Amino-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-
yl)phenyl)(phenyl)methanone (169). Same procedure as 51 using 99 (25 mg, 0.13 mmol) and 
(4-azidophenyl)(phenyl)methanone (30 mg, 0.13 mmol) as the starting materials. The compound 
169 was obtained as an orange solid (46 mg, 87%). 
1
H NMR (300 MHz, DMSO-d6)  8.03 (dd, 
J = 0.9, 3.3 Hz, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.90 - 7.87 (m, 2H), 7.85 - 7.79 (m, 3H), 7.72 (t, J 
= 7.5 Hz, 1H), 7.60 (t, J = 7.5 Hz, 2H), 7.29 (td, J = 1.2, 5.1 Hz, 1H), 7.09 (s, 2H). HRMS (ESI
+
) 
calcd for C21H14N6O2S (M+H)
+
 415.4478, found 415.0933. 
 
(2-Azidophenyl)(phenyl)methanone. Same procedure as (3-azidophenyl)(phenyl)methanone 
using 2-aminobenzophenone (150 mg, 0.76 mmol) as the starting material. The compound was 
obtained as a yellow solid (156 mg, 53%). 
1
H NMR (300 MHz, chloroform-d)  7.80 (dd, J = 
0.9, 8.1 Hz, 2H), 7.59 (tt, J = 1.5, 8.7 Hz, 1H), 7.54 - 7.43 (m, 3H), 7.38 (dd, J = 1.8, 7.8 Hz, 
1H), 7.27 - 7.20 (m, 2H). The analytical data matched literature reports.
183
 
 
(2-(5-Amino-4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-
yl)phenyl)(phenyl)methanone (170). Same procedure as 51 using 99 (25 mg, 0.13 mmol) and 
(2-azidophenyl)(phenyl)methanone (30 mg, 0.13 mmol) as the starting materials. The compound 
170 was obtained as an brown solid (53 mg, 94%) 
1
H NMR (300 MHz, DMSO-d6)  8.85 (d, J = 
8.1 Hz, 1H), 8.28 (t, J = 7.2 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.95 - 7.89 (m, 3H), 7.86 - 7.83 
(m, 2H), 7.71 - 7.69 (m, 3H), 7.30 (td, J = 0.9, 3.9 Hz, 1H), 7.11 (s, 2H). HRMS (ESI
+
) calcd for 
C21H14N6O2S (M+H)
+
 415.4478, found 415.0933. 
 
4-(Prop-2-yn-1-yloxy)benzonitrile (175). Cs2CO3 (2.73 g, 8.38 mmol) and propargyl bromide 
(80% in toluene, 0.467 mL, 4.19 mmol) were added to a solution of 4-cyanophenol (500 mg, 
4.19 mmol) in acetone (10 mL). The reaction mixture was heated to reflux for 2 h. After cooling 
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to rt, the reaction mixture was filtered through celite, the solid was washed with acetone (2 x 5 
mL) and the filtrate was concentrated. The residue was purified by flash chromatography on 
silica gel, eluting with hexanes/acetone (4:1) to deliver 175 as a light yellow solid (662 mg, 
100%). 
1
H NMR (300 MHz, chloroform-d)  7.60 (d, J = 9.0 Hz, 2H), 7.02 (d, J = 9.0 Hz, 2H), 
4.75 (d, J = 2.4 Hz, 2H), 2.57 (t, J = 2.1 Hz, 1H). The analytical data matched literature 
reports.
184
 
 
N-Hydroxy-4-(prop-2-yn-1-yloxy)benzimidamide (176). Same protocol as 97 using 175 (100 
mg, 0.64 mmol) as the starting material. The compound 176 was obtained as a yellow solid (114 
mg, 94%). 
1
H NMR (300 MHz, acetone-d)  7.66 (d, J = 8.7 Hz, 2H), 6.99 (d, J = 9.0 Hz, 2H), 
4.81 (d, J = 2.4 Hz, 2H), 3.10 (t, J = 2.4 Hz, 1H), 2.87 (s, 2H). 
 
2-(3-(4-(Prop-2-yn-1-yloxy)phenyl)-1,2,4-oxadiazol-5-yl)acetonitrile (177). Same protocol as 
99 using 98 (113 mg, 0.69 mmol) and 176 (111 mg, 0.58 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/acetone (3:1) to 
deliver 177 as a yellow solid (84 mg, 62%). 
1
H NMR (300 MHz, chloroform-d).  8.03 (dd, J = 
2.1, 6.9 Hz, 2H), 7.07  (dd, J = 2.1, 6.9 Hz, 2H), 4.77 (d, J = 2.4 Hz, 2H), 4.11 (s, 2H), 2.56 (t, J 
= 2.4 Hz, 1H). 
 
(3-(5-Amino-4-(3-(4-(prop-2-yn-1-yloxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-
yl)phenyl)(phenyl)methanone (171). Same protocol as 51 using 177 (31 mg, 0.13 mmol) and 
(3-azidophenyl)(phenyl)methanone (29 mg, 0.13 mmol) as the starting materials. The compound 
171 was obtained as a brown solid (45 mg, 76%). 
1
H NMR (300 MHz, DMSO-d6)  8.14 (dd, J 
= 1.8, 6.9 Hz, 2H), 7.97 - 7.93 (m, 3H), 7.87 - 7.83 (m, 3H), 7.71 (t, J = 7.5 Hz, 1H), 7.61 (t, J = 
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8.1 Hz, 2H), 7.17 (dd, J = 1.8, 6.9 Hz, 2H), 7.06 (s, 2H), 4.90 (d, J = 2.4 Hz, 2H), 3.63 (t, J = 2.1 
Hz, 1H). HRMS (ESI
+
) calcd for C26H18N6O3 (M+H)
+
 463.4675, found 463.1508. 
 
(4-(5-amino-4-(3-(4-(prop-2-yn-1-yloxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-
yl)phenyl)(phenyl)methanone (172). Same protocol as 51 using 177 (27 mg, 0.11 mmol) and 
(4-azidophenyl)(phenyl)methanone (25 mg, 0.11 mmol) as the starting materials. The compound 
172 was obtained as a brown solid (38 mg, 76%). 
1
H NMR (300 MHz, DMSO-d6)  8.16 (d, J = 
8.7 Hz, 2H), 7.98 (d, J = 8.4 Hz, 2H), 7.88 - 7.79 (m, 4H), 7.75 - 7.72 (m, 1H), 7.63 (t, J = 8.1 
Hz, 2H), 7.16 (d, J = 9.0 Hz, 2H), 7.11 (s, 2H), 4.90 (d, J = 2.4 Hz, 2H), 3.63 (t, J = 2.4 Hz, 1H). 
HRMS (ESI
+
) calcd for C26H18N6O3 (M+H)
+
 463.4675, found 463.1529. 
 
4-(Hept-6-yn-1-yloxy)benzonitrile (180). DIAD (635 mg, 3.14 mmol), triphenylphosphine (713 
mg, 2.71 mmol), and 6-heptyn-1-ol (0.39 ml, 3.14 mmol) were added to a solution of 4-
cyanophenol (250 mg, 2.09 mmol) in DCM (5 ml) at 0°C. The reaction mixture was allowed to 
warm up to rt and stirred overnight. The solvent was removed under vacuum and the residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (7:1) to deliver 180 
as a light yellow solid (548 mg, 100%). 
1
H NMR (300 MHz, chloroform-d)  7.56 (d, J = 8.7 Hz, 
2H), 6.92 (d, J = 8.7 Hz, 2H), 4.00 (t, J = 6.3 Hz, 2H), 2.22 - 2.18 (m, 2H), 1.95 (t, J = 2.7 HZ, 
1H), 1.87 - 1.78 (m, 2H), 1.61 - 1.50 (m, 4H), 1.41 (d, J = 6.3 Hz, 2H). 
 
(E)-4-(Hept-6-yn-1-yloxy)-N'-hydroxybenzimidamide (181). Same protocol as 97 using 180 
(200 mg, 0.94 mmol) as the starting material. The compound 181 was obtained as a white solid 
(75 mg, 35%). 
1
H NMR (300 MHz, chloroform-d)  7.77 (d, J = 9 Hz, 2H), 6.82 (d, J = 8.7 Hz, 
2H), 3.86 (t, J = 6.3 Hz, 2H), 2.24 - 2.20 (m, 2H), 1.97 - 1.94 (m, 1H), 1.87 - 1.78 (m, 2H), 1.61 - 
1.53 (m, 4H). 
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2-(3-(4-(Hept-6-yn-1-yloxy)phenyl)-1,2,4-oxadiazol-5-yl)acetonitrile (182). Same protocol as 
99 using 181 (39 mg, 0.16 mmol) and 98 (28 mg, 0.17 mmol). The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (5:1) to deliver 182 as a light yellow 
solid (21 mg, 47%). 
1
H NMR (300 MHz, chloroform-d)  8.01 (d, J = 6.9 Hz, 2H), 6.98 (d, J = 
6.9 Hz, 2H), 4.10 (s, 2H), 4.01 (t, J = 6.3 Hz, 2H), 2.24 - 2.20 (m, 2H), 1.97 - 1.94 (m, 1H), 1.87 
- 1.78 (m, 2H), 1.64 - 1.60 (m, 4H). 
 
(3-(5-Amino-4-(3-(4-(hept-6-yn-1-yloxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-1,2,3-triazol-1-
yl)phenyl)(phenyl)methanone (173). Same protocol as 51 using 178 (11 mg, 0.05 mmol) and 
182 (14 mg, 0.05 mmol) as the starting materials. The compound 173 was obtained as a brown 
solid (12 mg, 50%). 
1
H NMR (300 MHz, DMSO-d6)  8.10 (d, J = 9 Hz, 2H), 7.95 - 7.93 (m, 
3H), 7.86 - 7.82 (m, 3H), 7.71 - 7.68 (m, 1H), 7.62 - 7.56 (m, 2H), 7.09 (d, J = 8.7 Hz, 2H), 7.05 
(s, 2H), 4.05 (t, J = 6.6 Hz, 2H), 2.75 (t, J = 2.4 Hz, 1H), 2.19 - 2.17 (m, 2H), 1.76 - 1.72 (m, 
2H), 1.54 - 1.48 (m, 4H). HRMS (ESI
+
) calcd for C30H26N6O3 (M+H)
+
 519.5738, found 
519.2138. 
Attempted synthesis of the azide 189 
4-Azidobenzonitrile (184). Same protocol as 95 using 4-aminobenzonitrile (600 mg, 5.07 
mmol) as the starting material. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (9:1) to deliver 184 as a light yellow solid (486 mg, 66%). 
1
H NMR 
(300 MHz, chloroform-d)  7.64 (d, J = 9 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H). The analytical data 
matched literature reports.
173
 
4-Azido-N-hydroxybenzimidamide (185). H2NOHHCl (86 mg, 0.12 mmol) and NMP (0.136 
mL, 0.12 mmol) were added to a solution of 184 (30 mg, 0.2 mmol) in MeOH (1 mL). The 
reaction mixture was strirred overnight at 50 °C. The solvent was removed under vacuum and the 
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residue was suspended in EtOAc (4 mL). The organic layer was washed with saturated NaHCO3 
(3 mL), brine (3 mL), dried over Na2SO4, filtered, and concentrated to afford 185 as a white solid 
(32 mg, 88%). 
1
H NMR (300 MHz, DMSO-d6)  9.23 (s, 1H), 7.67 (d, J = 9 Hz, 2H), 7.10 (d, J 
= 8.4 Hz, 2H), 5.81 (s, 2H). 
2-(3-(4-Azidophenyl)-1,2,4-oxadiazol-5-yl)acetonitrile (186). Same protocol as 99 using 98 
(79 mg, 0.48 mmol) and 185 (72 mg, 0.40 mmol) as the starting materials. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (6:1) to deliver 186 
as a light orange solid (72 mg, 79%). 
1
H NMR (300 MHz, chloroform-d)  8.06 (d, J = 9 Hz, 
2H), 7.13 (d, J = 8.4 Hz, 2H), 4.13 (s, 2H). 
 
Synthesis of fluorescein-azide 191 
1,6-Diazidohexane (189). Sodium azide (676 mg, 10.4 mmol) was added to a solution of 1,6-
dibromohexane (0.4 mL, 2.59 mmol) in DMF (2 mL). The resulting mixture was stirred 
overnight at 60 °C. The solvent was removed under vacuum, the residue was diluted in Et2O (6 
mL), the organic layer was washed with NaHCO3 (2 x 5 mL). The aqueous layer was extracted 
with Et2O (2 x 6 mL), the organic layers were combined, dried with Na2SO4, filtered, and 
concentrated. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (3:2) to give 189 as a white solid (211 mg, 82%). 
1
H NMR (300 MHz, 
chloroform-d)  3.27 (t, J = 6.8 Hz, 4H), 1.66 - 1.55 (m, 4H), 1.47 - 1.37 (m, 4H). The analytical 
data matched literature reports.
145
 
6-Azidohexan-1-amine (190).
  
A solution of
 
1 M HCl (1.6 mL) was added to a solution of 1,6-
diazidohexane (286 mg, 1.7 mmol) in Et2O/EtOAc (1/1 mL). The mixture was cooled in an ice-
bath and stirred vigorously. Triphenylphosphine (446 mg, 1.7 mL) was introduced portion wise 
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during 20 min. After stirring for 4 h at rt, the two layers were separated. The aqueous layer was 
extracted with Et2O (2 x 5 mL). The combined aqueous layers were basified with NaOH 1 M 
until pH 12 and extracted with Et2O (3 x 6 mL). The organic layers were combined, dried with 
Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography on silica 
gel, eluting with 10% MeOH, 1% NH4OH in DCM to give 190 as a colorless oil (104 mg, 43%). 
1
H NMR (300 MHz, chloroform-d)  3.25 (t, J = 6.8 Hz, 2H), 2.69 (t, J = 6.9 Hz, 2H), 1.65 - 
1.44 (m, 2H), 1.52 - 1.29 (m, 6H). The analytical data matched literature reports.
145
 
 
1-(6-Azidohexyl)-3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-
yl)thiourea (191). The amine 190 (13.7 mg, 0.09 mmol) was added to a solution of fluorescein 
isothiocyanate (25 mg, 0.06 mmol) and DIPEA (0.021 mL, 0.12 mmol) in DMF (1 mL). The 
suspension was stirred overnight at rt. The reaction mixture was partitioned between EtOAc (4 
mL) and 1 M HCl (3 mL), the organic layer was separated and washed further with 1 M HCl (2 x 
4 mL) and brine (4 mL), the organic layers were combined, dried over Na2SO4, filtered, and 
concentrated. The residue was purified by flash chromatography on silica gel, eluting with 5% 
MeOH in DCM to give 191 as a bright yellow solid (22 mg, 71%). 
1
H NMR (300 MHz, 
methanol-d)  8.10 (d, J = 1.5 Hz, 1H), 7.40 (dd, J = 1.8, 8.1 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 
6.69 - 6.66 (m, 4H), 6.50 (dd, J = 2.4, 8.4 Hz, 2H), 3.61 (s, 2H), 1.70 - 1.63 (m, 5H), 1.46 - 1.43 
(m, 5H). HRMS (ESI
+
) calcd for C27H25N5O5S (M+H)
+
 532.5908, found 532.1669. 
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3.0  DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF MIR-122 
3.1 INTRODUCTION TO MIRNA-122a 
The microRNA miR-122, a liver-specific miRNA, is highly expressed in the liver at 
approximately 66,000 copies per cell, accounting for 70% of the total miRNAs in this tissue.
185
 
miR-122 is expressed in 18 species, such as mice, frogs, and zebrafish, where the entire sequence 
of mature miR-122 is highly conserved, suggesting that the whole sequence is necessary for the 
biological functions of miR-122.
185
 miR-122 is involved in the regulation of important processes 
such as lipid and cholesterol metabolism, liver development, and systemic iron homeostasis.
185
  
Krutzfeldt et al. were the first to show that complete loss of miR-122 activity was 
observed in mice injected with a miR-122 antagomir at a dose of 240 mg/kg body weight. The 
silencing effect was sustained for 23 days and was accompanied by a 40% decrease in plasma 
cholesterol levels. Gene expression analysis revealed that at least 11 genes involved in 
cholesterol biosynthesis, such as 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), 
7-dehydrocholesterol reductase (DHCR7), mevalonate kinase (MVK), 3-hydroxy-3-
methylglutaryl-coenzyme A synthase 1 (HMGCS1), and farnesyl diphosphate synthetase 
(FDPS), were downregulated following miR-122 silencing.
186
 Similarly, using an anti-miR-122 
                                                 
a
 Part of this chapter was reprinted from Curr. Med. Chem. Thomas, M.; Deiters, A. MicroRNA miR-122 as a Therapeutic Target for 
Oligonucleotides and Small Molecules, 2013, 20, 29, 3629, with permission from Bentham Science Publishers. 
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2′-O-methoxyethyl phosphorothioate-modified oligonucleotide (miR-122 2′-MOE) in cell culture 
and in mice, Esau et al. treated mice twice weekly for four weeks with intraperitoneal injections 
of the 2′-MOE at doses ranging from 12.5 to 75 mg/kg, leading to a 3- to 10-fold reduction of 
miR-122 levels. 
187
 Plasma cholesterol and triglyceride levels were lowered and several genes 
associated with cholesterol metabolism, fatty-acid synthesis, and fatty-acid oxidation were 
reduced, including PMVK (phosphomevalonate kinase), FASN (fatty acid synthase), ACC 
(acetyl-CoA carboxylase) ACC1, ACC2, SCD1 (stearoyl-CoA desaturase-1) and ACLY (ATP 
citrate lyase).
187
 
A correlation between the levels of miR-122 and the expression of four liver-enriched 
transcription factors (LETFs), notably C/EBP (CCAA T/enhancer-binding proteins), and 
HNF4α (nuclear factor 4α), was identified.188 Overexpression of these four LETFs in HCC-
derived cells resulted in a significant up-regulation of miR-122, implying their involvement in 
the transcriptional regulation of miR-122. Furthermore, a binding site for HNF4α was recently 
discovered in the miR-122 promoter region.
189
 Concomitant expressions of LETFs and miR-122 
gradually increase in mice from embryonic day 12.5 until birth when the expression levels 
plateau. This period corresponds with the differentiation of bipotential hepatoblasts into mature 
hepatocytes. Since miR-122 is primarily expressed in hepatocytes, this finding suggests a role for 
miR-122 in liver development.
188
 Additionally, a feedback loop between the LETF HNF6 and 
miR-122 was identified that tightly controls hepatocyte differentiation. HNF6 binds to the miR-
122 promoter to stimulate the expression of miR-122, which subsequently results in the 
stimulation of the core LETFs, including HNF6, and the regulation of hepatocyte-specific 
genes.
190
 In a similar fashion, a link between CUTL1, a transcriptional repressor of genes that 
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specifies terminal differentiation, and miR-122 was established, notably in the regulation of liver 
development and maintenance of the adult liver phenotype.
188
 
In addition to being a key-regulator in the proliferation and differentiation of hepatocytes, as well 
as in the modulation of lipid and cholesterol metabolisms, miR-122 plays a significant role in the 
appearance and progression of several diseases (Figure 3.1). 
 
Figure 3.1: Biological roles of miR-122 and involvement in liver diseases. 
miR-122 is controlled by the transcription factors HNF1α, HNF3β, HNF4α, HNF6, and C/EBPα, and regulates lipid 
and cholesterol metabolisms, as well as hepatocyte differentiation and proliferation. Down-regulation of miR-122 is 
found in HCC and interaction of miR-122 with the HCV genome enhances HCV replication and translation. 
Adapted from Curr. Med. Chem. 2013, 20, 3629.
b
  
 
                                                 
b
 HCV genome adapted from FEBS Letters, 584, C. Bung, Z. Bochkaeva, I. Terenin, R. Zinovkin, I. N. Shatsky, M. Niepmann, Influence of the 
hepatitis C virus 3′-untranslated region on IRES-dependent and cap-dependent translation initiation, 837. Copyright (2010), with permission from 
Elsevier. HBV mRNA adapted from J. Virol. 2000, 74, 12, 5502, with permission from American Society for Microbiology. 
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3.1.1 Implication of miR-122 in HCC 
Functional studies and miRNA profiling experiments of cell lines and patient tissues 
established a link between miR-122 and several hepatic disorders. Specifically, miR-122 
downregulation is associated with hepatocellular carcinoma, chronic inflammation, cirrhosis, and 
nonalcoholic steatohepatitis.
191
 HCC is among the five most common cancers; it is often detected 
at a late stage and due to a limited choice of current therapies a poor prognosis is typically 
observed. 
Experiments in mice, which had a germline (KO) or a liver-specific (LKO) deletion of 
miR-122 introduced, resulted in a 30% reduction of total cholesterol and an accumulation of 
triglycerides in the liver. More precisely, miR-122 depletion induced a 57% decrease in low-
density lipoprotein (LDL) cholesterol and a 25% decrease in high-density lipoprotein 
cholesterol.
191a
 Similarly, miR-122 inhibition in chimpanzees treated with a locked nucleic acid 
(LNA)-modified phosphorothioate oligonucleotide, resulted in a pronounced decrease in LDL 
cholesterol.
192
 Aging KO and LKO mice developed steatohepatitis and HCC as a result of an 
increased level of pro-inflammatory and tumor-promoting cytokines interleukin-6 and tumor 
necrosis factor.
191a
 The loss of miR-122 function also prompted hepatocarcinogenesis through a 
different pathway by targeting CCNG1 (cyclin G1) and Bcl-w (Figure 3.1), which induced 
chromosomal instability and increased anti-apoptotic activity.
149
 Additional miR-122 targets 
include ADAM10 (disintegrin and metalloprotease), IGF1R (insulin-like growth factor-1 
receptor), SRF (serum response factor), c-Myc, pituitary tumour-transforming gene 1-binding 
factor (PTTG1), and the proto-oncogene Wnt1; all of those have been reported to participate in 
hepatocarcinogenesis through the deregulation of epithelial-mesenchymal transition, apoptosis, 
tumor cells proliferation, and migration.
193
 Mice lacking miR-122 expression suffered from 
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HCC, with a 4:1 male-to-female ratio,
194
 matching the gender distribution found in humans.
195
 
Hydrodynamic injection of miR-122 mimic recovered miR-122 expression and produced a 
significant reduction in angiogenesis, tumor occurrence, and tumor size.
194
 A study performed in 
HCC-derived cell lines demonstrated that restoring miR-122 expression led to the recovery of 
Bcl-w function and increased the sensitivity of the cancer cells to the chemotherapeutic agent 
sorafenib.
153
  
As previously mentioned, HBV infection represents one of the major risk factors for 
HCC. Although the precise molecular mechanisms responsible for the development of HCC have 
not been fully deciphered yet, recent evidence started to unveil a role for miR-122 in HBV-
induced HCC.
196
 Since it was demonstrated that the viral load and miR-122 expression are 
inversely correlated in HBV-infected patients, several mechanisms have been proposed to 
explain HBV-mediated suppression of miR-122.
196
 One study reported that all HBV mRNAs 
possess a miR-122 binding site, and thus act as sponges to bind and sequester miR-122.
197
 In 
addition, the hepatitis B virus protein X (HBx) was shown to inhibit miR-122 transcription via 
direct binding to the transcription factor Peroxisome proliferator activated receptor-gamma 
(PPAR).198 Monoadenylation of miR-122 by the cytoplasmic poly(A) RNAse polymerase 
Germline development 2 (Gld2) promotes the specific stabilization of miR-122 in human 
fibroblasts. Another insight into the HBV-induced miR-122 silencing, revealed that HBx 
negatively regulates the transcription of Gld2 which results in reduced miR-122 levels in HBV 
cells.
199
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Taken together, these results demonstrate that downregulation of miR-122 largely 
increases the risks of inflammation and HCC manifestations and, more importantly, that re-
activation of miR-122 helps counteracting the progression of the disease.  
3.1.2 Role of miR-122 in HCV 
It is estimated that 185 million people are infected with HCV worldwide.
200
 Acute 
infection causes jaundice and clinical symptoms such as fever, fatigue, and abdominal pain. 
About 55% to 85% of patients suffering from acute illness develop chronic HCV infection.
201
 
Even though in some cases chronic hepatitis C is asymptomatic, often it slowly progresses and 
generates extra hepatic diseases or causes chronic liver disorders,
201
 such as cirrhosis (in 27% of 
cases) or HCC (25%).
202
 The standard care for HCV, pegylated interferon-α (IFN) and ribavirin, 
are only effective in 50% of cases and are accompanied with severe side effects.
203
 In addition, 
of the six different HCV genotypes, these treatments predominantly target genotype 1.
204
 In 2011 
the FDA approved two new protease inhibitors, boceprevir and telaprevir, which target the viral 
nonstructural protein 3 (NS3) or the enzyme NS3.4A serine protease, respectively. These new 
drugs complemented the current treatments, and even though they did not abolish the side effects 
and were only indicated toward HCV genotype 1, they significantly increased the cure rate (to 
about 70%).
205
 In 2013, a second-generation NS3.4A serine protease inhibitor, simeprevir, was 
approved for use in combination with IFN and ribavirin.206 Even though this new treatment was 
only beneficial against genotype 1, it reduced the duration of the therapy from 48 weeks to only 
24 weeks. Also in 2013, the nucleotide analog sofosbuvir, an inhibitor of the viral RNA 
polymerase NS5B, was approved as a 12-week combination therapy to treat genotypes 1 and 4, 
and allowed for the first time the formulation of an IFN-free regimen against genotypes 2 and 
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3.
206
 Given the inconveniences accompanied with IFN treatment, subcutaneous administration 
and serious side-effects, the discovery of new directly acting antiviral agents, orally available 
and bypassing the necessity of IFN has revolutionized HCV therapies.
207
 In 2014, new oral IFN-
free regimens for genotype 1 were approved, which included the combination of sofosbuvir with 
either a second-generation NS3/4A protease inhibitor (ledipasvir) or an NS5A replication 
complex inhibitor (ombitasvir) with or without ribavirin.  While these new treatments provide 
impressive cure rates (up to 90%), fewer side-effects, and greatly reduced duration of therapy 
(12-24 weeks versus 48 weeks previously), they still mostly target HCV genotype 1 and the 
occurrence of resistance has not been fully documented.
206
 
The HCV genome contains two miR-122 binding sites, S1 and S2, near its 5′-end and it 
has been reported that the presence of mature miR-122 is necessary for HCV replication and 
translation (Figure 3.1).
208
 Although the precise mechanisms by which miR-122 impacts the 
HCV life cycle is not clearly understood yet, recent studies suggest that miR-122 stabilizes the 
viral RNA.
209
 Furthermore, the direct interaction between miR-122 and its targets S1 and S2 is 
thought to stimulate the translation by facilitating the association of the viral RNA and 
ribosomes.
210
 In total contradiction with this hypothesis, another study unveiled a new 
mechanism for miR-122 participation in HCV, where miR-122 stimulates HCV RNA synthesis 
by competing with the ribonuclear protein PCBP2 for binding to the viral RNA, which prevents 
translation while simultaneously enhancing the amount of viral RNAs available for template 
RNA viral synthesis.
211
 Despite the fact that contradictory results have been reported in the 
literature regarding the participation of Ago2 in HCV replication,
212
 recent studies demonstrated 
that miR-122 interacts with the HCV RNA as a complex with Ago2 (Figure 3.1).
209b
 Since miR-
122 binds to the 5′-end of the viral RNA and it is well known that an RNA molecule can be 
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degraded from its 5′-end after cleavage of the monomethyl guanosine (m7G) cap, it was 
hypothesized that the complex formed by miR-122 and Ago2 could act as a cap, protecting the 
viral RNA from 5′ exonuclease degradation, more specifically by the exonuclease Xrn1.209a 
Experiments in murine embryonic fibroblasts transfected with synthetic HCV RNAs with or 
without a m7G cap and in the presence or absence of miR-122 duplex validated this hypothesis. 
The degradation rate of the 5′ capped RNA was not affected by the presence of miR-122 whereas 
the degradation rate of the 5′ uncapped RNA was significantly slower when co-transfected with 
miR-122 mimics.
209b
 However, miR-122 is specifically required for viral replication even in cells 
lacking the exonuclease Xrn1,
213
 indicating additional functions for miR-122 such as  promoting 
viral RNA synthesis.
211
 Similarly to HBV infection, it has been proposed that the HCV genome 
acts as a sponge for miR-122, and that binding to miR-122 to either S1 or S2 results in miR-122 
sequestration and prompts global up-regulation of host miR-122 targets, thus providing a 
favorable environment for carcinogenesis.
214
 
Most importantly the two miR-122 binding sites are conserved across the different HCV 
genotypes, which reinforces the therapeutic potential of targeting miR-122, as there is a critical 
necessity for new and broader antiviral therapies.
204, 215
 Li et al. developed an assay in Huh7.5 
cells where genotypes 1-6 HCV are expressed.  They found that transfection of Miravirsen, the 
well-established fully phosphorothioate-modified DNA/LNA mixmer targeting miR-122 (LNA-
antimiR-122), yielded an efficient, dose-dependent reduction of the infection in all six 
genotypes.
71
 Using the same LNA-antimiR-122, Lanford et al. treated HCV-infected 
chimpanzees through injections once a week for 12 weeks.
192
 They observed a significant 
decrease in the viral RNA load after 3 weeks with a maximum decrease reached 2 weeks after 
the end of the treatment. The reduction in the levels of HCV-infected RNA was not accompanied 
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with any rebound in viremia, either during the dosing phase or even up to 6 weeks after the end 
of the treatment. Overall, exposure to the LNA-antimiR-122 oligonucleotide led to a long-lasting 
effect, no noticeable toxicity, no viral resistance, and no side effects.
192
 In addition deep 
sequencing of the 5′ noncoding region of the HCV genome of the high-dose animals 
demonstrated that no adaptive mutations occurred in the S1 and S2 miR-122 recognition sites. 
This result was in strong opposition to another study which observed 67% of HCV clones 
presenting mutations within 2 days after administration of a non-nucleoside polymerase 
inhibitor.
192
 Another pre-clinical study aimed at investigating the effects caused by treatment 
with Miravirsen was conducted on cynomolgus monkeys at pharmacologic and supra-
pharmacologic doses. The monkeys were injected with the LNA-antimiR-122 twice weekly for 4 
weeks and a dose-dependent decrease in total serum cholesterol was observed. The LNA was 
rapidly cleared from plasma (t1/2 ~ 10 - 36 min) but was accumulated in the liver and the kidneys 
where elimination occurred at a much slower rate (t1/2 ~ 37 - 20 days). These effects were not 
associated with any evident toxicity, even at the highest dose, which largely went beyond the 
dose needed for maximal miR-122 inhibition.
216
 As previously mentioned, Miravirsen is 
currently investigated in clinical trials as a new HCV therapy, and promising results in phase 2a 
trials revealed that four out of the nine patients who received the drug for 4 weeks exhibited a 
complete reduction in HCV levels with no signs of viral resistance.
72
 One of the main challenges 
in creating new and effective HCV therapeutics stems from the fact that the HCV genome evades 
selection pressure through rapid mutation due to the lack of error-proofing of the viral RNA 
polymerase.
201
 Consequently, targeting a host factor at the miRNA-mRNA interface, rather than 
a viral component, could feature a novel and efficient anti-viral strategy since it is less likely to 
induce viral resistance.  
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Since interferon has long been the standard agent for HCV treatment, its effect on miR-
122 function was studied extensively. The levels of miR-122 in Huh7 cells treated with 
interferon-β were reduced by 80%.217 However, studies carried out on samples isolated from 
chronic hepatitis C (CHC) infected patients, where the miR-122 levels were evaluated before and 
4 hours after treatment with interferon-α, showed no modifications of the miR-122 levels.218 No 
effect of IFN on miR-122 levels was also observed in mice, indicating discrepancies between in 
vitro and in vivo experiments.
218
 Though no correlation could be established between serum 
levels of miR-122 and HCV RNA, a previous report suggested that miR-122 provides a practical 
biomarker for liver injuries, since its levels in CHC infected patients are higher than in healthy 
individuals.
219
 There were no differences noted, however, when comparing miR-122 levels in the 
serum of patients who responded well to IFN therapy and patients who did not.
220
 In contrast, 
liver biopsies revealed that subjects who did not respond to IFN displayed considerably lower 
pretreatment miR-122 levels than patients who responded well to the treatment.
218
 These results 
are somewhat surprising since miR-122 inhibition with LNA-antimiR-122 appeared effective in 
significantly reducing the HCV RNA infection in both responding and non-responding patients. 
This could suggest that even low miR-122 levels are sufficient to promote the replication and 
translation of HCV.
218
 Moreover, whereas five known IFN-regulated genes (IRGs) were strongly 
up-regulated in responding patients after administration of IFN-α, no effects were noticed in 
expression of IRGs in the non-responding population.
218
 Interestingly, chimpanzees treated with 
Miravirsen displayed a pronounced decrease in the expression levels of IRGs.
192
 This 
observation is important since patients who do not respond to current interferon-α therapies 
display particularly high IRG levels. Thus by normalizing the levels of IFN-regulated genes, 
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miR-122 antagonist-based therapies raise the possibility to sensitize IFN non-responding patients 
to IFN treatment.
192
 
These results provide additional evidence of the beneficial effects of targeting miR-122 
and, more importantly, suggest the possibility of developing more effective combination 
therapies. In conclusion, agents that can specifically regulate miR-122 activity constitute new 
tools to elucidate the involvement of miR-122 in HCC and in HCV infection and could provide 
potential new anticancer and antiviral therapies.  
3.2 PREVIOUS WORK 
The discovery of the first small molecule inhibitor of miR-21, the diazobenzene 24, was a 
successful proof-of-principle for the development of small molecules that selectively modulate 
the function of a miRNA of interest. A reporter assay was similarly developed to screen for small 
molecule modifiers of miR-122
124
 and the Deiters lab identified two inhibitors (29, 30) and one 
activator (31) of miR-122 function (Figure 1.5).
98
 In comparison with the previously described 
miR-21 assay, the miR-122 reporter construct was based on the psiCHECK-2 plasmid (Promega) 
and possesses two luciferase genes, Renilla and firefly luciferases. The miR-122 target sequence 
was inserted downstream of the Renilla luciferase gene, while the firefly expression serves as an 
internal control for normalization purposes and to account for variation in transfection efficiency 
and cell viability. This sensor can be used in cells to detect both a miR-122 inhibitor, indicated 
by an increase in the Renilla expression, and a miR-122 activator, indicated by a reduction in the 
Renilla signal.
98
 A pilot screen of 1,364 compounds, from the NCI Developmental Therapeutics 
Program (Diversity Set II) was performed in Huh7 cells stably expressing the psiCHECK-miR-
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122 reporter construct. The cells were exposed to 10 M of each small molecule for 48 h and 
assayed using a Dual Luciferase Assay Kit (Promega). Two miR-122 inhibitors were identified 
through this screen, compounds 29 and 30 which induced a 773  38% and a 1251  125% 
increase in the relative luciferase signal, respectively (Figure 3.2).
98
   
To validate the effect of these inhibitors on miR-122 expression, Huh7 cells were 
transfected with the psiCHECK-empty reporter (where the miR-122 binding site was replaced 
with a linker not targeted by any known miRNAs) and exposed to 10 M of 29 and 30 for 48 h. 
The luciferase signal was not affected by either compound, which confirmed that they did not 
interact with the luciferase reporter in a non-miRNA specific pathway. The inhibitors 29 and 30 
were also tested in the miR-21 luciferase assay in HeLa cells and did not exhibit any activity, 
indicating some selectivity of both of these small molecules for miR-122.
98
 Dose-response 
experiments were performed with 29 and 30 in the miR-122 luciferase assay, and their EC50 
values were determined as 3 and 0.6 μM, respectively. Both inhibitors were investigated by 
preliminary structure-activity relationship studies to understand the molecular requirements for 
miR-122 inhibition. Modifications in the amide linkage of 29 (shown in magenta in Figure 3.2) 
or replacement of the naphtyl group with diverse aromatic rings (shown in blue in Figure 3.2) 
resulted in significant decreases in activity. Attempts to modify the benzene substituents of 29 
(shown in red in Figure 3.2) led to similar losses in activity. Likewise, modifications were made 
on 30 to investigate the importance of the trans-decahydroquinoline motif (shown in blue in 
Figure 3.2). 
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Figure 3.2: Summary of the preliminary SAR studies of the miR-122 inhibitors 29 (right) and 30 (left). 
The data were adapted from J. Am. Chem. Soc., 2010, 132, 7976. 
 
Given that miR-122 is greatly downregulated in HCC, small molecules capable of 
restoring miR-122 function in cancer cells may have a therapeutic effect. The psiCHECK-
miR122 reporter was consequently used to screen for small molecule activators of miR-122. 
Among the same initial set of 1,364 compounds, the small molecule 31 was found to be a miR-
122 activator, it induced a 90% decrease in the Renilla luciferase signal, whereas no changes in 
luminescence were observed in Huh7 cells transfected with the control reporter, psiCHECK-
empty.
98
 In addition, the compound 31 was tested in the miR-21 assay and did not perturb 
luciferase expression, thus validating that 31 is not a general activator of the miRNA pathway 
but rather may be specific toward miR-122 upregulation.
98
 The miR-122 activator 31 displayed 
an IC50 value of 3 μM when tested in dose-response in the miR-122 luciferase assay. SAR 
studies of 31 indicted that the amino group on the fused rings (shown in red in Figure 3.3) 
appeared to be critical since removal or replacement with a nitro group induced decrease in 
activities. Substitutions of the N,N-dimethylpropanamine motif (shown in blue in Figure 3.3) 
with different functional groups drastically reduced the activity.
98
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Figure 3.3: Summary of the SAR studies of the miR-122 activator 31. 
The data were adapted from J. Am. Chem. Soc. 2010, 132, 7976. 
 
The intracellular levels of miR-122 were measured by qRT-PCR following exposure to 
these 3 small molecule modifiers of miR-122. Huh7 cells were treated with 29, 30, and 31 at 10 
M for 48 h. The activator 31 induced a 438% increase in miR-122 expression level in 
comparison with DMSO treated cells, whereas the inhibitors 30 and 29 exhibited a 72% and 45% 
knock-down of mature miR-122 levels relative to DMSO treated cells, respectively (Figure 
3.4).
98
 This was consistent with the higher activity of the sulfonamide 30 in the luciferase assay. 
To assess the specificity of these small molecules, the levels of mature miR-21 in HeLa cells 
treated with the three compounds at 10 M were also measured by qRT-PCR. None of the three 
modifiers perturbed miR-21 expression levels (Figure 3.4), suggesting that these small molecules 
displayed some degree of selectivity towards the regulation of miR-122.  
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Figure 3.4: qRT-PCR measurements of endogenous levels of miR-122 in Huh7 cells and miR-21 in HeLa cells 
after 10 M treatment with A. the miR-122 inhibitors 29 and 30 or B. the miR-122 activator 31. Adapted from J. 
Am. Chem. Soc. 2010, 132, 7976. Copyright (2010) American Chemical Society. 
 
In order to learn more about the mechanisms of these small molecules, the intracellular 
levels of primary miR-122 (pri-miR-122) were similarly measured by qRT-PCR (Figure 3.4A). 
The amide 29 and the sulfonamide 30 induced a 78% and 97% decrease in pri-miR-122 levels in 
comparison to DMSO treated cells, respectively. Conversely, upon treatment with the activator 
31 an increase in pri-miR-122 levels was observed (Figure 3.4B). Since the levels of pri-miR-
122 were significantly reduced following exposure to the inhibitors 29 and 30 (Figure 3.4A), it 
was hypothesized that, similarly to the miR-21 inhibitor 24, the small molecule miR-122 
inhibitors act at the post-transcriptional or transcriptional step rather than at any downstream 
processes of the miRNA pathway.
98
  
In addition, melting experiments were performed to investigate an eventual direct 
interaction of the small molecule miR-122 inhibitor 30 with the miR-122 oligonucleotide itself. 
The thermal stability of pre-miR-122 was analyzed in the absence and in the presence of the 
miR-122 inhibitor 30 as well as with the known RNA binder tobramycin.
98
 A variation of 10 °C 
was observed in the melting temperatures of pre-miR-122 in the absence and in the presence of 
tobramycin, which indicated a stabilization of the RNA upon direct interaction with tobramycin; 
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whereas the melting temperature was 60 °C regardless of the absence of presence of 30 (Figure 
3.5). This confirmed that the inhibition observed in the previous experiments (Figure 3.2 and 
Figure 3.4) was not due to the direct binding of the small molecule 30 to the miR-122 
oligonucleotide. 
 
Figure 3.5: Melting curves of pre-miR-122 in the absence and presence of the small molecule miR-122 inhibitor 30. 
Adapted from J. Am. Chem. Soc. 2010, 132, 7976. Copyright (2010) American Chemical Society. 
 
Subsequent experiments were performed to illustrate the therapeutic importance of these 
small molecule regulators of miR-122. Since the inhibitors 29 and 30 were shown to efficiently 
downregulate miR-122 expression, their ability to inhibit HCV replication was evaluated (Figure 
3.6A). Following transfection of Huh7 cells with genotype 1a H77c RNA, the cells were 
subsequently exposed for 48 h to either a miR-122 antagomir (positive control) or to the small 
molecules 29 and 30 (10 μM) and DMSO (negative control).98 Consistent with what has been 
reported in the literature, the HCV RNA levels were reduced by 80% upon treatment with the 
miR-122 antagomir, as determined by qRT-PCR (Figure 3.6A).
71
 Treatment with the small 
molecule miR-122 inhibitors 29 and 30 reduced by 52% and 53% the levels of HCV RNA, 
respectively (Figure 3.6A).
98
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On the other hand, an aberrantly low level of endogenous miR-122 has been found to 
promote HCC. In HCC-derived cell lines, Hep3B and HepG2, miR-122 is highly downregulated 
and as a consequence, its direct targets, such as Bcl-w, are abnormally upregulated.
149
 Treatment 
of HepG2 cells with a miR-122 duplex, mimicking an increase in endogenous miR-122 levels, 
led to a significant reduction of the Bcl-w protein expression. Repression of the gene Bcl-w by 
miR-122 was later shown to trigger apoptosis in diseased cells by restoring capase-3 activity.
149
 
To verify the positive effect of 31, which was hypothesized to stimulate miR-122 expression and 
to induce apoptosis of cancer cells, Huh7 and HepG2 cells were treated with the small molecule 
miR-122 activator at 10 and 20 M and the cell viability was measured after 48 hours. Treatment 
with the miR-122 activator 31 resulted in a 70% reduction in cell viability of HepG2 cells which 
express miR-122 at a greatly reduced level (≥99%), compared to only a 10% reduction in cell 
viability of Huh7 cells which express ≤85% miR-122 levels, compared to primary hepatocytes 
(Figure 3.6B).
98, 221
  
 
Figure 3.6: Demonstration of the therapeutic potential of the small molecule miR-122 modifiers. 
A. Small molecule miR-122 inhibitors 29 and 30 significantly reduced the levels of viral RNA. B. The small molecule miR-122 
activator 31 triggered apoptosis in cancer cells expressing low miR-122 levels. Adapted from J. Am. Chem. Soc. 2010, 132, 7976. 
Copyright (2010) American Chemical Society. 
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Together these results highlighted, for the first time, the therapeutic potential of small 
molecule modifiers of specific disease-causing microRNA. 
3.3 SYNTHESIS OF SMALL MOLECULE MIR-122 INHIBITORS 
Following the initial discovery of the miR-122 inhibitor 30,
98
 further SAR studies were 
conducted through the synthesis and testing of analogs in order to further optimize the activity 
and to better understand the molecular requirements for miR-122 inhibition. Three different 
series of analogs were investigated, through modifications of the trans-decahydroquinoline 
moiety, the sulfonamide linkage, or the aniline motif. 
3.3.1 SAR Studies of Inhibitor 30 through Modifications of the trans-
decahydroquinoline 
The sulfonamide derivatives 202-226 were prepared according to a procedure developed 
by Colleen Connelly and further optimized to increase the product yields (Scheme 3.1). The 
analogs 196-198, 200, 206, 207, and 213 were synthesized by Colleen Connelly.
98
 
Trifluoroacetic anhydride (TFAA) was added to a solution of the tetrahydroquinoline 192 and 
TEA in Et2O at 0 °C and stirred overnight. The protected amine 193 was refluxed in 
chlorosulfonic acid for 2 hours to yield the para-substituted sulfonyl chloride 194. Although the 
major product obtained was the para-substituted compound, the yield of the reaction was 
somewhat variable (50 to 69%), due to the formation of other regioisomers. The sulfonyl 
chloride intermediate 194 was treated with different amines and TEA in DCM to provide the 
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diverse analogs (Scheme 3.1). The reaction time of the sulfonamide-coupling step had to be 
carefully optimized and monitored since the TFA protecting group would fall off if exposed to a 
primary amine for too long. The sulfonamide 195 was deprotected in the last step upon treatment 
with K2CO3 in a mixture of MeOH/H2O (Scheme 3.1). 
 
Scheme 3.1: Synthesis of sulfonamide 30 and analogs 200-226. 
See Figures 3.9 and 3.10 for definition of R groups. 
 
First, an attempt was made to simplify the trans-decahydroquinoline ring, which was 
substituted with various linear amines of increasing sizes (Figure 3.7). The resulting analogs 
were tested in the miR-122 luciferase assay (10 M for 48 h) by Colleen Connelly, and their 
activities were compared to 30. A correlation was observed between the number of carbons in 
the amine chains and the activity. Indeed, the simplest free amine derivative 196 exhibited a 71% 
decrease in activity compared to 30, while extending the size of the linker by one (197) or three 
(198) additional carbons progressively restored some activity. This trend was observed in 
analogs bearing a chain of up to 4 carbons, the best one, 199, displayed a similar potency as the 
parent compound 30. The opposite trend was observed when the size of the linear amine was 
being further extended; substitution with hexylamine (200), octylamine (201), decanamine (202), 
and dodecylamine (203) functionalities resulted in a progressive reduction in the activity (Figure 
3.7). Since an amine chain of 4 carbons seemed to be optimal, the isobutyl (204) and the 
methylcyclopropyl (205) derivatives were designed to examine the importance of the linear alkyl 
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chain. Although the isobutyl group (204) was well tolerated since 204 was slightly more potent 
than 30, introduction of a cyclopropane (205) decreased the activity by 26% (Figure 3.7). 
Compounds 206 and 207 were designed with short 3-carbon linkers and functionalities allowing 
for further derivatization. For example, 207 was used in a “click reaction” with 1-azidopropanol 
to give the triazole 208. Modification with an allyl (206), a propargyl (207), or a triazole (208) 
motif resulted in a 31%, 28%, and 63% reduction in the activity relative to 30, respectively. 
Since the parent compound 30 is substituted with a tertiary amine, tertiary amine analogs of 199, 
204, and 207 were synthesized. Introduction of a methyl (210 and 211) or a second propargyl 
group (209) led to significant losses in activity. Surprisingly, the addition of a second butylamine 
group (212) led to a slight improvement over the monoalkylated analog 201, and yielded a 10% 
increase in activity compared to 30 (Figure 3.7). Simplification of the trans-decahydroquinoline 
with the smallest piperidine ring (213) abolished the activity. Based on the promising data for 
212, the macrocycles 214 and 215 were synthesized to determine if a rigidified cyclic structure 
would be beneficial. Introduction of a 7-member ring (214) or an 8-member ring (215) was not 
tolerated as the activity drastically dropped to 37% and 58%, respectively.  
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Figure 3.7: SAR investigation of the miR-122 inhibitor 30 through modification of the trans-decahydroquinoline 
ring (variations to the original structure are shown in blue). 
The numbers represent the activity (in percent) relative to 30 within the same miR-122 luciferase assay. Experiments 
were performed in triplicate and the standard deviations of the three independent assays were calculated. Syntheses 
of labeled analogs (*)
98
 and cell-based assays were performed by Colleen Connelly. 
 
The trans-decahydroquinoline ring was then replaced with a tetrahydroquinoline ring 
(216) to examine the effect on the activity upon the introduction of a planar unsaturated group, 
which resulted in a reduction of activity to 49% (relative to 30). Modification with a 
benzylamine (217), a 4-methylpyridine (218), or a benzothiazol-2-amine (220) moiety similarly 
reduced the activity. Surprisingly, introduction of a methoxy group on the benzothiazole ring 
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(221) rescued some activity, and substitution with a methyl-tetrahydropyran (219) led to slightly 
enhanced potency compared to 30 (Figure 3.8).  
The derivatives 222-225 were designed to introduce a nucleophilic handle in the small 
molecule that could be further used for other applications such as pull-down assays (Figure 
2.24).
222
 Modifications with a hydroxyl (222-224) or an amino (225) functionality resulted in 
>60% reductions in activity compared to 30 (Figure 3.8). Treatment of the sulfonyl chloride 194 
with 3 equivalents of hexane-1,6-diamine (Scheme 3.1) delivered the inactive dimer 226 as the 
major product. The expected product 225, was obtained using a large excess of the amine and 
keeping the reaction mixture at 0 °C. Unlike the other analogs in this series (Figure 3.8), the 
alcohol derivative 224 was obtained after treatment of 194 with 6-aminohexanol and pyridine.
223
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Figure 3.8: Structure-activity relationship investigation of the miR-122 inhibitor 30 through modification of the 
trans-decahydroquinoline ring (variations to the original structure are shown in blue). 
The numbers represent the activity (in percent) relative to 30 within the same miR-122 luciferase assay. Experiments 
were performed in triplicate and the standard deviations of the three independent assays were calculated. Syntheses 
of labeled analogs (*) and cell-based assays were performed by Colleen Connelly,
98
 the labeled analogs (**) were 
synthesized by Rohan Kumbhare. 
 
After structural modifications of the miR-122 inhibitor 30 through substitutions with 
linear and aliphatic amine functionalities, aromatic rings were introduced (Figure 3.9). Treatment 
of 194 with TEA and diverse anilines as described in Scheme 3.1 only gave low product yields; 
new conditions had to be implemented in order to synthesize the aromatic analogs 229-237 in 
satisfactory yields. Instead, the sulfonyl chloride 194 was heated to reflux overnight in presence 
of the aniline derivatives and pyridine. The intermediate 227 was then deprotected with K2CO3 
to afford the aromatic analogs 229-237 in high yields (Scheme 3.2).  
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Scheme 3.2: Synthesis of sulfonamide analogs 230-238. 
See Figure 3.8 for definition of R groups. 
 
Replacement of the trans-decahydroquinoline with a benzene ring (228) did not affect the 
activity. Substitution with a 3-naphtalene motif (229) to resemble the configuration of parent 
compound 30, reduced the activity by 22%, whereas substitution with a 2-napthalene motif (230) 
yielded a 46% increase in activity over 30. Introduction of the bulkier anthraquinone motif was 
well tolerated, as 231 was 9% more potent than 30, however this analog suffered from poor 
solubility. Modification with a 3-pyridine motif (232) resulted in ~50% loss in activity, as did 
substitution of the two meta positions with methoxy groups (233). Likewise, introduction of a 
nitro (234) or an amino (235) group in the para position negatively affected the activity. 
However, para modifications with the bulky tert-butyl group (236) or with an acetyl group (237) 
recovered the activity. The acetyl derivative 237 displayed a 10% increase in activity compared 
to 30 (Figure 3.9). These results (Figure 3.7, Figure 3.8, and Figure 3.9) suggested that either a 
short (<4 carbons) linear amine or a bulky aniline functionality is optimal for miR-122 
inhibition.  
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Figure 3.9: Structure-activity relationship investigation of the miR-122 inhibitor 30 through modification of the 
trans-decahydroquinoline ring (variations to the original structure are shown in blue). 
The numbers represent the activity (in percent) relative to 30 within the same miR-122 luciferase assay. Experiments were 
performed in triplicate and the standard deviations of the three independent assays were calculated. Syntheses of analogs labeled 
with an asterisk (*) and cell-based assays were performed by Colleen Connelly.98 Analogs labeled by a double-asterisk (**) were 
synthesized by Rohan Kumbhare. 
 
3.3.2 SAR Studies of Inhibitor 30 through Modifications of the Sulfonamide 
Linkage 
In order to determine whether the sulfonamide linkage is necessary for the miR-122 
inhibitory activity, it was replaced with a carboxamide group (Scheme 3.3). The amide 240 was 
synthesized in two steps (Scheme 3.3). The carboxylic acid 238 was stirred with trans-
decahydroquinoline in the presence of TEA and the peptide coupling reagents HOBt and EDCI 
in DCM to deliver the amide precursor 239. Reduction of the pyridine ring was performed with 
palladium on carbon (Pd/C) and ammonium formate in refluxing MeOH, and afforded 240 in 
55% yield (Scheme 3.3).
224
 Other conditions using platinum oxide and hydrogen in TFA were 
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tested but failed to deliver the expected product 240.
225
 Both amide derivatives 239 and 240 were 
completely inactive in the miR-122 luciferase assay (Scheme 3.3), validating the importance of 
the sulfonamide motif to maintain miR-122 activity. 
 
 
Scheme 3.3: Synthesis of the amide analog of 30. 
The numbers represent the activity (in percent) relative to 30 within the same miR-122 luciferase assay. Experiments 
were performed in triplicate and the standard deviations of the three independent assays were calculated. The cell-
based assays were performed by Colleen Connelly. 
 
3.3.3 SAR Studies of Inhibitor 30 through Modifications of the 
Tetrahydroquinoline 
Lastly, structural modifications around the tetrahydroquinoline ring were investigated 
(Figure 3.10). To determine whether the cyclic structure of the tetrahydroquinoline motif is 
necessary to maintain miR-122 inhibition, the free aniline 244 was synthesized and further tested 
in the miR-122 luciferase assay. The synthesis started with the protection of the aniline with a 
phthalic protecting group under microwave conditions (Scheme 3.4).
226
 The intermediate 241 
was refluxed in chlorosulfonic acid for 2 hours to yield the para sulfonyl chloride 242, which 
was subsequently treated with trans-decahydroquinoline to give compound 243 in 63% yield. 
The final compound 244 was obtained in 69% yield after removal of the protecting group with 
hydrazine (Scheme 3.4).
227
 Both the protected and deprotected analogs 243 and 244 were tested 
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in the miR-122 luciferase assay and were totally inactive (Figure 3.10). The same results were 
observed for the aniline 245, which was synthesized as described in Scheme 3.4. 
 
Scheme 3.4: Synthesis of aniline derivative 244. 
 
 
Substitution with a smaller 5-member ring was also envisioned, and analog 246 was 
synthesized according to the procedure previously discussed (Scheme 3.3) starting from the 
commercially available indoline. Compound 246 displayed an activity equivalent to 30 
demonstrating that a smaller but more strained ring can be well accommodated in the binding 
pocket of the putative target protein. Modifications with a hydroxylamine (247) or a sulfonamide 
(248) motif led to reductions in the activity. The methylated analog 249 was designed to assess 
the importance of having a hydrogen-bond donor functionality on the tetrahydroquinoline ring 
(Figure 3.10). An initial attempt was made to methylate the amine on the tetrahydroquinoline 
ring with acetic acid, formaldehyde (37%), and zinc but the product was not recovered. Instead, 
249 was obtained by reductive amination of 30 upon treatment with formaldehyde (37%) and 
sodium cyanoborohydrate in MeOH (Scheme 3.5).
228
 Introduction of a small methyl group (249) 
led to an 11% increase in activity over the parent compound 30 (Figure 3.10). Analogs 250, 251, 
252, and 253 were then synthesized to determine whether introducing additional hydrophobic 
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interactions by extending the aliphatic group on the tetrahydroquinoline would be beneficial for 
the activity (Figure 3.10). The sulfonamide 30 was alkylated with an allyl (250), a propargyl 
(251), and a butyl group (252) at elevated temperature in the presence of the corresponding 
alkylbromide and DIPEA (Scheme 3.5).
229
 The benzyl derivative 253 was obtained after 
treatment of 30 with benzyl chloride and K2CO3 in refluxing DMF.
229
 Extending the aliphatic 
linker by three additional carbons did not further increase the activity but was well tolerated, as 
250 and 251 displayed a similar activity as 30 in the miR-122 luciferase assay. However, 
substitutions with a longer butyl (252) and bulkier benzyl (253) groups led to increasing 
reductions in the activity (Figure 3.10). Given the conditions used to perform the alkylation of 
the secondary amine delivered low yields, another route was envisioned to conveniently access 
diverse propargylated analogs (Scheme 3.5). This was deemed advantageous since the propargyl 
group would be installed on the tetrahydroquinoline ring at an earlier stage of the synthesis, thus 
bypassing the need for any protecting group and shortening the synthesis by two steps (Scheme 
3.5). Although, 260 was obtained in 87% yield after treating 192 with propargyl bromide and 
DIPEA, efforts to introduce the sulfonyl chloride functionality were all unsuccessful. The 
propargylated intermediate 260 was treated with varying equivalents of chlorosulfonic acid, at 
different temperatures, and in different co-solvents but none of these conditions delivered the 
desired product 261. Instead, it seemed that due to the presence of the activating propargyl amine 
on the ring (compared to the trifluoroacetyl protecting group commonly used), a mixture of ortho 
and para substituted products was formed and the desired para-substituted sulfonyl chloride 261 
could not be isolated.
230
 Other conditions consisting of installing the sulfonic acid on the ring 
first and then adding the chloride group upon treatment with phosphorus chloride similarly failed 
to deliver 261. 
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Scheme 3.5: Conditions used and attempted to synthesize the alkylated analogs 249-253. 
The R groups are shown in Figure 3.10. 
 
The derivatives 254-256 were designed with functional groups susceptible to form a 
covalent bond upon reaction with a nucleophilic residue (i.e., cysteine) within a putative binding 
pocket. Not surprisingly, the chlorine (254) and alkene (255) analogs were highly toxic and no 
assay data could be generated for these compounds. The compound 256 was less toxic but did 
not show any activity in the miR-122 luciferase assay (Figure 3.10). 
The analog 257 was synthesized to investigate if a structure different from the fused 
tetrahydroquinoline ring could be tolerated. The commercially available iodobenzene was treated 
with chlorosulfonic acid to give a mixture of the ortho and para substituted sulfonyl chloride 
262. This mixture was stirred in the presence of trans-decahydroquinoline and TEA in DCM to 
deliver 263. Although the intermediate 263 was obtained as a mixture of ortho- and para-
sulfonamide analogs, it was still submitted to the copper catalyzed coupling reaction. 
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Gratifyingly, after irradiation of 263 under microwave conditions at 130 °C for 10 minutes in the 
presence of pyrrole, copper acetate, and diazabicycloundecene (DBU) in DMF the desired para-
substituted derivative 257 was obtained (Scheme 3.6).
231
 The synthesis of 257 was generally low 
yielding but since this compound did not show any miR-122 inhibition (Figure 3.10), no further 
optimization was performed.  
The amide 258 was designed to investigate whether installing either a less basic 
functionality or a hydrogen bond acceptor onto the ring would be beneficial for activity. The 
analog 258 was synthesized using the conditions depicted in Scheme 3.1, starting from the 
commercially available dihydroquinolinone. Since the basicity of the cyclic amine was lowered 
by the presence of the carbonyl group on the ring, 258 could be obtained in 2 steps without the 
need for any protecting group. Dihydroquinolinone was refluxed in chlorosulfonic acid for 3 
hours to give the sulfonyl chloride intermediate in 76% yield. This precursor was then stirred in 
pyridine at 40 °C in presence of trans-decahydroquinoline to give the analog 258. Introduction of 
an amide motif (258) on the tetrahydroquinoline ring drastically reduced the activity (Figure 
3.10).  
Lastly, 259 was synthesized to test if a quinoline would be tolerated. Oxidation of the 
piperidine ring was first tested on the commercially available tetrahydroquinoline. First, 
tetrahydroquinoline was treated with potassium iodide and tert-butylhydroperoxide (70% in 
H2O) in ACN but an inseparable mixture of the expected product and the partially oxidized 
compound was obtained.
232
 Tetrahydroquinoline was also heated to reflux in dioxane in the 
presence of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) to afford the expected product in 30% 
yield.
233
 Some product was also obtained, in lower yield, under microwave irradiation (300 W) 
of the tetrahydroquinoline and DDQ in toluene. Since both of these reactions showed total and 
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clean conversion by TLC, it was hypothesized that the low yields were due to the loss of some 
material during the extraction phase as the obtained quinoline was somewhat soluble in the 
aqueous layer. Under the same conditions, 30 was oxidized with DDQ to deliver the analog 259 
in 87% yield (Scheme 3.6). Oxidation of the tetrahydroquinoline ring led to a 58% loss in 
activity compared to the reference inhibitor 30 (Figure 3.10). 
 
Scheme 3.6: Syntheses of pyrrole and quinoline analogs 257 and 259. 
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Figure 3.10: Structure-activity relationship studies of the miR-122 inhibitor 30 through modification of the 
tetrahydroquinoline motif (variations to the original structure are shown in red). 
The numbers represent the activity (in percent) relative to 30 within the same miR-122 luciferase assay. Experiments 
were performed in triplicate and the standard deviations of three independent assays were calculated. The cell-based 
assays were performed by Colleen Connelly and the analogs labeled (**) were synthesized by Rohan Kumbhare. 
 
 
Overall, only the introduction of a short aliphatic group (up to 3-carbons long) was 
tolerated and gave analogs of similar potency as 30; every other modification of the 
tetrahydroquinoline motif resulted in a reduction of activity (Figure 3.8, Figure 3.9, and Figure 
3.10). 
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3.4 HIGH-THROUGHPUT SCREENING FOR SMALL MOLECULE MIR-122 
INHIBITORS 
A cell line stably expressing the luciferase reporter for miR-122, Huh7-psiCHECK-
miR122, was generated by Colleen Connelly in order to facilitate the high-throughput screening 
of a large number of small molecules.
124
 Since the reporter is stably expressed there is no need 
for transfection, which greatly improves the reproducibility and robustness of the assay. After the 
stable cell line was validated, it was submitted to the Broad Institute’s Probe Development 
Center (BIPDeC) for high-throughput screening of more than 300,000 small molecule miR-122 
modifiers, followed by several secondary assays to determine the specificity and selectivity of 
the hit compounds (Figure 3.11). The BIPDeC screened 336,006 compounds from the Broad 
Institute’s Diversity Oriented Synthesis (DOS) collection (71,424 compounds) and the NIH’s 
Molecular Libraries Probe Production Center Network library (MLPCN, 264,582 compounds) in 
a primary assay using the Huh7-psiCHECK-miR122 cell line. The previously discovered miR-
122 inhibitor 30 was used as a positive control throughout the assay. The cells were plated in 
384-well plates, treated with the small molecules at 10 M for 48 hours and the luminescence 
was measured with a Renilla-Glo reporter kit (Promega). Since the transfection is bypassed when 
using the stable cell line, it is not necessary to perform a Dual luciferase assay, so only the 
Renilla luciferase signal was recorded during the HTS.  
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Figure 3.11: Screening flow chart indicating the number of compounds that successfully passed each round of 
screening, leading to the preliminary hit compound 264. 
 
 
Following the primary screen, small molecules displaying an activity greater or equal to 
90% relative to the activity of 30 were considered as active and further investigated. From the 
336,006 compounds tested in the primary screen, 1,023 compounds (179 compounds from the 
DOS collection and 844 from the MLPCN library) were identified as active inhibitors, 
constituting a hit rate of 0.3%. The primary screen was performed in duplicate for each 
compound to verify the reproducibility (Figure 3.12). Figure 3.12B shows all compounds aligned 
along the diagonal, indicating a good correlation between the results obtained in both assays. 
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Figure 3.12: Results of the HTS performed in Huh7-psiCHECK-miR122 cells by the Broad Institute’s Probe 
Development Center. 
A. Activity data for all small molecules screened in the primary assay, where each point represents one compound. 
B. Activity comparison of two replicates (A and B) for each compound. Data was provided by Kate Hartland 
(BIPDeC). 
 
Following the primary screen, BIPDeC analyzed the list of active compounds to 
eliminate any potential false-positives by: 1) removing any pan-assay interference compounds or 
“PAINs” which are known to be promiscuous in many biological assays;234 and 2) discarding 
any compounds with chemically reactive groups, metabolically labile groups, pH sensitive or 
hydrolytically unstable groups, or other groups not amenable to SAR studies. The 825 remaining 
compounds were tested in an 8-point dose-response assay in the Huh7-psiCHECK-miR122 cell 
line, and 406 compounds were selected that displayed EC50 values of less than 10 M. The 
specificity of these compounds was then investigated by cross-referencing the active compounds 
with the compounds tested in an HTS assay for miR-21 inhibitors (PubChem AID 2289). The 
derivatives found active in both the miR-122 and miR-21 assays were disregarded as they were 
not considered miR-122 specific, but more likely represent general inhibitors of the miRNA 
pathway. 
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Solid samples of the 65 compounds selected after the cross-analysis were obtained from 
the MLPCN and re-tested in the Huh7-psiCHECK-miR122 assay. Only 34 compounds displayed 
the expected activity and were tested in dose-response in Huh7 cells by qRT-PCR to measure 
their effect on the miR-122 expression levels. Three compounds induced a significant reduction 
in miR-122 expression and were subsequently examined in their selectivity based on the 
expression levels of miR-21 and miR-27b in Huh7 cells treated with the 3 derivatives. After this 
series of secondary assays, compound 264 was identified as an active hit: 264 has an EC50 value 
of 832 nM and selectively reduced miR-122 expression by 1.5-fold (Figure 3.11). 
3.4.1 Investigation of Hit Compounds Identified in the Primary Screen 
The four most active compounds in the primary assay were re-synthesized and tested in 
the miR-122 luciferase assay at 10 M (Figure 3.13) or in dose-response (Figure 3.14). Although 
265 and 266 were 13% and 27% less potent than the reference inhibitor 30, respectively at 10 
M, their EC50 values were equivalent (265) or improved (266) relative to 30 (EC50 value of 1 
M). The methyl ester 267 and the compound 268 showed an activity and EC50 comparable to 
30.  
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Figure 3.13: Structure of the best compounds identified in the primary assay and additional analogs. 
The compounds were tested at 10 M in Huh7-psiCHECK-miR122 cells. The numbers represent the activity (in percent) relative 
to 30 within the same assay. EC50 values are shown in blue. Experiments were performed in triplicate and the standard deviations 
of three independent assays were calculated. 
 
A few analogs were also synthesized that combined structural motifs of both the 
reference inhibitor 30 and the newly identified hits (Figure 3.13). Combining the trans-
decahydroquinoline motif of 30 with the benzene rings of 265, 266, and 268 led to the inactive 
analogs 269, 270, and 271. Substituting the dimethylbenzene motif of 268 with the 
tetrahydroquinoline motif of 30 led to a 12% increase in activity (272). 
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Figure 3.14: Dose-response curves in Huh7-psiCHECK-miR122 cells treated with the best compounds identified in 
the primary assay in the HTS. 
All experiments were conducted in triplicate and normalized to a DMSO control. The error bars represent the 
standard deviation from three independent experiments. 
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The hit compound 265 was synthesized as described in Scheme 3.2, whereas the 
compound 266 was obtained in 3 steps (Scheme 3.7). 4-Nitrobenzoyl chloride (61) was treated 
with TEA and pyrrolidine in DCM to deliver 273 in 86% yield. The intermediate 273 was 
reduced to the corresponding amine 274 and subsequently heated to reflux with 2,3,5,6-
tetramethylbenzene-1-sulfonyl chloride to afford 266. 4-Aminobenzoic acid was heated to reflux 
in the presence of SOCl2 in MeOH to yield the corresponding methyl ester and was further 
refluxed in pyridine with 2-methoxy-4-methylbenzene-1-sulfonyl chloride to deliver 267. The 
derivative 268 was synthesized in 4 steps: 1,2-dihydroacenaphthylene was treated with acetic 
acid and nitric acid to give the nitro 275, which was reduced with H2 in the presence of 
palladium on carbon. 2,4-Dimethylbenzene-1-sulfonyl chloride was obtained using 
chlorosulfonic acid as described in Scheme 3.1 and added to a solution of the amine 276 in 
pyridine (Scheme 3.7). The analogs 269-271 were prepared according to the conditions depicted 
in the Scheme 3.1, and 272 was obtained following the route shown in Scheme 3.2. 
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Scheme 3.7: Re-synthesis of best compounds identified in the primary assay of the HTS. 
 
 
It was recently reported that similarly to the firefly luciferase, the Renilla luciferase is 
susceptible to undergo ligand-based stabilization by small molecule inhibitors leading to the 
accumulation of the protein in cell-based assays, and possibly creating false-positive hits in high-
throughput screens.
235
 Conversely, biochemical evaluation of these same inhibitors causes a 
significant decrease in luciferase signal. In addition, it was indicated that sulfonamide derivatives 
may be prone to stabilizing the Renilla luciferase, as was demonstrated with the compound 
277.
235
 The sulfonamide 277 was synthesized in one step (Scheme 3.8) to provide a positive 
control in follow-up studies aimed to determine the effect of the promising compounds identified 
 175 
in the HTS on Renilla luciferase. The derivative 277 was tested in Huh7-psiCHECK-miR122 
cells at 10 M and in dose-response, where it exhibited a 23% increased activity over 30 but an 
equivalent EC50 value (Scheme 3.8). Both 30 and 277 were further tested in dose-response 
experiments in an in vitro Renilla luciferase (RLuc) assay (Figure 3.15); 277 displayed similar 
EC50 values in both the in vitro assay (4.7 M) and the miR-122 luciferase assay, while 30 
showed a significantly higher EC50 value in the RLuc assay (21.8 M) than in Huh7-psiCHECK-
miR122 cells. These results validate previous reports that Renilla inhibitors might deliver false-
positive hits in the HTS, as these compounds also induce an increase in Renilla luminescence. 
Given that 277 significantly increased the Renilla luciferase signal in the miR-122 luciferase 
assay, this highlights the necessity to investigate the promising compounds in the Huh7-
psiCHECK-miR122 assay to validate that their activity is actually due to miR-122 inhibition and 
not Renilla luciferase stabilization.  
 
Scheme 3.8: Synthesis of the reported Renilla luciferase inhibitor 277. 
The numbers represent activity relative to 30 within the same miR-122 luciferase assay. EC50 value is shown in blue.  
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Figure 3.15: Dose-response curves for the sulfonamides 30 and 277 in the in vitro RLuc assay. 
All experiments were conducted in triplicate and normalized to a DMSO control. The error bars represent the 
standard deviation from three independent experiments. 
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Except for compound 268, none of these analogs, that displayed the highest activities in 
the primary screen, were identified as a hit compound. This suggested that these derivatives did 
not exhibit sufficient selectivity and specificity for miR-122 inhibition, and thus were not further 
pursued.  
3.4.2 Preliminary SAR studies of the Hit Compounds 278-279 Identified in the 
HTS 
After performing the HTS, the Broad Institute provided solid samples for the 34 
compounds that passed their powder re-test in order to validate the results in our lab. Each 
compound was tested by Colleen Connelly in: 1) the Huh7-psiCHECK-miR122 assay to confirm 
miR-122 inhibition, 2) the psiCHECK-empty assay in Huh7 cells to assess the specificity, and 3) 
the HeLa-miR21-Luc assay to determine the selectivity for miR-122 inhibition. In these 
confirmatory experiments, the active compound 264 identified by the BIPDeC was found 
inactive, and instead the two sulfonamides 278 and 279 were identified as new hit compounds 
(Figure 3.16). 
 
 
Figure 3.16: Structure of the best compounds identified in the HTS by Colleen Connelly. 
The numbers represent the activity (in percent) relative to 30 within the same miR-122 luciferase assay. EC50 values 
are shown in blue. Experiments were performed in triplicate and the standard deviations of three independent assays 
were calculated. The analog 278 was re-synthesized by Haley Grimm. 
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These hit compounds were re-synthesized in collaboration with Haley Grimm (278) to 
allow for full characterization and further investigation. The hit 278 was prepared in 2 steps 
(Scheme 3.9). 1,2-Dichloro-4-methylbenzene was treated with chlorosulfonic acid to afford the 
sulfonyl chloride 280, which was subsequently stirred in the presence of 1-(3-
aminopropyl)imidazole and NaH to provide 278. The derivative 279 was obtained in 3 steps 
(Scheme 3.9). 4-Isopropyl-3-methylphenol was converted to the corresponding methylether, 
which was heated to reflux in the presence of chlorosulfonic acid to deliver 281. The sulfonyl 
chloride 281 was treated with 4-methylimidazole to afford 279 in 79% yield (Scheme 3.9). These 
two hit compounds were tested in the miR-122 luciferase assay at 10 M (Figure 3.16) and in 
dose-response experiments (Figure 3.21 and Figure 3.25). They both displayed an EC50 value 
comparable to that of 30, but at a concentration of 10 M, 278 exhibited a similar activity to 30 
while 279 was found 26% less potent. Subsequent examination of these compounds in the in 
vitro RLuc assay revealed that while 279 did not interact with the Renilla luciferase, 278 potently 
inhibited it. 
 
Scheme 3.9: Re-synthesis of the hit compounds 278 and 279 identified in the HTS. 
 
Since the two hit compounds identified in the HTS belong to the sulfonamide-class, the 
Broad Institute provided a series of additional sulfonamide derivatives to start preliminary SAR 
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studies. The analogs 282-297 were tested in the miR-122 luciferase assay at 10 M (Figure 
3.17). Most of these 16 compounds were inactive and only 7 showed an activity 10 to 49% 
higher than 30. 
 
Figure 3.17: Structure of additional sulfonamides for preliminary SAR studies of the best compounds identified in 
the HTS. 
The numbers represent the activity (in percent) relative to 30 within the same miR-122 luciferase assay. EC50 values are shown in 
blue. Experiments were performed in triplicate and the standard deviations of three independent assays were calculated. The best 
analogs, labeled with one or two asterixes (* or  **), were re-synthesized by me or by Haley Grimm, respectively. 
 
 
The derivatives 286, 289, 290, 292, and 293 were tested in dose-response in Huh7-
psiCHECK-miR122 cells (Figure 3.18), and all displayed a satisfying EC50 value less than 1 M. 
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Figure 3.18: Dose-response curves in Huh7-psiCHECK-miR122 cells treated with the best sulfonamide analogs 
identified by the HTS after preliminary SAR. 
All assays were conducted in triplicate and normalized to a DMSO control. The error bars represent the standard 
deviation from three independent experiments. 
 
 
As previously mentioned, Renilla luciferase inhibitors are likely to create false-positive 
hits in the miR-122 luciferase assay.
235
 Stabilization of the enzyme leads to the accumulation of 
the protein and therefore an increase in the Renilla luminescence signal at the time of readout. In 
order to determine the specificity for miR-122 inhibition, the best analogs were re-synthesized 
and submitted to secondary assays to evaluate their effect on Renilla luciferase (Figure 3.19). 
The most promising compounds 286, 288, 289, 290, 292, 293, and 294 were tested at 10 M in 
either an in vitro RLuc assay (Figure 3.19A) or in Huh7 cells using the control reporter (Figure 
3.19B). The previously reported Renilla luciferase inhibitor 277 was used as a positive control. 
In the RLuc assay, 277 induced an 80% decrease in the luminescence signal, and all compounds 
tested showed a greater or equal reduction in luminescence, indicating strong Renilla luciferase 
inhibition (Figure 3.19A). The analogs were also assayed in the control experiment in Huh7 cells 
transfected with the psiCHECK-empty reporter construct (Figure 3.19B). The compounds 
elicited a 3- to 8-fold increase in luminescence, suggesting that the high activity observed in the 
miR-122 luciferase assay might be due to a non-specific interaction of the compounds with the 
Renilla luciferase enzyme, rather than to their ability to inhibit miR-122. 
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Figure 3.19: Secondary assays to determine the selectivity of the best sulfonamide analogs identified by the HTS 
after preliminary SAR. 
A. In vitro RLuc assay, the compounds were tested at 10 M. B. Dual Luciferase assay of Huh7 cells transfected 
with psiCHECK-empty and treated with the analogs at 10 M for 48 h. The luciferase signal was normalized to a 
DMSO control. The error bars indicate the standard deviations determined from three independent measurements.  
 
3.4.3 Validation of the Hit Compound 278 Identified in the HTS 
Along with the previous set of sulfonamides (Figure 3.17), the Broad Institute provided 
analogs of the two hit compounds 278 and 279 for SAR investigation. Simplifying the 3-
propanamine-imidazole motif with an ethyl (299) or propyl (300) group led to ~10% decreased 
activities (Figure 3.20) compared to the hit compound 278. Replacing the 2 chlorine atoms with 
2 methyl groups (301) restored the activity, but modification with a hydroxyethyl group (302 and 
303) yielded a significant reduction in activity. Similarly, replacing the 3-propanamine-imidazole 
moiety with an isobutyl (304), a cyclopentyl (305), or a morpholine group (306) negatively 
affected the activity. Substitution of the 4,5-dichloro-2-methylbenzene-1-sulfonyl chloride (278) 
with the tetra-methylbenzene-sulfonyl chloride (307) or with the 3,5-dichloro-2-methylbenzene-
1-sulfonyl chloride (308) slightly increased the activity. Conversely, replacement with the 4-
fluoro-2-methylbenzene-1-sulfonyl chloride (309) induced a 70% decrease in activity compared 
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to 278. Similarly, introduction of a benzimidazole motif (310) abolished the activity (Figure 
3.20). 
 
Figure 3.20: Structure-activity relationship studies of the hit compound 278 through modification of the ring 
substituents or the amine motif (variations to the original structure are shown in blue and red). 
The numbers represent the activity (in percent) relative to 278 within the same miR-122 luciferase assay. EC50 
values are shown in blue. Experiments were performed in triplicate and the standard deviations of three independent 
assays were calculated. The analogs labeled with an asterix (*) were re-synthesized by Haley Grimm. 
 
 
The best analogs 299, 300, 301, 304, 305, 307, and 308 were tested in dose-response in 
Huh7-psiCHECK-miR122 cells (Figure 3.21). All the analogs displayed similar EC50 values to 
278 (~1 M), except 299, which had an EC50 value of 5.4 M. 
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A. B. 
 
Figure 3.21: Dose response curves in Huh7-psiCHECK-miR122 cells treated with the best analogs of hit compound 
278. 
A. Compounds 299, 300, 301, and the hit compound 278. B. Compounds 304, 305, 307, and 308. All assays were 
conducted in triplicate and normalized to a DMSO control. The error bars represent the standard deviation from 
three independent experiments. 
 
The specificity of the best analogs was further investigated. Unfortunately, as Figure 3.22 
shows, all of these compounds are potent Renilla luciferase inhibitors. They significantly 
reduced the Renilla luminescence (≥80%) in the in vitro RLuc assay (Figure 3.22A), and 
increased the signal by 3- to 8-fold in the control experiment using psiCHECK-empty (Figure 
3.22B). These results suggest that the high activities of these analogs observed in the miR-122 
luciferase assay, were mostly due to stabilization of the Renilla luciferase enzyme and not due to 
the perturbation of miR-122 expression. In fact, the compound 278 consisted in a false-positive 
hit in the HTS. 
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Figure 3.22: Secondary assays to determine the selectivity of the best analogs of hit 278 identified in the HTS. 
A. In vitro RLuc assay, the compounds were tested at 10 M. B. Dual Luciferase assay of Huh7 cells were transfected with 
psiCHECK-empty and treated with the analogs at 10 M for 48 h. The luciferase signal was normalized to a DMSO control. The 
error bars indicate the standard deviations determined from three independent measurements.  
 
3.4.4 Validation of the Hit Compound 279 Identified in the HTS 
Structural modifications were made on the hit compound 279 in an attempt to improve its 
potency. First, the 4-methylimidazole motif was simplified with a hydroxy (311), a 
dimethylamine (312), or an ethylamine group (313), all of which resulted in a significant loss in 
activity (Figure 3.23). Introduction of an ethanolamine motif (314) greatly increased the activity 
by 212%. Replacing the 4-methylimidazole ring on 279 with a 4-methylpyrazole (315), 4,5-
dichloro-imidazole (316), imidazole (317), or pyrrole (318) motifs abolished the activity. 
Modification with a 4-methylpyrrole group (319) led to a 35% decrease in activity compared to 
279, highlighting the importance of the 4-methylimidazole ring to maintain miR-122 inhibition. 
Replacement of the methyl with a phenyl group (320) significantly reduced the activity. 
Modifications with the bulky benzimidazole (321) or indole (322) led to a 33% and 45% 
decrease in activity compared to 279, respectively. Introduction of a benzoimidazole-2-amine 
(323) or trans-decahydroquinoline (325) motifs negatively affected the activity. Surprisingly, 
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substitution with a benzotriazole (324) group delivered a compound as potent as 279 (Figure 
3.23). 
 
Figure 3.23: Structure-activity relationship studies of the hit compound 279 through modification of the 4-methyl-
imidazole motif (variations to the original structure are shown in red). 
The numbers represent the activity (in percent) relative to 279 within the same miR-122 luciferase assay. EC50 
values are shown in blue. Experiments were performed in triplicate and the standard deviations of three independent 
assays were calculated. The compounds were provided by the Broad Institute, excepted the analogs labeled with one 
or two asterixes (* or **), which were synthesized by me or by Rohan Kumbhare, respectively. 
 
 
Removal of the isopropyl group (326 and 327) or replacement with a methyl group (328) 
abrogated the activity. Removal of the methyl in the meta position, however, seemed to be more 
tolerated as the activity was only slightly decreased by 12% and 16% for 329 and 330 compared 
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to 279, respectively. Modifications of the methoxy group with an ethoxy (331) or a propargyl 
motif (332) induced an 18% and 44% loss in activity, respectively. As expected, the 
benzotriazole analog substituted with a propargyl (333) motif instead of the methoxy (324) group 
exhibited a significant loss in potency. Substitution of the benzene ring with a 
tetrahydroquinoline motif as in 30, or with 4,5-dichloro-2-methylbenzene similarly to 278, 
resulted in drastic reductions in activity (Figure 3.24). 
 
Figure 3.24: Structure-activity relationship studies of the hit compound 279 through modification of the benzene 
ring substituents (variations to the original structure are shown in blue). 
The numbers represent activity relative to 279 within the same miR-122 luciferase assay. EC50 values are shown in 
blue. Experiments were performed in triplicate and the standard deviations of three independent assays were 
calculated. The compounds were provided by the Broad Institute, excepted the analogs labeled with one or two 
asterixes (* or **), which were synthesized by me or by Rohan Kumbhare, respectively. 
 
 
The best analogs identified through structural modifications of 279, were tested in dose-
response in Huh7-psiCHECK-miR122 cells (Figure 3.25). Analogs 330 and 331 were less potent 
than 279 with EC50 values of ~7 M. The compounds 314 and 324 displayed EC50 values 
equivalent to 279. Surprisingly, the indole derivative 321, which exhibited a 23% reduced 
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activity compared to 279 in the miR-122 luciferase assay (at 10 M), was found 10 times more 
potent than 279 when tested in dose-response (Figure 3.25).  
A. B. 
 
Figure 3.25: Dose-response curves in Huh7-psiCHECK-miR122 cells treated with the best analogs of hit compound 
279. 
A. Compounds 314, 321, and hit compound 279. B. Compounds 324, 330, and 331. All assays were conducted in 
triplicate and normalized to a DMSO control. The error bars represent the standard deviation from three independent 
experiments. 
 
 
To verify the specificity of these analogs for miR-122 inhibition, they were submitted to 
secondary assays (Figure 3.26). The compounds 279, 314, 321, 324, 329, 330, and 331 were 
tested in the in vitro RLuc assay; 314, 321, 330, and 331 induced ≥30% decrease in Renilla 
luminescence, while the analogs 279, 324, and 329 only modestly affected the enzyme, with 
≤20% inhibition observed (Figure 3.26A). Not surprisingly, 314, which induced the most Rluc 
inhibition in vitro, most strongly affected the luminescence signal in the psiCHECK-empty assay 
(Figure 3.26B). The compounds 324, 329, 330, and 331 induced a 2- to 2.5-fold increase in the 
psiCHECK-empty assay. The derivatives 279 and 321 did not perturb the luminescence signal in 
the control assay (Figure 3.26B), suggesting some level of specificity for miRNA inhibition. 
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Figure 3.26: Secondary assays to determine the selectivity of the best analogs of hit 279 identified in the HTS. 
A. In vitro RLuc assay, the compounds were tested at 10 M. B. Dual Luciferase assay of Huh7 cells transfected 
with psiCHECK-empty and treated with the analogs at 10 M for 48 h. The luciferase signal was normalized to a 
DMSO control. The error bars indicate the standard deviations determined from three independent measurements.  
 
The most promising inhibitors 279, 321, and 324 were tested in qRT-PCR experiments 
(Figure 3.27). Huh7 cells were exposed to a DMSO control or to the inhibitors at 10 M for 48 
hours. The total RNA was isolated using the miRNeasy kit (Qiagen), and the qRT-PCR was 
performed in triplicate using TaqMan probes for miR-122 and RNU19 (control). The data was 
then normalized to the DMSO and RNU19 controls using the  method.
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 The 2 most 
promising inhibitors 279 and 321 reduced the level of miR-122 expression by 43% and 23% 
compared to the DMSO control, respectively. The benzotriazole analog 324, unfortunately, did 
not induce any down-regulation of miR-122 expression (Figure 3.27). Follow-up studies will be 
performed in the future to investigate the selectivity of 279 and 321, as well as their mode of 
action. 
 
 188 
0 
20 
40 
60 
80 
100 
DMSO 279 321 324 
m
iR
N
A
 e
x
p
re
s
s
io
n
 /
 %
 
 
Figure 3.27: qRT-PCR measurements of mature miR-122 levels in Huh7 cells treated with the hit compound 279 
and the best analogs (10 μM). 
The relative expression of miR-122 for small molecule treated cells was normalized to a DMSO control (100% 
expression) and RNU19 expression. The error bars indicate the standard deviation determined from three independent 
measurements.  
 
3.4.5 Re-examination of the 34 Hit Compounds Identified in the HTS 
Since the sulfonamide chemotype was observed in the majority of the active compounds 
identified in the HTS, and most of them were found to be potent Renilla luciferase inhibitors, it 
was decided to re-investigate the top 34 hit compounds provided by the Broad Institute, which 
included 6 non-sulfonamide derivatives (264, 336, 337, 338, 347, and 362 Figure 3.28 and 
Figure 3.29). All the analogs were re-tested in the miR-122 luciferase assay. Only 18 compounds 
were found as active or more active than 30 in the Huh7-psiCHECK-miR122 assay. The 
derivatives 341 and 360 were as active as 30; compounds 338, 342, 344, 349, 350, 351, 353-356, 
359, and 362 elicited a 10 to 50% increase in activity. The analogs 268 and 346 induced ≥200% 
increase in activity and compounds 348 and 352 promoted a significant ≥300% enhancement in 
activity. It is noteworthy that 338 and 362 were the only active compounds not presenting a 
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sulfonamide scaffold. The analog 268, which was one of the top 4 most active compounds in the 
primary screen, was the only one remaining after all the secondary assay studies. 
These compounds were then tested in the in vitro RLuc assay to determine their effect on 
Renilla luciferase (Figure 3.28 and Figure 3.29). Unfortunately, most of the derivatives showed a 
strong Renilla luciferase inhibition. Only 336, 339, 357, 362, and 363 elicited a modest (≤50%) 
interaction with the enzyme. The compounds 336 and 357 were disregarded because they were 
inactive in the miR-122 luciferase assay. The analogs 339, 362, and 363 were further 
investigated; 339 showed an activity comparable to 279 in Huh7-psiCHECK-miR122 cells, and 
362 exhibited an 18% increased activity compared to 30. 
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Figure 3.28: Structure of best 34 compounds identified in the HTS. 
The numbers in black represent the activity (in percent) relative to 30 within the same miR-122 luciferase assay. Ri 
values (in green) represent Renilla luciferase in vitro activity (in percent) relative to a DMSO control (100%). Lower 
numbers indicate a stronger inhibition. EC50 values are shown in blue. Experiments were performed in triplicate and 
the standard deviations of three independent assays were calculated. 
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Figure 3.29: Structure of best 34 compounds identified in the HTS – continued. 
The numbers in black represent the activity (in percent) relative to 30 within the same miR-122 luciferase assay. Ri values (in 
green) represent Renilla luciferase in vitro activity (in percent) relative to a DMSO control (100%). Lower numbers indicate a 
stronger inhibition.  EC50 values are shown in blue. Experiments were performed in triplicate and the standard deviations of three 
independent assays were calculated. 
 
The best 3 compounds 339, 362, and 363 were tested in dose-response in Huh7-
psiCHECK-miR122 cells (Figure 3.30), and displayed significantly lower EC50 values  (≤10-
fold) than 30. 
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Figure 3.30: Dose response curves in Huh7-psiCHECK-miR122 cells treated with the most promising hit 
compounds identified in the HTS (339, 362, and 362) and the positive control 30. 
All assays were conducted in triplicate and normalized to a DMSO control. The error bars represent the standard 
deviation from three independent experiments. 
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These three analogs, along with the two non-sulfonamide derivatives 264 and 338 were 
further evaluated in Huh7 cells transfected with the psiCHECK-empty reporter (Figure 3.31). 
The hit compound 264, identified by the Broad Institute, but deemed inactive in subsequent 
assays, did not show any effect on the luminescence signal in the reporter assay, similarly to 363. 
Conversely, the sulfonamide 339 and the two amide derivatives 338 and 362 induced a 2- and 
2.5-fold increase in the signal over the DMSO control, respectively. These results indicated that 
the compounds 338, 339, 362, and 363 might lack specificity for miR-122, as they induced an 
increase in the luminescence signal of the control reporter. However, since the in vitro data 
indicated a modest inhibition of the Renilla luciferase by 338 and 362, and only a weak 
inhibition by 339 and 363, the direct effect of these compounds on miR-122 regulation should be 
examined. 
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Figure 3.31: Specificity study of interesting compounds from the HTS. 
Dual Luciferase assay of Huh7 cells transfected with psiCHECK-empty and treated with the analogs 264, 338, 339, 
362, and 363 at 10 M for 48 h. The luciferase signal was normalized to a DMSO control. The error bars indicate 
the standard deviations determined from three independent measurements.  
 
These five compounds were also tested in qRT-PCR experiments to directly measure 
their effect on miR-122 expression levels (Figure 3.32). Huh7 cells were treated with DMSO or 
the inhibitors at 10 M for 48 hours. The total RNA was isolated with the miRNeasy kit and 
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used in qRT-PCR experiments in conjunction with the TaqMan probes for miR-122 or the 
control RNU19. Although 338 and 363 displayed a relatively high activity in the miR-122 
luciferase assay, they did not reduce miR-122 expression. In agreement with what had been 
observed in the luciferase assay (Figure 3.28), 264 did not affect miR-122 expression. The 
sulfonamide 339 similarly did not induce any change in the intracellular levels of miR-122. 
Interestingly, the amide 362 showed a somewhat promising 24% reduction in miR-122 
expression levels. Extensive re-analysis of the hit compounds identified by the Broad Institute 
revealed that most of these derivatives are Renilla luciferase inhibitors (Figure 3.28 and Figure 
3.29), and do not actually affect miR-122 activity. 
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Figure 3.32: qRT-PCR measurements of mature miR-122 levels in Huh7 cells treated with 264, 338-339, and 362-
363 at 10 μM. 
The relative expression of miR-122 for small molecule treated cells was normalized to a DMSO control (100% 
expression) and RNU19 expression. The error bars indicate the standard deviation determined from three 
independent measurements.  
 
3.5 SUMMARY AND OUTLOOK 
The previously identified miR-122 inhibitor 30 was extensively investigated through 
SAR studies. A total of 43 analogs were synthesized in order to better understand the molecular 
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requirement for miR-122 inhibition. A few compounds displayed activities comparable to 30 or 
slightly higher, but unfortunately this SAR investigation did not provide any analog significantly 
more potent than the inhibitor 30.  
A recent HTS of >300,000 compounds was conducted in collaboration with the Broad 
Institute to identify additional small molecule miR-122 inhibitors. From the 336,006 compounds 
tested in the primary screen, 1,023 compounds that displayed an activity ≥90% relative to 30 (at 
10 M) were identified as active. Following dose-response experiments, removal of compounds 
structurally problematic, known to be promiscuous, or that were also found as active in an 
unrelated HTS for miR-21 inhibitors, and powder re-test, only 34 small molecules remained. 
These were re-tested in the miR-122 luciferase assay and in qRT-PCR experiments to measure 
the levels of expression of miR-122, miR-21, and miR-27b. Subsequent validation of the hit 
compounds identified in the HTS led to the discovery of the two potent sulfonamide inhibitors 
278 and 279. Preliminary SAR studies were performed for both compounds to further improve 
their activity. The best analogs of both series were tested in dose-response and submitted to 
secondary assays to evaluate their specificity. All the analogs of 278, along with 278, were found 
to be potent Renilla luciferase inhibitors. Gratifyingly, 279 and its analog 321 showed some 
specificity for miR-122 inhibition and induced a significant reduction in miR-122 expression, as 
found in qRT-PCR experiments. The compound 279 had an EC50 value equivalent to 30, and 321 
was found to be 10 times more potent. Follow-up studies need to be performed to further 
investigate the selectivity of 279 and 321 for miR-122 inhibition and determine their mechanism 
of action. 
Additionally, careful re-investigation of the hits identified in the HTS, suggested that 
most of the compounds represent potent inhibitors of the Renilla luciferase enzyme rather than 
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actual miR-122 inhibitors. This highlights the importance of conducting secondary assays to 
distinguish compounds that showed activity by inhibiting the target of interest (miR-122), from 
non-specific compounds, which interfered with the assay read out. It would have been helpful to 
include the in vitro RLuc assay as a control, following the primary screen of 336,006 compounds 
in the HTS. Nonetheless, this study also revealed the structurally diverse 362 as a promising new 
miR-122 inhibitor. It displayed an improved EC50 value of 0.2 M and, more importantly, 
reduced the expression levels of miR-122 by 24% compared to a DMSO control. Of note, the 
amide 362 exhibited some degree of non-specificity as it showed 46% inhibition in the RLuc 
assay. SAR studies need to be conducted to improve the activity and specificity of 362 for miR-
122 inhibition. 
More importantly, miR-122 represents an attractive therapeutic target, since it is required 
for HCV replication. Exposure of infected liver cells to the previously identified small molecule 
miR-122 inhibitors 29 and 30 resulted in >50% reduction of HCV RNA levels.
98
 Once the 
selectivity profile of the newly identified miR-122 inhibitors is determined, these compounds 
279, 321, and 362 need to be tested for their ability to reduce HCV replication in liver cells. 
In conclusion, additional small molecule inhibitors of miR-122 have been identified 
through HTS, that could provide potential new tools to elucidate the involvement of miR-122 in 
HCV as well as new antiviral therapies. 
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3.6 EXPERIMENTALS 
Cell culture. Experiments were performed using the Huh7 cell line (gift from Dr. Asokan, UNC) 
cultured in Dulbecco’s Modified Eagle Medium (DMEM; Hyclone) supplemented with 10% 
Fetal Bovine Serum (FBS; Seradigm catalog number 97068-085, lot #093B13) and 2% 
penicillin/streptomycin (VWR) and maintained at 37 °C in a 5% CO2 atmosphere. Huh7-
psiCHECK-miR122 cells
124
 were cultured in Dulbecco’s Modified Eagle Medium (DMEM; 
Hyclone) supplemented with 10% fetal bovine serum (FBS; Seradigm catalog number 97068-
085, lot #093B13), 500 μg/mL of G418 (Sigma Aldrich), and 2% penicillin/streptomycin (VWR) 
and maintained at 37 °C in a 5% CO2 atmosphere. 
 
Screening of the compounds in the miR-122 luciferase assay. Huh7-psiCHECK-miR122 cells 
were seeded at a density of 5,000 cells per well in white, clear-bottom, 384-well plates (Greiner). 
After an overnight incubation in media (DMEM, 10% FBS, free of antibiotics and free of G418, 
45 L), the cells were treated with compounds at a concentration of 10 M (by addition of 5 L 
of a 0.1 mM solution stock in 1% DMSO) or a DMSO control (0.1% DMSO final concentration) 
in triplicate. The cells were incubated for 48 h followed by analysis with a Dual Luciferase 
Reporter Assay Kit (Promega) using 20 L passive lysis buffer and 25 L of each luciferase 
reagent. The luminescence was measured on a Tecan M1000 platereader with a measurement 
time of 1 s and a delay time of 2 s. All experiments were performed in triplicate, for each well 
the Renilla luciferase read out was normalized to the firefly luciferase read out, and the average 
for each sample was further normalized to the DMSO control. 
 
Quantitative real time PCR analysis. Huh7 cells were seeded at a density of 150,000 cells per 
well in 6-well plates and grown overnight. The media was replaced with 1,98 mL DMEM and 
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the cells were treated with compounds at a 10 μM concentration (20 μL of 1 mM DMSO stock) 
or with DMSO (1% final DMSO concentration). The cells were incubated at 37 °C for 48 h 
(DMEM, antibiotics-free, 5% CO2, 2 mL final volume). The media was removed, and the cells 
were washed with PBS buffer (1 mL, pH 7.4) followed by RNA isolation with a miRNeasy mini 
kit (Qiagen) using the procedure described in the appendix 6.2. Following quantification, the 
RNA samples were diluted to 3 ng/μL in RNAse-free water, and 15 ng (5 μL) of each sample 
were reverse transcribed using the TaqMan microRNA Reverse Transcription Kit (Life 
Technologies) in conjunction with the RNU19 (control) or the miR-122 TaqMan RT primer. The 
real time PCR was then carried out with a TaqMan 2x Universal PCR Master Mix and the 
appropriate TaqMan miRNA assay for miR-122 and RNU19 (Life Technologies). The triplicate 
threshold cycles (Ct) obtained for each small molecule treatment were used to determine the 
relative levels of miR-122 in small molecule treated cells relative to the DMSO control using the 
 method.
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Assessment of the specificity of the inhibitors using the psiCHECK-empty reporter. Huh7 
cells were seeded at a density of 15,000 cells per well in a white clear-bottom 96-well plates 
(VWR), in 200 μL media (DMEM, 10% FBS, no-antibiotics) and grown overnight. The cells 
were transfected with 40 ng of psiCHECK-empty using Lipofectamine 2000 (Life Technologies) 
in 200 μL OptiMEM (Life Technologies). After 2 h incubation at 37 °C, the media was replaced 
with DMEM (198 μL, 10% FBS, no antibiotics) supplemented with the compounds at 10 M (2 
μL of a 1 mM 10% DMSO stock) or DMSO control (0.1% DMSO final concentration). The cells 
were incubated for 48 h followed by analysis with a Dual Luciferase Reporter Assay Kit 
(Promega) using 30 L passive lysis buffer and 50 L of each luciferase reagent. The 
luminescence was measured on a Tecan M1000 platereader with a measurement time of 1 s and a 
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delay time of 2 s. All experiments were performed in triplicates, for each well the Renilla read 
out was normalized to the firefly luciferase read out, and the average for each sample was further 
normalized to the DMSO control. 
 
In vitro RLuc inhibition assay. The protocol was adapted from previous reports.
235
 The 
experiment was performed in a white 384-well plate in triplicate. The compounds were diluted at 
50 M (20% final DMSO concentration) in PBS (6 L of a 250 M DMSO stock in 24 L of 
PBS). The recombinant Renilla luciferase enzyme (RayBiotech, 9 L of a 0.3 mg/L PBS stock) 
was added to each well. The compounds were added to obtain a final concentration of 10 M 
(4% final DMSO concentration, addition of 6 L of the 50 M stock). Then, 15 L of Renilla-
glo buffer (Promega) supplemented with the substrate (10 L of substrate per 1 mL of buffer) 
was added to each well. The plate was quickly centrifuged at 1,000 x g for 1 min and shaken in 
the dark for 10 min. The luminescence was measured on a Tecan M1000 luminometer with a 
measurement time of 1 s. All experiments were performed in triplicates, and the average for each 
sample was normalized to the DMSO control. 
Organic synthesis.  
All reactions were performed in flame-dried glassware under a nitrogen atmosphere and stirred 
magnetically. Reactions were followed by thin layer chromatography (TLC) using glass-backed 
silica gel plates (Sorbent technologies, 250 µm thickness). Tetrahydrofuran and DCM were 
obtained from a dry solvent delivery system. MeCN, EtOH, MeOH and pyridine were distilled 
from calcium hydride and stored over 4 Ǻ molecular sieves. Other reagents and solvents were 
obtained from commercial sources (Sigma, VWR, Fisher, Accros), stored under nitrogen and 
used directly without further purification. Yields refer to pure compounds unless otherwise 
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stated. Flash chromatography was performed on silica gel (60 Å, 40-63 μm (230 × 400 mesh), 
Sorbtech) as a stationary phase. High-resolution mass spectral analysis (HRMS) was performed 
at the University of Pittsburgh on a Q-Exactive (Thermo Scientific) mass spectrometer. The 
1
H 
NMR and 
13
C NMR spectra were recorded on a 300 MHz or a 400 MHz Varian or Bruker NMR 
spectrometers. Chemical shifts are given in δ units (ppm) for NMR spectra. 
 
1-(3,4-Dihydroquinolin-1(2H)-yl)-2,2,2-trifluoroethanone (193). TEA (6.3 mL, 45.3 mmol) 
was added to a stirred solution of tetrahydroquinoline (1.9 mL, 15.1 mmol) in Et2O (10 mL). The 
solution was cooled to 0 °C and TFAA (4.23 mL, 30.2 mmol in 5 mL of Et2O) was added drop-
wise. The resulting mixture was allowed to warm up to room temperature and was stirred 
overnight. The mixture was diluted with Et2O (5 mL), washed with H2O (3 x 20 mL) and brine 
(16 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (6:1) to give 193 as a yellow solid 
(3.1 g, 88%). 
1
H NMR (300 MHz, chloroform-d)  7.62 (d, J = 9.6 Hz, 1H), 7.22 (d, J = 6.3 Hz, 
2H), 3.84 (t, J = 6.2 Hz, 2H), 2.86 (t, J = 6.9 Hz, 2H), 2.07 (t, J = 6.6 Hz, 2H). The analytical 
data is in agreement with literature reports.
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1-(2,2,2-Trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonyl chloride (194). The 
intermediate 193 (200 mg, 0.87 mmol) was added to chlorosulfonic acid (0.3 mL, 4.4 mmol) at 0 
°C. The reaction mixture was slowly allowed to warm up to room temperature over 30 min and 
heated to reflux for 2.5 h. The solution was cooled down to 0 °C in an ice bath and ice-cold water 
(3 mL) was slowly added, followed by EtOAc (5 mL). The layers were separated, the aqueous 
layer was extracted with EtOAc (3 x 5 mL), the organic layers were combined, washed with H2O 
(3 x 10 mL) and brine (8 mL), dried over Na2SO4, filtered, and concentrated. The residue was 
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purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (5:1) to give 194 as 
a yellow solid (199 mg, 69%). 
1
H NMR (300 MHz, chloroform-d)  7.99 (d, J = 9.6 Hz, 1H), 
7.89 (dd, J = 7.2, 2.2 Hz, 2H), 3.91 (m, 2H), 3.02 (dd, J = 7.7, 6.1 Hz, 2H), 2.16 (td, J = 7.0, 5.8 
Hz, 2H). The analytical data is in agreement with literature reports.
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2,2,2-Trifluoro-1-(6-(((4aR,8aS)-octahydroquinolin-1(2H)-yl)sulfonyl)-3,4-dihydroquinolin-
1(2H)-yl)ethanone (195). TEA (0.306 mL, 2.19 mmol) was added to a solution of trans-
decahydroquinoline (102 mg, 0.73 mmol) in DCM (6 mL) at 0 °C. A solution of 194 (120 mg, 
0.37 mmol) in DCM (3 mL) was added drop-wise. The reaction mixture was allowed to warm to 
room temperature and stirred for 3 h. A 1 M HCl solution (2 mL) and DCM (6 mL) were added, 
the layers were separated, the aqueous layer was extracted with DCM (2 x 6 mL), the organic 
layers were combined, washed with H2O (2 x 5 mL) and brine (4 mL), dried over Na2SO4, 
filtered, and concentrated. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (4:1) to give 195 as a white solid (97 mg, 61%). 
1
H NMR (400 
MHz, chloroform-d)  7.82 (s, 1H), 7.68 - 7.55 (m, 2H), 4.08 (m, 1H), 3.85 (dd, J = 6.9, 5.0 Hz, 
2H), 2.93 (t, J = 6.9 Hz, 2H), 2.75 (ddd, J = 13.2, 7.9, 6.0 Hz, 1H), 2.49 (ddd, J = 11.4, 10.0, 3.6 
Hz, 1H), 2.23 - 2.05 (m, 3H), 1.80 - 1.37 (m, 6H), 1.31 - 0.87 (m, 3H). The analytical data is in 
agreement with literature reports.
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6-(((4aR,8aS)-Octahydroquinolin-1(2H)-yl)sulfonyl)-1,2,3,4-tetrahydroquinoline (30). 
K2CO3 (540 mg, 4.12 mmol) was added to a solution of 195 (93 mg, 0.21 mmol) in MeOH:H2O 
(3.9:1.6 mL),  and the reaction mixture was stirred for 2 h at rt. The solvents were removed under 
vacuum, the residue was dissolved in H2O (5 mL), the product was extracted with DCM (3 x 8 
mL), and the combined organic layers were washed with brine (6 mL), dried over Na2SO4, 
 201 
filtered, and concentrated. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (4:1) to afford 30 as a white solid (49 mg, 72%). 
1
H NMR (400 
MHz, chloroform-d)  7.31 - 7.21 (m, 2H), 6.41 - 6.34 (m, 1H), 4.40 (s, 1H), 4.04 - 3.94 (m, 1H), 
3.30 (t, J = 5.6 Hz, 2H), 2.71 (t, J = 6.3 Hz, 2H), 2.65 - 2.54 (m, 1H), 2.37 - 2.25 (m, 2H), 1.93 - 
1.82 (m, 2H), 1.75 - 1.31 (m, 8H), 1.23 - 1.00 (m, 2H), 1.00 - 0.81 (m, 2H); 
13
C NMR (400 MHz, 
chloroform-d)  148.265, 128.856, 126.861, 126.248, 120.528, 112.949, 65.097, 48.993, 41.810, 
41.403, 33.746, 32.146, 32.046, 27.225, 26.186, 25.702, 25.459, 21.372. The analytical data is in 
agreement with literature reports.
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The compounds 201-215 and 220-221 were prepared from 194 and the corresponding amines 
using the procedure described for 30: 
 
N-Butyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (199). Same procedure as 195 using 
butylamine (0.051 mL, 0.52 mmol) and 194 (85 mg, 0.26 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (4:1) to 
deliver 199 as a white solid (45 mg, 86%). 
1
H NMR (300 MHz, chloroform-d)  7.45 - 7.37 (m, 
2H), 6.43 (d, J = 9.0 Hz, 1H), 4.35 (s, 1H), 4.12 (t, J = 6.2 Hz, 1H), 3.40 - 3.32 (m, 2H), 2.90 (q, 
J = 6.7 Hz, 2H), 2.77 (t, J = 6.3 Hz, 2H), 1.95 - 1.90 (m, 2H), 1.49 - 1.37 (m, 2H), 1.33 - 1.25 
(m, 4H), 0.86 (t, J = 7.2 Hz, 3H). The analytical data is in agreement with literature reports.
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N-Octyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (201). Same procedure as 195 using 
octylamine (0.075 mL, 0.45 mmol) and 194 (50 mg, 0.15 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (6:1) to 
deliver 201 as a colorless oil (20 mg, 31%). 
1
H NMR (300 MHz, chloroform-d)  7.46 - 7.38 (m, 
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2H), 6.43 (d, J = 8.2 Hz, 1H), 4.37 (s, 1H), 4.22 (bs, 1H), 3.36 (t, J = 6.0 Hz, 2H), 2.92 - 2.85 (m, 
2H), 2.76 (t, J = 6.4 Hz, 2H), 1.95 - 1.91 (m, 2H), 1.42 (t, J = 6.6 Hz), 1.28 - 1.22 (m, 10H), 0.86 
(t, J = 6.4 Hz, 3H). HRMS (ESI
+
) calculated for C17H28N2O2S (M+Na)
+
 347.1769, found 
347.1739. 
 
N-Decyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (202). Same procedure as 30 using 1-
aminodecane (0.091 mL, 0.45 mmol) and 194 (50 mg, 0.15 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (6:1) to 
afford 202 as a white solid (19 mg, 40%). 
1
H NMR (300 MHz, chloroform-d)  7.42 - 7.39 (m, 
2H), 6.42 (d, J = 9.0 Hz, 1H), 4.35 (s, 1H), 4.16 (t, J = 6.1 Hz, 1H), 3.36 (t, J = 5.4 Hz, 2H), 2.89 
(q, J = 7.0 Hz, 2H), 2.77 (t, J = 6.2 Hz, 2H), 1.95 - 1.91 (m, 2H), 1.43 (t, J = 6.7 Hz, 2H), 1.22 (s, 
14H), 0.87 (t, J = 6.8 Hz, 3H). HRMS (ESI
+
) calculated for C19H32N2O2S (M+Na)
+
 375.2082, 
found 375.2046. 
 
N-Dodecyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (203). Same procedure as 195 using 
dodecylamine (0.104 mL, 0.45 mmol) and 194 (50 mg, 0.15 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (8:1) to 
deliver 203 as a white solid (8 mg, 25%). 
1
H NMR (300 MHz, chloroform-d)  7.41 - 7.39 (m, 
2H), 6.42 (d, J = 9.0 Hz, 1H), 4.33 (s, 1H), 4.12 (t, J = 6.2 Hz, 1H), 3.36 (t, J = 6.0 Hz, 2H), 2.89 
(q, J = 6.8 Hz, 2H), 2.77 (t, J = 6.3 Hz, 2H), 1.97 - 1.91 (m, 2H), 1.43 (t, J = 7.0 Hz, 2H), 1.23 
(d, J = 7.8 Hz, 18H), 0.88 (t, J = 6.7 Hz, 3H). HRMS (ESI
+
) calculatedd for C21H36N2O2S 
(M+H)
+
 381.2576, found 381.2545. 
N-Isobutyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (204). Same procedure as 195 using 
isobutylamine (0.051 mL, 0.52 mmol) and 194 (85 mg, 0.26 mmol) as the starting materials. The 
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residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (7:1) to 
deliver 204 as a colorless oil (35 mg, 75%). 
1
H NMR (300 MHz, chloroform-d)  7.41 - 7.39 (m, 
2H), 6.42 (d, J = 9.0 Hz, 1H), 4.35 (s, 1H), 4.24 (t, J = 6.5 Hz, 1H), 3.36 (t, J = 4.8 Hz, 2H), 2.77 
(t, J = 6.3 Hz, 2H), 2.70 (t, J = 6.7 Hz, 2H), 1.95 - 1.91 (m, 2H), 1.75 - 1.71 (m, 1H), 0.87 (d, J = 
6.7 Hz, 6H). 
 
N-(Cyclopropylmethyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (205). Same procedure as 
195 using cyclopropanemethylamine (0.026 mL, 0.30 mmol) and 194 (50 mg, 0.15 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (8:1) to deliver 205 as a colorless oil (28 mg, 83%). 
1
H NMR (400 MHz, 
chloroform-d)  7.48 - 7.34 (m, 2H), 6.41 (d, J = 9.1 Hz, 1H), 4.50 (t, J = 5.9 Hz, 1H), 3.34 (t, J 
= 5.2 Hz, 2H), 2.77 - 2.72 (m, 4H), 1.94 - 1.88 (m, 2H), 0.90 - 85 (m, 2H), 0.44 (q, J = 5.4 Hz, 
2H), 0.08 (q, J = 5.1 Hz, 2H). HRMS (ESI
+
) calculated for C13H18N2O2S (M+H)
+
 267.3672, 
found 267.1152. 
 
N-(Prop-2-yn-1-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. 
Same procedure as 195 using propargylamine (0.059 mL, 0.91 mmol) and 194 (100 mg, 0.30 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (2:1) to deliver a white solid (71 mg, 67%). 
1
H NMR (300 MHz, 
chloroform-d)  7.76 (s, 1H), 7.73 (d, J = 7.8 Hz, 2H), 4.66 - 4.64 (m, 1H), 3.89 - 3.85 (m, 2H), 
2.94 (t, J = 6.9 Hz, 2H), 2.14 - 2.12 (m, 2H).  
 
N-((1-(3-Hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-
tetrahydroquinoline-6-sulfonamide. Sodium ascorbate (13.7 mg, 0.07 mmol) and copper 
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sulfate pentahydrate (4.3 mg, 0.01 mmol) were added to a solution of 3-azidopropanol (10.5 mg, 
0.10 mmol) and N-(prop-2-yn-1-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide (30 mg, 0.09 mmol) in tBuOH:H2O (0.5:0.5 mL). The resulting mixture was stirred 
at room temperature overnight. The solvents were removed under vacuum and the residue was 
purified by flash chromatography on silica gel, eluting with 5% MeOH in DCM to give a white 
oil (24 mg, 78%). 
1
H NMR (300 MHz, chloroform-d)  7.80 (d, J = 8.1 Hz, 1H), 7.70 - 7.66 (m, 
2H), 7.48 (s, 1H), 5.81 (t, J = 6.3 Hz, 1H), 4.33 (t, J = 6.6 Hz, 2H), 4.27 (d, J = 6.0 Hz, 2H), 3.88 
- 3.84 (m, 2H), 3.57 (t, J = 5.7 Hz, 2H), 2.96 - 2.91 (t, J = 6.9 Hz, 2H), 2.15 - 2.04 (m, 4H). 
HRMS (ESI
+
) calculated for C17H20F3N5O4S (M+Na)
+
 370.1086, found 370.1095. 
 
N-((1-(3-Hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide (208). Same procedure as 30 using N-((1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-
yl)methyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (7 mg, 0.015 
mmol) and K2CO3 (41 mg, 0.29 mmol) as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with 5% MeOH in DCM to afford 208 as a white oil 
(4 mg, 60%). 
1
H NMR (300 MHz, acetone-d)  7.62 (s, 1H), 7.35 - 7.32 (m, 2H), 6.51 (d, J = 9.3 
Hz, 1H), 6.40 (s, 1H), 5.80 (s, 1H), 4.43 (t, J = 6.9 Hz, 2H), 4.10 (s, 2H), 3.54 (t, J = 6.0 Hz, 2H), 
3.36 - 3.32 (m, 2H), 2.82 - 2.76 (m, 2H), 2.75 (t, J = 6.3 Hz, 2H), 1.99 - 1.87 (m, 2H). HRMS 
(ESI
+
) calculated for C15H21N5O3S (M+H)
+
 352.4319, found 352.1454. 
 
N,N-Di(prop-2-yn-1-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. 
Same procedure as 195 using dipropargylamine (0.066 mL, 0.64 mmol) and 194 (70 mg, 0.21 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (2:1) to deliver a colorless oil (45 mg, 56%). 
1
H NMR (300 MHz, 
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chloroform-d)  7.82 (s, 1H), 7.67 (d, J = 7.8 Hz, 2H), 4.16 (s, 4H), 3.85 (t, J = 4.5 Hz, 2H), 2.94 
(t, J = 5.1 Hz, 2H), 2.18 (s, 2H), 2.12 - 2.10 (m, 2H).  
N,N-Di(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (209). Same procedure as 
30 using N,N-di(prop-2-yn-1-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide (45 mg, 0.12 mmol) and K2CO3 (315 mg, 2.28 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to 
deliver 209 as a yellow oil (24 mg, 71%). 
1
H NMR (300 MHz, chloroform-d)  7.36 - 7.34 (m, 
2H), 6.40 (d, J = 9.1 Hz, 1H), 4.44 (s, 1H), 4.11 (s, 4H), 3.34 (t, J = 5.7 Hz, 2H), 2.74 (t, J = 6.3 
Hz, 2H), 2.17 (s, 2H), 1.93 - 1.86 (m, 2H). HRMS (ESI
+
) calculated for C15H16N2O2S (M+H)
+
 
289.1011, found 289.1003. 
N-Butyl-N-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. 
Same procedure as 195 using N-methyl-butylamine (0.09 mL, 0.78 mmol) and 194 (85 mg, 0.26 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (2:1) to deliver a white solid (47 mg, 48%). 
1
H NMR (300 MHz, 
chloroform-d)  7.76 (s, 1H), 7.60 (d, J = 7.8 Hz, 2H), 3.86 (t, J = 4.2 Hz, 2H), 3.01 - 2.94 (m, 
4H), 2.71 (s, 3H), 2.12 - 2.09 (m, 2H), 1.52 - 1.48 (m, 2H), 1.36 - 1.33 (m, 2H), 0.9 (t, J = 5.4 
Hz, 3H).  
N-Butyl-N-methyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (210). Same procedure as 30 
using N-butyl-N-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (47 
mg, 0.12 mmol) and K2CO3 (315 mg, 2.28 mmol) as the starting materials. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (5:1) to deliver 210 
as a colorless oil (47 mg, 48%). 
1
H NMR (300 MHz, chloroform-d)  7.30 (d, J = 6.6 Hz, 2H), 
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6.42 (d, J = 9.1 Hz, 1H), 4.41 (s, 1H), 3.33 (t, J = 5.4 Hz, 2H), 2.92 (t, J = 7.1 Hz, 2H), 2.74 (t, J 
= 6.3 Hz, 3H), 2.64 (s, 3H), 1.94 - 1.90 (m, 2H), 1.50 - 1.45 (m, 2H), 1.38 - 1.29 (m, 2H), 0.90 (t, 
J = 7.2 Hz, 3H). HRMS (ESI
+
) calculated for C14H22N2O2S (M+H)
+
 283.1480, found 283.1496. 
N-Isobutyl-N-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. 
Same procedure as 195 using N-methylisobutylamine (0.05 mL, 0.51 mmol) and 194 (85 mg, 
0.26 mmol) as the starting materials. The residue was purified by flash chromatography on silica 
gel, eluting with hexanes/EtOAc (2:1) to deliver a white solid (37 mg, 37%). 
1
H NMR (300 
MHz, chloroform-d)  7.86 (s, 1H), 7.58 (d, J = 7.8 Hz, 2H), 3.90 - 3.84 (m, 2H), 2.97 - 2.92 (m, 
2H), 2.81 - 2.71 (m, 5H), 2.16 - 2.09 (m, 2H), 1.90 - 1.83 (m, 2H), 0.95 - 0.90 (m 5H). 
N-Isobutyl-N-methyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (211). Same procedure as 
30 using N-isobutyl-N-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide (36 mg, 0.09 mmol) and K2CO3 (251 mg, 1.8 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to 
deliver 211 as a colorless oil (15 mg, 60%). 
1
H NMR (300 MHz, chloroform-d)  7.32 (d, J = 6.6 
Hz, 2H), 6.42 (d, J = 9 Hz, 1H), 4.36 (s, 1H), 3.42 - 3.33 (m, 2H), 2.84 - 2.64 (m, 7H), 2.00 - 
1.77 (m, 3H), 0.94 (d, J = 5.1 Hz, 6H). HRMS (ESI
+
) calculated for C14H22N2O2S (M+H)
+
 
283.1480, found 283.1562. 
N,N-Dibutyl-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. Same 
procedure as 195 using dibutylamine (0.13 mL, 0.78 mmol) and 194 (85 mg, 0.26 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (6:1) to deliver a white solid (55 mg, 50%). 
1
H NMR (400 MHz, chloroform-d) 
 7.72 (s, 1H), 7.63 (d, J = 7.8 Hz, 2H), 3.85 (t, J = 6.4 Hz, 2H), 3.12 - 3.08 (m, 4H), 2.93 (t, J = 
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6.9 Hz, 2H), 2.12 - 2.09 (m, 2H), 1.52 - 1.48 (m, 4H), 1.28 - 1.26 (m, 4H), 0.89 (t, J = 7.6 Hz, 
6H). 
N,N-Dibutyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (212). Same procedure as 30 using 
N,N-dibutyl-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (55 mg, 0.13 
mmol) and K2CO3 (341 mg, 2.1 mmol) as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to deliver 212 as a 
colorless oil (14 mg, 32%). 
1
H NMR (300 MHz, chloroform-d)  7.34 (d, J = 6.6 Hz, 2H), 6.41 
(d, J = 9.0 Hz, 1H), 4.31 (s, 1H), 3.35 (t, J = 5.7 Hz, 2H), 3.04 (t, J = 7.5 Hz, 4H), 2.76 (t, J = 6.3 
Hz, 2H), 1.96 - 1.90 (m, 2H), 1.57 - 1.44 (m, 4H), 1.34 - 1.23 (m, 4H), 0.90 (t, J = 7.3 Hz, 6H). 
HRMS (ESI
+
) calculated for C17H28N2O2S (M+H)
+
 325.4894, found 325.1957. 
1-(6-(Azepan-1-ylsulfonyl)-3,4-dihydroquinolin-1(2H)-yl)-2,2,2-trifluoroethanone. Same 
procedure as 195 using hexamethyleneimine (0.038 mL, 0.33 mmol) and 194 (55 mg, 0.17 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (3:1) to deliver a white solid (52 mg, 84%). 
1
H NMR (300 MHz, 
chloroform-d)  7.76 (s, 1H), 7.60 (d, J = 7.8 Hz, 2H), 3.87 (t, J = 6 Hz, 2H), 3.27 (t, J = 5.7 Hz, 
4H), 2.94 (t, J = 6.9 Hz, 2H), 2.14 - 2.12 (m, 2H), 1.73 - 1.58 (m, 8H). 
6-(Azepan-1-ylsulfonyl)-1,2,3,4-tetrahydroquinoline (214). Same procedure as 30 using 1-(6-
(azepan-1-ylsulfonyl)-3,4-dihydroquinolin-1(2H)-yl)-2,2,2-trifluoroethanone (52 mg, 0.13 
mmol) and K2CO3 (349 mg, 2.5 mmol) as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with hexanes/EtOAc (5:1) to deliver 214 as an off-
white solid (42 mg, 90%). 
1
H NMR (300 MHz, chloroform-d)  7.39 - 7.28 (m, 2H), 6.42 (d, J = 
9.0 Hz, 1H), 4.15 (s, 1H), 3.33 (t, J = 5.4 Hz, 2H), 3.20 (t, J = 6.0 Hz, 4H), 2.74 (t, J = 6.3 Hz, 
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2H), 1.97 - 1.85 (m, 2H), 1.75 - 1.63 (m, 4H), 1.58 - 1.54 (m, 4H). HRMS (ESI
+
) calculated for 
C15H22N2O2S (M+H)
+
 295.4203, found 295.1474. 
1-(6-(Azocan-1-ylsulfonyl)-3,4-dihydroquinolin-1(2H)-yl)-2,2,2-trifluoroethanone. Same 
procedure as 195 using heptamethyleneimine (0.038 mL, 0.30 mmol) and 194 (50 mg, 0.15 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (2:1) to deliver a white solid (52 mg, 87%). 
1
H NMR (300 MHz, 
chloroform-d)  7.65 (s, 1H), 7.60 (d, J = 7.8 Hz, 2H), 3.86 (t, J = 5.7 Hz, 2H), 3.14 (t, J = 5.4 
Hz, 4H), 2.94 (t, J = 6.9 Hz, 2H), 2.15 - 2.09 (m, 2H), 1.73 - 1.63 (m, 10H). 
6-(Azocan-1-ylsulfonyl)-1,2,3,4-tetrahydroquinoline (215). Same procedure as 30 using 1-(6-
(azocan-1-ylsulfonyl)-3,4-dihydroquinolin-1(2H)-yl)-2,2,2-trifluoroethanone (48 mg, 0.12 
mmol) and K2CO3 (314 mg, 2.3 mmol) as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with hexanes/EtOAc (6:1) to deliver 215 as a white 
solid (20 mg, 54%). 
1
H NMR (400 MHz, chloroform-d)  7.37 (d, J = 5.6 Hz, 2H), 6.51 (d, J = 
9.0 Hz, 1H), 3.36 (t, J = 5.6 Hz, 2H), 3.10 (t, J = 6.0 Hz, 4H), 2.78 (t, J = 6.3 Hz, 2H), 1.98 - 
1.94 (m, 2H), 1.74 - 1.63 (m, 10H). HRMS (ESI
+
) calculated for C16H24N2O2S (M+H)
+
 
309.4469, found 309.1640. 
N-(Benzo[d]thiazol-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide. Same procedure as 195 using 2-aminobenzothiazole (33 mg, 0.22 mmol) and 194 
(52 mg, 0.22 mmol) as the starting materials. The residue was purified by flash chromatography 
on silica gel, eluting with DCM/EtOAc (1:1) to deliver a white solid (69 mg, 71%). 
1
H NMR 
(300 MHz, CD3OD)  7.78 (d, J = 9.6 Hz, 2H), 7.65 (d, J = 6.9 Hz, 1H), 7.39 - 7.25 (m, 4H), 
3.86 (t, J = 5.7, 2H), 2.94 (t, J = 6.9 Hz, 2H), 2.09 - 2.00 (m, 2H). 
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N-(Benzo[d]thiazol-2-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (220). Same procedure 
as 30 using N-(benzo[d]thiazol-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide (68 mg, 0.15 mmol) and K2CO3 (404 mg, 2.9 mmol) as the staring materials. The 
residue was purified by flash chromatography on silica gel, eluting with DCM/EtOAc (1:1) to 
deliver 220 as a white solid (7.3 mg, 15%). 
1
H NMR (300 MHz, methanol-d4)  7.62 (d, J = 6.7 
Hz, 1H), 7.40 - 7.19 (m, 5H), 6.45 (d, J = 7.7 Hz, 1H), 2.74 - 2.70 (m, 2H), 1.88 (t, J = 5.7 Hz, 
2H), 1.26 - 1.18 (m, 2H). HRMS (ESI
+
) calculated for C16H15N3O2S2 (M+H)
+
 346.4471, found 
346.0672. 
N-(6-Methoxybenzo[d]thiazol-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide. Same procedure as 195 using 2-amino-6-methoxybenzothiazole (27 mg, 0.15 
mmol) and 194 (50 mg, 0.15 mmol) as the starting materials. The residue was purified by flash 
chromatography on silica gel, eluting with DCM/acetone (1:1) to deliver a white solid (50 mg, 
46%). 
1
H NMR (300 MHz, acetone-d)  7.76 (s, 3H), 7.50 - 7.46 (m, 1H), 3.88 (t, J = 5.7 Hz, 
2H), 3.84 (s, 3H), 3.14 (t, J = 5.4 Hz, 3H), 2.15 - 2.09 (m, 2H). 
N-(6-Methoxybenzo[d]thiazol-2-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (221). Same 
procedure as 30 using N-(6-methoxybenzo[d]thiazol-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-
tetrahydroquinoline-6-sulfonamide (30 mg, 0.06 mmol) and K2CO3 (157 mg, 0.14 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
DCM/acetone (2:1) to deliver 221 as a white solid (16 mg, 54%). 
1
H NMR (300 MHz, methanol-
d)  7.58 - 7.46 (m, 2H), 7.44 (d, J = 7.6 Hz, 1H), 7.16 - 7.10 (m, 1H), 6.80 (d, J = 8.0 Hz, 1H), 
6.42 (d, J = 7.8 Hz, 1H), 3.78 - 3.74 (m, 3H), 3.33 - 3.26 (m, 5H), 2.62 (t, J = 5.6 Hz, 2H), 1.92 - 
1.86 (m, 2H). HRMS (ESI
+
) calculated for C17H17N3O3S2 (M+H)
+
 376.0790, found 376.0792. 
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N-(6-Hydroxyhexyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. 6-
Aminohexanol (61 mg, 0.51 mmol) was added to a stirred solution of 194 (60 mg, 0.18 mmol) 
and pyridine (0.043 mL, 0.54 mmol) in DCM (1.4 mL). The reaction mixture was stirred at rt for 
1 h, and H2O (3 mL) was added. The organic layer was extracted with DCM (4 mL), the aqueous 
layer was further washed with DCM (3 x 4 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated. The compound was obtained as an oil (76 mg, 78%) and was 
used without further purification. 
1
H NMR (400 MHz, chloroform-d)  7.80 (s, 1H), 7.66 (d, J = 
6.4 Hz, 2H), 5.42 (s, 1H), 3.84 (t, J = 6.2 Hz, 2H), 3.60 - 3.57 (m, 2H), 2.93 - 2.90 (m, 4H), 2.12 
- 2.04 (m, 2H), 1.54 - 1.39 (m, 8H). 
N-(6-Hydroxyhexyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (224). Same procedure as 30 
using N-(6-hydroxyhexyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide 
(70 mg, 0.17 mmol) and K2CO3 (450 mg, 3.26 mmol) as the starting materials. The residue was 
purified by flash chromatography on silica gel, eluting with 5% MeOH in DCM to deliver 224 as 
a light yellow oil (42 mg, 79%). 
1
H NMR (400 MHz, chloroform-d)  7.37 (d, J = 6.4 Hz, 2H), 
6.42 (d, J = 9.1 Hz, 1H), 4.71 (t, J = 6.2 Hz, 1H), 3.56 (t, J = 6.6 Hz, 2H), 3.32 (t, J = 6.0 Hz, 
2H), 2.85 (q, J = 6.8 Hz, 2H), 2.73 (t, J = 6.3 Hz, 2H), 2.04 - 1.87 (m, 2H), 1.54 - 1.39 (m, 4H), 
1.33 - 1.18 (m, 4H). HRMS (ESI
+
) calculated for C15H24N2O3S (M+Na)
+
 335.1504, found 
335.1398. 
N-(6-aminohexyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (225). Same procedure as 195 
using 1,6-diaminohexane (105 mg, 0.91 mmol) and 194 (50 mg, 0.15 mmol) as the starting 
materials. The residue was purified by flash chromatography on silica gel, eluting with 
DCM/MeOH 5% to deliver 225 as a colorless oil (13 mg, 28%). 
1
H NMR (300 MHz, 
chloroform-d)  7.44 - 7.35 (m, 2H), 6.42 (d, J = 9.0 Hz, 1H), 4.42 (s, 2H), 3.33 (d, J = 5.4 Hz, 
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2H), 2.88 (t, J = 7.1 Hz, 2H), 2.76 (t, J = 6.1 Hz, 2H), 2.66 - 2.62 (m, 2H), 1.96 - 1.88 (m, 2H), 
1.58 - 1.24 (m, 8H). HRMS (ESI
+
) calculated for C15H25N3O2S (M+H)
+
 312.1746, found 
312.1833. 
N,N'-(hexane-1,6-diyl)bis(1,2,3,4-tetrahydroquinoline-6-sulfonamide) (226). Same procedure 
as 195 using 1,6-diaminohexane (53 mg, 0.45 mmol) and 194 (50 mg, 0.15 mmol. The residue 
was purified by flash chromatography on silica gel, eluting with 5% MeOH in DCM to deliver 
226 as a white oil (17 mg, 20%). 
1
H NMR (300 MHz, chloroform-d)  7.47 - 7.34 (m, 4H), 6.43 
(d, J = 9.1 Hz, 2H), 4.43 (s, 2H), 4.34 (t, J = 6.3 Hz, 2H), 3.62 (t, J = 5.4 Hz, 4H), 2.86 (q, J = 
6.6 Hz, 4H), 2.76 (t, J = 6.2 Hz, 4H), 1.92 (t, J = 6.2 Hz, 4H), 1.60 (s, 2H), 1.37 (t, J = 6.5 Hz, 
2H), 1.26 - 1.11 (m, 2H). HRMS (ESI
+
) calculated for C24H34N4O2S2 (M+H)
+
 507.2100, found 
507.2066. 
N-Phenyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (228). Same procedure as 30 using N-
phenyl-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (223 mg, 0.58 mmol) 
and K2CO3 (1.5 g, 11.5 mmol) as the starting materials. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to deliver 228 as a yellow solid 
(150 mg, 90%). 
1
H NMR (300 MHz, chloroform-d)  7.35 - 7.32 (m, 2H), 7.26 - 7.20 (m, 2H), 
7.08 - 7.04 (m, 3H), 6.88 (s, 1H), 6.35 (d, J = 9.3 Hz, 1H), 3.32 (t, J = 5.4 Hz, 2H), 2.68 (t, J = 
6.6 Hz, 2H), 1.91 - 1.82 (m, 2H). The analytical data is in agreement with literature reports.
98
 
N-(Naphthalen-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. 2-
Naphtylamine (15 mg, 0.11 mmol) was added to a stirred solution of 194 (35 mg, 0.11 mmol) in 
pyridine (0.3 mL). The reaction mixture was refluxed overnight, and allowed to cool to room 
temperature. DCM (4 mL) and H2O (3 mL) were added, the organic layer was washed with 1 M 
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HCl (3 mL), H2O (3 x 4 mL) and brine (3 mL), dried over MgSO4, filtered, and concentrated. 
The residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc 
(3:1) to deliver a colorless oil (38 mg, 88%). 
1
H NMR (300 MHz, chloroform-d)  7.67 - 7.65 
(m, 5H), 7.56 (s, 1H), 7.45 - 7.36 (m, 3H), 7.38 - 7.25 (m, 1H), 3.77 (t, J = 6.0 Hz, 2H), 2.78 (t, J 
= 6.6 Hz, 2H), 2.05 - 1.98 (m, 2H). 
N-(Naphthalen-2-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (229). Same procedure as 30 
using N-(naphthalen-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide 
(38 mg, 0.09 mmol) and K2CO3 (230 mg, 1.6 mmol) as the starting materials. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to deliver 229 
as a white solid (22 mg, 76%). 
1
H NMR (300 MHz, chloroform-d)  7.75 - 7.69 (m, 3H), 7.53 (s, 
1H), 7.45 - 7.40 (m, 3H), 7.38 - 7.25 (m, 1H), 7.02 (s, 1H), 6.44 - 6.39 (m, 1H), 3.30 (t, J = 6.0 
Hz, 2H), 2.65 (t, J = 6.6 Hz, 2H), 1.90 - 1.82 (m, 2H). HRMS (ESI
+
) calculated for C19H18N2O2S 
(M+H)
+
 339.4314, found 339.1139. 
N-(Naphthalen-1-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. 
Same procedure as N-(naphthalen-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide using 1-naphtylamine (0.027 mL, 0.21 mmol) and 194 (70 mg, 0.21 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (2:1) to deliver a white solid (31 mg, 70%). 
1
H NMR (300 MHz, chloroform-d) 
 7.88 - 7.75 (m, 3H), 7.50 - 7.52 (m, 1H), 7.48 - 7.44 (m, 5H), 6.73 (s, 1H), 3.78 (t, J = 5.7 Hz, 
2H), 2.71 (t, J = 6.3 Hz, 2H), 2.01 - 1.88 (m, 2H).  
N-(Naphthalen-1-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (230). Same procedure as 30 
using N-(naphthalen-1-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide 
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(31 mg, 0.07 mmol) and K2CO3 (187 mg, 1.35 mmol) as the staring materials. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (4:1) to deliver 230 
as a white solid (23 mg, 96%). 
1
H NMR (300 MHz, chloroform-d)  7.88 - 7.79 (m, 2H), 7.66 (t, 
J = 4.8 Hz, 1H), 7.48 - 7.44 (m, 2H), 7.36 - 7.32 (m, 3H), 7.28 - 7.26 (m, 1H), 6.73 (s, 1H), 6.40 
(d, J = 8.7 Hz, 1H), 3.30 (t, J = 5.7 Hz, 2H), 2.65 (t, J = 6.3 Hz, 2H), 1.88 - 1.84 (m, 2H). HRMS 
(ESI
-
) calculated for C19H18N2O2S (M-H)
-
 337.4155, found 337.1021. 
N-(9,10-Dioxo-9,10-dihydroanthracen-1-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-
tetrahydroquinoline-6-sulfonamide. Same procedure as N-(naphthalen-2-yl)-1-(2,2,2-
trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide using 1-aminoanthraquinone (54 mg, 
0.24 mmol) and 194 (80 mg, 0.24 mmol) as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to deliver an orange solid 
(7 mg, 10%). 
1
H NMR (300 MHz, acetone-d)  8.37 - 8.27 (m, 1H), 8.26 - 8.19 (m, 1H), 8.02 (d, 
J = 8.0 Hz, 1H), 7.95 - 7.85 (m, 3H), 7.82 (d, J = 8.4 Hz, 1H), 7.45 (s, 2H), 6.45 (d, J = 7.9 Hz, 
1H), 3.27 (t, J = 6.0 Hz, 2H), 2.69 (t, J = 5.9 Hz, 2H), 1.82 - 1.76 (m, 2H). 
N-(9,10-Dioxo-9,10-dihydroanthracen-1-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide 
(231). Same procedure as 30 using N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-1-(2,2,2-
trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (6.5 mg, 0.01 mmol) and K2CO3 (33 
mg, 0.24 mmol) as the starting materials. The residue was purified by flash chromatography on 
silica gel, eluting with hexanes/EtOAc (2:1) to deliver 231 as an orange solid (4 mg, 78%). 
1
H 
NMR (300 MHz, acetone-d)  8.37 - 8.27 (m, 1H), 8.26 - 8.19 (m, 1H), 8.02 (d, J = 8.0 Hz, 1H), 
7.95 - 7.85 (m, 2H), 7.82 (d, J = 8.4 Hz, 1H), 7.45 (s, 3H), 6.45 (d, J = 7.9 Hz, 1H), 3.27 (t, J = 
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6.0 Hz, 2H), 2.69 (t, J = 5.9 Hz, 2H), 1.82 - 1.76 (m, 2H). HRMS (ESI
+
) calculated for 
C23H18N2O4S (M+H)
+
 419.4730, found 419.1080. 
N-(4-nitrophenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. 
Same procedure as N-(naphthalen-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide using 4-nitroaniline (211 mg, 1.52 mmol) and 194 (500 mg, 1.52 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
DCM/acetone (8:1) to deliver a yellow solid (598 mg, 92%). 
1
H NMR (300 MHz, acetone-d6)  
8.16 (d, J = 9.3 Hz, 2H), 7.90 - 7.70 (m, 3H), 7.47 (d, J = 9.0 Hz, 2H), 3.90 (t, J = 5.2 Hz, 2H), 
2.98 (t, J = 6.2 Hz, 2H), 1.89 - 1.79 (m, 2H). 
N-(4-Nitrophenyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (234). Same procedure as 30 
using N-(4-nitrophenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (598 
mg, 1.39 mmol) and K2CO3 (3.6 g, 26.5 mmol) as the staring materials. The residue was purified 
by flash chromatography on silica gel, eluting with hexanes/EtOAc (1:1) to deliver 234 as a 
yellow solid (455 mg, 98%). 
1
H NMR (300 MHz, acetone-d6)  8.14 (d, J = 9.3 Hz, 2H), 7.42 
(dd, J = 1.5, 7.8 Hz, 4H), 6.50 (d, J = 9.0 Hz, 1H), 6.02 (s, 1H), 3.36 - 3.27 (m, 2H), 2.71 (t, J = 
6.2 Hz, 2H), 1.89 - 1.79 (m, 2H). 
N-(4-(tert-Butyl)phenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide. Same procedure as N-(naphthalen-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-
tetrahydroquinoline-6-sulfonamide using 4-tert-butylaniline (0.029 mL, 0.18 mmol) and 194 (60 
mg, 0.18 mmol) as the starting materials. The residue was purified by flash chromatography on 
silica gel, eluting with hexanes/EtOAc (4:1) to deliver a yellow oil (72 mg, 90%). 
1
H NMR (300 
MHz, chloroform-d)  8.63 (d, J = 8.8 Hz, 1H), 7.73 - 7.71 (m, 2H), 7.61 - 7.59 (m, 1H), 7.31 - 
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7.23 (m, 1H), 7.01 (d, J = 8.6 Hz, 2H), 3.82 (t, J = 6.4 Hz, 2H), 2.81 (t, J = 6.2 Hz, 2H), 1.86 - 
1.80 (m, 2H), 1.25 (s, 9H). 
N-(4-(tert-Butyl)phenyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (236). Same procedure 
as 30 using N-(4-(tert-butyl)phenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide (72 mg, 0.16 mmol) and K2CO3 (420 mg, 3.04 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (1:1) to 
deliver 236 as a light yellow solid (39 mg, 71%). 
1
H NMR (300 MHz, chloroform-d)  7.34 (d, J 
= 8.8 Hz, 2H), 7.22 (d, J = 8.6 Hz, 2H), 7.03 - 6.96 (m, 3H), 6.31 (d, J = 8.3 Hz, 1H), 3.27 (t, J = 
6.4 Hz, 2H), 2.63 (t, J = 6.2 Hz, 2H), 1.86 - 1.80 (m, 2H), 1.24 (s, 9H). HRMS (ESI
+
) calculated 
for C19H24N2O2S (M+H)
+
 345.4795, found 345.1644. 
N-(4-Acetylphenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide. 
Same procedure as N-(naphthalen-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide using 4-aminoacetophenone (21 mg, 0.15 mmol) and 194 (50 mg, 0.15 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (2:1) to deliver a yellow solid (45 mg, 71%). 
1
H NMR (300 MHz, chloroform-d) 
 7.85 (d, J = 8.8 Hz, 3H), 7.69 - 7.7.67 (m, 2H), 7.15 (d, J = 8.8 Hz, 2H), 3.81 (t, J = 5.6 Hz, 
2H), 2.87 (t, J = 6.0 Hz, 2H), 2.51 (s, 3H), 1.27 - 1.22 (m, 2H). 
N-(4-Acetylphenyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (237). Same procedure as 30 
using N-(4-acetylphenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (45 
mg, 0.11 mmol) and K2CO3 (278 mg, 2.01 mmol) as the starting materials. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (1:1) to give 237 as 
a light orange solid (45 mg, 71%). 
1
H NMR (400 MHz, chloroform-d)  7.81 (d, J = 8.8 Hz, 2H), 
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7.68 (s, 1H), 7.45 - 7.42 (m, 2H), 7.15 (d, J = 8.8 Hz, 2H), 6.35 (d, J = 9.2 Hz, 1H), 3.31 (t, J = 
5.6 Hz, 2H), 2.68 (t, J = 6.0 Hz, 2H), 2.51 (s, 3H), 1.86 - 1.82 (m, 2H). HRMS (ESI
+
) calcualted 
for C17H18N2O3S (M+H)
+
 331.4094, found 331.1087. 
((4aR,8aS)-Octahydroquinolin-1(2H)-yl)(quinolin-6-yl)methanone (239). TEA (0.16 mL, 
1.15 mL), HOBt (171 mg, 1.26 mmol), and EDCI (242 mg, 1.26 mmol) were added to a stirred 
solution of 6-quinolinecarboxylic acid (200 mg, 1.15 mmol) in DCM (5 mL) at 0 °C. The 
suspension was slowly allowed to warm to rt and stirred for 1 h. trans-Decahydroquinoline (176 
mg, 1.26 mmol) was added to the solution and the resulting mixture was stirred overnight at rt. 
The solvent was removed under vacuum and the residue was purified by flash chromatography 
on silica gel, eluting with 10% MeOH in DCM to deliver 239 as an orange solid (179 mg, 53%). 
1
H NMR (300 MHz, chloroform-d)  8.87 - 8.85 (m, 1H), 8.16 - 8.02 (m, 2H), 7.82 (d, J = 1.9 
Hz, 1H), 7.66 (dd, J = 8.6, 1.9 Hz, 1H), 7.39 - 7.34 (m, 1H), 3.53 - 3.48 (m, 1H), 3.40 - 3.31 (m, 
2H), 2.27 - 2.25 (m, 1H), 1.78 - 1.48 (m, 4H), 1.39 - 1.02 (m, 6H). 
((4R, 8S)-Octahydroquinolin-1(2H)-yl)(1,2,3,4-tetrahydroquinolin-6-yl)methanone (240). 
Pd/C (10%, 40 mg) was added to a solution of 239 (66 mg, 0.22 mmol) and ammonium formate 
(222 mg, 3.52 mmol) in MeOH (1 mL). The reaction mixture was heated to reflux for 4 h. After 
allowing the mixture to cool down to rt, it was filtered through a pad of silica, washed with 
EtOAc (4 x 4 mL) and MeOH (2 x 4 mL), and the filtrate was concentrated. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes:EtOAc (5:1) to afford 240 
as a white solid (31 mg, 48%). 
1
H NMR (300 MHz, chloroform-d)  7.09 - 6.98 (m, 2H), 6.37 (d, 
J = 8.0 Hz, 1H), 4.19 - 4.00 (m, 1H), 3.55 - 3.26 (m, 5H), 2.73 (t, J = 6.4 Hz, 2H), 2.25 - 2.22 
(m, 1H), 1.98 - 1.83 (m, 2H), 1.81 - 1.50 (m, 6H), 1.50 - 1.33 (m, 2H), 1.36 - 0.96 (m, 4H). 
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2-Phenylisoindoline-1,3-dione (241). A solution of phthalic anhydride (486 mg, 3.28 mmol) 
and aniline (0.3 mL, 3.28 mmol) in DMF (6.5 mL) was irradiated under microwave conditions at 
300 W for 1 h. The reaction mixture was poured into crushed ice (4 mL) and the precipitate was 
isolated by filtration, washed with cold H2O (2 x 6 mL), and dried under vacuum affording 241 
as a light brown solid (587 mg, 80%). 
1
H NMR (300 MHz, chloroform-d)  8.02 - 7.94 (m, 2H), 
7.81 - 7.78 (m, 2H), 7.57 - 7.38 (m, 5H). The analytical data is in agreement with literature 
reports.
236
 
4-(1,3-Dioxoisoindolin-2-yl)benzene-1-sulfonyl chloride (242). Same procedure as 194 using 
241 (200 mg, 0.89 mmol) as the starting material delivered 242 as a white solid (178 mg, 62%). 
1
H NMR (300 MHz, DMSO-d6)  8.00 - 7.86 (m, 4H), 7.69 (dd, J = 6.6, 1.8 Hz, 2H), 7.43 - 7.35 
(m, 2H). The analytical data is in agreement with literature reports.
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2-(4-(((4aR,8aS)-Octahydroquinolin-1(2H)-yl)sulfonyl)phenyl)isoindoline-1,3-dione (243). 
TEA (0.45 mL, 3.24 mmol) was added to a stirred solution of trans-decahydroquinoline (152 
mg, 1.09 mmol) and 242 (175 mg, 0.54 mmol) in DCM (2.5 mL) at 0 °C. The reaction mixture 
was allowed to warm to rt and stirred overnight. The reaction mixture was diluted with DCM (6 
mL), washed with 1 M HCl (4 mL), H2O (2 x 5 mL) and brine (5 mL), dried over Na2SO4, 
filtered, and concentrated. The residue was purified by flash chromatography on silica gel, 
eluting with DCM/EtOAc (5:1) to deliver 243 as a white solid (145 mg, 63%). 
1
H NMR (400 
MHz, chloroform-d)  8.04 - 7.97 (m, 2H), 7.96 - 7.89 (m, 2H), 7.88 - 7.81 (m, 2H), 7.69 (m, 
2H), 4.15 (d, J = 12.8 Hz, 2H), 2.79 (m, 2H), 2.61 - 2.51 (m, 2H), 2.24 - 2.20 (m, 2H), 1.82 - 
1.58 (m, 4H), 1.48 - 1.33 (m, 2H), 1.30 - 0.91 (m, 2H). HRMS (ESI
+
) calcd for C23H24N2O4S 
(M+H)
+
 425.5206, found 425.1547. 
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4-(((4R, 8S)-Octahydroquinolin-1(2H)-yl)sulfonyl)aniline (244). Hydrazine monohydrate (0.1 
mL, 3.25 mmol) was added to a solution of 243 (55 mg, 0.13 mmol) in MeOH (1 mL). The 
resulting solution was heated to 55 °C for 3 h. After allowing the mixture to cool down to rt, the 
precipitate was collected by filtration and washed with MeOH (2 x 4 mL). The filtrate was 
evaporated down, and the residue was suspended in DCM (4 mL), washed with H2O (2 x 4 mL), 
NaHCO3 (4 mL) and brine (4 mL), dried over Na2SO4, filtered, and concentrated to afford 244 as 
a white solid (26 mg, 69%). 
1
H NMR (300 MHz, chloroform-d)  7.55 - 7.50 (m, 2H), 6.78 - 
6.60 (m, 2H), 4.15 (s, 2H), 4.06 - 4.01 (m, 1H), 2.70 - 2.65 (m, 1H), 2.45 - 2.23 (m, 2H), 1.86 - 
1.32 (m, 6H), 1.20 - 0.82 (m, 6H). HRMS (ESI
+
) calcd for C15H22N2O2S (M+H)
+
 295.4203, 
found 295.1488. 
N-(4-(tert-butyl)phenyl)-4-(1,3-dioxoisoindolin-2-yl)benzenesulfonamide. Same procedure as 
N-(naphthalen-2-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide using 
tert-butylaniline (0.049 mL, 0.31 mmol) and 242 (100 mg, 0.31 mmol) as the starting materials. 
The residue was purified by flash chromatography on silica gel, eluting with DCM/EtOAc (3:1) 
to deliver an oil (81 mg, 60%). 
1
H NMR (300 MHz, chloroform-d)  7.96 - 7.94 (m, 4H), 7.82 - 
7.80 (m, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.27 - 7.24 (m, 2H), 7.22 - 7.20 (m, 2H), 6.31 (d, J = 8.3 
Hz, 1H), 1.24 (s, 9H).  
4-Amino-N-(4-(tert-butyl)phenyl)benzenesulfonamide (245). Same protocol as 244 using N-
(4-(tert-butyl)phenyl)-4-(1,3-dioxoisoindolin-2-yl)benzenesulfonamide (81 mg, 0.19 mmol) as 
the starting material. The residue was purified by flash chromatography on silica gel, eluting 
with hexanes/EtOAc (1:1) to deliver 245 as a white solid (31 mg, 57%). 
1
H NMR (300 MHz, 
chloroform-d)  7.54 (d, J = 8.6 Hz, 2H), 7.23 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 8.5 Hz, 2H), 6.31 
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(t, J = 8.3 Hz, 2H), 1.24 (s, 9H). LRMS (ESI
+
) calcd for C16H20N2O2S (M+Na)
+
 327.1, found 
327.1. 
2,2,2-Trifluoro-1-(indolin-1-yl)ethanone. Same procedure as 193 using indoline (0.56 mL, 5.03 
mmol) as the starting material. The compound was obtained as a white solid (1.1 g, 100%). 
1
H 
NMR (300 MHz, chloroform-d)  8.20 (d, J = 8.6 Hz, 1H), 7.33 - 7.21 (m, 2H), 7.16 (d, J = 7.6 
Hz, 1H), 4.28 (t, J = 8.2 Hz, 2H), 3.26 (t, J = 8.2 Hz, 2H). The analytical data is in agreement 
with literature reports.
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1-(2,2,2-Trifluoroacetyl)indoline-5-sulfonyl chloride. Same procedure as 194 using 2,2,2-
trifluoro-1-(indolin-1-yl)ethanone (300 mg, 1.87 mmol) as the starting material. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (6:1) to deliver a 
brown solid (253 mg, 43%). 
1
H NMR (300 MHz, chloroform-d)  8.42 (d, J = 8.6 Hz, 1H), 8.05 
- 7.92 (m, 2H), 4.43 (t, J = 8.4 Hz, 2H), 3.40 (t, J = 8.5 Hz, 2H). 
(4aR,8aS)-1-(Indolin-5-ylsulfonyl)decahydroquinoline (246). Same procedure as 30 using 1-
(2,2,2-trifluoroacetyl)indoline-5-sulfonyl chloride (43 mg, 0.10 mmol) and K2CO3 (270 mg, 1.95 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (2:1) to deliver 246 as a white solid (27 mg, 82%). 
1
H NMR (400 
MHz, chloroform-d)  7.43 (d, J = 8.6 Hz, 2H), 6.56 (d, J = 8.8 Hz, 1H), 4.19 (s, 1H), 4.09 - 3.99 
(m, 1H), 3.66 (t, J = 8.6 Hz, 2H), 3.06 (t, J = 8.6 Hz, 2H), 2.73 - 2.62 (m, 1H), 2.45 - 2.26 (m, 
2H), 1.74 - 1.72 (m, 1H), 1.70 - 1.37 (m, 6H), 1.33 - 1.04 (m, 2H), 1.03 - 0.85 (m, 3H). HRMS 
(ESI
+
) calcd for C17H24N2O2S (M+H)
+
 321.4576, found 321.1647. 
1-Methyl-6-(((4R,8S)-octahydroquinolin-1(2H)-yl)sulfonyl)-1,2,3,4-tetrahydroquinoline 
(249). Sodium cyanoborohydride (165 mg, 2.63 mmol) and formaldehyde (37% in aqueous 
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solution, 0.11 mL) were added to a solution of 30 (24 mg, 0.07 mmol) in MeOH (0.5 mL).  The 
reaction mixture was stirred at rt for 1 h. The solvent was removed under vacuum, the residue 
was suspended in EtOAc (6 mL), washed with H2O (2 x 5 mL), NaHCO3 (4 mL) and brine (4 
mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (4:1) to give 249 as a colorless oil (6 
mg, 25%). 
1
H NMR (300 MHz, chloroform-d)  7.06 - 6.81 (m, 3H), 4.16 - 4.00 (m, 1H), 3.30 - 
3.26 (m, 2H), 3.29 (s, 3H), 2.78 (t, J = 6.3 Hz, 2H), 2.74 - 2.62 (m, 1H), 2.52 - 2.30 (m, 2H), 
2.04 - 1.95 (m, 2H), 1.82 - 1.35 (m, 6H), 1.34 - 1.07 (m, 4H), 1.08 - 0.82 (m, 2H). LRMS (ESI
+
) 
calcd for C19H28N2O2S (M+H)
+
 349.19, found 349. 
1-Allyl-6-(((4R,8S)-octahydroquinolin-1(2H)-yl)sulfonyl)-1,2,3,4-tetrahydroquinoline (250). 
Same procedure as 252 using 30 (40 mg, 0.12 mmol) and allyl bromide (0.016 mL, 0.18 mmol) 
as the starting materials. The residue was purified by flash chromatography on silica gel, eluting 
with hexanes/EtOAc (3:1) to afford 250 as a white solid (30 mg, 68%). 
1
H NMR (400 MHz, 
chloroform-d)  7.38 (dd, J = 8.8, 2.4 Hz, 1H), 7.29 (d, J = 2.4 Hz, 1H), 6.48 (d, J = 8.8 Hz, 1H), 
5.81 - 5.77 (m, 1H), 5.21 - 5.11 (m, 2H), 4.10 - 4.03 (m, 1H), 3.95 (t, J = 5.6 Hz, 2H), 2.76 (t, J = 
6.0 Hz, 2H), 2.67 - 2.59 (m, 1H), 2.42 - 2.30 (m, 2H), 1.96 (t, J = 8.7 Hz, 2H), 1.89 - 1.81 (m, 
1H), 1.80 - 1.49 (m, 8H), 1.21 - 1.08 (m, 2H), 1.02 - 0.88 (m, 2H). LRMS (ESI
+
) calcd for 
C21H30N2O2S (M+H)
+
 375.21, found 375.2. 
6-(((4aR,8aS)-Octahydroquinolin-1(2H)-yl)sulfonyl)-1-(prop-2-yn-1-yl)-1,2,3,4-
tetrahydroquinoline (251). Same procedure as 252 using 30 (40 mg, 0.12 mmol) and propargyl 
bromide (0.02 mL, 0.18 mmol, 80% solution in toluene) as the starting materials. The residue 
was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to afford 
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251 as a white solid (11 mg, 25%). 
1
H NMR (300 MHz, chloroform-d)  7.47 (dd, J = 8.7, 2.3 
Hz, 1H), 7.38 - 7.31 (m, 1H), 6.70 (d, J = 8.7 Hz, 1H), 4.12 - 3.98 (m, 3H), 3.41 (t, J = 6.7 Hz, 
2H), 2.78 (t, J = 6.3 Hz, 2H), 2.71 - 2.60 (m, 1H), 2.44 - 2.26 (m, 2H), 2.21 (t, J = 2.4 Hz, 1H), 
2.06 - 1.95 (m, 2H), 1.80 - 1.54 (m, 8H), 1.32 - 1.10 (m, 2H), 1.03 - 0.85 (m, 2H). HRMS (ESI
+
) 
calcd for C21H28N2O2S (M+H)
+
 373.5322, found 373.1959. 
1-Butyl-6-(((4R,8S)-octahydroquinolin-1(2H)-yl)sulfonyl)-1,2,3,4-tetrahydroquinoline (252). 
DIPEA (0.028 mL, 0.16 mmol) and bromobutane (0.018 mL, 0.16 mmol) were added to a 
solution of 30 (37 mg, 0.11 mmol) in DMF (0.2 mL). The mixture was heated to reflux for 3 h. 
The reaction mixture was allowed to cool down to rt and diluted with Et2O (5 mL), washed with 
H2O (3 x 5 mL) and brine (4 mL), dried over Na2SO4, filtered, and concentrated. The residue 
was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (4:1) to give 
252 as a white solid (13 mg, 31%). 
1
H NMR (400 MHz, chloroform-d)  7.40 (dd, J = 8.8, 2.5 
Hz, 1H), 7.28 (d, J = 2.4 Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 4.08 - 4.00 (m, 1H), 3.35 (t, J = 5.6 
Hz, 2H), 3.28 (t, J = 8.0 Hz, 2H), 2.75 (t, J = 6.3 Hz, 2H), 2.70 - 2.58 (m, 1H), 2.43 - 2.32 (m, 
2H), 1.96 - 1.80 (m, 2H), 1.76 (d, J = 6.9 Hz, 1H), 1.70 - 1.50 (m, 8H), 1.49 - 1.30 (m, 3H), 1.30 
- 1.06 (m, 3H), 1.03 - 0.90 (m, 3H). HRMS (ESI
+
) calcd for C22H34N2O2S (M+H)
+
 391.24, found 
391.2. 
1-Benzyl-6-(((4R,8S)-octahydroquinolin-1(2H)-yl)sulfonyl)-1,2,3,4-tetrahydroquinoline 
(253). K2CO3 (25 mg, 0.18 mmol) and benzyl chloride (0.021 mL, 0.18 mmol) were added to a 
solution of 30 (40 mg, 0.12 mmol) in DMF (0.1 mL). The resulting mixture was heated to reflux 
for 4 h. The reaction mixture was allowed to cool down to rt and diluted with Et2O (5 mL), 
washed with H2O (3 x 5 mL) and brine (4 mL), dried over Na2SO4, filtered, and concentrated. 
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The residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc 
(3:1) to deliver 253 as a white solid (10 mg, 21%). 
1
H NMR (400 MHz, chloroform-d)  7.36 - 
7.26 (m, 5H), 7.22 (d, J = 6.8 Hz, 2H), 6.47 (d, J = 6.8 Hz, 1H), 4.55 (s, 2H), 4.09 - 3.99 (m, 
1H), 3.42 (t, J = 6.0 Hz, 2H), 2.84 (t, J = 6.3 Hz, 2H), 2.83 - 2.65 (m, 1H), 2.39 - 2.32 (m, 2H), 
2.06 - 2.01 (m, 2H), 1.80 - 1.37 (m, 7H), 1.30 - 1.05 (m, 3H), 1.04 - 0.85 (m, 2H). HRMS (ESI
+
) 
calcd for C25H32N2O2S (M+H)
+
 425.23, found 425.2. 
4-Iodobenzene-1-sulfonyl chloride (262). Same procedure as 196 using iodobenzene (0.33 mL, 
2.96 mmol) as the starting material. The residue was purified by flash chromatography on silica 
gel, eluting with hexanes/EtOAc (8:1) to deliver 262 as a yellow solid (875 mg, 98%). 
1
H NMR 
(300 MHz, chloroform-d) (ortho/para mixture)  8.04 - 7.96 (m, 2H), 7.90 - 7.84 (m, 2H), 7.77 - 
7.71 (m, 2H), 7.65 - 7.59 (m, 2H). The analytical data are in agreement with literature reports.
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(4aR,8aS)-1-((4-Iodophenyl)sulfonyl)decahydroquinoline (263). Same procedure as 195 using 
262 (875 mg, 2.89 mmol) and trans-decahydroquinoline (1.2 g, 8.68 mmol) as the starting 
materials. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (6:1) to deliver 263 as a white solid (385 mg, 35%). 
1
H NMR (400 MHz, 
chloroform-d) (ortho/para mixture)  7.91 - 7.81 (m, 4H), 7.65 - 7.59 (m, 2H), 7.54 - 7.47 (m, 
2H), 4.12 - 4.05 (m, 2H), 2.82 - 2.71 (m, 2H), 2.49 - 2.45 (m, 2H), 2.14 - 2.12 (m, 2H), 1.79 - 
1.49 (m, 6H), 1.49 - 1.40 (m, 2H), 1.29 - 1.04 (m, 2H), 1.04 - 0.87 (m, 2H). 
(4S,8R)-1-((4-(1H-Pyrrol-1-yl)phenyl)sulfonyl)decahydroquinoline (257). Copper (II) acetate 
(76 mg, 0.42 mmol) and DBU (0.126 mL, 0.84 mmol) were added to a solution of pyrrole (0.035 
mL, 0.5 mmol) and 263 (170 mg, 0.42 mmol) in DMF (0.6 mL). The reaction mixture was 
irradiated under microwave conditions at 130 °C for 10 min. After allowing the solution to cool 
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down, it was filtered through a cotton plug in a pasteur pipette, the filtrate was diluted with Et2O 
(4 mL), washed with H2O (3 x 4 mL) and brine (4 mL), dried over Na2SO4, filtered, and 
concentrated. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (6:1) to afford 257 as a white solid (16 mg, 11%). 
1
H NMR (300 MHz, 
chloroform-d)  7.86 - 7.82 (m, 2H), 7.77 - 7.52 (m, 4H), 7.23 - 7.11 (m, 1H), 6.47 - 6.35 (m, 
1H), 4.12 - 4.06 (m, 1H), 2.90 - 2.71 (m, 1H), 2.63 - 2.41 (m, 1H), 2.35 - 2.14 (m, 2H), 1.97 - 
1.37 (m, 6H), 1.35 - 1.07 (m, 4H), 1.03 - 0.82 (m, 2H). HRMS (ESI
+
) calcd for C19H24N2O2S 
(M+Na)
+
 367.1456, found 367.1450. 
2-Oxo-1,2,3,4-tetrahydroquinoline-6-sulfonyl chloride. Same procedure as 194 using 3,4-
dihydroquinolin-2(1H)-one (100 mg, 0.68 mmol) as the starting material. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (1:1) to afford a 
light brown solid (126 mg, 76%). 
1
H NMR (300 MHz, DMSO-d6)  10.11 (s, 1H), 7.41 - 7.28 
(m, 2H), 6.75 (d, J = 8.1 Hz, 1H), 2.84 (t, J = 7.5 Hz, 2H), 2.42 (t, J = 7.8 Hz, 2H). 
6-(((4aR,8aS)-Octahydroquinolin-1(2H)-yl)sulfonyl)-3,4-dihydroquinolin-2(1H)-one (258). 
2-Oxo-1,2,3,4-tetrahydroquinoline-6-sulfonyl chloride (50 mg, 0.20 mmol) was added to a 
solution of trans-decahydroquinoline (28.4 mg, 0.20 mmol) in pyridine (1.6 mL). The resulting 
mixture was heated to 40 °C overnight. H2O (4 mL) and EtOAc (5 mL) were added, the layers 
were separated, the combined organic layers were washed with 1 M HCl (4 mL), H2O (4 mL) 
and brine (4 mL), dried over Na2SO4, filtered, and concentrated to deliver 258 as a light yellow 
solid (14.4 mg, 20%). 
1
H NMR (300 MHz, chloroform-d)  8.61 (s, 1H), 7.61 (d, J = 7.1 Hz, 
2H), 6.87 (d, J = 8.9 Hz, 1H), 4.10 (m, 1H), 3.04 (t, J = 7.6 Hz, 2H), 2.83 - 2.58 (m, 2H), 2.68 - 
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2.47 (m, 1H), 2.19 - 2.11 (m, 1H), 1.82 - 1.36 (m, 6H), 1.36 - 1.07 (m, 4H), 1.07 - 0.83 (m, 4H). 
HRMS (ESI
+
) calcd for C18H24N2O3S (M+Na)
+
 371.1405, found 371.1405. 
6-(((4S,8R)-Octahydroquinolin-1(2H)-yl)sulfonyl)quinoline (259). DDQ (67 mg, 0.35 mmol) 
was added to a solution of 30 (47 mg, 0.14 mmol) in dioxane (0.6 mL). The resulting mixture 
was heated to reflux for 24 h. After allowing the mixture to cool down, the solvent was removed 
under vacuum, the residue was suspended in EtOAc (5 mL) and washed with NaHCO3 (2 x 5 
mL). The aqueous layer was extracted with EtOAc (2 x 5 mL), the combined organic layers were 
washed with brine (4 mL), dried over Na2SO4, filtered, and concentrated. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to afford 259 
as a green oil (40 mg, 87%). 
1
H NMR (400 MHz, chloroform-d)  9.03 (d, J = 4.2 Hz, 1H), 8.35 
(d, J = 2.1 Hz, 1H), 8.28 (dd, J = 8.5, 1.7 Hz, 1H), 8.20 (d, J = 8.9 Hz, 1H), 8.00 (dd, J = 8.9, 2.2 
Hz, 1H), 7.53 - 7.50 (m, 1H), 4.20 - 4.15 (m, 1H), 2.90 - 2.84 (m, 1H), 2.61 - 2.55 (m, 1H), 2.23 
- 2.12 (m, 1H), 1.76 - 1.41 (m, 8H), 1.17 - 0.83 (m, 4H). HRMS (ESI
+
) calcd for C18H22N2O2S 
(M+H)
+
 331.4524, found 331.1489. 
1-(Prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline (260). Same procedure as 252 using 192 (0.57 
mL, 5.57 mmol) and propargyl bromide (0.74 mL, 8.36 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to 
deliver 260 as a dark oil (83 mg, 87%). 
1
H NMR (300 MHz, chloroform-d)  7.10 (t, J = 1.8 Hz, 
1H), 7.01 (d, J = 7.3 Hz, 1H), 6.79 - 6.67 (m, 2H), 4.04 (d, J = 2.4 Hz, 2H), 3.31 (t, J = 5.4 Hz, 
2H), 2.80 (t, J = 6.5 Hz, 2H), 2.17 (t, J = 2.4 Hz, 1H), 2.09 - 1.97 (m, 2H). The analytical data 
are in agreement with literature reports.
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Analogs synthesized as part of the HTS investigation 
4-Methyl-N-(naphthalen-2-yl)benzenesulfonamide (265). 2-Naphtylamine (0.02 mL, 0.18 
mmol) was added to a stirred solution of 4-toluenesulfonyl chloride (35 mg, 0.18 mmol) in 
pyridine (0.3 mL). The reaction mixture was heated to reflux overnight. After allowing the 
mixture to cool down to rt, EtOAc (4 mL) was added. The organic layer was washed with 1 M 
HCl (2 mL), H2O (2 x 3 mL) and brine (3 mL), dried over Na2SO4, filtered, and concentrated. 
The residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAC 
(6:1) to afford 265 as a red solid (20 mg, 38%). 
1
H NMR (300 MHz, chloroform-d)  7.76 (m, 
5H), 7.52 (d, J = 2.1 Hz, 1H), 7.45 - 7.40 (m, 2H), 7.26 - 7.17 (m, 3H), 6.90 (s, 1H), 2.34 (s, 3H). 
The analytical data is in agreement with literature reports.
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(4-Nitrophenyl)(pyrrolidin-1-yl)methanone (273). Pyrrolidine (0.111 mL, 1.35 mmol) and 
TEA (0.235 mL, 1.69 mmol) were added to a stirred solution of 4-nitrobenzoylchloride (300 mg, 
1.61 mmol) in DCM (1.2 mL) at 0 °C. The mixture was stirred at 0 °C for 3 h and poured into 
H2O (6 mL). The organic layer was separated and washed with 0.5 M HCl (2 x 5 mL), NaHCO3 
(6 mL) and brine (4 mL), dried over MgSO4, filtered, and concentrated. The residue was purified 
by flash chromatography on silica gel, eluting with acetone/DCM (1:8) to deliver 273 as a yellow 
solid (256 mg, 86%). 
1
H NMR (300 MHz, chloroform-d)  8.24 (d, J = 9.0 Hz, 2H), 7.67 (d, J = 
8.7 Hz, 2H), 3.66 (t, J = 6.9 Hz, 2H), 3.37 (t, J = 6.6 Hz, 2H), 2.01 - 1.90 (m, 4H). 
(4-Aminophenyl)(pyrrolidin-1-yl)methanone (274). A solution of 273 (235 mg, 1.07 mmol) in 
MeOH (1.4 mL) was stirred at rt, the reaction flask was purged with dry N2 to remove oxygen 
and Pd/C (10%, 18 mg) was added. The flask was purged with H2 and the reaction mixture was 
stirred overnight at rt under H2 atmosphere. After completion of the reaction, the mixture was 
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filtered through a silica pad and washed with EtOAc (4 x 6 mL) and MeOH (2 x 5 mL). The 
filtrate was concentrated and the residue was purified by flash chromatography on silica gel, 
eluting with DCM/EtOAc (2:1) to give 274 as a yellow solid. 
1
H NMR (300 MHz, chloroform-d) 
 7.43 - 7.38 (m, 2H), 6.75 - 6.69 (m, 2H), 3.90 (s, 2H), 3.60 - 3.46 (m, 4H), 4.22 - 4.16 (m, 4H). 
The analytical data is in agreement with literature reports.
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2,3,5,6-Tetramethyl-N-(4-(pyrrolidine-1-carbonyl)phenyl)benzenesulfonamide (266). Same 
protocol as 265 using 274 (16 mg, 0.09 mmol) and 2,3,5,6-tetramethylbenzenesulfonyl chloride 
(20 mg, 0.09 mmol) as the starting materials. The residue was purified by flash chromatography 
on silica gel, eluting with acetone/DCM (1:4) to afford 266 as a white solid (26 mg, 77%). 
1
H 
NMR (300 MHz, DMSO-d6)  10.45 (s, 1H), 7.35 (d, J = 8.4 Hz, 2H), 7.21 (s, 1H), 6.90 (d, J = 
8.4 Hz, 2H), 3.34 - 3.32 (m, 4H), 2.19 (s, 6H), 1.98 - 1.80 (m, 4H). HRMS (ESI
+
) calcd for 
C21H26N2O3S (M+H)
+
 387.5157, found 387.1754. 
Methyl 4-aminobenzoate. Thionyl chloride (1 mL, 14.5 mmol) was slowly added to a stirred 
solution of 4-aminobenzoic acid (100 mg, 0.73 mmol) in MeOH (7 mL) at 0 °C. The resulting 
mixture was stirred at rt for 30 min and then heated to reflux for 6 h. After allowing the solution 
to cool down to rt, the solvent was removed under vacuum and the residue was suspended in 
H2O (4 mL). The resulting solution was neutralized with K2CO3 (52 mg) and extracted with 
DCM (2 x 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated to afford a white solid (96 mg, 87%). 
1
H NMR (300 MHz, DMSO-d6)  7.61 (d, J 
= 8.7 Hz, 2H), 6.53 (d, J = 6.6 Hz, 2H), 5.95 (s, 2H), 3.70 (s, 3H). The analytical data are in 
agreement with literature reports.
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Methyl 4-(2-methoxy-4-methylphenylsulfonamido)benzoate (267). Same procedure as 265 
using methyl 4-aminobenzoate (14 mg, 0.09 mmol) and 2-methoxy-5-methylbenzene-1-sulfonyl 
chloride (20 mg, 0.09 mmol) as the starting materials. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAC (4:1) to afford 267 as a white solid 
(17 mg, 57%). 
1
H NMR (300 MHz, chloroform-d)  7.88 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 1.9 Hz, 
1H), 7.28 - 7.22 (m, 1H), 7.11 (d, J = 9.0 Hz, 2H), 6.85 (d, J = 8.4 Hz, 1H), 3.97 (s, 3H), 3.82 (s, 
3H), 2.28 (s, 3H). HRMS (ESI
+
) calcd for C16H17NO5S (M+H)
+
 336.3828, found 336.0913. 
5-Nitro-1,2-dihydroacenaphthylene (275). Acenaphtene (50 mg, 0.32 mmol) was dissolved in 
a solution of glacial acetic acid (0.38 mL). The solution was placed in an ice bath and cooled 
down to  10 °C. Nitric acid (0.024 mL) was slowly added, the reaction mixture was kept at  10 
°C for 20 min and slowly allowed to warm to rt. The resulting mixture was stirred for 5 h, after 
completion of the reaction ice-cold H2O (4 mL) was added and the product was extracted with 
EtOAc (3 x 4 mL). The combined organic layers were washed with NaHCO3 (2 x 5 mL) and 
brine (4 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (9:1) to give 275 as a yellow solid (25 
mg, 40%). 
1
H NMR (300 MHz, chloroform-d)  8.55 (dd, J = 0.6, 8.1 Hz, 2H), 7.73 (t, J = 6.9 
Hz, 1H), 7.44 (d, J = 6.6 Hz, 1H), 7.32 (dd, J = 2.4, 7.8 Hz, 1H), 3.52 - 3.44 (m, 4H). The 
analytical data is in agreement with literature reports.
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1,2-Dihydroacenaphthylen-5-amine (276). Same procedure as 274 using 275 (80 mg, 0.41 
mmol) as the starting material. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (4:1) to give 276 as a dark oil (21 mg, 100%). 
1
H NMR (300 MHz, 
chloroform-d)  7.55 (d, J = 8.2 Hz, 1H), 7.70 (t, J = 8.4 Hz, 1H), 7.28 - 7.24 (m, 1H), 7.10 (d, J 
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= 7.2 Hz, 1H), 6.85 (d, J = 6.9 Hz, 1H), 3.41 - 3.30 (m, 4H). The analytical data is in agreement 
with literature reports.
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2,4-Dimethylbenzene-1-sulfonyl chloride. Chlorosulfonic acid (0.19 mL, 2.82 mmol) was 
added to a stirred solution of m-xylene (0.115 mL, 0.94 mmol) in CHCl3 (0.3 mL) at 0 °C. The 
reaction mixture was slowly allowed to warm to room temperature and stirred for 1 h. The 
mixture was poured into ice-cold H2O (4 mL) and the aqueous layer was extracted with CHCl3 (3 
x 5 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated to 
afford a yellow oil (139 mg, 72%). 
1
H NMR (300 MHz, chloroform-d)  7.94 (d, J = 8.1 Hz, 
1H), 7.26 - 7.20 (m, 2H), 2.74 (s, 3H), 2.43 (s, 3H). The analytical data are in agreement with 
literature reports.
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N-(1,2-Dihydroacenaphthylen-5-yl)-2,4-dimethylbenzenesulfonamide (268). Same procedure 
as 265 using 276 (20 mg, 0.12 mmol) and 2,4-dimethylbenzene-1-sulfonyl chloride (36 mg, 0.17 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (4:1) to afford 268 as a yellow solid (26 mg, 63%). 
1
H NMR (300 
MHz, chloroform-d)  7.78 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H), 7.44 (t, J = 6.9 Hz, 1H), 
7.29 - 7.26 (m, 1H), 7.17 (d, J = 7.2 Hz, 1H), 7.11 - 6.99 (m, 4H), 6.99 (s, 1H), 3.40 - 3.31 (m, 
4H), 2.60 (s, 3H), 2.33 (s, 3H). HRMS (ESI
+
) calcd for C20H19NO2S (M+H)
+
 338.4433, found 
338.3430. 
(4aR,8aS)-1-Tosyldecahydroquinoline (269). Same procedure as 195 from trans-
decahydroquinoline (43 mg, 0.31 mmol) and 4-toluenesulfonyl chloride (30 mg, 0.15 mmol) as 
the starting materials. The residue was purified by flash chromatography on silica gel, eluting 
with hexanes/EtOAc (9:1) to deliver 269 as a colorless oil (34 mg, 77%). 
1
H NMR (400 MHz, 
 229 
chloroform-d)  7.66 (d, J = 8.1 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 4.12 - 4.08 (m, 1H), 2.76 - 
2.71 (m, 1H), 2.42 (s, 3H), 2.26 - 2.22 (m, 1H), 1.65 - 25 (m, 9H), 1.20 - 1.02 (m, 2H), 0.98 - 
0.91 (m, 2H). HRMS (ESI
+
) calcd for C16H23NO2S (M+H)
+
 294.4323, found 294.1517. 
(4aR,8aS)-1-((2,4-Dimethylphenyl)sulfonyl)decahydroquinoline (270). Same procedure as 
195 using trans-decahydroquinoline (24 mg, 0.24 mmol) and 2,4-dimethylbenzene-1-sulfonyl 
chloride (25 mg, 0.12 mmol) as the starting materials. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (6:1) to deliver 270 as a light yellow 
solid (25 mg, 69%). 
1
H NMR (300 MHz, chloroform-d)  7.80 (d, J = 8.4 Hz, 1H), 7.08 - 7.06 
(m, 2H), 4.22 (m, 1H), 2.98 - 2.78 (m, 2H), 2.54 (s, 3H), 2.36 (s, 3H), 1.80 - 1.54 (m, 10H), 1.18 
- 0.98 (m, 3H). HRMS (ESI
+
) calcd for C17H25NO2S (M+H)
+
 308.4588, found 308.1669. 
(4aR,8aS)-1-((2,3,5,6-Tetramethylphenyl)sulfonyl)decahydroquinoline (271). Same protocol 
as 195 from trans-decahydroquinoline (47 mg, 0.34 mmol) and 2,3,4,5-tetramethylsulfonyl 
chloride (40 mg, 0.17 mmol) as the starting materials. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (9:1) to deliver 271 as a white solid 
(16 mg, 61%). 
1
H NMR (400 MHz, chloroform-d)  7.11 (s, 1H), 4.08 - 4.05 (m, 2H), 2.80 - 
2.73 (m, 2H), 2.50 (s, 6H), 2.25 (s, 6H), 1.75 - 1.50 (m, 10H), 1.17 - 0.90 (m, 2H). HRMS (ESI
+
) 
calcd for C19H29NO2S (M+H)
+
 336.5120, found 336.2005. 
N-(1,2-dihydroacenaphthylen-5-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide. Same protocol as 195 from 276 (15 mg, 0.09 mmol) and 194 (30 mg, 0.09 mmol) 
as the starting materials. The residue was purified by flash chromatography on silica gel, eluting 
with hexanes/EtOAc (3:1) to deliver a white solid (28 mg, 68%). 
1
H NMR (300 MHz, 
chloroform-d)  7.70 - 7.62 (m, 2H), 7.53 (s, 1H), 7.42 - 7.25 (m, 4H), 7.19 (d, J = 7.5 Hz, 1H), 
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6.92 (s, 1H), 3.79 (t, J = 5.7 Hz, 2H), 3.40 - 3.34 (m, 4H), 2.73 (t, J = 5.4 Hz, 2H), 2.01 (t, J = 
6.6 Hz, 2H). 
N-(1,2-Dihydroacenaphthylen-5-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (272). Same 
protocol as 30 using N-(1,2-dihydroacenaphthylen-5-yl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-
tetrahydroquinoline-6-sulfonamide (28 mg, 0.06 mmol) and K2CO3 (161 mg, 1.17 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (2:1) to deliver 272 as a light yellow solid (19 mg, 86%). 
1
H NMR (300 MHz, 
acetone-d)  8.40 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.41 - 7.15 (m, 5H), 6.37 (d, J = 9.3 Hz, 1H), 
5.82 (s, 1H), 3.35 - 3.25 (m, 4H), 2.80 (t, J = 7.0 Hz, 2H), 2.60 (t, J = 6.6 Hz, 2H), 1.85 - 1.76 
(m, 2H). HRMS (ESI
+
) calcd for C21H20N2O2S (M+H)
+
 365.4686, found 365.1332. 
N-Benzyl-4-methylbenzenesulfonamide (277). Benzylamine (0.077 mL, 0.71 mmol) and 
K2CO3 (194 mg, 1.4 mmol) were added to a stirred solution of p-toluenesulfonyl chloride (68 
mg, 0.36 mmol) in DCM (2 mL) at 0 °C. The mixture was allowed to warm to rt, stirred for 3 h 
and poured into H2O (4 mL). The organic layer was separated and washed with H2O (2 x 5 mL), 
NaHCO3 (4 mL) and brine (4 mL), dried over MgSO4, filtered, and concentrated. The residue 
was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (1:1) to deliver 
277 as white solid (72 mg, 79%). 
1
H NMR (400 MHz, chloroform-d)  7.84 (d, J = 8.4 Hz, 2H), 
7.37 (d, J = 8 Hz, 2H), 7.34 - 7.33 (m, 3H), 7.28 - 7.26 (m, 2H), 4.68 (t, J = 5.6 Hz, 1H), 4.18 (d, 
J = 6 Hz, 2H), 2.51 (s, 3H). The analytical data are in agreement with literature reports.
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1-Isopropyl-4-methoxy-2-methylbenzene. Tetra-n-butylammonium bromide (536 mg, 1.66 
mmol) and K2CO3 (459 mg, 3.32 mmol) were added to a solution of 4-isopropyl-3-methylphenol 
(500 mg, 3.32 mmol) in dimethylcarbonate (2.8 ml). The reaction mixture was stirred under 
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refluxing conditions overnight. After allowing the mixture to cool down to rt, H2O (5 ml) and 
DCM (6 ml) were added. The organic layer was separated and further washed with NaHCO3 (4 
mL) and brine (4 mL), dried over MgSO4, filtered, and concentrated. The residue was purified by 
flash chromatography on silica gel, eluting with hexanes/EtOAc (10:1) to afford a white solid 
(504 mg, 92%). 
1
H NMR (300 MHz, chloroform-d)  7.15 (d, J = 8.4 Hz, 1H), 6.75 - 6.69 (m, 
2H), 3.55 (s, 3H), 3.10 - 3.04 (m, 1H), 2.32 (s, 3H), 1.21 (d, J = 6.9 Hz, 6H). 
5-Isopropyl-2-methoxy-4-methylbenzene-1-sulfonyl chloride (281). Chlorosulfonic acid 
(0.461 mL, 6.94 mmol) was added to a stirred solution of 1-isopropyl-4-methoxy-2-
methylbenzene (380 mg, 2.31 mmol) in CHCl3 (2.5 ml) at 0 °C. The reaction mixture was slowly 
allowed to warm to room temperature and stirred for 1 h. The suspension was cooled down to 0 
°C in an ice bath and ice-cold water (5 mL) was slowly added. The aqueous layer was extracted 
with DCM (3 x 8 mL), the combined organic layers were then washed with H2O (3 x 8 mL) and 
brine (4 mL), dried over MgSO4, filtered, and concentrated to deliver 281 as a white solid (490 
mg, 81%). 
1
H NMR (300 MHz, chloroform-d)  7.76 (s, 1H), 6.87 (s, 1H), 4.01 (s, 3H), 3.10 - 
3.04 (m, 1H), 2.43 (s, 3H), 1.22 (d, J = 6.8 Hz, 6H). 
1-((5-Isopropyl-2-methoxy-4-methylphenyl)sulfonyl)-4-methyl-1H-imidazole (279). TEA 
(0.084 mL, 0.6 mmol) was added to a stirred solution of 281 (40 mg, 0.15 mmol) and 4-
methylimidazole (25 mg, 0.30 mmol) in THF (0.6 mL) at 0 °C. The reaction mixture was slowly 
allowed to warm to rt and stirred for 2 h. The solvent was removed under vacuum and the 
residue was purified by flash chromatography on silica gel, eluting with acetone/DCM (1:12) to 
afford 279 as a white solid (20 mg, 66%). 
1
H NMR (400 MHz, chloroform-d)  7.98 (s, 1H), 
7.81 (s, 1H), 6.92 (s, 1H), 6.72 (s, 1H), 3.80 (s, 3H), 3.10 - 3.05 (m, 1H), 2.36 (s, 3H), 2.15 (s, 
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3H), 1.22 (d, J = 6.8 Hz, 6H). HRMS (ESI
+
) calcd for C15H20N2O3S (M+H)
+
 309.4938, found 
309.1279. 
5-(tert-Butyl)-2-methyl-N-(pyridin-3-ylmethyl)benzenesulfonamide (288). K2CO3 (87 mg, 
0.63 mmol) and 5-(tert-butyl)-2-methylbenzene-1-sulfonyl chloride (39 mg, 0.16 mmol) were 
added to a stirred solution of 3-aminomethylpyridine (34 mg, 0.32 mmol) in DCM (2 ml) at 0 
°C. The reaction mixture was stirred at rt for 2 h. The solvent was removed under vacuum. The 
residue was purified by flash chromatography on silica gel, eluting with 5% MeOH/DCM to 
afford 288 as a light yellow solid (35 mg, 74%). 
1
H NMR (400 MHz, chloroform-d)  8.48 (s, 
1H), 8.37 (s, 1H), 7.95 (s, 1H), 7.54 (d, J = 8 Hz, 1H), 7.45 (d, J = 8 Hz, 1H), 7.30 - 7.17 (m, 
2H), 4.83 - 4.80 (m, 1H), 4.18 - 4.16 (m, 2H), 2.58 (s, 3H), 1.31 (s, 9H). HRMS (ESI
-
) calcd for 
C17H22N2O2S (M-H)
-
 317.1324, found 317.1337. 
5-(tert-Butyl)-N-(3-methoxypropyl)-2-methylbenzenesulfonamide (289). Same procedure as 
288 using 5-(tert-butyl)-2-methylbenzene-1-sulfonyl chloride (44 mg, 0.18 mmol) and 3-
methoxypropylamine (0.036 mL, 0.36 mmol) as the starting materials. The residue was purified 
by flash chromatography on silica gel, eluting with hexanes:EtOAc (3:1) to afford 289 as a 
colorless oil (45 mg, 88%). 
1
H NMR (400 MHz, chloroform-d)  7.87 (s, 1H), 7.45 (d, J = 7.6 
Hz, 1H), 7.22 (d, J = 8 Hz, 1H), 5.30 - 5.28 (m, 1H), 3.48 (t, J = 6 Hz, 2H), 3.28 (s, 3H), 3.04 - 
3.02 (m, 2H), 2.59 (s, 3H), 1.71 - 1.69 (m, 2H), 1.31 (s, 9H). 
13
C NMR (300 MHz, Chloroform-
d)  156.1, 149.3, 137.3, 133.7, 132.3, 129.5, 126.4, 71.9, 58.8, 42.1, 34.6, 31.2, 28.8, 19.6. 
HRMS (ESI
-
) calcd for C15H25NO3S (M-H)
-
 298.4210, found 298.1487. 
4-(tert-Butyl)-N-(2-(pyridin-4-yl)ethyl)benzenesulfonamide (292). Same procedure as 288 
using 4-(tert-butyl)benzene-1-sulfonyl chloride (60 mg, 0.26 mmol) and 2-(pyridin-4-
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yl)ethanamine (0.061 mL, 0.51 mmol) as the starting materials. The residue was purified by flash 
chromatography on silica gel, eluting with 5% MeOH in DCM to deliver 292 as a white solid (40 
mg, 77%). 
1
H NMR (400 MHz, chloroform-d)  8.42 (d, J = 6 Hz, 2H), 7.74 (d, J = 8.8 Hz, 2H), 
7.50 (d, J = 8.8 Hz, 2H), 7.02 (d, J = 6 Hz, 2H), 4.44 (s, 1H), 3.28 - 3.26 (m, 2H), 2.80 (t, J = 7.8 
Hz, 2H), 1.35 (s, 9H). HRMS (ESI
-
) calcd for C17H22N2O2S (M-H)
-
 317.4258, found 317.1334. 
5-(tert-Butyl)-2,3-dimethylbenzene-1-sulfonyl chloride. Same procedure as 196 using 4-tert-
butyl-o-xylene (200 mg, 1.23 mmol) as the starting material. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (4:1) to deliver a colorless oil (181 
mg, 56%). 
1
H NMR (300 MHz, chloroform-d)  7.93 (s, 1H), 7.51 (s, 1H), 2.85 (s, 3H), 2.39 (s, 
3H), 1.33 (s, 9H). 
5-(tert-Butyl)-N-(2-hydroxyethyl)-2,3-dimethylbenzenesulfonamide (294). Same procedure as 
195 using 5-(tert-butyl)-2,3-dimethylbenzene-1-sulfonyl chloride (40 mg, 0.15 mmol) and 
ethanolamine (0.01 mL, 0.17 mmol) as the starting materials. The residue was purified by flash 
chromatography on silica gel, eluting with 5% MeOH/DCM to afford 294 as a colorless oil (77 
mg, 90%). 
1
H NMR (300 MHz, chloroform-d)  7.85 (s, 1H), 7.37 (s, 1H), 3.70 (t, J = 5.1 Hz, 
2H), 3.08 (t, J = 4.8 Hz, 2H), 2.55 (s, 3H), 2.34 (s, 3H), 1.31 (s, 9H). HRMS (ESI
-
) calcd for 
C14H23NO3S (M-H)
-
 284.3944, found 284.1329. 
N-(2-Hydroxyethyl)-5-isopropyl-2-methoxy-4-methylbenzenesulfonamide (314). Same 
procedure as 195 using 281 (45 mg, 0.17 mmol) and ethanolamine (0.029 mL, 0.48 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
5% MeOH in DCM to deliver 314 as a colorless oil (7 mg, 15%). 
1
H NMR (400 MHz, 
chloroform-d)  8.65 (s, 1H), 7.71 (s, 1H), 6.78 (s, 1H), 5.34 - 5.32 (m, 1H), 3.94 (s, 3H), 3.69 - 
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3.66 (m, 2H), 3.00 - 2.98 (m, 3H), 2.38 (s, 3H), 1.22 (d, J = 6.8 Hz, 6H). HRMS (ESI
-
) calcd for 
C13H21NO4S (M-H)
-
 286.3672, found 286.1122. 
1-((5-Isopropyl-2-methoxy-4-methylphenyl)sulfonyl)-1H-imidazole (317). Imidazole (23 mg, 
0.34 mmol) was added to a stirred solution of 281 (30 mg, 0.11 mmol) in DCM (0.3 mL) at 0 °C. 
The reaction mixture was allowed to warm to rt and further stirred for 3 h. The solvent was 
removed under vacuum and the residue was purified by flash chromatography on silica gel, 
eluting with acetone:DCM (1:8) to afford 317 as a white solid (26 mg, 79%). 
1
H NMR (300 
MHz, chloroform-d)  8.17 (s, 1H), 7.85 (s, 1H), 7.32 (s, 1H), 7.07 (s, 1H), 6.75 (s, 1H), 3.84 (s, 
3H), 3.12 - 3.07 (m, 1H), 2.39 (s, 3H), 1.23 (d, J = 6.8 Hz, 6H). HRMS (ESI
+
) calcd for 
C14H18N2O3S (M+H)
+
 295.3773, found 295.1104. 
1-((5-Isopropyl-2-methoxy-4-methylphenyl)sulfonyl)-4-phenyl-1H-imidazole (320). Same 
procedure as 317 using 281 (40 mg, 0.15 mmol) and 4-phenylimidazole (66 mg, 0.45 mmol) as 
the starting materials. The residue was purified by flash chromatography on silica gel, eluting 
with DCM to afford 320 as a white solid (54 mg, 96%). 
1
H NMR (300 MHz, chloroform-d)  
8.16 (s, 1H), 7.88 (s, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.71 (s, 1H), 7.40 (t, J = 8.7 Hz, 2H), 7.28 (t, 
J = 7.5 Hz, 1H), 6.74 (s, 1H), 3.84 (s, 3H), 3.13 - 3.08 (m, 1H), 2.38 (s, 3H), 1.28 (d, J = 6.9 HZ, 
6H). HRMS (ESI
+
) calcd for C20H22N2O3S (M+H)
+
 371.4732, found 371.1416. 
(4aR,8aS)-1-((5-Isopropyl-2-methoxy-4-methylphenyl)sulfonyl)decahydroquinoline (325). 
Same procedure as 195 using 281 (25 mg, 0.09 mmol) and trans-decahydroquinoline (26 mg, 
0.19 mmol) as the starting materials. The residue was purified by flash chromatography on silica 
gel, eluting with hexanes:EtOAc (5:1) to afford 325 as a colorless oil (25 mg, 70%). 
1
H NMR 
(300 MHz, chloroform-d)  7.71 (s, 1H), 6.72 (s, 1H), 4.15 - 4.10 (m, 1H), 3.88 (s, 3H), 3.08 - 
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3.03 (m, 1H), 2.85 - 2.65 (m, 1H), 2.64 - 2.35 (m, 1H), 2.34 (s, 3H), 2.04 - 2.02 (m, 2H), 1.69 - 
1.59 (m, 6H), 1.20 (d, J = 6.8 Hz, 8H), 1.17 - 1.04 (m, 7H). HRMS (ESI
+
) calcd for C20H31NO3S 
(M+H)
+
 366.5380, found 366.2091. 
1-((2-Methoxy-4-methylphenyl)sulfonyl)-4-methyl-1H-imidazole (326). 6-Methoxy-m-
toluenesulfonyl chloride (40 mg, 0.18 mmol) was added to a solution of 4-methylimidazole (45 
mg, 0.54 mmol) in DCM (0.5 ml) at 0 °C. The reaction mixture was stirred at rt overnight. The 
solvent was removed under vacuum. The residue was purified by flash chromatography on silica 
gel, eluting with DCM/acetone (8:1) to deliver 326 as a white solid (45 mg, 85%). 
1
H NMR (300 
MHz, Chloroform-d)  8.04 (s, 1H), 7.82 (s, 1H), 7.42 (d, J = 8.4 Hz, 1H), 6.95 (s, 1H), 6.86 (d, 
J = 8.1 Hz, 1H), 3.85 (s, 3H), 2.36 (s, 3H), 2.14 (s, 3H). HRMS (ESI
+
) calcd for C12H14N2O3S 
(M+H)
+
 267.0803, found 267.0809. 
1-((2-Methoxy-4-methylphenyl)sulfonyl)-1H-imidazole (327). Same procedure as 265 using 6-
methoxy-m-toluenesulfonyl chloride (50 mg, 0.23 mg) and imidazole (15 mg, 0.23 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
5% MeOH in DCM to afford 327 as a white solid (14 mg, 24%). 
1
H NMR (300 MHz, 
chloroform-d)  8.09 (s, 1H), 7.84 (d, J = 2.1 Hz, 1H), 7.42 (dq, J = 0.6, 8.4 Hz, 1H), 7.28 (s, 
1H), 7.04 (s, 1H), 6.87 (d, J = 8.4 Hz, 1H), 3.83 (s, 3H), 2.36 (s, 3H). HRMS (ESI
+
) calcd for 
C11H12N2O3S (M+H)
+
 253.2975, found 253.0638. 
6-((4-Methyl-1H-imidazol-1-yl)sulfonyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-
tetrahydroquinoline. Same procedure as 195 using 194 (35 mg, 0.10 mg) and 4-
methylimidazole (26 mg, 0.30 mmol) and as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with acetone/DCM (1:11) to give a white solid (38 
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mg, 84%). 
1
H NMR (300 MHz, chloroform-d)  7.98 - 7.91 (m, 2H), 7.77 - 7.74 (m, 2H), 6.99 
(s, 1H), 3.86 (t, J = 6 Hz, 2H), 2.96 (t, J = 5.6 Hz, 2H), 2.20 (s, 3H), 2.14 - 2.10 (m, 2H). 
6-((4-Methyl-1H-imidazol-1-yl)sulfonyl)-1,2,3,4-tetrahydroquinoline (334). Same procedure 
as 30 using 6-((4-Methyl-1H-imidazol-1-yl)sulfonyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-
tetrahydroquinoline (34 mg, 0.09 mmol) and K2CO3 (234 mg, 1.69 mmol) as the starting 
materials. The residue was purified by flash chromatography on silica gel, eluting with 
acetone/DCM (1:9) to deliver 334 as a white solid (17 mg, 67%). 
1
H NMR (300 MHz, 
chloroform-d)  7.98 (s, 1H), 7.47 - 7.44 (m, 1H), 6.97 (s, 1H), 6.44 (d, J = 8.7 Hz, 1H), 4.80 (s, 
1H), 3.88 (t, J = 5.4 Hz, 2H), 2.75 (t, J = 6.3 Hz, 2H), 2.22 (s, 3H), 1.94 - 1.90 (m, 2H). 
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4.0  MODE OF ACTION STUDIES OF THE MIR-122 INHIBITORS 
Investigations into the biogenesis of miRNAs, as well as the molecular mechanisms 
responsible for their participation in various diseases, constitute an active field of research. 
Additional knowledge into the regulation of specific miRNAs will bring valuable insight to 
promote the development of miRNA-based therapeutics.
2
 It is now well established that miR-122 
intricately drives the replication of the HCV virus,
211
 spurring interest in the development of new 
anti-HCV therapies based on miR-122 inhibition,
2
 pioneered by the LNA anti-miR122 
miravirsen.
72, 192
 Additionally, small molecule miR-122 specific inhibitors represent promising 
new antiviral strategies since they can reduce HCV replication.
98
 However, the mode of action of 
the small molecule miR-122 inhibitors has not been elucidated. Identifying the protein(s) 
specifically targeted by the small molecule miR-122 inhibitor 30 would not only expand the 
current knowledge of miR-122 biogenesis but could also lead to potential new drug targets for 
the treatment of HCV infection. 
4.1 PREVIOUS WORK: RECOVERY OF INHIBITION BY TRANSFECTION OF 
PRECURSOR PRE-MIR-122  
Preliminary experiments suggested that the regulatory effect of the small molecule 30 
was not due to direct binding with the miRNA oligonucleotide (Figure 3.5). It was further 
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demonstrated by qRT-PCR experiments that exposure of Huh7 cells to 10 M of compound 30 
led to a 97% and a 72% knockdown of both pri-miR-122 and mature miR-122 expression levels, 
respectively (Figure 3.4).
98
 These data indicated that 30 acts either at the transcriptional level, by 
inhibiting a necessary factor for the transcription of the miR-122 gene into the primary pri-miR-
122 transcript, or at the pre-transcriptional level, by interfering with epigenetic events, such as 
DNA methylation or acetylation. To further validate this hypothesis, Huh7-psiCHECK-miR122 
cells were exposed to both 30 and transfected with the precursor pre-miR-122. If the small 
molecule 30 acts upstream of the formation of the pri-miR-122 transcript, as hypothesized, 
introduction of exogenous precursor pre-miR-122 should recover the inhibitory activity of 30. 
The proper processing of exogenous pre-miR-122 through the miRNA pathway should then 
deliver mature miR-122, capable of repressing their targets including the engineered miR-122 
luciferase reporter. 
As expected, transfection of Huh7-psiCHECK-miR122 cells with xtremeGENE (vehicle) 
or precursor pre-miR-21, followed by exposure to DMSO did not have any effect on the 
luciferase expression. The pre-miR-21 was used as a control in that experiment, to verify that the 
transfection of a precursor was not interfering with the activities of the small molecules 
independently of their miR-122 regulatory effect. In contrast, transfection with pre-miR-122 
induced a 50% decrease in the Renilla luciferase signal (Figure 4.1). This was due to the 
presence of additional mature miR-122, which induced the silencing of the luciferase through 
specific binding to the mRNA. In the cells transfected with xtremeGENE (no precursor) or the 
control precursor pre-miR-21, treatment with the inhibitors 29 and 30 led to a 7- and 4-fold 
increase in Renilla luciferase expression over the DMSO control, respectively, due to the 
inhibition of miR-122 by the small molecules. However, in the cells treated with 29 and 30, the 
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presence of precursor pre-miR-122 significantly reduced the Renilla luciferase signal, almost to 
the level of the DMSO control (Figure 4.1). This demonstrated that the precursor pre-miR-122 
was correctly processed into mature miR-122, even in the presence of the small molecules 29 
and 30, and reinforced the hypothesis that the inhibitors act at the transcriptional or the pre-
transcriptional step. 
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Figure 4.1: Recovery of the inhibitory activity of the miR-122 inhibitors 29 and 30 through transfection of a pre-
miR-122 precursor. 
Huh7-psiCHECK-miR122 cells were transfected with the precursors pre-miR-122 or pre-miR-21 and treated with 
DMSO, 29, or 30 for 48 h. All experiments were conducted in triplicate and the data was normalized to the vehicle 
control (xtremeGENE transfection reagent). The error bars indicate standard deviations determined from three 
independent experiments. These experiments were performed by Colleen Connelly. 
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4.2 INVESTIGATION INTO THE PROTEIN TARGETED BY THE SMALL 
MOLECULE MIR-122 INHIBITOR 
4.2.1 Synthesis of Small Molecule Probes 
Although the SAR studies of the previously discovered miR-122 inhibitor 30 did not 
provide any significantly more potent inhibitors (Chapter 3.3), the knowledge collected during 
this investigation was crucial in locating suitable positions where modifications were tolerated. 
Since the introduction of a nucleophilic handle, such as the (CH2)4-6OH, C6H4NH2, or (CH2)6NH2 
groups, in place of the trans-decahydroquinoline ring led to  significant losses in activity (Figure 
3.8 and Figure 3.9), applying a solid-phase immobilization of 30 for pull-down experiments 
(Figure 2.22) did not seem suitable. Instead, since it was shown that an alkyne functionality 
could be introduced into the tetrahydroquinoline motif without affecting the activity, and that 
some modifications on the benzene ring could be accommodated (Figure 3.9), a photo-
crosslinking strategy was designed to identify the target protein of 30 (Figure 2.24).
248
 It was 
envisioned that a small molecule photoprobe miR-122 inhibitor functionalized with an alkyne 
group could be synthesized to allow for covalent attachment to the target protein. Further 
derivatization with a fluorescent tag via a [3+2] cycloaddition would facilitate the detection of 
the protein. 
A photoprobe consists of a bioactive small molecule substituted with a photoreactive 
group, which is able to form a covalent bond with the target protein after brief irradiation with 
UV light (Figure 2.24). Due to the formation of a covalent bond between the inhibitor and its 
cellular target, photoaffinity labeling is amenable to the detection of proteins with low abundance 
or with a low affinity for the modified small molecule. A good photoprobe must be reasonably 
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stable under ambient light, its excited state needs to have a short life-time to avoid non-specific 
binding, and it must be able to form a covalent bond with various residues.
144
 The most 
commonly used photoactive groups are arylazides and diazirines because of their relative 
stability, small sizes, and ease of introduction into a molecule.
249
 Benzophenones are also 
employed, as they are generally efficient and selective, they are stable under ambient light and 
protic solvent condition, and they preferentially react with unreactive C-H bonds.
114
 
An additional SAR investigation of 30 was performed to determine which position on the 
small molecule could be substituted with a photo-crosslinking group, and which one would be 
more suitable. Since it was previously observed that a para tert-butyl (237) or acetyl (238) 
groups could be introduced, these compounds were further functionalized with a propargyl motif, 
which yielded the analogs 364 and 365 that were slightly more active than 30 (Figure 4.2). Based 
on these results, the para arylazide 366 was synthesized and displayed a promising 28% increase 
in activity over 30. Modification with a small alkyne group was well tolerated, as 367 exhibited 
an activity comparable to 30, thus representing a probe suitable for photo-crosslinking 
experiments. Since it was reported in the literature that 4-azidotetrafluoroaniline derivatives are 
often more efficient at photo-crosslinking than their arylazide counterparts,
250
 368 was 
synthesized to assess the effect of introducing highly electronegative fluorine. However, 
compound 368 showed a 25% loss in activity, suggesting that functionalization with fluoro 
groups might lead to an inactive photoprobe. In addition, a benzophenone photoactive group was 
installed in the ortho (369), meta (370), or para (371) positions. Modification in the ortho or 
para positions with the bulky benzophenone resulted in a 22% and 60% increase in activity 
compared to 30, respectively. However, the meta substitution negatively affected the activity 
(Figure 4.2). The corresponding alkyne-derivatives of the potent 369 and 371 were synthesized, 
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but unfortunately significant reductions in activity were observed for 372 and 373. The slightly 
smaller indoline analog 374 was designed with the hope that this compound might be better 
accommodated in the putative binding pocket of the target protein than 371. Although 374 
showed an activity equivalent to 30, the subsequent introduction of an alkyne into 375, similarly 
abolished the activity. Given that 30 is substituted with a tertiary sulfonamide, a methyl group 
was added to the ortho-benzophenone compound 369 to mimic the H-bond configuration of the 
reference inhibitor 30. The analog 376 displayed a favorable 51% increase in activity relative to 
30, and furthermore, the propargyl derivative 377 showed an activity similar to the reference 
inhibitor 30. The same strategy was applied to the arylazide analog 378, which was totally 
inactive (Figure 4.2). The high activity exhibited by the benzophenone derivatives in the 
luciferase assay was somewhat surprising, and the results would need to be further confirmed by 
qRT-PCR experiments. 
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Figure 4.2: Structural modifications performed on 30 aimed towards the installation of functionalities necessary for 
photo-crosslinking experiments. 
The modifications from the initial structure are shown in blue and red. The percentages represent luciferase activity 
relative to 30 within the same assay. Experiments were performed in triplicate and the standard deviations of the 
three independent assays were calculated. Cell-based assays were performed by Colleen Connelly.  
 
The analogs 364, 365, 368-369, 371-375 were synthesized according to Scheme 4.1. The 
sulfonyl chloride 194 was heated to reflux in pyridine in the presence of the corresponding 
anilines, and the TFA protecting group was subsequently removed with K2CO3 in MeOH/H2O. 
The propargyl group was installed as previously described, through treatment with propargyl 
bromide and DIPEA in refluxing DMF.
251
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Scheme 4.1: Synthesis of analogs designed for use in photoaffinity labeling experiments. 
For R groups see Figure 4.2. 
 
The azide 366 was first synthesized from the nitro 379, which was reduced with tin(II) 
chloride in refluxing EtOH (Scheme 4.2).
118
 The intermediate 380 was converted to the 
corresponding azide through treatment with NaNO2 and NaN3 and subsequently deprotected with 
K2CO3 to deliver 366. The propargylated analog 367 was similarly obtained from the nitro 
compound 381, after successive treatments with tin(II) chloride, NaNO2, and NaN3 (Scheme 4.2). 
Since 367 acted as a potent small molecule miR-122 inhibitor possessing the two functionalities 
necessary to carry out 1) the photo-crosslinking experiments and 2) the subsequent “click 
reaction” with a fluorescent tag, the synthesis of 367 was scaled up to afford enough material for 
the biological studies. As the previous conditions used for the synthesis of 366 and 367 were 
generally low yielding, especially the step where the azido group was introduced, a different 
optimized route was designed (Scheme 4.2). 4-Nitroaniline was quantitatively protected using 
trifluoroacetic anhydride. Several conditions had to been screened for the reduction of the nitro 
382 (Scheme 4.2), which was eventually carried out with H2 and Pd/C in MeOH. Treatment of 
the aniline intermediate 383 at 0 °C sequentially with HCl, NaNO2, and NaN3 in H2O delivered 
the corresponding azide in 98% yield, which was further exposed to K2CO3 to afford 4-
azidoaniline. This intermediate 384 was then stirred at rt in pyridine for 2 h in the presence of 
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194 to deliver the TFA protected precursor 385 in 94% yield, which was further deprotected with 
K2CO3. Finally, 366 was treated with propargyl bromide to yield the photo-crosslinking probe 
367 (Scheme 4.2). Unlike previous alkylation reactions, which were performed under refluxing 
conditions, the alkylation of 366 with propargyl bromide was carried out at 50 °C due to the 
decomposition of the starting material at higher temperatures. 
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Scheme 4.2: Different synthetic approaches towards the azides 366 and 367. 
 
The ortho- and para-substituted benzophenone derivatives were synthesized as shown in 
Scheme 4.1. However, these conditions failed to deliver the meta-analog 370. Several test 
reactions were performed using the commercially available para-toluenesulfonyl chloride and 3-
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aminobenzophenone in order to optimize the coupling reaction, but were similarly unsuccessful 
in delivering the expected product. For example, when p-toluenesulfonyl chloride and 3-
aminobenzophenone were treated with TEA in DCM, NaH in DMF,
252
 or refluxed in pyridine,
253
 
only trace amount of the product was obtained. Similarly, only unreacted starting materials were 
observed following treatment with copper(II) oxide in ACN
254
 or with pyridine in DCM at rt. It 
was then attempted to render the carbonyl group less electron withdrawing via protection of the 
ketone with ethylene glycol. 3-Aminobenzophenone was heated under Dean-Stark conditions in 
toluene, with ethylene glycol and p-toluene sulfonic acid, but the corresponding acetal was not 
obtained.
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 Another strategy was adopted, which aimed to transform the deactivating carbonyl 
group into a corresponding electron-donating hydroxyl group (Scheme 4.3). 3-
Aminobenzophenone was heated to reflux in EtOH in presence of sodium borohydride to 
provide the alcohol 386 in 88% yield.
256
 The intermediate 386 was treated with 194 in refluxing 
pyridine, which successfully delivered the meta sulfonamide derivative 387. The alcohol was 
subsequently oxidized with pyridinium chlorochromate (PCC) in DCM.
257
 Removal of the 
protecting group delivered the final analog 370 as a yellow solid in 81% yield (Scheme 4.3).  
 
Scheme 4.3: Synthesis of the meta-benzophenone analog 370. 
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Treatment of 2-aminobenzophenone with 194 in refluxing pyridine (Scheme 4.1) 
provided the TFA-protected derivative 389, which was subsequently treated with iodomethane 
and K2CO3 to afford the methylated sulfonamide 390.
258
 Removal of the protecting group yielded 
376, which was further alkylated with propargyl bromide and K2CO3 to deliver 377 (Scheme 
4.4). In summary, two small molecule inhibitors of miR-122 (367 and 377) have been 
successfully synthesized that contain either an arylazide or a benzophenone functionality that can 
be used in photo-crosslinking experiments. 
 
Scheme 4.4: Synthesis of benzophenone analogs 376 and 377. 
 
 
It was envisioned that a small molecule structurally similar to the active photoprobe, also 
substituted with the photo-crosslinking and the alkyne functional groups, but which does not 
exhibit any miR-122 inhibition would provide an important negative control for the photoaffinity 
labeling experiments, and help to distinguish the target protein from non-specific protein-small 
molecule interactions. Previously, it was observed that the amide analog of 30, 240 was 
completely inactive in the luciferase reporter assay. Based on this observation, the amide 394 
was synthesized as a negative control (Scheme 4.5). 6-Quinolinecarboxylic acid was protected as 
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a methylester after being heated to reflux in MeOH in presence of thionyl chloride.
259
 The 
pyridine ring was reduced with Pd/C and ammonium formate in refluxing MeOH.
224
 The amine 
391 was alkylated with propargyl bromide and K2CO3 to deliver the propargylated intermediate 
392 in 88% yield.
251
 Hydrolysis of the ester was carried out with NaOH in a mixture of 
MeOH/H2O for 4 h at 50 °C. Treatment of the acid 393 with 4-azidoaniline (384), the peptide 
coupling reagent HATU, and DIPEA afforded the amide derivative 394 (Scheme 4.5). As 
expected, 394 displayed very little miR-122 inhibitory activity, which validated its function as a 
negative control.  
 
Scheme 4.5: Synthesis of the inactive small molecule probe 394. 
The alkyne functionality is shown in red, the arylazido photo-crosslinking group is shown in blue, and the amide 
deviation from the parent structure 30 is shown in magenta. 
4.2.2 Target Identification Experiments with the Inhibitor 30 
In order to selectively detect proteins crosslinked to 367/377, the azido-rhodamine 396 
was synthesized in 4 steps (Scheme 4.6) to perform [3+2] cycloaddition reactions.
260
 1,6-
Dibromohexane was heated to 55 °C in DMF in the presence of NaN3 to deliver 1-azido-6-
bromohexane, following nucleophilic substitution of the bromine was achieved after treatment 
with methylamine in THF. Rhodamine B was heated to reflux in carbon tetrachloride (CCl4) and 
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thionyl chloride, and the resulting acyl chloride was treated with the amine 395 and K2CO3 to 
afford the azido-rhodamine 396 as a bright pink powder (Scheme 4.6).
261
 Since it was reported 
that when substituted with a secondary amide, the rhodamine can quickly undergo cyclization to 
form a non-fluorescent lactam derivative,
262
 the azide-rhodamine 396 was modified with a 
tertiary methylamide to prevent the formation of the cyclic by-product. 
 
 
Scheme 4.6: Synthesis of the azido-rhodamine 396. 
 
 
The photo-crosslinking strategy employed using the developed photoprobes 367, 377, 
and 394 and the azido-rhodamine is outlined in Figure 4.3. Huh7 cells were passaged into 10 cm 
plates and were grown to 90% confluency. The cells were treated either with DMSO, the 
inhibitor 30, the small molecule probes 367 and 377 or the inactive derivative 394 (10 M, 0.5% 
DMSO). After overnight incubation at 37 °C, the cells were washed with PBS to remove any 
excess probe and irradiated for 10 min at 365 nm (based on literature reports; further 
optimization of the photocrosslinking experiment are discussed below). The cells were pelleted 
by centrifugation and lysis was carried out with mammalian protein extraction buffer, followed 
by incubation on ice for 20 min and vortexing every 5 min. After centrifugation, the supernatant 
containing the protein lysate was submitted to a [3+2] cycloaddition reaction with the azido-
rhodamine 396, in the presence of TCEP, copper (II) sulfate, and TBTA.
146
 Each sample was 
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analyzed by SDS-PAGE and the gel was imaged on a phosphorimager (filter 580 nm, rhodamine 
B: excitation wavelength is 540 nm and emission wavelength is 625 nm).  
 
Figure 4.3: Representation of the photo-crosslinking strategy applied to detect the target protein(s) of the miR-122 
inhibitor 30. 
The inhibitor was modified with a photoreactive group, incubated with live cells, and covalently linked to its target 
protein upon UV irradiation. Following click reaction with a fluorophore-azide (F), the lysate was analyzed by SDS-
PAGE and the target protein was detected when the fluorescence was imaged. X represents the binding site residue 
of the target protein that covalently reacts with the photoprobe.  
 
Figure 4.4 shows an example of a gel obtained after photoaffinity labeling experiments 
using the probes 367, 377, and the negative control 394 in conjunction with the azido-rhodamine 
396. As expected, there was no fluorescence detected when the cells were treated either with 
DMSO or the inhibitor 30, which represents a negative control as it lacks a photoreactive group 
(lanes 2 and 3, Figure 4.4). However, two distinct bands were observed at ~50-60 kDa for the 
sample containing the photoactive probe 367 (lane 4, Figure 4.4). A competitive experiment was 
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also performed where the cells were exposed to both 367 (10 M) and a 5-fold excess of 30 (50 
M). A slight decrease in fluorescence intensity was observed for the competition experiment 
(lane 5, Figure 4.4). Notably, the top band was less intense in lane 5 than in lane 4, indicating 
that the inhibitor 30 was able to successfully compete with the photoprobe 367 for binding to the 
target protein. In the sample treated with the negative-control probe 394, which displayed only 
minimal miR-122 inhibitory activity, no fluorescence was detected (lane 6) indicating that the 
two fluorescently-labeled proteins observed in lane 4 are specific to the miR-122 inhibitor probe 
367. Although, the benzophenone 377 exhibited a higher potency than 367 in the luciferase 
assay, no protein labeling was achieved with this probe (lane 7). This lack of efficiency might be 
due to the substitution in the ortho position of the benzophenone moiety, which may lead to 
lower effectiveness of the probe 377.
114
 It was attempted to optimize the photoaffinity labeling of 
the benzophenone probe 377. A time course experiment was performed where cells treated with 
377 (10 M) were irradiated with UV light for 10, 20, 30, or 45 min. The cells were lysed, 
treated with the azido-rhodamine, and analyzed by SDS-PAGE. Even with longer irradiation 
times, no fluorescence was detected, except for the 45 min time point where some fluorescent 
bands were visible. However, efforts to reproduce this data were unsuccessful. It was also 
attempted to treat the cells with higher concentrations of 377, but even after treatment at 20 or 40 
M the photoaffinity labeling remained unsuccessful.  
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Figure 4.4: Fluorescence imaging of an SDS-PAGE of protein samples isolated from Huh7 cells treated with 
DMSO, the miR-122 inhibitor 30, the photoprobes 367 and 377, or the negative control 394. 
Fluorescence was imaged on a phosphorimager. The two fluorescently labeled proteins are indicated by a red box. 
 
Since 367 was the only probe capable of selectively labeling the target proteins, it was 
used in subsequent target ID studies. Higher concentrations of 367 were tested, but due to 
toxicity, it only resulted in lower protein recovery. The cells were incubated with 367 either for 3 
h or 16 h, but only a low level of fluorescence was detected after the 3 h incubation, suggesting 
the overnight incubation was favorable. The cells were irradiated with UV light at different 
wavelengths and the same two bands were detected after irradiation at 254 or 365 nm, but only 
the top band was detected - albeit very weakly - after irradiation at 302 nm. Since it was 
previously reported that the optimal wavelength for photolysis of aryl azides is >315 nm, given 
they absorb UV light in the 300-320 nm range, the subsequent photo-labeling experiments were 
performed at 365 nm.
263
 The labeling experiment was also tested under denaturing conditions. 
The samples were heated to 95 °C for 10 min (in 1% SDS) prior to the click reaction, and 
analyzed by PAGE side by side with the corresponding non-denatured samples. The same two 
fluorescently labeled bands were detected in both lanes, indicating that the alkyne group of 367 
was similarly accessible to the azido-rhodamine under native or denaturing conditions. In 
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another experiment, following exposure to 367, the proteins were extracted with a nuclear 
protein extraction kit (NE-PER kit, Pierce), which allowed for the extraction of the nuclear and 
cytoplasmic proteins separately. The proteins issued from both fractions were submitted to the 
click reaction with the azido-rhodamine and analyzed by SDS-PAGE. No fluorescence was 
detected in the nuclear extract sample, however the two bands previously observed were present 
in the cytoplasmic fraction, indicating that the target proteins are localized in the cytoplasm. 
The previous experiments with the rhodamine 396 represented a proof-of-principle for 
the successful realization of photoaffinity labeling and allowed for the detection of the protein 
targets of the inhibitor. However, the main goal is to identify the proteins through isolation and 
MS analysis. The proteins must be isolated in a high purity and quantity in order to be accurately 
identified. The azido-biotin 397
264
 was then synthesized from the azidoamine 190 and biotin-
NHS (Scheme 4.7) to facilitate the isolation of the target proteins via affinity purification with a 
streptavidin resin. Since biotin and streptavidin have extremely high affinity for each other, the 
biotin group serves as a linker to attach the biotinylated probe/protein complex to the streptavidin 
resin, allowing non-specific proteins to be removed through a series of washes and enriching the 
target protein by elution from the resin.
222
 
 
Scheme 4.7: Synthesis of the azido-biotin 397. 
 
 
The crosslinking experiments were repeated in Huh7 cells treated with 367, except the 
azido-biotin 397 was used in the click reaction instead of the rhodamine 396 (Figure 4.5). 
Following the click reaction, an acetone precipitation was performed to remove any excess click 
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reagents and the proteins were re-dissolved in PBS supplemented with different amounts of the 
streptavidin resin and incubated at 4 °C overnight. The resins were thoroughly washed to remove 
any non-specific proteins and then suspended in SDS loading buffer, denatured at 95 °C for 15 
min, and analyzed via a 12% SDS-PAGE. This experiment was repeated several times, using 
varying amounts of protein and the streptavidin resin, in attempts to improve the purification. A 
representative gel is shown in Figure 4.5. Unfortunately, lower amounts of streptavidin (<80 L, 
lane 2) did not enable efficient pull-down of the target proteins, and higher amounts of resin 
(>100 L, lanes 3-5) resulted in the isolation of a significant amount of non-specifically binding 
proteins.  
ladder   80 µL 100 µL 120 µL 160 µL     streptavidin resin 
 
Figure 4.5: Example of a silver-stained 12% SDS-PAGE of protein samples isolated from Huh7 cells treated with 
the photoprobe 367, labeled with the biotin-azide, and purified with various amounts of streptavidin resin. 
 
 
The same results were observed with varying amounts of protein. When the experiment 
was carried out with 150 g of protein, only one very faint band of the expected size (~50-60 
kDa) was detected on the gel after silver staining. Although the protein was pure, it was obtained 
in a quantity too low for MS analysis. Subsequent attempts to increase the protein yield, by 
performing the labeling experiment with higher amounts of protein for example, resulted in the 
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isolation of many non-specific proteins, some of which were biotinylated (as determined by an 
anti-biotin Western blot). Since biotin binds to streptavidin with a high affinity, the conditions 
required for the elution of the biotinylated probe/protein complex were somewhat harsh: the 
protein samples were eluted after being heated in SDS loading buffer at 95 °C for 15 min. 
Therefore, any protein bound to the streptavidin resin was denatured and eluted along with the 
target protein(s).  
Next, a different purification of the target protein(s) was attempted by using two-
dimensional gel electrophoresis (2-D gel), which is a technique commonly employed to purify 
proteins from complex samples based on their isoelectric points and molecular weights. First the 
solubilized samples are loaded onto an IPG (immobilized pH gradient) strip, and an electric 
current is applied. The proteins separate as they migrate through the pH gradient until they reach 
their isoelectric point, which corresponds to the pH where the net charge of the protein becomes 
neutral.
265
 The second dimension consists of a standard SDS-PAGE, where the proteins are 
separated based on their molecular weights in a perpendicular direction to the first dimension. 
The proteins are then separated and aligned along two axes: isoelectric points vs molecular 
weights. Although quite straightforward in theory, the 2-D gel technique required extensive 
optimization. Since the IPG strips are supplied dried, a critical step prior to running the 
isoelectric focusing consists in solubilizing the proteins in a compatible buffer in order to 
rehydrate the IPG strip. The rehydration step can be performed in two different ways: active 
rehydration is done in 30 min under low voltage current, whereas passive rehydration is often 
done overnight on a bench top. The experimental conditions, such as amounts of proteins used, 
rehydration method, and incubation time were extensively optimized. Although time consuming, 
24 h passive rehydration was found to give the best results.  
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Huh7 cells were treated with the aryl azide probe 367 (10 M) and incubated overnight at 
37 °C. The cells were irradiated at 365 nm for 10 min and then lysed using mammalian protein 
extraction buffer supplemented with protease inhibitor cocktail. A Bradford assay was performed 
to quantify the protein extract, and 100 μg of total protein was used in a click reaction with the 
rhodamine-azide 396, which was carried out in the presence of TCEP, CuSO4, and TBTA for 2 h 
at room temperature.
146
 A comprehensive optimization of the [3+2] cycloaddition reaction 
conditions was not conducted. An acetone precipitation was then performed to remove excess 
click reaction reagents, and the sample was analyzed by 2-D gel electrophoresis. The sample was 
loaded onto a pH 4-7 ReadyStrip IPG strip (Bio-Rad) through passive in-gel rehydration for 24 h 
at room temperature. The proteins were then separated according to their isoeletric points on a 
PROTEAN IEF Cell (Bio-Rad) following the manufacturer’s protocol. The IPG strip was loaded 
onto a 12% SDS-PAGE and the proteins were further separated according to their molecular 
weights. The fluorescence was then visualized on a Typhoon 7000 phosphorimager, and the gel 
was silver stained to determine whether the target protein(s) could be selectively excised from 
the gel (Figure 4.6A). The procedure was repeated to obtain an additional non-stained gel for 
mass spectrometry analysis (Figure 4.6B).  
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Figure 4.6: Representative gels obtained following 2-D gel experiments in Huh7 cells. 
A. Fluorescence imaging and silver staining of a 2-D gel containing proteins isolated from Huh7 cells treated with 
the photoprobe 367 and labeled with the rhodamine-azide 396. B. Fluorescence imaging of the 2-D gel containing 
proteins isolated from Huh7 cells treated with the photoprobe 367 and labeled with the rhodamine-azide 396 that 
was submitted for analysis by mass spectrometry. The fluorescently labeled proteins are indicated by a red box. C. 
The directions of the two separation steps are indicated. 
 
The gel in Figure 4.6B was submitted to Nedyalka Dicheva at the UNC Michael Hooker 
Proteomics Center at UNC Chapel Hill for protein identification. At the Proteomics Center, the 
gel was stained with coomassie blue and the fluorescent proteins were excised in a single sample, 
as the two fluorescent spots were not resolved enough to be individually excised. The sample 
was destained and digested in-gel using trypsin (performed by Nedyalka Dicheva). The resulting 
peptide fragments were extracted from the gel and analyzed with an ABI 4800 MALDI-
TOF/TOF MS. The identity of the target protein was determined upon examination of the 
resulting mass spectrum of the digest peptide products and comparison with theoretical peptide 
maps stored in publicly available database (Mascot). The results obtained for the mass 
spectrometry analysis are shown in Table 4.1. The “Peptide Count” refers to the number of 
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observed peptides matching the theoretical digest of the identified protein, the “MS & MS/MS 
score” is the combined score of the quality of the peptide-mass fingerprint match and MS/MS 
peptide fragment ion matches, the “Peptide Sequenced Ion Score” is the score of the quality of 
MS/MS peptide fragment ion matched only, and the “Scoring Threshold” is a threshold set to 
determine hits based on the “MS & MS/MS score” or “Ion score” where score above this value 
are considered a significant identification. The top hit for the target protein corresponded to -
tubulin, which is a ~50 kDa protein involved in the assembly of microtubules.  
 
Protein MW (Da) 
Peptide 
count 
MS & 
MS/MS 
score 
Peptide 
sequenced 
ion score 
Scoring 
threshold 
tubulin beta 47736 21 983 850 71 
tubulin beta-4B 
chain 
49799 21 897 770 71 
tubulin alpha-1C 
chain 
49864 5  143 71 
ATP synthase, H+ 
transporting 
56525 25 1740 1558 71 
Table 4.1: Protein identification results for mass spectrometry analysis of rhodamine-labeled target proteins excised 
from a 2-D gel (data provided by Nedyalka Dicheva, UNC Michael Hooker Proteomics Center). 
 
To correlate the previous results, the 2-D gel experiment was repeated with the 
photoprobe 367, and the gel was submitted to the UNC Michael Hooker Proteomics Center for 
protein identification, which was performed as previously described. Similarly to the previous 
experiment, the two fluorescent spots could not be separated and were analyzed in a single 
sample. -Tubulin did not appear as a hit in this experiment. Instead, ATP synthase subunit beta 
(~56 kDa), 26S protease regulatory subunit 6B (~47 kDa), and the heat shock protein HSP-60 
(~61 kDa) were identified (Table 4.2).  
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Protein MW (Da) 
Peptide 
count 
MS & 
MS/MS 
score 
Peptide 
sequenced ion 
score 
Scoring 
threshold 
ATP synthase 
subunit beta 
56525 20 621 557 61 
26S protease 
regulatory subunit 
6B 
47337 15 250 179 61 
protein disulfide-
isomerase A6 
48091 9 104 79 61 
60 kDa heat shock 
protein 
61016 11 257 228 61 
Table 4.2: Protein identification results for mass spectrometry analysis of rhodamine-labeled target proteins excised 
from a 2-D gel (data provided by Nedyalka Dicheva, UNC Michael Hooker Proteomics Center). 
 
The same experiment was repeated: Huh7 cells were treated with the arylazide 367, 
irradiated with UV light, lysed, conjugated with the azido-rhodamine 396, and the lysate was 
analyzed on a 2-D gel. Two similar gels were obtained (Figure 4.7), the fluorescent areas 
(comprised of the 2 unresolved fluorescent protein spots) were excised and submitted to the 
Biomedical Mass Spectrometry Center at the University of Pittsburgh for comparison. 
fluorescence imaging fluorescence imaging 
 
Figure 4.7: Fluorescence imaging of the 2-D gel containing proteins isolated from Huh7 cells treated with the 
photoprobe 367 and labeled with the rhodamine-azide 396 that were submitted for analysis by mass spectrometry. 
The fluorescently labeled proteins are indicated by a red box.  
 
The samples were digested with trypsin and the tryptic peptides were analyzed by nano 
reverse phase HPLC interfaced with a mass spectrometer. The tandem mass spectra (MS/MS) 
were analyzed as previously with the search engine MASCOT and identified peptides and 
proteins were further statistically validated with the Scaffold software. A total of 66 putative 
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target proteins were identified, and the top “hits” from both samples were in good correlation 
(Table 4.3). The percent numbers represent the “sequence coverage” or the similitude between 
the theoretical sequence and the numbers of matching peptides from the analyzed sample. 
Although there was no correlation found between the 2 previous analyses (Table 4.1 and Table 
4.2), the most probable protein identified in both new samples was -tubulin and the third most 
probable was the ATP synthase subunit beta, which were previously detected in the first and 
second protein identification experiments, respectively. The second highly probable protein 
(>60% percent coverage) identified in both samples was vimentin (Table 4.3), a type III 
intermediate filament that is a major component of the cytoskeleton with tubulin and actin 
proteins. Other proteins were predicted with a lower probability, such as keratin, which probably 
resulted from contamination. 
 
Protein MW (kDa) Sample 1 (%) Sample 2 (%) 
tubulin beta 50 74.3 70.5 
vimentin 54 62.7 59 
ATP synthase subunit 
beta 
57 69.4 39.5 
keratin, type II 66 51.7 15.5 
keratin, type I 59 52.1 9.93 
tubulin alpha-1B 50 42.4 55.9 
Table 4.3: Protein identification results for mass spectrometry analysis of rhodamine-labeled target proteins excised 
from a 2-D gel (data provided by Biomedical Mass Spectrometry Center, University of Pittsburgh). 
 
The identification of the binding partner of a small molecule drug/probe is critical in 
understanding the precise mechanism of the compound and in predicting its safety profile.
266
 
However, target identification is a challenging process, associated with multiple obstacles, and 
often represents the bottleneck in chemical genetics approaches. For example, the specific 
detection of low-abundant proteins is very difficult due to the presence of highly abundant non-
specific binding proteins, such as cytoskeleton proteins tubulin, actin, and heat shock proteins, as 
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well as mitochondrial ATP synthases.
266
 In fact, actin and tubulin proteins have been reported to 
commonly interfere with target identification analyses due to their high abundance and their 
molecular weight (42 and 50 kDa), which is similar to that of many putative target proteins.
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Since -tubulin was identified as a positive hit for the target protein in three out four analyses, 
follow-up experiments were implemented in order to evaluate -tubulin as a real hit and confirm 
that it corresponds to one of the fluorescently-labeled proteins. Huh7 cells were treated with the 
photoprobe 367 (10 M) and incubated overnight at 37 °C. The cells were irradiated at 365 nm 
for 10 min, lysed, submitted to a click reaction with the rhodamine-azide 396, and acetone 
precipitated. The samples were run on a 12% SDS-PAGE, the fluorescence was imaged (Figure 
4.8A), and the samples were further analyzed by Western Blot using -tubulin and GAPDH 
(control) primary antibodies and a goat-anti-rabbit-IgG-HRP secondary antibody. The Western 
Blot was developed by HRP colorimetric staining and imaged on a phosphorimager (Figure 
4.8A). These results suggested that the lightest band detected after photo-crosslinking with 367 
may be -tubulin. The same Western Blot analysis was also performed on a sample separated via 
2-D gel, and validated that the fluorescently-labeled spot corresponded to -tubulin (Figure 
4.8B). The correct identification of -tubulin as one of the fluorescently-tagged proteins, 
although promising, does not guarantee that -tubulin is a real cellular target for 367, and it still 
needs to be considered that its detection might be due to non-specific hydrophobic interactions 
with the probe or the fluorophore, or alternatively that the target protein simply has a similar 
molecular weight. One method to address this question would consist in depleting the cell lysate 
of any abundant non-specific binders prior to the click reaction. For instance, the cell lysate 
might be pre-cleared using an agarose resin before being used in the [3+2] cycloaddition 
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reaction,
267
 and both conditions, ±lysate pre-clearing, can be analyzed side by side on an SDS-
PAGE to examine for any differences in the proteins fluorescently-labeled. 
A. 
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Figure 4.8: Validation studies of β-tubulin as a potential target for the miR-122 inhibitor 30. 
A. Fluorescence imaging of an SDS-PAGE containing proteins isolated from Huh7 cells treated with the photoprobe 
367 and labeled with the rhodamine-azide 396 (left). Colorimetric HRP detection of -tubulin by Western blot 
(right). Lane 1: Ladder, Lane 2: 367 (10 M). B. Fluorescence imaging of a 2-D gel containing proteins isolated 
from Huh7 cells treated with the photoprobe 367 and labeled with the rhodamine-azide 396 (right). Colorimetric 
HRP detection of -tubulin by Western blot (right). The fluorescently labeled proteins are indicated by a red box.  
 
 
Given that one of the fluorescently-tagged proteins was identified as -tubulin, a loss of 
function experiment was performed to determine whether inhibiting -tubulin affected miR-122 
expression. Huh7-psiCHECK-miR122 cells were transfected with an siRNA targeting -tubulin 
(class 4B, Sigma Aldrich, NM_006088) at 50 or 100 pmol. Following transfection the cells were 
incubated at 37 °C for 48 h and the luminescence was analyzed with a dual luciferase assay 
(Promega). Figure 4.9 shows that the -tubulin siRNA did not modify the intensity of the 
luciferase signal compared to the XtremeGENE control, suggesting that inhibiting -tubulin did 
not promote the inhibition of miR-122. However, only the isotype 4B was targeted with the 
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siRNA (based on the MS analysis Table 4.1). Since -tubulin has diverse isotypes, further 
experiments should be performed, with a pool of siRNA corresponding to the different isotypes 
for example, and the efficiency of the silencing should be confirmed either by Western Blot 
analysis or qRT-PCR measurements, before concluding that the inhibition of -tubulin does not 
affect miR-122 regulation. 
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Figure 4.9: Assessment of the validity of β-tubulin as the target protein of the inhibitor 30. 
Huh7-psiCHECK-miR122 cells were transfected with an siRNA for -tubulin at (50 or 100 pmol).  Data were 
normalized to the vehicle (XtremeGENE transfection reagent) control. Experiments were performed in triplicate and 
the standard deviations of the three independent assays were calculated. 
 
Due to the large number of putative proteins identified in the mass spectrometry analyses, 
it was hypothesized that the protein separation using 2-D gel did not afford samples with the 
desired/necessary purity. Indeed, the two fluorescent spots could not be resolved on the 2-D gel, 
and the protein spots were not detected after coomassie blue staining, which complicated the 
delicate step of band excision from the gel and increased the risk of including non-specific 
proteins. Another strategy was then designed to try to further purify the target proteins. Since 
pull-down experiments using biotin-streptavidin were unsuccessful due to the harsh elution 
conditions required, it was hypothesized that immunopurification might achieve efficient 
recovery of the target proteins since this method necessitates milder elution conditions. 
It was then attempted to isolate the target proteins by immunopurification (IP) using the 
fluorescein-azide 191. Huh7 cells were treated overnight with the aryl azide 367 or the negative 
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control 394 (10 μM), irradiated at 365 nm for 10 min, and lysed. Following the [3+2] 
cycloaddition reaction with the fluorescein-azide 191 and acetone precipitation (as previously 
described), the samples were re-suspended in tris-buffered saline (TBS) and incubated with a 
monoclonal anti-fluorescein IgG antibody (Sigma) at 4 °C overnight. The samples were then 
incubated with protein A/G agarose beads (Sigma) at 4 °C for 3 h. Proteins A/G are 
immunoglobulin (IgG)-binding proteins. Supported by the agarose resin they provide an affinity 
ligand for polyclonal and monoclonal IgG antibodies, therefore facilitating their purification 
(Figure 4.10). The mixtures were loaded onto spin columns and washed several times to remove 
any unbound proteins. Several conditions were tested for the elution of the target proteins, and 
only similar treatment as previously described for the biotin-streptavidin purification (95 °C for 
15 min in SDS loading buffer followed by centrifugation) enabled the detection of proteins by 
SDS-PAGE. A representative gel is shown in Figure 4.11.  
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Figure 4.10: Representation of the immunopurification strategy. 
F represents the fluorescein tag added to the complex of the small molecule/target protein via click reaction. 
 
Again, several experimental conditions were tested, where the amounts of total protein 
subjected to the click reaction, the amounts of antibody, and the quantity of the agarose-protein 
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A/G beads were modified to improve the purification. Although the optimized conditions 
enabled the selective detection of only one fluorescently-labeled protein with the active 
photoprobe (lane 2, Figure 4.11), coomassie blue staining revealed that some other, non-labeled 
proteins were recovered as well. For example, no band was detected in lane 3 when the 
fluorescence was imaged, but the same bands were observed in both lanes 2 and 3 after 
coomassie staining. Similar to the purification using the streptavidin resin described previously, 
non-specific interactions between the protein A/G agarose beads and non-labeled proteins within 
the sample may occur. If the non-specific proteins are not effectively removed during the wash 
steps, these proteins will be eluted along the target proteins. Prior to the elution step the samples 
are denatured directly on the resin, which results in the co-elution of the target proteins and the 
antibody. Given that the molecular weight of IgG antibody heavy chain is ~50 kDa, it is possible 
that the heavy chains co-migrate with the target proteins on the SDS-PAGE gel, which may 
explain the detection of several bands around this area after coomassie staining (lanes 2 and 3, 
Figure 4.11). 
 
ladder   367   394 
fluorescence imaging coomassie blue staining  
 
Figure 4.11: Imaging of a 12% SDS-PAGE containing protein samples isolated from Huh7 cells treated with the 
photoprobe 367 (10 µM) or the negative control 394 (10 µM), labeled with the fluorescein-azide, and purified with 7 
µL of anti-fluorescein antibody and 80 µL protein A/G agarose beads. 
Fluorescence was imaged on a phosphorimager.  
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Since one important drawback of the previous method lied in the co-migration of the 
target proteins and the heavy chains of the anti-fluorescein antibody due to their similar 
molecular weights, it was hypothesized that their isoelectric points might be different, and 
therefore they could be separated on a 2-D gel. The immunopurification procedure previously 
described was repeated, except the elution was performed using the rehydration buffer (BioRad) 
required for the proper rehydration of the IPG strip. Figure 4.12 shows a representative gel. 
Although some fluorescence was detected, the intensity was much weaker than previously 
observed, and after silver staining no spots were visible in the expected area of the target proteins 
(indicated with a red box), suggesting that the target protein was recovered in a quantity too low 
for accurate mass spectrometry analysis. 
fluorescence imaging silver staining  
 
Figure 4.12: Imaging of a 2-D gel of protein samples isolated from Huh7 cells treated with the photoprobe 367, 
labeled with the fluorescein-azide 191, and purified with the anti-fluorescein antibody and the protein A/G agarose 
beads. 
Fluorescence was imaged on a ChemiDoc.  
 
Lastly, it was attempted to purify the target proteins using an aldehyde-activated resin to 
covalently immobilize the antibody on the agarose beads (Direct IP kit, Pierce), which would 
prevent the antibody interference previously described. The aldehyde-activated resin was 
incubated for 2 h at rt in the presence of the anti-fluorescein antibody and cyanoborohydride, 
which enabled the covalent attachment of the antibody to the agarose beads. Huh7 cells were 
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treated overnight with the aryl azide 367 or the negative control 394 (10 μM), irradiated at 365 
nm for 10 min, and lysed. Following click reaction with the fluorescein-azide 191 and acetone 
precipitation (as previously described), the samples were re-suspended in 300 L of IP lysis 
buffer supplemented with the protease inhibitors sodium fluoride and vanadate, and loaded onto 
spin columns containing the resin modified with the anti-FITC antibody. The samples were 
shaken overnight at 4 °C and thoroughly washed. The proteins were then eluted by incubation of 
50 µL elution buffer at rt for 10 min followed by centrifugation. Most antibody-antigen binding 
interactions are optimal under physiological conditions (pH 7.4), and elution methods often rely 
on the alteration of the pH and/or ionic state of the environment to effectively dissociate these 
interactions. The elution buffer used in that study was a 0.1 M glycine•HCl solution (pH ~2.8). 
Another strategy, that should be tested, consists in the selective elution of the small 
molecule/protein complex via the addition of an excess of the free antigen (ie. fluorescein). The 
antigen would compete with the probe/protein complex for binding to the antibody, thus 
displacing and releasing the complex. The elution process was repeated three times and the 
isolated fractions were recovered separately. The samples were analyzed on a 12% SDS-PAGE. 
A representative gel is shown in Figure 4.13. Once again, the procedure was repeated several 
times varying the amount of total protein subjected to the click reaction, the quantity of antibody, 
and the quantity of the resin used in order to optimize the purification. A very intense 
fluorescently-labeled protein (top band in all lanes Figure 4.13) was observed across all the 
conditions tested (~70 kDa), and remains to be identified. The fractions containing the resin 
washes should be similarly analyzed by SDS-PAGE to determine whether this protein is already 
present or if it is being eluted off the column only at the same time as the target protein. The gel 
showed that the target proteins were efficiently eluted off the columns after two washes with 
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elution buffer, however the eluted fractions were still contaminated with non-specific proteins. 
More surprisingly, the target proteins were also detected in the sample treated with the negative 
control 394 (lane 3, Figure 4.13). This was in contrast to previous experiments, when samples 
from Huh7 cells treated with the photoprobe 367 or the negative control 394 (10 μM) were 
loaded on a SDS-PAGE following the acetone precipitation (no purification performed), the 
fluorescently-tagged target proteins were only detected in the sample treated with 367, in a 
similar fashion to what was observed in Figure 4.4. Similarly to Figure 4.4, including a 
competitive experiment, where the cells are exposed to both 30 (5-fold excess) and the 
photoprobe 367, may provide a better control, presenting the same band pattern as 367 but with 
the target protein bands being competed out and fainter. The photo-labeling experiment might be 
attempted by treating the cells with a lower concentration of 367 (for example 5 μM), which may 
reduce the background, or non-specifically bound proteins, but may also result in a very low 
amount of target protein being recovered. 
ladder 367  394   367    394    367   394   
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Figure 4.13: Imaging of a 12% SDS-PAGE containing protein samples isolated from Huh7 cells treated with the 
photoprobe 367 or the negative control 394, labeled with the fluorescein-azide, and purified with anti-fluorescein 
antibody-conjugated beads. 
Lane 1: ladder, Lane 2: 367 elution #1 (E1), Lane 3: 394 E1, Lane 4: 367 E2, Lane 5: 394 E2, Lane 6: 367 E3, Lane 
7: 394 E3. Fluorescence was imaged on a ChemiDoc (left) and the gel was stained with coomassie blue (right).  
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Unfortunately, all attempts to purify and concentrate the target protein(s) remained 
unsuccessful. An alternative approach would be to introduce a selective cleavable linker between 
the target protein and the biotin moiety.
268
 That way, the proteins could be isolated by affinity 
purification using the strong biotin-streptavidin interaction, and eluted using specific mild 
cleavage conditions, allowing for the release of the target proteins but leaving the non-specific 
proteins immobilized on the resin. Such tri-functional probes have been designed that contain an 
azido motif (shown in blue in Figure 4.14), a biotin group, a fluorophore, and a cleavable linker 
(shown in red in Figure 4.14). Although the fluorophore tag is not necessary, it greatly facilitates 
the detection of the target proteins on a gel. Unlike the previous biotin-streptavidin affinity 
purifications, which required harsh conditions, mild and selective elution of the target proteins 
could be achieved with UV light irradiation (365 nm) for the o-nitrobenzyl linker 398,
268
 with 
sodium periodate for the diol 399,
268
 or with sodium dithionite for the diazobenzene derivative 
400.
269
 
 
 
 271 
 
Figure 4.14: Potential tri-functional linkers that would facilitate the isolation of the target proteins 
following biotin-streptavidin pull-down and specific elution with UV light (398), NaIO4 (399), or Na2S2O4 (400). 
The azide (shown in blue) is required to attach the probe to the protein/small molecule complex using click reaction, 
the biotin group enables affinity purification with a streptavidin resin, the fluorophore (FT) tags the target proteins 
and facilitates their detection, and the selective cleavable linker (shown in red) allows for mild non-denaturing 
elution. 
 
4.3 INVESTIGATION INTO MIR-122 EPIGENETIC REGULATION 
As previously mentioned in Chapter 1.3, miRNA promoters share many characteristics 
with the promoters of protein-coding genes, implying that they are subjected to similar 
regulatory mechanisms, such as epigenetic modifications. For example, DNA methylation 
significantly affects gene transcription, either by blocking the binding of important 
transcriptional proteins to the gene promoter, or by stimulating the interaction between 
methylated DNA and methyl-CpG-binding domain proteins.
270
 These proteins often recruit 
additional chromatin-modifying enzymes, which promote alteration in chromatin compaction 
and negatively affect transcription. Since the miR-122 promoter does not contain any CpG 
 272 
islands,
198
 the transcription of miR-122 was not thought to be directly influenced by DNA 
methylation. However, an increase in miR-122 expression was observed in hESCs (human 
embryonic stem cells) and HCC cells, following exposure to the DNA methyltransferase 
inhibitor 5-aza-2-deoxycytidine (5-Aza-dC).271 Chromatin immunoprecipitation assays and 
bisulfite sequencing revealed that miR-122 is repressed in those cell lines due to the 
hypermethylation of the promoter, which prevents the binding of RNA polymerase II to miR-122 
promoter, thus blocking the transcription of miR-122.
271
 Similarly, it was recently shown that co-
treatment of HCC cells with 5-Aza-dC and the histone deacetylase (HDAC) inhibitor 
phenylbutyrate (PBA) inhibited the expression of SUV39H1 (an H3K9 methyltransferase), 
which resulted in a decreased binding between SUV39H1 and the miR-122 promoter and 
consequently stimulated miR-122 expression.
198
 5-Aza-dC/PBA co-treatment has also been 
found to induce miR-122 expression in HCC cells through the enhancement of the binding 
interaction between the transcription factor heterodimer PPARγ/RXRα (peroxisome proliferator-
activated receptor-gamma/retinoid X receptor-alpha) and the DNA response elements DR1 and 
DR2 motifs within the miR-122 promoter.
198
 Although some preliminary experiments have been 
attempted to determine the ability of 30 to interfere with the stimulatory effect of 5-Aza-dC on 
miR-122 expression, the results have been inconclusive. More work is needed to fully investigate 
if the miR-122 inhibitor 30 acts via the modulation of this regulatory pathway; for example by 
co-treating Huh7 cells with 5-Aza-dC and 30 and by measuring the effects on miR-122 
expression in the miR-122 luciferase assay and by qRT-PCR. 
Gene expression is under the control of a tightly regulated balance, where acetylation of 
lysine residues in core histones promotes a less compact transcriptionally active chromatin, and 
conversely deacetylation leads to a strong compaction between the positively charged histones 
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and the negatively charged DNA, therefore negatively affecting gene transcription. HDAC 
inhibitors, by disturbing this balance, alter the expression of several genes by inducing either 
transcriptional activation or repression.
272
   
Experiments were carried out to investigate whether 30 may act as an HDAC inhibitor 
using the HDAC-Glo assay (Promega). The nuclear proteins from Huh7 cells were extracted 
using the nuclear extraction kit (NE-PER kit, Pierce) and the resulting amount was quantified 
with a Bradford assay. A titration curve was performed with different amounts of nuclear extract 
in order to determine the optimal concentration for the assay. The largest dynamic range was 
obtained with 10 g/mL of nuclear extract; this concentration was then used in subsequent 
analysis. The Huh7 nuclear extract was diluted to 10 g/mL in HDAC-Glo buffer, added to the 
wells containing increasing concentrations of 30 or TSA (HDAC inhibitor control, trichostatin 
A), and the plate was incubated at rt for 30 min. The HDAC-Glo reagent was added, the plate 
was quickly shaken to ensure proper mixing of the reagents, further incubated for 45 min, and 
the luminescence was measured. Figure 4.15 showed that 30 did not induce any HDAC 
inhibition even at high concentrations, contrary to the TSA control, which displayed >90% 
inhibition at 1 M. 
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Figure 4.15: Analysis of small molecule 30 interference with HDAC activity. 
HDAC-Glo assay of Huh7 nuclear extract treated with increasing concentration of A. the HDAC inhibitor TSA 
(positive control), and B. the miR-122 inhibitor 30. Data were normalized to the DMSO control. Experiments were 
performed in triplicate and the standard deviations of the three independent assays were calculated 
4.4 ANALYSIS OF THE SMALL MOLECULE INTERACTION WITH THE MIR-122 
PROMOTER 
4.4.1 Development of a Reporter Construct to Study miR-122 Promoter 
Activity 
Since the inhibitor 30 does not seem to regulate epigenetic events involved in miR-122 
regulation, it was hypothesized that it may target a transcription factor necessary for the 
expression of the miR-122 gene. To test this theory, a reporter plasmid containing a firefly 
luciferase gene under the control of the miR-122 promoter was constructed in collaboration with 
Colleen Connelly.
189
 The miR-122 promoter was inserted into the pGL3-basic plasmid 
(Promega) within the multi-cloning site upstream of the firefly luciferase gene (Figure 4.16). The 
plasmid was sequentially digested with KpnI and XhoI at 37 °C for 2 h and gel purified. The 
promoter region of the miR-122 gene was PCR amplified from Huh7 genomic DNA using 
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primers containing the restriction sites for KpnI (forward primer, Table 4.4; IDT DNA) and XhoI 
(reverse primer, Table 4.4; IDT DNA).
189
 The PCR product was gel purified and similarly 
digested with KpnI and XhoI. The miR-122 promoter insert was then ligated with the digested 
pGL3-basic backbone at 4 °C overnight, followed by treatment of the ligation reactions with 
NheI to remove any re-circularized plasmid that did not contain the insert, and were subsequently 
transformed into Top 10 cells. The resulting colonies were analyzed by PCR screening to detect 
the presence of the miR-122 promoter insert, and further DNA sequencing validated the 
construction of the pGL3-basic-miR122promoter. 
 
Figure 4.16: Vector map of the pGL3-basic plasmid (left) and the pRL-TK plasmid (right) (Promega). 
The miR-122 promoter sequence was inserted in the multi-cloning site upstream of the firefly luciferase gene 
between the KpnI and XhoI restriction sites to create the reporter construct pGL3-basic-miR122 promoter.  
 
The pGL3-basic-miR122promoter and the parent construct pGL3-basic were transfected 
in Huh7 cells in conjunction with the pRL-TK plasmid, which encodes the Renilla luciferase and 
was used as a transfection control; and a Dual Luciferase assay was performed after 48 h 
incubation. As expected, almost no luminescence was observed for the control pGL3-basic 
reporter (Figure 4.17A), which does not possess any promoter. In the contrary, high level of 
luminescence was detected in cells transfected with the pGL3-basic-miR122promoter (Figure 
4.17A), which is consistent with the elevated levels of miR-122 in Huh7 cells. Then the ability of 
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the small molecule 30 to inhibit the activity of the miR-122 promoter was evaluated using the 
luciferase reporter construct newly established. Huh7 cells were co-transfected with the pRL-TK 
and the pGL3-basic-miR122promoter plasmids using lipofectamine 2000, following transfection 
the cells were treated with 30 (10 M) or DMSO (0.1% final concentration) for 48 h and 
analyzed with a Dual Luciferase assay (Figure 4.17B). Treatment with 30 resulted in a 60% 
decrease in firefly luciferase expression, indicating that the mode of action of the inhibitor 30 
relies, in part, on its inhibitory effect on the miR-122 promoter. This result is in agreement with 
the pri-miR-122 quantification (Figure 3.4) and recovery of luciferase silencing through pre-
miR-122 transfection (Figure 4.1). 
 
Figure 4.17: Investigation of the miR-122 promoter activity. 
A. Dual Luciferase assay of Huh7 cells co-transfected with pRL-TK (transfection control) and pGL3-basic or 
pGL3basic-miR122-promoter using Lipofectamine 2000. B. Dual Luciferase assay of Huh7 cells co-transfected with 
the pRL-TK and the pGL3basic-miR122-promoter plasmids and treated with DMSO or 30 (10 M) for 48 h. All 
experiments were conducted in triplicate. The error bars represent the standard deviation from three independent 
experiments 
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4.4.2 Analysis of Potential Interaction between the Inhibitor 30 and known 
miR-122 Transcription Factors 
After confirming that 30 is inhibiting the activity of the miR-122 promoter, a more 
detailed study was performed to investigate the potential interaction between 30 and one of the 
miR-122 transcription factors. Five liver-enriched transcription factors, HNF1α, HNF3β, 
HNF4α, HNF6, and C/EBPα have been reported to regulate miR-122 transcription.188-190 In 
addition, it was demonstrated that HNF1α, HNF3β, HNF4α, and HNF6 directly bind to the miR-
122 promoter at their corresponding binding sites shown in Figure 4.18. In order to study the 
effect of 30 on each individual transcription factor, it was first attempted to construct 
overexpression vectors for the five transcription factors that would be co-transfected with the 
pGL3-basic-miR122promoter in Huh7 cells. RNA from Huh7 cells was isolated using TRIzol 
reagent (Life Technologies) and reverse transcribed with the iScript cDNA kit (BioRad). PCR 
amplification of the transcription factors was performed with the corresponding primers but 
systematically failed to deliver the expected PCR products. Another strategy was then adopted 
which consisted in mutating the binding sites for the transcription factors in the miR-122 
promoter. New primers were designed in order to introduce specific mutation within the miR-
122 promoter sequence using site directed mutagenesis.
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The primers (Table 4.5) were designed to introduce the mutation “GCCTAAGGTCG” to 
“GCTCGGAGTCG” within the HNF4α binding site, as it was previously reported to 
significantly decrease the activity of the resulting miR-122 promoter.
188
 The primers (Table 4.5) 
were designed to introduce the following mutation within the HNF6 binding site “ATCGAT” to 
“GACGGG”.190 Since there is an overlap between the binding sites for the transcription factors 
 278 
HNF1α and HNF3β, the mutatation was introduced at the three overlapping nucleotides “GTT” 
to “CAA” as previously reported (primers see Table 4.5).188 
In addition, the sequence of the miR-122 promoter was analyzed using a publicly 
available database (http://www.cbrc.jp/research/db/TFSEARCH.html) to identify the putative 
binding sites for additional transcription factors. Since the AP-1 transcription factor was 
predicted to bind to the miR-122 promoter (binding site shown in orange in Figure 4.18), a 
pGL3-basic-miR-122promoter containing a mutated AP-1 binding site was also constructed, 
using the primers (Table 4.5) to mutate the sequence “GAC” to “TAA”. Following PCR 
amplification of the pGL3-basic-miR-122promoter with the various sets of primers, designed to 
introduce specific mutations within the promoter, the PCR reactions were treated with DpnI to 
ensure proper removal of any parental DNA. The digested products were then transformed in 
Top 10 cells, and the presence of the desired mutations was confirmed by sequencing. Although, 
different conditions were tested (various temperatures) for the amplification of the promoter 
containing mutations within the HNF6 binding site, the correctly mutated promoter could not be 
constructed. 
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- 496 GAATGCATGGTTAACTACGTCAGAAATGACCAGTTCAAGAGGAGAATGAG 
- 446 ATTGGCTTCCAAATGTTGGTCAAGAGCTCTACGTAGCATGAGCCAAGGAT  
- 396 CTATTGAACTTAGTAGGCTCCTGTGACCGGTGACTCTTCTGTCTCTAGAA 
- 346 ATCTGGGGAGGTGACCAGGTCATACATGGCAGTCTTCCCGTGAGGAACGT 
- 296 TAAACTGGTTGGAAGTTGGGGTTCTGAGGGGAAGGTGTATTCACTAGGTG 
- 246 ACCTGTCTTCTCTGCCTCGGTGGCCTCCATGGCTGCCTGCTGGCCGCACA 
- 196 CCCCCACTCAGCAGAGGAATGGACTTTCCAATCTTGCTGAGTGTGTTTGA 
- 146 CCAAAGGTGGTGCTGACTTAGTGGCCTAAGGTCGTGCCCTCCCTCCCCCA 
- 96  CTGAATCGATAAATAATGCGACTTATCAGAAAGAGAAAGAATTGTTTACT 
- 46 TTTAAACCCTGGATCCCATAAAGGGAGAGGGGAGAGGCCTAAAGCCACAG 
+ 5 AAGCTGTGGAAGGCGCCATCCTGCCTGCCACAGGAAGGGCCTTGGACTGA 
+ 55 GAGGACCGGAGCTGACTGGGGGTAAGTGCGGCTCTCCCCCGGCGCCTGCC 
+105 GACCCCCCTGAGTGATCAGGCCGTTCTTTGGGGTGGCCGCTGACCGAGAA 
+ 155 ATGACGGGAGGCTCGAG 
TSS 
TATA-box 
A. 
B. 
 
Figure 4.18: Transcription factor analysis. 
A. Sequence of the miR-122 promoter. The binding sites for the transcription factors are indicated in color:  DR1 is 
shown in light blue, DR2 is shown in grey, AP-1 is shown in orange, HNF4α is shown in green, HNF6 is shown in 
blue, HNF3β is shown in red, and HNF1α in magenta. TSS indicates the transcription start site. Figure adapted from 
J. Hepatol., 52, Li, ZY; et al, Positive regulation of hepatic miR-122 expression by HNF4α, 602. Copyright (2011), 
with permission from Elsevier. B. Representation of the miR-122 promoter, the binding sites for the transcription 
factors are shown in color, and the locations of the mutation are indicated in yellow. 
 
 
 
Once the three mutated miR-122 promoter constructs were established, they were 
individually co-transfected in Huh7 cells with the control plasmid pRL-TK. All the mutated 
constructs caused significant reductions in activity compared to the parent reporter pGL3-basic-
miR-122promoter (Figure 4.19A), suggesting that the interactions between the transcription 
factors and their corresponding promoters were efficiently abrogated by the introduction of 
mutations. It is of note that the inhibitor 30 showed a stronger effect on the pGL3-basic-miR-
122promoter activity in Figure 4.17 than in Figure 4.19. Although 30 consistently elicited a 
reduction in the miR-122 promoter activity, the response was more or less pronounced (40-70% 
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reduction) and might be explained by day-to-day variations. Then, the ability of 30 to selectively 
interfere with one of these transcription factors was investigated. Huh7 cells were co-transfected 
with pRL-TK and either the parent plasmid pGL3-basic-miR122promoter or one of the mutated 
reporter constructs and treated with the inhibitor 30 (10 μM) or DMSO (0.1% final DMSO 
concentration) for 48 h. Figure 4.19B shows that 30 was still able to inhibit the activity of the 
mutated miR-122 promoters, suggesting that the cellular target of 30 may not be the transcription 
factor AP-1, HNF1α, HNF3β, or HNF4α. The expectation was that if a transcription factor is 
targeted by 30, mutation of its corresponding binding site within the miR-122 promoter would 
relieve the effect of the transcription factor studied and alleviate the inhibitory activity of 30. 
Mutations within the binding sites of HNF1α/HNF3β and HNF4α yielded significant reductions 
in the promoter activity (≥70%), whereas a moderate decrease in activity was observed for the 
promoter containing a mutated AP-1 binding site (Figure 4.19A). The analysis of the putative 
binding sites for AP-1 revealed two potential binding sites for AP-1 within the miR-122 
promoter. Only the binding site predicted with the highest confidence score (95%) was mutated 
(shown in orange in Figure 4.18). An additional binding site for AP-1 was predicted, with a 
lower score (87%), which overlaps with DR1 (shown in light blue in Figure 4.18). A new 
reporter plasmid would need to be constructed containing mutations within both AP-1 binding 
sites, to see if that further diminishes the activity of the miR-122 promoter. It would be similarly 
interesting to combine the mutations within the miR-122 promoter. For example, additional 
reporters can be constructed that contain either two or multiple mutations within the miR-122 
promoter; a reporter encompassing mutations within all the binding sites would provide a control 
for the background level of promoter activity.  
 
 281 
A. B. 
0 
20 
40 
60 
80 
100 
120 
miR122               
promoter 
AP-1 mutant HNF1/3 
mutant 
HNF4 
mutant 
R
L
U
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
DMSO 30 
R
L
U
 
pGL3-miR122 promoter 
AP-1 mutant 
HNF3/1 mutant 
HNF4 mutant 
 
Figure 4.19: Investigation of the potential inhibition of miR-122 transcription factors by 30. 
A. Dual Luciferase assay of Huh7 cells co-transfected with pRL-TK (transfection control) and the miR-122 
promoter reporter constructs with mutated binding sites corresponding to the transcription factors AP-1, 
HNF1α/HNF3Β, and HNF4α. B. Dual Luciferase assay of Huh7 cells co-transfected with pRL-TK (transfection 
control) and the three mutated miR-122 promoter reporter constructs and treated with DMSO or the miR-122 
inhibitor 30 (10 μM). The data were normalized to the DMSO control. All experiments were conducted in triplicate. 
The error bars represent the standard deviation from three independent experiments.  
 
Given there is no consensus in the literature regarding the binding site of C/EBPα within 
the miR-122 promoter, the previous strategy is not applicable to study the ability of 30 to 
interfere with this transcription factor. Instead, it could be attempted to silence C/EBPα either 
with an siRNA or an shRNA,
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 and to evaluate the effect of 30 on the miR-122 promoter 
following C/EBPα knockdown. To determine whether the inhibitor 30 regulates miR-122 
expression acts through the regulation of PPARγ/RXRα pathway,198 additional miR-122 
promoter plasmids could be constructed that contain mutations within the DR1 and DR2 binding 
sites (alone or in combination).  
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4.5 SUMMARY AND OUTLOOK 
Preliminary data indicated that the miR-122 inhibitor 30 acts by blocking the 
transcription of the miR-122 gene, but its precise mode of action remains to be deciphered. Small 
molecule miR-122 inhibitors represent potential new antiviral agents for the treatment of HCV, 
thus the elucidation of the molecular mechanisms of the miR-122 inhibitor 30 could provide new 
drug targets. The extensive SAR investigation of 30 delivered crucial knowledge about positions 
in the molecule that could be modified without causing a loss in the miR-122 inhibitory activity. 
Two photoprobes were synthesized that displayed satisfactory miR-122 inhibition and were 
substituted with an alkyne motif and either an arylazide (367) or a benzophenone (377) 
photoreactive groups. The arylazide analog 394 was designed to provide a negative control, 
presenting the same functionalities that the active probe 367 but no inhibitory activity. 
Photoaffinity labeling experiments were performed in Huh7 cells that enabled the detection of 
two fluorescently-labeled target proteins. 
Several strategies were employed to purify the target proteins, such as biotin-streptavidin 
pull-down, immunopurification with a FITC-probe and an anti-FITC antibody, and using 2-D 
gel. Following 2-D gel purification, the fluorescently-labeled proteins were isolated and 
submitted for mass spectrometry analysis. The most probable target protein identified in 3 out 4 
submissions was -tubulin. However, knockdown experiments with a -tubulin siRNA did not 
show any effect on miR-122 expression. Unfortunately, despite considerable optimization of 
each purification method attempted, the efforts to isolate pure target proteins remained 
unsuccessful. An alternative approach may be attempted in the future which would require the 
synthesis of a new biotin derivative substituted with a selective cleavable linker, allowing for the 
release of the target proteins under specific and mild elution conditions. 
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A luciferase-based reporter construct was established to investigate the effect of 30 on the 
miR-122 promoter. The compound 30 inhibited the activity of the miR-122 promoter but did not 
seem to target any of the transcription factors tested AP-1, HNF1α, HNF3β, or HNF4α. 
Additional reporters will be established in the future, to evaluate the ability of 30 to interfere 
with the transcription factors C/EBPα, HNF6, and the PPARγ/RXRα pathway. Furthermore, 
selectivity studies using diverse engineered promoters (i.e. pGL4-basic-miR-21 promoter) should 
be performed to investigate the selectivity profile of 30 and further assess its effect on 
transcription. 
4.6 EXPERIMENTALS 
Cell culture. Experiments were performed using the Huh7 cell line (gift from Dr. Asokan, UNC) 
cultured in Dulbecco’s Modified Eagle Medium (DMEM; Hyclone) supplemented with 10% 
Fetal Bovine Serum (FBS; Seradigm catalog number 97068-085, lot #093B13) and 2% 
penicillin/streptomycin (VWR) and maintained at 37 °C in a 5% CO2 atmosphere. Huh7-
psiCHECK-miR122 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; 
Hyclone) supplemented with 10% fetal bovine serum (FBS; Seradigm), 500 μg/mL of G418 
(Sigma Aldrich), and 2% penicillin/streptomycin (VWR) and maintained at 37 °C in a 5% CO2 
atmosphere. 
Target Identification Experiments for the miR-122 Inhibitor 30 
Rhodamine labeling and SDS-PAGE analysis. Huh7 cells were passaged into 10 cm plates and 
were grown to 80% confluency. The media was removed and the cells (in 9.95 mL DMEM 
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media, antibiotics-free) were treated with either DMSO (50 L; 0.5% DMSO final 
concentration), the miR-122 inhibitor 30 (50 M, 50 L of a 10 mM DMSO stock), the small 
molecule probes 367 and 377 (10 M, 50 L of a 2 mM DMSO stock), the inactive probe 394 
(10 M, 50 L of a 2 mM DMSO stock), or a combination of the probe 367 (10 M) and the 
miR-122 inhibitor 30 (50 μM). After an overnight incubation at 37 °C, the media was removed, 
the cells were washed with PBS (1 mL), and irradiated in PBS (5 mL) on a transilluminator (365 
nm, 25 W, UVP TFML-20) for 10 min. The PBS was removed, mammalian protein extraction 
buffer (1 mL, GE Healthcare) was added, the plates were shaken on ice for 10 min, the cells 
were detached by pipetting them up and down, transferred to a microcentrifuge tube, and pelleted 
by centrifugation at 12,000 x g for 20 min at 4 °C. The supernatants were collected, the protein 
concentrations were determined with a Bradford assay (absorbance measured at 595 nm on a 
Tecan M1000), and an equal amount of proteins (50 μg) for each sample was treated with 16 μL 
of freshly prepared “click reaction cocktail”146 (see appendix 6.3.1) containing the rhodamine-
azide 396. The click reaction was performed at room temperature for 2 h. The proteins were 
subsequently isolated via acetone precipitation, 400 L of prechilled acetone was added into the 
click reaction mixtures, which were then incubated for 60 min at −20 °C. The proteins were 
pelleted by centrifugation (13,000 x g for 10 min at 4 °C), the supernatants were discarded and 
the pellets were washed twice with prechilled MeOH (200 μL, 4 min centrifugation at 10,000 x 
g) and finally air dried at rt for 10 min. The pellets were re-suspended in PBS (40 μL), 
denaturing loading dye (5x) was added (10 μL) and the samples were heated to 95 °C for 5 min. 
The samples (40 μL) were then analyzed by a 12% SDS-PAGE (4% stacking gel) at 60 V for 30 
min followed by 150 V for 90 min. The fluorescence was detected on a ChemiDoc (BioRad, 
setting: Filter 3: 605/50 nm, light: green epi illumination).  
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Isolation of the target proteins via biotin-streptavidin affinity purification. Huh7 cells were 
passaged into 10 cm plates and grown to 80% confluency. The media was removed, and the cells 
(in 9.95 mL DMEM media, antibiotics-free) were treated with the aryl azide 367 (10 μM, 50 L 
of a 2 mM DMSO stock) and incubated overnight. The media was removed, the cells were 
washed with PBS (1 mL), irradiated in PBS (5 mL) on a transilluminator (365 nm, 25 W, UVP 
TFML-20) for 10 min. The PBS was removed, trypsin (1 mL) was added, the cells were 
detached by pipetting them up and down, transferred to a microcentrifuge tube, pelleted by 
centrifugation (3,000 x g for 10 min), and lysed using mammalian protein extraction buffer (50 
μL, GE Healthcare). The cells were quickly vortexed, and incubated on ice for 20 min, vortexing 
every 5 min. The lysate was centrifuged (12,000 x g for 30 min at 4 °C), the supernatant was 
collected and the protein extract was quantified by a Bradford assay. The click reaction was then 
performed using 200 μg of total protein and 66 μL of freshly prepared “click reaction cocktail”146 
(see appendix 6.3.1) containing the rhodamine-azide 396. Following a 2 h incubation at room 
temperature, the proteins were isolated via acetone precipitation, as previously described. The 
proteins were then re-suspended in 50 μL of 0.1% SDS in PBS. The samples were treated with 
80, 100, 120, or 160 μL of streptavidin-agarose resin at 4 °C overnight. The samples were 
centrifuged at 10,000 x g for 5 min, the supernatants were discarded, and the resins were 
sequentially washed with 0.1% SDS in PBS buffer (100 μL) or PBS buffer (3 x 100 μL, 10,000 x 
g centrifugation between each wash). The supernatants were discarded and the pellets were re-
suspended in 35 L PBS. SDS-loading dye (5x, 7 L) was added and the samples were 
denatured at 95 °C for 15 min. The samples (40 L) were analyzed on a 12% SDS-PAGE (4% 
stacking gel) at 60 V for 40 min, followed by 150 V for 70 min. The gel was silver stained using 
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a Pierce Silver Stain Kit (Thermo Scientific) according to the manufacturer’s protocol, and 
imaged on a ChemiDoc (BioRad, setting: Filter 1: standard, light: white Trans illumination). 
 
2-D gel electrophoresis of rhodamine-labeled target proteins. Huh7 cells were passaged into 
10 cm plates and grown to 80% confluency. The media was removed, and the cells (in 9.95 mL 
DMEM media, antibiotics-free) were treated with the aryl azide probe 367 (10 μM, 50 L of a 2 
mM DMSO stock) and incubated overnight at 37 °C. The media was removed, the cells were 
washed with PBS (1 mL), and irradiated in PBS (5 mL) on a transilluminator (365 nm, 25 W, 
UVP TFML-20) for 10 min. The PBS was removed, mammalian protein extraction buffer (1 mL, 
GE Healthcare) was added, the plates were shaken on ice for 10 min, the cells were detached by 
pipetting them up and down, transferred to a microcentrifuge tube, and pelleted by centrifugation 
at 12,000 x g for 20 min at 4 °C. The supernatants were collected, and the protein concentrations 
were determined with a Bradford assay (absorbance measured at 595 nm on a Tecan M1000). 
The click reaction was performed using 100 μg of total protein and 33 μL of freshly prepared 
“click reaction cocktail”146 containing the rhodamine-azide 396 (see appendix 6.3.1). Following 
a 2 h incubation at room temperature, the proteins were isolated via acetone precipitation, as 
previously described. The proteins were then re-suspended in 125 μL of rehydration buffer 
(ReadyPrep 2-D Starter Kit; BioRad) for analysis by 2-D gel electrophoresis. The samples were 
loaded onto 7 cm pH 4-7 ReadyStrip IPG strips (BioRad) through passive in-gel rehydration for 
24 h at room temperature. The proteins were then separated by IEF on a PROTEAN IEF Cell 
(BioRad) according to the ReadyPrep 2-D Starter Kit manufacturer protocol (250 V, 20 min, 
linear ramp; 4,000 V, 2 hr, linear ramp; 4,000 V, 10,000 V/hr, rapid ramp; total run time of 5-6 
h). The IPG strips were equilibrated for 10 min in Equilibration Buffers 1 and 2 (ReadyPrep 2-D 
Starter Kit), and loaded onto a pre-cast 12% SDS-PAGE (pre-cast gel 12% Mini-PROTEAN 
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TGX Precast Gel, BioRad). The proteins were then analyzed by SDS-PAGE at 200 V for 50 min. 
The fluorescence was visualized on a ChemiDoc (BioRad, settings: Filter 3: 605/50 nm, light: 
green epi illumination). The gels were then either fixed (6:3:1 water:ethanol:acetic acid, 20 min), 
stained with coomassie blue, or silver stained (Pierce Silver Stain Kit; Thermo Scientific) 
according to the manufacturers’ protocols.  
 
Western blot for -tubulin. Huh7 cells were treated with the photoprobe 367 (10 μM, 50 L of 
a 2 mM DMSO stock), followed by UV irradiation, lysis, click reaction with the rhodamine-
azide 396, and acetone precipitation as described previously. The samples were then analyzed by 
either a 12% SDS-PAGE (60 V for 40 min, followed by 150 V for 70 min) or a 2-D gel 
according to the procedure described previously. The fluorescence was imaged on a Typhoon 
7000 phosphorimager (laser 580 nm). A Western blot was then performed for each gel. The 
proteins were transferred to a membrane (80 V for 1.5 h in transfer buffer). The membrane was 
then washed twice with 20 mL ice-cold TBST. The membrane was incubated with blocking 
buffer (2.5 g powdered milk in 50 mL TBST) for 1 h at rt. The membrane was washed twice 
with 20 mL ice-cold TBST. The membrane was separated (with a scalpel) into two parts right 
under the 46 kDa molecular weight line. The upper part of the membrane (>50 kDa) was 
incubated with polyclonal anti--tubulin antibody (1:1,000 dilution, Santa Cruz Biotechnology), 
and the lower part of the membrane (<50 kDa) was incubated with anti-GAPDH primary 
antibody (1:1,000 dilution, Santa Cruz Biotechnology) at 4 °C overnight. The membranes were 
washed twice with TBST, and incubated with a goat-anti-rabbit-IgG-HRP (1:1,000 dilution, 
Santa Cruz Biotechnology) secondary antibody at rt for 1 h. The membranes were washed 3 
times with TBST (15 mL) and twice with TBS (15 mL). The blots were then developed by HRP 
colorimetric staining. A solution containing the detection reagent (24 mg of 4-chloro-1-naphthol 
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(4CN, BioRad) in 8 mL MeOH) was added to a cold peroxide-containing solution (40 mL TBS, 
240 L 3% cold hydrogen peroxide) and quickly added to the membranes. The membranes were 
incubated with the development reagents for 20 min at rt, and imaged on a Typhoon 7000 
phosphorimager (blue laser 473 nm).  
Anti-fluorescein antibody purification of FITC-labeled target proteins: with protein A/G 
resin. Huh7 cells were passaged into 10 cm plates and grown to 80% confluency. The media was 
removed, and the cells (in 9.95 mL DMEM media, antibiotics-free) were treated with the aryl 
azide 367 (10 μM, 50 L of a 2 mM DMSO stock) or the negative control 394 (10 μM, 50 L of 
a 2 mM DMSO stock) and incubated overnight at 37 °C. The media was removed, the cells were 
washed with PBS (1 mL), and irradiated in PBS (5 mL) on a transilluminator (365 nm, 25 W, 
UVP TFML-20) for 10 min. The PBS was removed, trypsin (1 mL) was added, the cells were 
detached by pipetting them up and down, transferred to a microcentrifuge tube, pelleted by 
centrifugation (3,000 x g for 10 min), and lysed using mammalian protein extraction buffer (480 
μL, GE Healthcare) supplemented sodium fluoride (NEB, 10 L of 500 mM stock) and sodium 
orthovanadate (NEB, 10 L of 100 mM stock). The cells were quickly vortexed, and incubated 
on ice for 20 min, vortexing every 5 min. The lysate was centrifuged (12,000 x g for 30 min at 4 
°C), the supernatant was collected and the protein extract was quantified by a Bradford assay. 
The click reaction was then performed using 350 μg of protein (diluted with the corresponding 
amount of PBS to have a total volume of 350 L) and 115 μL of freshly prepared “click reaction 
cocktail”146 (see appendix protocol 6.3.1) containing the fluorescein-azide 193. Following a 2 h 
incubation at room temperature, the proteins were isolated via acetone precipitation as previously 
described. The pellets were then re-suspended in 420 L TBS buffer, the anti-fluorescein 
antibody (Sigma) was added (7 L), and the samples were slowly agitated overnight at 4 °C. The 
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resin was quickly washed before being used: an aliquot of 90 L agarose-proteins A/G beads 
(Sigma) was transferred to a microcentrifuge tube, pelleted by centrifugation at 1,000 x g for 1 
min, the supernatant was removed (77.5 L), and the same volume of PBS (77.5 L) was added 
to re-suspend the beads. Following the overnight incubation, the samples were treated with the 
protein A/G resin (42 L) and incubated for 2 h at 4 °C. The mixtures were transferred to spin 
columns (0.45 m PVDF microcentrifugal filter, Thermo Scientific) centrifuged for 10 min at 
2,000 x g, and the flow-through was discarded. The resins were washed successively with 400 
L buffer A (200 L of 1 M Tris.HCl pH 7.4, 1.67 mL 3 M NaCl to 10 mL in H2O) and 400 L 
buffer B (200 L of 1 M Tris.HCl pH 8, 100 L of MgCl2 to 10 mL in H2O), followed by 
centrifugation for 8 min at 3,000 x g. The flow-through was discarded, the columns were placed 
in a clean tube, 40 L of PBS and 10 L of 5x SDS loading buffer were added. The columns 
were capped, heated to 95 °C for 15 min, and centrifuged for 10 min at 5000 x g. After allowing 
the elution fractions to cool down to rt, the fractions (40 L) were analyzed by SDS-PAGE 
(12%; 60 V for 60 min followed by 150 V for 90 min). The gel was imaged on a Typhoon 7000 
phosphorimager (green laser: 532 nm) and coomassie stained. 
Immunopurification of the target proteins using the fluorescein azide 193 and anti-FITC 
antibody. Huh7 cells were passaged into 10 cm plates and grown to 80% confluency. The media 
was removed and the cells (in 9.95 mL DMEM media, antibiotics-free) were treated with the 
probes 367 and 394 (10 M, 50 L of a 2 mM DMSO stock) and incubated overnight at 37 °C. 
The media was removed, the cells were washed with PBS (1 mL), and irradiated in PBS (5 mL) 
on a transilluminator (365 nm, 25 W, UVP TFML-20) for 10 min. The PBS was removed, 
mammalian protein extraction buffer (1 mL, GE Healthcare) was added, the plates were shaken 
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on ice for 10 min, the cells were detached by pipetting them up and down, transferred to a 
microcentrifuge tube, and pelleted by centrifugation at 12,000 x g for 20 min at 4 °C. The 
supernatants were collected, and the protein concentrations were determined with a Bradford 
assay (absorbance measured at 595 nm on a Tecan M1000). The click reaction was performed 
using 500 μg of total protein (diluted with the corresponding amount of PBS to have a total 
volume of 500 L), and 165 μL of freshly prepared “click reaction cocktail”146 (see appendix 
6.3.1) containing the fluorescein-azide 191. Following a 2 h incubation at room temperature, a 
methanol precipitation was performed. The click reaction mixtures were treated with 4 volumes 
of MeOH (2.6 ml), 1 volume of chloroform (660 μl), and 3 volumes of H2O (2 ml). The tubes 
were quickly vortexed and centrifuged for 1 min at 13,000 x g at rt. The upper phase was 
removed and discarded, 3 volumes of MeOH (2 ml) were added, the tubes were vortexed, and 
centrifuged at 13,000 x g for 2 min at rt. The supernatants were removed, the pellets were 
washed twice with MeOH (200 μL, centrifuged for 1 min at 13,000 x g) and air dried. The pellets 
were re-suspended in 300 L IP Lysis buffer (direct IP kit, Pierce) supplemented with 6 L of 
each protease inhibitor sodium fluoride and sodium orthovanadate (NEB), transferred to the 
columns containing the anti-FITC antibody resin, and slowly agitated overnight at 4 °C. The 
anti-FITC antibody functionalized resin was prepared according to the supplier’s protocol. 
Briefly, 20 μL of AminoLink plus coupling resin (Pierce) was transferred to a spin column 
(provided in the kit), the column was centrifuged at 1,000 x g for 1 min, the flow-through was 
discarded, the resin was washed twice with 200 μL of coupling buffer, and centrifuged at 1,000 x 
g for 1 min. Then the resin was treated with 20 μL of anti-FITC antibody, 3 μL of 
cyanoborohydride, incubated at rt for 2 h, and thoroughly washed. Following an overnight 
incubation, the columns containing samples were centrifuged at 1,000 x g for 4 min and washed 
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according to the supplier’s protocol. The samples were washed with 200 μL of IP lysis/wash 
buffer (4 x), centrifuged at 1,000 x g for 1 min, and once with 100 μL of conditioning buffer. The 
elution buffer (50 L) was added, the samples were incubated for 10 min at rt, and the proteins 
were then eluted by centrifugation at 1,000 x g for 2 min. SDS loading dye (5x, 12 L) was 
added to the elution fractions, and the resulting mixtures were heated to 95 °C for 5 min, and 
analyzed on a 12% SDS-PAGE (60 V for 40 min followed by 150 V for 80 min). The gel was 
imaged on a ChemiDoc (BioRad, setting: Filter 4: 530/28 nm, light: blue epi illumination) and 
coomassie stained. 
Investigation of -tubulin as a potential target protein. Huh7-psiCHECK-miR122 cells were 
seeded at a density of 14,000 cells per well in a white clear-bottom 96-well plate (Greiner), in 
200 μL media (DMEM, no-antibiotics) and grown overnight. The media was removed and 170 
μL OptiMEM (Life Technologies) was added. The cells were transfected with 50 or 100 pmol of 
the -tubulin siRNA (class 4B, Sigma Aldrich, NM_006088) using XtremeGENE (Roche). For 
the transfection, 3 different transfection mixes were prepared containing (per reaction): mix 1 
xtremegene only (control): 0.8 μL XtremeGENE and OptiMEM (the volume was adjusted to 
obtain a total volume of 30 μL). Mix 2 50 pmol treatment: 0.8 μL XtremeGENE, 1 μL of siRNA 
(50 μM DEPC water stock), and OptiMEM (the volume was adjusted to obtain a total volume of 
30 μL). Mix 3 100 pmol treatment: 0.8 μL XtremeGENE, 2 μL of siRNA (50 μM DEPC water 
stock), and OptiMEM (the volume was adjusted to obtain a total volume of 30 μL). The siRNA 
was annealed by heating to 80 °C for 10 min prior to be used in the transfection mix. The mixes 
were incubated at rt for 20 min, and added to the cells (30 μL/well). The cells were then 
incubated for 4 h at 37 °C, the media was replaced with DMEM (200 μL, no antibiotics), and the 
cells were incubated for 48 h, followed by analysis with a Dual Luciferase Reporter Assay Kit 
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(Promega) using 30 L passive lysis buffer and 50 L of each luciferase reagent. The 
luminescence was measured on a Tecan M1000 platereader with a measurement time of 1 s and a 
delay time of 2 s. All experiments were performed in triplicates, for each well the Renilla readout 
was normalized to the firefly readout, and the average for each sample was further normalized to 
the XtremeGENE (no siRNA) control. 
HDAC-Glo assay:  The nuclear proteins from Huh7 cells were extracted using the NE-PER 
nuclear and cytoplasmic kit (Pierce), and the concentration was determined with a Bradford 
assay (absorbance measured at 595 nm on a Tecan M1000). The proteins were diluted to 15 
μg/mL in HDAC-Glo buffer (Promega). Serial dilutions of TSA were prepared as follow: 
200 μM solution: add 4 μL of a 1 mM DMSO stock to 16 μL HDAC-Glo buffer 
2 μM solution: add 1 μL of the 200 μM solution to 99 μL HDAC-Glo buffer 
200 nM solution: add 20 μL of the 2 μM solution to 80 μL HDAC-Glo buffer 
40 nM solution: add 20 μL of the 200 nM solution to 80 μL HDAC-Glo buffer 
8 nM solution: add 20 μL of the 40 nM solution to 80 μL HDAC-Glo buffer 
1.6 nM solution: add 20 μL of the 40 nM solution to 80 μL HDAC-Glo buffer 
Serial dilutions of 30 were prepared as follow: 
500 μM solution: add 5 μL of a 10 mM DMSO stock to 95 μL HDAC-Glo buffer 
100 μM solution: add 25 μL of the 500 μM solution to 100 μL HDAC-Glo buffer 
50 μM solution: add 50 μL of the 100 μM solution to 50 μL HDAC-Glo buffer 
25 μM solution: add 50 μL of the 50 μM solution to 50 μL HDAC-Glo buffer 
12.5 μM solution: add 50 μL of the 25 μM solution to 50 μL HDAC-Glo buffer 
6.25 μM solution: add 50 μL of the 12.5 μM solution to 50 μL HDAC-Glo buffer 
3.13 μM solution: add 50 μL of the 6.25 μM solution to 50 μL HDAC-Glo buffer 
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The nuclear extract (10 μL) was added to a white 384-well plate, 10 μL of each compound 
solution was added to the plate (in triplicates), the plate was centrifuged at 1000 x g for 1 min, 
and incubated for 1 h at rt. The HDAC-Glo reagent (20 μL) was added to each well, the plate 
was centrifuged at 1000 x g for 1 min, and incubated in the dark for 20 min at rt. The 
luminescence was measured on a Tecan M1000 platereader with a measurement time of 1 s. All 
experiments were performed in triplicates, and the average for each sample was further 
normalized to the DMSO control. 
Construction of the pGL3-basic-miR122 promoter reporter. The pGL3-basic plasmid (5 μg; 
Promega) was sequentially digested with KpnI (10 units, 100 μL reaction; New England Biolabs) 
and XhoI (10 units, 50 μL reaction; New England Biolabs) at 37 °C for 2 h. The digestion 
product was analyzed on a 0.8% agarose gel (90 V, 40 min), the band corresponding to the 
expected product (4790 bp) was visualized on a transilluminator (365 nm), excised, and gel 
purified using the E.Z.N.A. Gel Extraction Kit (VWR) according to the manufacturer protocol. 
The digested plasmid was eluted in 40 μL milliQ water pre-warmed to 65 °C. The promoter 
region of the miR-122 gene was PCR amplified from Huh7 genomic DNA that was isolated 
using the Trizol Reagent (Life Technologies) according to the manufacturer’s protocol using 
primers containing KpnI (forward primer, Table 4.4) and XhoI (reverse primer, Table 4.4) 
restriction sites. The PCR product was analyzed on a 0.8% agarose gel (90 V, 40 min), the band 
corresponding to the expected product (665 bp) was visualized on a transilluminator (365 nm), 
excised, and gel purified using the E.Z.N.A. Gel Extraction Kit (VWR) according to the 
manufacturer’s protocol. The insert was eluted 30 μL milliQ water pre-warmed to 65 °C, and 
then digested with KpnI (5 units, 50 μL reaction) and XhoI (10 units) at 37 °C for 2 h, followed 
by purification with a QIAquick PCR purification kit (Qiagen). The miR-122 promoter insert 
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was then ligated with T4 DNA ligase (200 units, 10 μL reaction, 1:6 vector/insert ratio; New 
England Biolabs) into the digested pGL3-basic backbone at 4 °C overnight. The ligation 
reactions were treated with NheI (1 unit; New England Biolabs) at 37 °C for 30 min to remove 
any re-circularized plasmid that did not contain insert, and the ligation reactions were 
transformed into Top 10 cells. For the transformation, 1 μL of each ligation reaction was added 
to Top 10 competent cells, that were incubated on ice for 30 min. The cells were then heat-
shocked at 42 °C for 45 s, placed on ice for 2 min, and 500 μL of SOC media was added. The 
cells were incubated at 37 °C for 1 h, and 250 μL of transformation reaction were plated on LB 
agar plates treated with ampicillin. Positive colonies were selected by PCR colony screen using 
the primers described above and construction of the pGL3-basic-miR122 promoter plasmid was 
confirmed by DNA sequencing. 
primers sequence 5' - 3' 
KpnI forward primer AAGGGGTACCGAATGCATGGTTAACTACGTCAG 
XhoI reverse primer AACCCCTCGAGCCTCCCGTCATTTCTCGGTC 
forward sequencing primer CTAGCAAAATAGGCTGTCCC 
Table 4.4: List of primers (IDT) used to construct the miR-122 promoter reporter. 
 
Assessment of the pGL3-basic-miR122 promoter reporter system. Huh7 cells were plated in 
a 96-well plate at 15,000 cells/well in 200 μL media (DMEM, no antibiotics) and were grown 
overnight at 37 °C. The cells were co-transfected with pRL-TK (Promega, 5 ng) and pGL3-basic, 
or pGL3-basic-miR122 promoter (200 ng/well) in triplicate using Lipofectamine 2000 (0.5 
μL/well) in 200 μL OptiMEM for 3 h at 37 °C. The media was removed and replaced with 
DMEM (200 μL) and the cells were incubated at 37 °C for 48 h, before being assayed with a 
Dual Luciferase assay kit (Promega) using 30 L passive lysis buffer and 100 L of each 
luciferase reagent. The luminescence was measured on a Biotek Synergy 4 plate-reader with a 
measurement time of 1 s and a delay time of 2 s. All experiments were performed in triplicates, 
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for each well the firefly readout was normalized to the Renilla readout, and the average for each 
sample was further normalized to the DMSO control. 
Site directed mutagenesis. The mutated miR-122 promoter constructs were obtained via PCR 
amplification of the pGL3-basic-miR-122promoter using the corresponding primers (Table 4.5). 
A 25 μL PCR reaction was set-up for each transcription factor: 1.74 μL of pGL3-basic-miR-
122promoter (5 ng, 2.88 ng/μL stock), 2.5 μL of the forward primer (10 μM stock), 2.5 μL of the 
reverse primer (10 μM stock), 0.5 μL dNTP (10 μM stock), 5 μL Phusion buffer (5x stock), 4.24 
μL H2O, and 1 μL Phusion DNA polymerase (NEB). The PCR amplifications were performed on 
a T100 thermocycler (BioRad) using the following settings:  
- for HNF4α: 95 °C, 5 min; followed by 12 cycles of 95 °C, 1 min; 58 °C, 1 min; 72 °C, 
10 min; 52 °C, 1 min; followed by 72 °C for 30 min. 
- for HNF1α/3: 95 °C, 5 min; followed by 12 cycles of 95 °C, 1 min; 44 °C, 1 min; 72 °C, 
10 min; 32 °C, 1 min; followed by 72 °C for 30 min. 
- for AP-1: 95 °C, 5 min; followed by 12 cycles of 95 °C, 1 min; 44 °C, 1 min; 72 °C, 10 
min; 35 °C, 1 min; followed by 72 °C for 30 min. 
Following PCR amplification, 2.7 μL of CutSmart buffer (NEB) and 0.3 μL of the DpnI 
restriction enzyme (NEB) were added to the PCR reactions, that were further incubated at 37 °C 
for 1 h. The DpnI digested products (2 μL) were then transformed in Top 10 competent cells, as 
previously described, and plated on LB agar plates containing ampicillin. The construction of the 
mutated pGL3-basic-miR122 promoter plasmids was confirmed by DNA sequencing (forward 
sequencing primer: 5' CTAGCAAAATAGGCTGTCCC 3'; IDT DNA). 
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gene sequence 5' - 3' 
HNF4α 
forward AGTGGCTCGGAGTCGTGCCCTCCCTCCCCCACTGAATCG 
reverse CACGACTCCGAGCCACTAAGTCAGCACCACCTTTGGTCAAACACACT 
HNF1α 
and 
HNF3β 
forward AAGAATTCAATACTTTTAAACCCTGGATCCCAT 
reverse AAAAGTATTGAATTCTTTCTCTTTCTGATAAGTCGC 
AP-1 
forward GGTGCTTTATTAGTGGCCTAAGGTCGTGC 
reverse CACTAATAAAGCACCACCTTTGGTCAAACACAC 
HNF6 
forward CCACTGAGACGGGAAATAATGCGACTTATCAGAAAGAGAAAGAATTGTTTACTTTTAAACCCTGGAT 
reverse ATTATTTCCCGTCTCAGTGGGGGAGGGAGGGCACGACC 
Table 4.5: sequences of the primers (IDT) used to introduce mutations within the binding sites of the miR-122 
transcription factors, the sites of mutation are underlined. 
 
Examination of the potential interaction of the small molecule inhibitor 30 with the miR-
122 transcription factors.  Huh7 cells were plated in a 96-well plate at 15,000 cells/well in 200 
μL media (DMEM, no antibiotics), and were grown overnight at 37 °C. The cells were co-
transfected with pRL-TK (Promega, 2 ng) and either the pGL3-basic-miR-122promoter or the 
mutated promoter reporter construct  (200 ng/well) using Lipofectamine 2000 (0.5 μL/well) in 
200 μL OptiMEM. After 2 h incubation, the media was removed and replaced with DMEM (198 
L) supplemented with DMSO or the miR-122 inhibitor 30 (10 M final concentration, 2 L of 
a 1 mM 10% DMSO stock) in triplicate. The cells were incubated at 37 °C for 48 h before being 
assayed using a Dual Luciferase Assay kit (Promega) using 30 L passive lysis buffer and 50 L 
of each luciferase reagent. The luminescence was measured on a Tecan M1000 plate-reader with 
a measurement time of 1 s and a delay time of 2 s. All experiments were performed in triplicates, 
for each well the firefly readout was normalized to the Renilla readout, and the average for each 
sample was further normalized to the DMSO control. 
 
Synthetic Protocols 
All reactions were performed in flame-dried glassware under a nitrogen atmosphere and stirred 
magnetically. Reactions were followed by thin layer chromatography (TLC) using glass-backed 
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silica gel plates (Sorbent technologies, 250 µm thickness). Tetrahydrofuran and DCM were 
obtained from a dry solvent delivery system. MeCN, EtOH, MeOH and pyridine were distilled 
from calcium hydride and stored over 4 Ǻ molecular sieves. Other reagents and solvents were 
obtained from commercial sources (Sigma, VWR, Fisher, Accros), stored under nitrogen and 
used directly without further purification. Yields refer to pure compounds unless otherwise 
stated. Flash chromatography was performed on silica gel (60 Å, 40-63 μm (230 × 400 mesh), 
Sorbtech) as a stationary phase. High resolution mass spectral analysis (HRMS) was performed 
at the University of Pittsburgh on a Q-Exactive (Thermo Scientific) mass spectrometer. The 
1
H 
NMR and 
13
C NMR spectra were recorded on a 300 MHz or a 400 MHz Varian or Brucker NMR 
spectrometers. Chemical shifts are given in δ units (ppm) for NMR spectra. 
N-(4-(tert-Butyl)phenyl)-1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide 
(364). Propargylbromide (0.022 mL, 0.25 mmol) was added to a stirred solution of 237 (46 mg, 
0.14 mmol) and DIPEA (0.036 mL, 0.21 mmol) in DMF (1 mL). The resulting mixture was 
heated to reflux for 5 h, allowed to cool down to rt, and diluted with Et2O (5 mL). The mixture 
was washed with H2O (3 x 5 mL), brine (4 mL), dried over Na2SO4, filtered, and concentrated. 
The residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc 
(4:1) to give 364 as a yellow solid (12 mg, 38%). 
1
H NMR (300 MHz, chloroform-d)  7.50 (dd, 
J = 8.8, 2.3 Hz, 1H), 7.33 (d, J = 2.2 Hz, 1H), 7.24 (d, J = 8.6 Hz, 1H), 6.98 (d, J = 8.6 Hz, 2H), 
6.60 (d, J = 9.0 Hz, 2H), 4.01 (d, J = 2.4 Hz, 2H), 3.36 (t, J = 6.0 Hz, 2H), 2.68 (t, J = 6.3 Hz, 
2H), 2.18 (t, J = 2.4 Hz, 1H), 1.97 - 1.92 (m, 2H), 1.25 (s, 9H). HRMS (ESI
+
) calcd for 
C22H26N2O2S (M+H)
+
 383.5270, found 383.1778. 
N-(4-Acetylphenyl)-1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (365). 
Same procedure as 364 using 238 (456 mg, 1.38 mmol) and propargylbromide (0.221 mL, 2.49 
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mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (2:1) to give 365 as a light brown solid (39 mg, 10%). 
1
H NMR 
(300 MHz, Chloroform-d)  7.82 (d, J = 9.0 Hz, 1H), 7.58 (dd, J = 8.8, 2.4 Hz, 1H), 7.44 (dd, J = 
2.3, 1.2 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 8.7 Hz, 2H), 6.63 (d, J = 8.8 Hz, 1H), 4.00 
(d, J = 2.4 Hz, 2H), 3.37 (t, J = 6.0 Hz, 2H), 2.71 (t, J = 6.4 Hz, 2H), 2.53 (s, 3H), 2.19 (s, 1H), 
2.01 - 1.89 (m, 2H). 
N-(4-Azidophenyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (366). Same procedure as 30 
using 385 (606 mg, 1.42 mmol) and K2CO3 (3.7 g, 27.1 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to 
afford 366 as a yellow solid (449 mg, 96%). 
1
H NMR (300 MHz, acetone-d6)  8.65 (s, 1H), 
7.32 - 7.19 (m, 4H), 6.96 (d, J = 8.8 Hz, 2H), 6.44 (d, J = 9.1 Hz, 1H), 5.87 (s, 1H), 3.36 - 3.25 
(m, 2H), 2.67 (t, J = 6.3 Hz, 2H), 1.87 - 1.76 (m, 2H). 
N-(4-Azidophenyl)-1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (367). 
Same procedure as 364 using 366 (30 mg, 0.09 mmol) and propargyl bromide (0.024 mL, 0.18 
mmol) as the starting materials, except the reaction mixture was heated to 50 °C for 2 h. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to 
deliver 367 as an orange solid (15 mg, 45%). 
1
H NMR (300 MHz, acetone-d6)  7.25 (d, J = 8.9 
Hz, 2H), 7.14 - 7.04 (m, 4H), 6.48 (d, J = 8.6 Hz, 1H), 6.00 (s, 1H), 4.41 (d, J = 2.5 Hz, 2H), 
3.39 - 3.30 (m, 2H), 2.76 - 2.66 (m, 2H), 2.05 (m, 1H), 1.89 - 1.84 (m, 2H). HRMS (ESI
+
) calcd 
for C18H17N5O2S (M+H)
+
 368.4328, found 368.1165. 
N-(Perfluorophenyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (368). Same procedure as 30 
using N-(perfluorophenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (9 
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mg, 0.01 mmol) and K2CO3 (50 mg, 0.36 mmol) as the starting materials. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to afford 368 
as a white solid (6 mg, 89%). 
1
H NMR (300 MHz, chloroform-d)  7.47 - 7.42 (m, 2H), 6.42 (d, 
J = 9.3 Hz, 1H), 3.39 (t, J = 5.7 Hz, 2H), 2.77 (t, J = 6.3 Hz, 2H), 1.98 - 1.92 (m, 2H). 
N-(2-Benzoylphenyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (369). Same procedure as 30 
using N-(2-benzoylphenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide 
(57 mg, 0.11 mmol) and K2CO3 (289 mg, 2.09 mmol) as the starting materials. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (1:1) to afford 369 
as a yellow solid (32 mg, 74%). 
1
H NMR (300 MHz, chloroform-d)  9.89 (s, 1H), 7.78 (d, J = 
8.4 Hz, 1H), 7.60 - 7.47 (m, 2H), 7.47 - 7.31 (m, 6H), 7.17 - 7.06 (m, 2H), 6.51 (s, 1H), 3.22 (t, J 
= 6.0 Hz, 2H), 2.45 (t, J = 6.2 Hz, 2H), 1.77 (t, J = 6.4 Hz, 2H). HRMS (ESI
+
) calcd for 
C22H20N2O3S (M+H)
+
 393.4787, found 393.1284. 
N-(4-Benzoylphenyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (371). Same procedure as 30 
using N-(4-benzoylphenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide 
(76 mg, 0.15 mmol) and K2CO3 (407 mg, 2.9 mmol) as the starting materials. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (1:1) to afford 371 
as a light pink solid (21 mg, 40%). 
1
H NMR (300 MHz, chloroform-d)  7.72 (dd, J = 1.8, 4.8 
Hz, 4H), 7.56 (d, J = 5.4 Hz, 2H), 7.53 - 7.42 (m, 4H), 7.18 (dd, J = 2.1, 6.9 Hz, 1H), 6.37 (d, J = 
9.0 Hz, 1H), 3.32 (t, J = 5.7 Hz, 2H), 2.69 (t, J = 5.8 Hz, 2H), 1.90 - 1.86 (m, 2H). HRMS (ESI
+
) 
calcd for C22H20N2O3S (M+H)
+
 393.4787, found 393.1284. 
N-(2-Benzoylphenyl)-1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (372). 
Same procedure as 364 using 369 (130 mg, 0.33 mmol) and propargyl bromide (0.089 mL, 0.68 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
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eluting with hexanes/EtOAc (2:1) to afford 372 as a yellow solid (32 mg, 25%). 
1
H NMR (300 
MHz, acetone-d6)  7.73 - 7.59 (m, 3H), 7.59 - 7.36 (m, 6H), 7.23 (d, J = 8.2 Hz, 1H), 7.12 (s, 
1H), 6.63 (d, J = 8.8 Hz, 1H), 4.12 (s, 2H), 4.04 (t, J = 7.2 Hz, 2H), 3.37 (t, J = 5.2 Hz, 2H), 1.97 
(s, 1H), 1.94 - 1.81 (m, 2H). 
N-(4-Benzoylphenyl)-1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (373). 
Same procedure as 364 using 371 (29 mg, 0.07 mmol) and propargyl bromide (0.02 mL, 0.14 
mmol) as the starting materials. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (3:1) to afford 373 as a yellow solid (32 mg, 48%). 
1
H NMR (300 
MHz, acetone-d6)  7.78 (dt, J = 1.2, 8.1 Hz, 3H), 7.69 - 7.63 (m, 1H), 7.58 (dt, J = 0.6, 6.9 Hz, 
2H), 7.47 (d, J = 8.8 Hz, 2H), 7.22 - 7.13 (m, 2H), 6.49 (d, J = 8.5 Hz, 1H), 6.04 (s, 1H), 4.56 (d, 
J = 2.5 Hz, 2H), 3.34 (t, J = 5.9 Hz, 2H), 2.80 (t, J = 2.5 Hz, 1H), 2.70 (t, J = 6.2 Hz, 2H), 1.84 - 
1.82 (m, 2H). HRMS (ESI
+
) calcd for C25H22N2O3S (M+H)
+
 431.5267, found 431.1442. 
N-(4-Benzoylphenyl)indoline-5-sulfonamide (374). Same procedure as 30 using N-(4-
benzoylphenyl)-1-(2,2,2-trifluoroacetyl)indoline-5-sulfonamide (65 mg, 0.13 mmol) and K2CO3 
(360 mg, 2.6 mmol) as the starting materials. The residue was purified by flash chromatography 
on silica gel, eluting with hexanes/EtOAc (4:1) to afford 374 as a white solid (45 mg, 90%). 
1
H 
NMR (300 MHz, chloroform-d)  7.75 - 7.68 (m, 4H), 7.60 - 7.54 (m, 3H), 7.50 - 7.44 (m, 2H), 
7.16 (d, J = 8.4 Hz, 2H), 6.72 - 6.68 (m, 1H), 3.72 (t, J = 6.8 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H). 
HRMS (ESI
+
) calcd for C21H18N2O3S (M+H)
+
 379.4522, found 379.1126. 
N-(4-Benzoylphenyl)-1-(prop-2-yn-1-yl)indoline-5-sulfonamide (375). Same procedure as 364 
using 374 (41 mg, 0.10 mmol) and propargyl bromide (0.014 mL, 0.16 mmol) as the starting 
materials. The residue was purified by flash chromatography on silica gel, eluting with 
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hexanes/EtOAc (1:1) to afford 375 as a light yellow solid (7 mg, 17%). 
1
H NMR (300 MHz, 
chloroform-d)  7.75 - 7.68 (m, 4H), 7.60 - 7.54 (m, 3H), 7.50 - 7.44 (m, 2H), 7.15 (d, J = 8.7 
Hz, 2H), 6.45 (d, J = 8.7 Hz, 1H), 3.94 (d, J = 2.4 Hz, 2H), 3.57 (t, J = 8.7 Hz, 2H), 2.99 (t, J = 
8.4 Hz, 2H), 2.18 (t, J = 2.4 Hz, 1H). HRMS (ESI
+
) calcd for C24H20N2O3S (M+H)
+
 417.5001, 
found 417.1285. 
2,2,2-Trifluoro-N-(4-nitrophenyl)acetamide (382). TFAA (1 mL, 7.24 mmol, in 1.5 mL of 
Et2O) was added dropwise to a stirred solution of 4-nitroaniline (500 mg, 3.62 mmol) and TEA 
(1.5 mL, 10.8 mmol) in Et2O (1.2 mL) at 0 °C. The resulting mixture was allowed to warm to rt 
and stirred for 2 h. The mixture was diluted with Et2O (5 mL), washed with H2O (3 x 10 mL) and 
brine (4 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to give 382 as a yellow solid 
(522 mg, 62%). 
1
H NMR (300 MHz, chloroform-d)  8.19 (dd, J = 1.8, 9.6 Hz, 2H), 7.85 (dd, J 
= 1.8, 9.3 Hz, 2H), 4.52 (s, 1H). The analytical data is in agreement with literature reports.
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N-(4-Aminophenyl)-2,2,2-trifluoroacetamide (383). Same procedure as 274 using 382 (200 
mg, 0.85 mmol) and Pd/C (10%, 14 mg) as the starting materials. The residue was purified by 
flash chromatography on silica gel, eluting with DCM/EtOAc (2:1) to give 383 as a yellow solid 
(150 mg, 75%). 
1
H NMR (300 MHz, DMSO-d6)  10.85 (s, 1H), 7.28 (dd, J = 1.8, 8.8 Hz, 2H), 
6.56 (dd, J = 2.4, 8.7 Hz, 2H), 5.31 (s, 2H). 
N-(4-Azidophenyl)-2,2,2-trifluoroacetamide. NaNO2 (75 mg, 1.1 mmol, in solution in 0.2 mL 
H2O) was added to a stirred solution of 383 (150 mg, 0.73 mmol) and HCl (0.36 mL) in H2O (0.2 
mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, then NaN3 (95 mg, 1.46 mmol, in 
solution in 0.5 mL H2O) was added. The reaction mixture was stirred for 30 min at 0 °C and then 
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at rt for 2 h. The product was isolated by filtration and washed with ice-cold H2O (3 x 5 mL) to 
afford a light orange solid (112 mg, 66%). 
1
H NMR (300 MHz, DMSO-d6)  11.34 (s, 1H), 7.75 
(d, J = 8.8 Hz, 2H), 7.17 (d, J = 8.7 Hz, 2H). HRMS (ESI
-
) calcd for C8H5F4N4O (M-H)
-
 
229.1388, found 229.0338. 
4-Azidoaniline (384). Same procedure as 30 from N-(4-azidophenyl)-2,2,2-trifluoroacetamide 
(1.3 g, 5.89 mmol) and K2CO3 (16.3 g, 118 mmol) as the starting materials. The residue was 
purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to give 384 as 
a red solid (479 mg, 61%). 
1
H NMR (300 MHz, acetone-d6)  6.80 (dd, J = 1.5, 8.4 Hz, 2H), 
6.70 (dd, J = 1.4, 8.4 Hz, 2H), 4.72 (s, 2H). HRMS (ESI
+
) calcd for C6H6N4 (M)
+
 134.0592, 
found 134.9250. The analytical data is in agreement with literature reports.
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N-(4-Azidophenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide 
(385). The azide 384 (205 mg, 1.52 mmol) was added to a solution of 196 (500 mg, 1.52 mmol) 
in pyridine (1.5 mL). The solution was stirred at rt for 2 h and EtOAc (16 mL) was added. The 
organic layer was washed with 1 M HCl (10 mL), H2O (2 x 10 mL) and brine (6 mL), dried over 
Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography on silica 
gel, eluting with hexanes/EtOAc (3:1) to give 385 as a yellow solid (607 mg, 94%). 
1
H NMR 
(300 MHz, acetone-d6)  9.05 (s, 1H), 7.81 (s, 1H), 7.69 - 7.58 (m, 1H), 7.27 (d, J = 8.9 Hz, 2H), 
7.01 (d, J = 8.9 Hz, 2H), 3.90 (t, J = 7.8 Hz, 2H), 2.94 (t, J = 6.8 Hz, 2H), 2.85 (t, J = 9.7 Hz, 
2H). 
3-Aminophenyl(phenyl)methanol (386). Sodium borohydride (63 mg, 1.67 mmol) was added 
to a solution of 3-aminobenzophenone (300 mg, 1.52 mmol) in EtOH (1.5 mL) and the mixture 
was refluxed overnight. After allowing the mixture to cool down to rt, it was poured into H2O (8 
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mL) and extracted with DCM (3 x 8 mL). The combined organic layers were washed with H2O 
(10 mL), dried over Na2SO4, filtered, and concentrated to give a white solid (267 mg, 88%). 
1
H 
NMR (300 MHz, acetone-d6)  7.45 - 7.36 (m, 4H), 7.26 (t, J = 7.4 Hz, 1H), 7.10 (t, J = 7.2 Hz, 
1H), 6.77 (d, J = 7.7 Hz, 1H), 6.61 (t, J = 6.8 Hz, 1H), 5.73 (s, 1H). The analytical data is in 
agreement with literature reports.
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N-(3-(Hydroxy(phenyl)methyl)phenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-
tetrahydroquinoline-6-sulfonamide (387). Same procedure as 197 using 386 (160 mg, 0.49 
mmol) and 196 (97 mg, 0.49 mmol) as the starting materials. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to deliver 387 as a white solid 
(119 mg, 50%). 
1
H NMR (400 MHz, chloroform-d)  7.68 (s, 1H), 7.54 (dd, J = 2.2, 1.1 Hz, 1H), 
7.30 - 7.24 (m, 7H), 7.20 - 7.05 (m, 3H), 6.98 (dd, J = 7.9, 2.3 Hz, 1H), 5.67 (s, 1H), 3.80 (t, J = 
6.0 Hz, 2H), 2.75 (t, J = 6.9 Hz, 2H), 2.03 - 1.97 (m, 3H). 
N-(3-Benzoylphenyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide 
(388). PCC (26 mg, 0.12 mmol) was added to a stirred solution of 387 (40 mg, 0.08 mmol) in 
DCM (0.2 mL). The reaction mixture was stirred at rt for 4 h. The suspension was filtered 
through a cotton plug and the filtrate was concentrated in vacuo. The residue was purified by 
flash chromatography on silica gel, eluting with DCM/EtOAc (6:1) to afford 388 as a yellow oil 
(36 mg, 90%). 
1
H NMR (400 MHz, chloroform-d)  7.75 (d, J = 7.6 Hz, 3H), 7.67 - 7.56 (m, 
3H), 7.55 - 7.34 (m, 6H), 3.82 (t, J = 5.9 Hz, 2H), 2.84 (t, J = 6.9 Hz, 2H), 2.12 - 2.09 (m, 2H). 
N-(3-Benzoylphenyl)-1,2,3,4-tetrahydroquinoline-6-sulfonamide (370). Same procedure as 30 
from 388 (36 mg, 0.07 mmol) and K2CO3 (192 mg, 1.39 mmol) as the starting materials. The 
residue was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (6:1) to 
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afford 370 as a yellow solid (23 mg, 81%). 
1
H NMR (400 MHz, chloroform-d)  7.71 (dd, J = 
8.3, 1.4 Hz, 2H), 7.62 - 7.54 (m, 1H), 7.54 - 7.30 (m, 8H), 6.34 (d, J = 9.1 Hz, 1H), 3.32 (t, J = 
5.6 Hz, 2H), 2.66 (t, J = 6.3 Hz, 2H), 1.87 (t, J = 6.2 Hz, 2H). HRMS (ESI
+
) calcd for 
C22H20N2O3S (M+H)
+
 393.1273, found 393.1219. 
N-(2-Benzoylphenyl)-N-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide (390). Potassium carbonate (66 mg, 0.60 mmol) and iodomethane (0.01 mL, 0.16 
mmol) were slowly added to a stirred solution of N-(2-benzoylphenyl)-1-(2,2,2-trifluoroacetyl)-
1,2,3,4-tetrahydroquinoline-6-sulfonamide (50 mg, 0.10 mmol) in DMF (0.4 mL). The resulting 
mixture was stirred at rt for 1 h. The solvent was removed under vacuum and the residue was 
suspended in Et2O (4 mL), washed with H2O (2 x 4 mL) and brine (4 mL), dried over Na2SO4, 
filtered, and concentrated. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/EtOAc (1:1) to deliver 390 as a light yellow solid (59 mg, 90%). 
1
H NMR 
(300 MHz, chloroform-d)  7.75 (d, J = 7.2 Hz, 2H), 7.56 - 7.53 (m, 1H), 7.46 - 7.40 (m, 6H), 
7.34 (d, J = 9.3 Hz, 2H), 7.02 (d, J = 8.8 Hz, 1H), 3.79 (t, J = 7.2 Hz, 2H), 3.12 (s, 3H), 2.74 (t, J 
= 7.5 Hz, 2H), 2.04 - 2.00 (m, 2H). 
N-(2-Benzoylphenyl)-N-methyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (376). Same 
procedure as 30 using 390 (59 mg, 0.11 mmol) and K2CO3 (307 mg, 2.22 mmol) as the starting 
materials. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (1:1) to afford 376 as a light yellow solid (35 mg, 79%). 
1
H NMR (300 MHz, 
chloroform-d)  7.78 (dd, J = 0.9, 8.1 Hz, 2H), 7.58 - 7.51 (m, 1H), 7.46 - 7.40 (m, 5H), 7.11 
(dd, J = 1.8, 7.8 Hz, 1H), 7.05 - 6.99 (m, 2H), 6.26 (d, J = 8.4 Hz, 1H), 3.29 (t, J = 5.4 Hz, 2H), 
3.00 (s, 3H), 2.56 (t, J = 6.0 Hz, 2H), 1.88 - 1.82 (m, 2H). 
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N-(2-Benzoylphenyl)-N-methyl-1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-
sulfonamide (377). Same procedure as 364 using 376 (34 mg, 0.08 mmol) and propargyl 
bromide (0.011 mL, 0.12 mmol) as the starting materials. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to deliver 377 as a white solid 
(11 mg, 31%). 
1
H NMR (300 MHz, chloroform-d)  7.80 (dd, J = 0.3, 7.5 Hz, 2H), 7.58 - 7.54 
(m, 1H), 7.47 - 7.40 (m, 5H), 7.26 - 7.23 (m, 1H), 7.15 (d, J = 7.8 Hz, 1H), 7.01 (s, 1H), 6.54 (d, 
J = 9.0 Hz, 1H), 4.00 (d, J = 2.1 Hz, 2H), 3.35 (t, J = 5.4 Hz, 2H), 3.03 (s, 3H), 2.58 (t, J = 6.3 
Hz, 2H), 2.21 (t, J = 2.0 Hz, 1H), 1.95 - 1.91 (m, 2H). HRMS (ESI
+
) calcd for C26H24N2O3S 
(M+H)
+
 445.5533, found 445.1570. 
N-(4-Azidophenyl)-N-methyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide (378). Same 
procedure as 30 using N-(4-azidophenyl)-N-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,4-
tetrahydroquinoline-6-sulfonamide (21 mg, 0.05 mmol) and K2CO3 (127 mg, 0.92 mmol) as the 
starting materials. The residue was purified by flash chromatography on silica gel, eluting with 
hexanes/EtOAc (1:1) to deliver 378 as a yellow solid (15 mg, 93%). 
1
H NMR (300 MHz, 
chloroform-d)  7.15 - 7.10 (m, 4H), 6.94 (d, J = 9.3 Hz, 2H), 6.54 (d, J = 8.3 Hz, 1H), 3.37 (t, J 
= 5.4 Hz, 2H), 3.11 (s, 3H), 2.73 (t, J = 6.2 Hz, 2H), 2.01 - 1.93 (m, 2H). HRMS (ESI
+
) calcd for 
C16H17N5O2S (M+H)
+
 344.4114, found 344.1171. 
Methyl quinoline-6-carboxylate. Thionyl chloride (0.629 mL, 8.6 mmol) was slowly added to a 
solution of 6-quinolinecarboxylic acid (500 mg, 2.88 mmol) in MeOH (3.5 mL). The mixture 
was stirred at 0 °C for 1 h and then heated to reflux overnight. The solvent was removed under 
vacuum, the residue was dissolved in EtOAc (12 mL) and washed with NaHCO3 (3 x 10 mL), 
H2O (2 x 10 mL) and brine (6 mL), dried over Na2SO4, filtered, and concentrated. The residue 
was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (1:1) to deliver 
 306 
a white solid (444 mg, 85%). 
1
H NMR (300 MHz, chloroform-d)  9.01 (dd, J = 4.3, 1.8 Hz, 
1H), 8.60 (d, J = 2.0 Hz, 1H), 8.36 - 8.24 (m, 2H), 8.15 (d, J = 8.8 Hz, 1H), 7.48 (dd, J = 8.3, 4.2 
Hz, 1H), 4.00 (s, 3H). The analytical data is in agreement with literature reports.
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Methyl 1,2,3,4-tetrahydroquinoline-6-carboxylate (391). Same procedure as 240 using methyl 
quinoline-6-carboxylate (430 mg, 2.29 mmol) as the starting material. The residue was purified 
by flash chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to deliver 391 as a 
white solid (336 mg, 77%). 
1
H NMR (300 MHz, chloroform-d)  7.68 - 7.61 (m, 2H), 6.42 (d, J 
= 8.9 Hz, 1H), 3.83 (s, 3H), 3.35 (t, J = 5.4 Hz, 2H), 2.77 (t, J = 6.4 Hz, 2H), 1.99 - 1.87 (m, 2H). 
Methyl 1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-carboxylate (392). K2CO3 (453 mg, 
3.28 mmol) and propargyl bromide (87% in toluene, 0.35 mL) were added to a solution of 391 
(251 mg, 1.31 mmol) in DMF (1 mL), and the resulting mixture was stirred at 50 °C overnight. 
Et2O (6 mL) was added and the organic phase was washed with H2O (2 x 5 mL), NaHCO3 (2 x 5 
mL) and brine (4 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified 
by flash chromatography on silica gel, eluting with hexanes/EtOAc (7:1) to afford 392 as a 
yellow oil (265 mg, 88%). 
1
H NMR (300 MHz, chloroform-d)  7.78 (dd, J = 8.7, 2.2 Hz, 1H), 
7.66 - 7.64 (m, 1H), 6.69 (d, J = 8.6 Hz, 1H), 4.76 (d, J = 2.4 Hz, 1H, rotamer), 4.06 (d, J = 2.4 
Hz, 2H), 3.84 (s, 3H), 3.39 (t, J = 5.7 Hz, 2H), 2.78 (t, J = 6.3 Hz, 2H), 2.54 (t, J = 2.4 Hz, 0.5H, 
rotamer), 2.19 (t, J = 2.4 Hz, 1H), 2.06 - 1.95 (m, 3H). (free rotation around the amine bond 
yielded additional peaks for the propargyl group).  
1-(Prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-carboxylic acid (393). NaOH (363 mg, 9.1 
mmol) was added to a solution of 392 (208 mg, 0.91 mmol) in MeOH:H2O (1.5:1.5 mL). The 
reaction mixture was heated to 50 °C for 2.5 h. MeOH was removed under vacuum. The residue 
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was suspended in H2O (5 mL) and extracted with EtOAc (4 mL). The aqueous layer was 
acidified with 1 M HCl (pH ~ 3) and extracted with EtOAc (3 x 6 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated to give a light yellow solid (168 mg, 
86%). 
1
H NMR (300 MHz, DMSO-d6)  12.09 (s, 1H), 7.63 - 7.53 (m, 2H), 6.71 (d, J = 9.4 Hz, 
2H), 4.13 (s, 2H), 3.11 (s, 1H), 2.69 - 2.71 (m, 2H), 2.54 - 2.45 (m, 2H), 1.94 - 1.81 (m, 2H). 
HRMS (ESI
+
) calcd for C13H13NO2 (M+H)
+
 216.1025, found 216.0873. 
N-(4-Azidophenyl)-1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinoline-6-carboxamide (394). 
HATU (53 mg, 0.14 mmol) was added to a solution of 393 (20 mg, 0.09 mmol), DIPEA (0.048 
mL, 0.28 mmol) and 384 (12.5 mg, 0.09 mmol) in DMF (0.3 mL). The reaction mixture was 
stirred at rt overnight. The reaction was diluted with Et2O (4 mL), washed with H2O (2x 4 mL), 
NaHCO3 (2x 3 mL) and brine (4 mL), dried over Na2SO4, filtered, and concentrated. The residue 
was purified by flash chromatography on silica gel, eluting with hexanes/EtOAc (3:1) to afford 
394 as a yellow solid (10 mg, 46%). 
1
H NMR (300 MHz, chloroform-d)  8.71 (dd, J = 4.5, 1.4 
Hz, 1H), 8.43 (dd, J = 8.4, 1.4 Hz, 1H), 8.03 (dd, J = 8.8, 2.3 Hz, 1H), 7.87 (dd, J = 2.2, 1.1 Hz, 
1H), 7.43 (dd, J = 8.4, 4.5 Hz, 1H), 7.26 - 7.23 (m, 1H), 6.77 (d, J = 8.8 Hz, 1H), 4.11 (d, J = 2.4 
Hz, 2H), 3.47 (t, J = 5.7 Hz, 2H), 2.82 (t, J = 6.4 Hz, 2H), 2.25 (t, J = 2.4 Hz, 1H), 2.08 - 1.98 
(m, 2H). 
13
C NMR (100 MHz, chloroform-d)  165.5, 147.6, 135.3, 128.4, 126.3, 123.4, 122.3, 
121.4, 119.5, 110.9, 78.8, 71.9, 49.3, 40.6, 27.7, 22.3. HRMS (ESI
+
) calcd for C19H17N5O 
(M+H)
+
 332.3791, found 332.1501. 
1-Azido-6-bromohexane. Sodium azide (142 mg, 2.19 mmol) was added to a solution of 1,6-
dibromohexane (0.5 mL, 3.28 mmol) in DMF (1 mL). The reaction mixture was stirred overnight 
at 60 °C. After allowing the solution to cool down, the solvent was removed under vacuum, the 
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residue was suspended in Et2O (3 mL) and washed with 1 M NaOH (3 mL). The aqueous layer 
was extracted with Et2O (2 x 3 mL), the organic layers were combined, dried over Na2SO4, 
filtered, and concentrated. The residue was purified by flash chromatography on silica gel, 
eluting with hexanes/Et2O (8:1) to give a colorless oil (880 mg, quantitative). 
1
H NMR (400 
MHz, chloroform-d)  3.40 (t, J = 6.7 Hz, 2H), 3.27 (t, J = 6.9 Hz, 2H), 1.66 - 1.56 (m, 2H), 1.53 
- 1.36 (m, 6H). The analytical data is in agreement with literature reports.
145
 
6-Azido-N-methylhexan-1-amine (395). A solution of methylamine (40% aq, 2 mL) in THF 
(1.7 mL) was added dropwise to a stirred solution of 1-azido-6-bromohexane (240 mg, 1.16 
mmol) in THF (0.9 mL). The resulting mixture was stirred at rt for 48 h, and DCM (4 mL) and 1 
M NaOH (6 mL) were added. The two layers were separated and the aqueous layer was extracted 
with DCM (2 x 6 mL), the organic layers were combined, dried over Na2SO4, filtered, and 
concentrated to afford 395 as a light yellow oil (91 mg, 50%). 
1
H NMR (400 MHz, chloroform-
d)  3.27 - 3.20 (m, 2H), 2.54 (t, J = 6.8 Hz, 2H), 2.41 (s, 3H), 1.61 - 1.55 (m, 2H), 1.49 - 1.43 
(m, 2H), 1.41 - 1.30 (m, 4H). The analytical data is in agreement with literature reports.
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N-(9-(2-((6-Azidohexyl)(methyl)carbamoyl)phenyl)-6-(diethylamino)-3H-xanthen-3-
ylidene)-N-ethylethanaminium (396). Thionyl chloride (0.038 mL, 0.53 mmol) was added to a 
solution of rhodamine B (43 mg, 0.09 mmol) in CCl4 (1.8 mL). The mixture was stirred under 
reflux for 3 h. The solvent and the excess of thionyl chloride were removed under vacuum. The 
residue was suspended in DCM (1.8 mL) and 395 (70 mg, 0.45 mmol) and K2CO3 (62 mg, 0.45 
mmol) were added. The reaction mixture was stirred at rt overnight. The solvent was removed 
under vacuum, the residue was purified by flash chromatography on silica gel, eluting with 8% 
MeOH in DCM to deliver 396 as a purple solid (19 mg, 35%). 
1
H NMR (300 MHz, chloroform-
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d)  7.69 - 7.62 (m, 2H), 7.56 - 7.51 (m, 1H), 7.38 - 7.29 (m, 3H), 7.09 (dd, J = 9.5, 2.4 Hz, 2H), 
6.83 - 6.75 (m, 2H), 3.72 - 3.60 (m, 8H), 3.19 (t, J = 6.9 Hz, 4H), 2.93 (s, 2H), 2.38 (s, 3H), 1.42 
- 1.31 (m, 2H), 1.33 (t, J = 7.2 Hz, 12H), 1.28 - 1.10 (m, 4H). HRMS (ESI
+
) calcd for 
C35H45N6O2 (M)
+
 581.3599, found 581.3645. 
N-(6-Azidohexyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (397). 
The amine 192 (7.5 mg, 0.05 mmol) and DIPEA (0.011 mL, 0.06 mmol) were added to a 
solution of biotin-NHS (18 mg, 0.05 mmol) in DMF (0.2 mL). The reaction mixture was stirred 
overnight at 95 °C, allowed to cool to rt and was slowly poured into Et2O (5 mL) at 0 °C. The 
product precipitated out and was isolated by filtration. The solid was washed with ice-cold H2O 
(3 mL) and Et2O (3 x 4 mL) and was dried under vacuum to deliver 397 as a white solid (16 mg, 
83%). 
1
H NMR (300 MHz, DMSO-d6)  7.78 (s, 1H), 6.40 - 6.34 (m, 2H), 4.28 (s, 1H), 4.11 (s, 
1H), 3.10 - 3.01 (m, 3H), 2.82 - 2.78 (m, 1H), 2.10 - 2.03 (m, 2H), 1.50 - 1.26 (m, 11H). HRMS 
(ESI
+
) calcd for C16H28N6O2S (M+Na)
+
 391.1892, found 391.1881. The analytical data are in 
agreement with literature reports.
279
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5.0  SYNTHESIS OF SMALL MOLECULE PROBES FOR BIOLOGICAL 
PATHWAYS 
5.1 SYNTHESIS OF A FOLIC-ACID DERIVATIVE TO DELIVER ANTISENSE-
AGENTS TO CANCER CELLS 
5.1.1 Introduction to Antisense Agents 
The applicability of traditional medicines, small molecule and antibody drugs, is limited 
to “druggable” protein targets. The majority of small molecule drugs target well-defined binding-
sites within proteins, while antibodies are generally limited to cell-surface receptors and 
circulating proteins.
280
 In contrast, antisense agent oligonucleotides (ASOs) can selectively 
inhibit any gene of interest, offering tremendous therapeutic opportunities for many diseases 
whose molecular targets remain inaccessible to other agents.
281
 ASOs are synthetic DNA 
oligonucleotides comprised of 16-21 nucleotides that bind to their complementary RNA targets 
through sequence-specific Watson-Crick base-pair interactions. There are two main classes of 
ASOs, 1) single-stranded ASOs whose binding to their mRNA targets either induces mRNA 
degradation through RNase H, alters its splicing activity, or prevents mRNA translation through 
steric blocking of the ribosome; and 2) double-stranded RNAs that promote the degradation of 
their mRNA targets through RNA interference.
281
 However as previously discussed in Chapter 1, 
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the broad application of ASO therapeutics currently faces various challenges, principally their 
delivery. There are two main approaches to facilitate ASO delivery, the incorporation of ASOs 
into lipid or polymer nanocarriers, and the conjugation of ASOs to ligands targeting specific 
cellular receptors.
282
  
Cell-penetrating peptides, short basic amino acid-rich peptides, are often conjugated to 
biomacromolecules, including ASOs, to facilitate their delivery across the plasma membrane, 
most likely via direct translocation or endocytosis.
283
 Cell-targeting peptides have been further 
developed to improve the cellular uptake as well as to deliver the ASO to specific cell types.
280
 
For example, a PNA conjugated with a short peptide analog of insulin like growth factor 1 was 
efficiently and selectively delivered to cells presenting high levels of the insulin like growth 
factor 1 receptor.
284
 As mentioned earlier, the leading ASO conjugate in clinical development is 
the trivalent-liver targeting-carbohydrate GalNAc (Figure 5.1).
280
 Another commonly used 
modification consists in the introduction of a lipid motif, such as cholesterol or -tocopherol 
(Figure 5.1). Cholesterol-siRNA conjugates can form particles with lipoproteins present in the 
bloodstream, which increases circulation time and enhances the uptake into hepatocytes via 
lipoprotein receptors.
285
 Although, the precise delivery pathway of -tocopherol-conjugated 
siRNAs has not been fully elucidated, it was hypothesized that similarly to the cholesterol 
derivatives, they may be incorporated into serum lipoproteins and enter the hepatocytes via 
lipoprotein receptors.
286
 In addition to carbohydrates and lipids, receptor-specific ligands have 
been developed which enable targeted delivery. For example, an anisamide-conjugated splice-
switching antisense agent was specifically delivered to PC3 cells.
287
 Anisamide (Figure 5.1) 
presents a high affinity for the sigma receptors, which are commonly overexpressed in diverse 
tumor cells. Similarly, folate- and anandamide-modified ASOs have been developed to promote 
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selective delivery to cells expressing a high degree of folate or cannabinoid receptors, 
respectively.
280
 The development of these technologies represents clinically valuable approaches 
for selective delivery of therapeutic ASOs.  
 
 
Figure 5.1: Conjugating groups developed to promote targeted delivery of ASO into diseased cells. 
. 
 
However, successes of these strategies have been mostly limited to delivery to the liver, 
and the delivery systems for extrahepatic targets have to be further optimized. Ideally, they must 
possess cell-targeting ability to enable cell selective delivery, and present an endosomal release 
functionality.
280
 Indeed, the delivery of conjugated ASOs might be limited in some instances, 
due to endosome trapping. For example, to achieve successful gene inhibition using a folate-
conjugated ASO, the agent must be released from the folic acid residue before it can escape the 
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endosomal compartment.
288
 Thus a variety of linkers have been developed to allow direct 
conjugation of the ligands to the ASOs that are readily cleavable under physiological conditions, 
such as disulfide- and acylhydrazone-based linkers.
280
 
5.1.2 Molecular Caging Technology 
Light can also be used as an external trigger to induce selective cleavage of a chemical 
bond.
289
 A classical method to temporally mask the activity of a biomolecule consists in the 
introduction of a light-removable protecting group, or caging group, on a residue where 
modifications are known to block the biological activity. Typically, the caging group is 
introduced through chemical modification, rendering the biomolecule inactive, and upon short 
UV light irradiation the protecting group is removed and the biological activity is restored 
(Figure 5.2A).
290
 Ortho-nitrobenzyl derivatives represent classical caging groups (Figure 5.2B). 
This technology is most commonly employed as a switch to study biological activity in a spatial 
and temporal fashion, and is also amenable to the specific release of macromolecules.
291
 
 
Figure 5.2: A. General decaging mechanism. B. Structure of the commonly used ortho-nitrobenzyl caging group. 
Adapted from Org. Biomol. Chem. 2007, 5, 999, with permission of The Royal Society of Chemistry.  
 
 
The specific incorporation of the propargyl-6-nitroveratryloxymethyl (PNVOM) caged 
thymidine phosphoramidite into hairpin protected antisense agents targeting Renilla luciferase or 
the endogenous gene Eg5, allowed the conjugation of the HIV TAT cell-penetrating peptide 
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(CPP) to the ASOs through a copper-catalyzed 
  
3+2[ ] cycloaddition.c Although, the presence of 
the CPP enabled delivery of the ASOs into mammalian cells without any transfection reagents, 
the ASOs effectively silenced their target mRNAs only after UV light was applied, removing the 
caging group and thus releasing the active ASOs (Scheme 5.1).
291
 
 
 
 
Scheme 5.1: Delivery and light-activation of antisense agents containing caging groups conjugated with cell-
penetrating peptides. 
PNVOM-caged thymidine nucleotides were site-specifically incorporated into antisense agents and bioconjugated 
with azido-CPPs. The CPP-caged antisense agent conjugates were 1. simply added to the cell culture media and 2. 
taken up by mammalian cells but remain inactive due to the presence of the caging groups. 3. UV irradiation 
triggered decaging, cleaving the CPPs from the antisense agent and induced sequence-specific mRNA binding. This 
led to 4. the silencing of gene expression either by blocking the ribosome or by inducing RNase H-mediated mRNA 
degradation. Adapted from ACS Chem. Biol. 2013, 8, 2272. 
 
 
The ASOs CNTRL (negative control), Luc-AA (positive control, unmodified ASO), 
caged CLuc-AA, and caged HIV TAT-conjugated CLuc-AA-TAT were added directly to the cell 
culture media of human embryonic kidney (HEK) 293T cells, in the absence of any transfection 
reagent, and incubated overnight. Following brief UV light irradiation (2 min, 365 nm), the cells 
were co-transfected with the reporter plasmids pGL3 and pRL-TK, encoding the firefly and 
Renilla luciferases, respectively.
291
 The same experiment was performed on cells that were kept 
                                                 
c Part of this section is reprinted with permission from ACS Chem. Biol., Cellular Delivery and Photochemical Activation of Antisense Agents 
through a Nucleobase Caging Strategy, Govan JM, Uprety R, Thomas M, Lusic H, Lively MO, Deiters A., 8, 2272. Copyright 2013, American 
Chemical Society.  
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in a dark as a control. The pGL3 plasmid was used as a control for normalization purposes and to 
account for transfection efficiency. The scrambled antisense agent (CNTRL) and a non-caged 
Renilla luciferase antisense agent (Luc-AA) were also transfected as negative and positive 
controls, respectively. As expected, no inhibition was observed after transfection of the CNTRL 
antisense agent, while Luc-AA reduced Renilla luciferase expression by 85% relative to the 
CNTRL antisense agent (Figure 5.3). The direct addition of the scrambled ASO, or the caged and 
non-caged ASOs to the cell media did not affect the Renilla luciferase enzyme. In contrast, brief 
UV irradiation of the cells treated with the CPP conjugate CLuc-AA-TAT elicited a 92% 
inhibition of Renilla luciferase expression (Figure 5.3).
291
 These results demonstrated that the 
CNTRL, Luc-AA, and CLuc-AA ASOs failed to enter the cells without the help of transfection 
reagents. However, conjugation with the HIV TAT peptide enabled the effective cellular uptake 
of the ASO, but gene silencing was only achieved after UV irradiation, releasing the sequence of 
the ASO from the caging group. 
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Figure 5.3: Light-activation of antisense agents targeting Renilla luciferase. 
Antisense agents (CNTRL, Luc-AA, CLuc-AA, and CLuc-AA-TAT) were simply added to HEK293T cell culture 
media or actively transfected (CNTRL and Luc-AA). Cells were either irradiated (365 nm, 2 min, 25 W) or kept in 
the dark. The cells were expressing firefly and Renilla luciferases from pGL3 and pRL-TK plasmids, respectively, 
and a dual-luciferase assay was performed after 48 h. Renilla luciferase expression was normalized to firefly 
luciferase expression and the negative control antisense agent (CNTRL) was set to 100%. All experiments were 
performed in triplicate, and error bars represent standard deviations. ** p value <0.005. Experiments were 
performed by Jeane Govan. Adapted from ACS Chem. Biol. 2013, 8, 2272. 
5.1.3 Synthesis of an Azido Folate for Selective Targeting of Cancer Cells 
Next, it was hypothesized that replacing the HIV TAT peptide with a folic acid derivative 
would allow for the selective delivery of the ASO to cancer cells and precise photo-regulation of 
gene expression.
291
 As previously mentioned, folate-modification promotes cellular uptake via 
natural vitamin endocytosis pathways, specifically to cancer cells that overexpress the folate 
receptors in comparison with healthy cells, which only express low levels of this receptor.
292
 The 
“folate targeting” strategy has been employed to deliver anticancer drugs, such as doxorubicin or 
desacetylvinblastine,
293
 specifically to cancer cells thereby reducing the toxicity caused to 
normal cells.
288
 
In order to achieve targeted delivery of PNVOM-caged antisense agents, the folic acid 
azide 401 was synthesized through the coupling of folic acid with the amine 190 in presence of 
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DCC and pyridine in DMSO, followed by reverse phase HPLC purification (Scheme 5.2).
294
 The 
folate receptor does not recognize the di-substituted derivatives, but retains a strong affinity for 
the γ-carbonyl modified compounds.294 Since α-substitutions gave inconclusive results, the γ-
azido folate was synthesized for this study. Using the conditions described in Scheme 5.2, the γ-
substituted folate was predominantly obtained (≥60% product yield) which was in agreement 
with previous reports.
294-295
 Bioconjugations of 401 and CLuc-AA were conducted via Cu-
catalyzed [3 + 2] cycloaddition, the antisense agent containing three PNVOM groups was treated 
with the azide 401, copper sulfate, sodium ascorbate, and the tris(3-hydroxypropyl-
triazolylmethyl)amine (THPTA) ligand in an aqueous environment.
291
 The folate-conjugated 
ASO was immediately purified using a NAP5 column in order to minimize potential DNA 
degradation caused by any residual copper catalyst.
296
  
 
 
Scheme 5.2: Synthesis of the azido folate 401. 
 
 
The cellular delivery of the folic acid-conjugated antisense agent was evaluated in 
mammalian cell culture using the previously described luciferase assay (see Figure 5.3). The 
conjugated antisense agent CLuc-AA-FA and the control CLuc-AA were added directly to HeLa 
cells, which overexpress the folate receptor.
297
 Luc-AA was transfected into HeLa cells to 
provide a positive control, and produced an 80% inhibition in Renilla luciferase expression 
(Figure 5.4A). As expected, no effect on the luminescence signal was detected upon treatment 
with CLuc-AA, which lacks the cancer cell-targeting agent 401. In agreement with the previous 
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assay (Figure 5.3), the addition of the folic acid conjugate CLuc-AA-FA directly to the cell 
culture media only resulted in a significant inhibition of the Renilla luciferase expression after 
brief exposure to UV light (2 min, 365 nm, Figure 5.4A).
291
 To assess the selectivity of the 
delivery system, the same experiment was then repeated in MCF7 cells that do not express the 
folate receptor.
298
 Under these conditions, CLuc-AA-FA directly added to the cell culture media 
failed to inhibit Renilla luciferase even after UV light irradiation (Figure 5.4B). The lack of gene 
silencing shown by the folic acid conjugate in MCF7 cells confirmed the ability to selectively 
deliver light-activated antisense agents into certain cancer cells.
291
  
 
A. B. 
 
Figure 5.4: Targeted delivery and light-activation of antisense agents. 
Antisense agents (CLuc-AA and CLuc-AA-FA) were added directly to cell culture media of A. HeLa cells or B. 
MCF7 cells, or alternatively transfected. Cells were either irradiated (2 min, 365 nm, 25 W) or kept in the dark. 
Firefly and Renilla luciferase were expressed from pGL3 and pRL-TK plasmids, respectively, and a dual-luciferase 
assay was performed after 48 h. Renilla luciferase expression was normalized to firefly luciferase expression and the 
negative control antisense agent (CLuc-AA−UV) was set to 100%. All experiments were performed in triplicate, and 
error bars represent standard deviations. ** = p value <0.005. These experiments were performed by Jeane Govan. 
Adapted from ACS Chem. Biol. 2013, 8, 2272. 
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5.2 SYNTHESIS OF A BIOTINYLATED-HCV INHIBITOR TO FACILITATE 
MODE OF ACTION STUDIES
A
 
As previously discussed in Chapter 3, the development of a new IFN-free regimen has 
revolutionized HCV therapy. The direct-acting antiviral daclatasvir is a common component of 
these new combination treatments.
299
 It was thought to target the HCV nonstructural protein 
NS5A, though its precise mechanism of action remained unclear.
300
 The NS5A protein plays 
important roles in the HCV life cycle, particularly in HCV replication and virion assembly 
(Figure 5.5).
301
 One major function of NS5A is to recruit and activate the cellular kinase 
phosphatidylinositol-4-kinase alpha (PI4KA), which is critical for HCV replication.
302
 The 
NS5A inhibitors block HCV at two different stages of life cycle: HCV replication complex 
formation and assembly of infectious HCV particles.
303
 Since it was noticed that the aggregation 
of non-structural proteins in the presence of daclatasvir is similar to that observed in cells treated 
with siRNAs against PI4KA, it was hypothesized that daclatasvir might be altering the NS5A–
PI4KA interaction.
301
 To enable more detailed mode of action studies a biotinylated analog of 
daclatasvir was synthesized according to a previous report, which demonstrated that although 
less potent (EC50 value of 33 nM vs 50 pM for daclatasvir) the compound 409 can be used as a 
probe to facilitate the investigation into the mechanims of daclatasvir.
304
 
 
 
 
                                                 
a
 Part of this work was reprinted from Virology, 476, Vineela Chukkapalli, Kristi L. Berger, Sean M. Kelly, Meryl Thomas, Alexander Deiters 
,Glenn Randall, “Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides”, 168. Copyright 2015, with 
permission from Elsevier. 
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Figure 5.5: Representation of the HCV life cycle. 
1. Extracellular HCV virions interact with receptor molecules at the cell surface and 2. undergo receptor-mediated 
endocytosis. 3. Following HCV glycoprotein-mediated membrane fusion, the virion's nucleocapsid is released into 
the cytoplasm. 4. The genomic RNA is translated to generate a single large polyprotein that is processed into the 10 
mature HCV proteins. The endoplasmic reticulum is modified by viral and cellular factors to form a membranous 
web, which is the major site of viral RNA amplification. 5. Six of the mature HCV proteins assist the replication of 
viral RNA via synthesis of positive strands (+) from a replicative intermediate negative RNA strand (-) template. 6. 
A portion of this newly synthesized RNA is packaged into nucleocapsids and associated with the HCV 
glycoproteins, a process that leads to virion budding into the endoplasmic reticulum, 7. during processing through 
the cellular secretory pathway the virions achieve maturation. 8. Mature virions are released from the cell to 
complete the life cycle. Reprinted by permission from Macmillan Publishers Ltd: Nat. Rev. Gastroenterol. Hepatol., 
New and experimental therapies for HCV, Pereira, A.; Jacobson, I., 6, 403. Copyright 2009.
d
 
 
Several synthetic routes were designed to access the biotinylated NS5A inhibitor 409, it 
was first attempted to selectively protect one aniline motif with a Boc-protecting group or with a 
proline derivative (Scheme 5.3). Treatment of 4,4-diaminostilbene with Boc-proline in the 
presence of various amide-coupling reagents failed to deliver 403. Boc-proline was then 
activated with the succinimide ester, and treated with 4,4-diaminostilbene under several 
conditions, varying the solvents, the bases, and the temperature, but 403 still could not be 
isolated. Similarly the coupling of 4,4-diaminostilbene and 402 using EDCI, HOBt, and DIPEA 
                                                 
d
 This figure was modified with permission from J. Virology, Studying Hepatitis C Virus: Making the Best of a Bad Virus, 81, 8853, 
Tellinghuisen, L. T.; et al. Copyright 2007, American Society for Microbiology.    
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did not afford the expected product (Scheme 5.3). Although, the mono Boc-protected 
intermediate 404 was obtained in decent yield, subsequent coupling with the amine 402 
systematically failed to deliver the compound 405 (Scheme 5.3). 
 
 
Scheme 5.3: Conditions tested to selectively couple one amine motif. 
 
 
Finally, it was decided to follow the conditions previously reported to synthesize 409.
304
 
Prior to the synthesis, 4,4-diaminostilbene di-hydrochloride was suspended in H2O, neutralized 
through the addition of 2.5 equivalents of K2CO3, and extracted with Et2O to remove the salts. 
4,4-Diaminostilbene was then treated with N-Boc proline and EEDQ to obtain the di-Boc 
substituted intermediate 406, which was subsequently deprotected with TFA to deliver the 
diamine 407. This precursor was treated with phenylacetyl chloride and TEA in DCM to provide 
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the mono-substituted compound 408. Finally, treatment of 408 with biotin-NHS and DIPEA 
afforded the biotinylated probe in the modest yield of 47% (Scheme 5.4). 
 
 
Scheme 5.4: Synthesis of the biotinylated NS5A inhibitor 409. 
 
The effectiveness against HCV replication of the inhibitor 409 was measured by qRT-
PCR in Huh7.5 cells electroporated with HCV RNA (Figure 5.6A).
301
 To examine the ability of 
the drug to bind NS5A expressed from both UHCV (Tet-inducible osteosarcoma cell line that 
expresses full-length viral proteins independent of replication) and UNS5A (cells expressing 
NS5A alone) cells, the tool compound 409 was incubated with induced or non-induced cells for 
16 h before lysis. The biotinylated drug was then pulled down with streptavidin beads, washed, 
and the recovery of the NS5A protein was analyzed by western blot. Figure 5.6B shows that the 
biotinylated drug precipitated NS5A at similar efficiency in both UHCV and UNS5A cells.
301
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In conclusion, a model was suggested wherein daclatasvir inhibits conformational 
changes in the NS5A protein, or protein complex formations that occur in the context of HCV 
polyprotein expression. These NS5A conformational changes are likely required to both 
stimulate PI4P hyper-accumulation and form HCV replication compartment.
301
  
 
A. B. 
 
Figure 5.6: Investigation into the mode of action of the biotin-tagged NS5A inhibitor. 
A. Huh7.5 cells were electroporated with HCV RNA and treated with either DMSO, daclatasvir (DCV), or the 
biotin-tagged NS5A inhibitor 409. The RNA was extracted 72 h post-electroporation and HCV RNA was quantified 
using real time PCR using the  method. B. UHCV cells and UNS5A cells were induced or left non-induced for 
72 h and were either treated with DMSO or the biotin-tagged NS5A inhibitor. Cells were lysed, and 409 was 
precipitated using streptavidin dynabeads. Amount of NS5A that was pulled down with the drug was detected by 
western blotting. Experiments were conducted by the Randall lab (University of Chicago). Adapted from Virology, 
2015, 476, 168. 
 
5.3 SUMMARY AND OUTLOOK 
Small organic molecules can be modified with functionalities that enable the precise 
control of a biomolecule or to facilitate the study of a biological pathway of interest. An azido 
folate was synthesized and subsequently conjugated, via click reaction, to a PNVOM-caged 
antisense agent targeting the Renilla luciferase. The ASO CLuc-AA-FA was efficiently delivered 
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to HeLa cells without any transfection reagents, and caused an 80% inhibition in Renilla 
expression only after being briefly exposed to UV light. In comparison, no inhibition in Renilla 
luminescence was observed when CLuc-AA-FA was added to MCF7 cells, which lack the folate 
receptor. Modification of an ASO with an o-nitrobenzyl-caging group derivatized with a folate 
tumor-targeting motif enabled the specific uptake of the antisense agent into certain cancer cells, 
in a precise spatial and temporal fashion.
291
 The developed technology can be easily adapted to 
any antisense agent or biomolecule through direct conjugation to a carrier peptide or small 
molecule ligand for targeted delivery through a cell surface receptor. Additionally, two-photon 
caging groups, such as 3-nitro-2-ethyldibenzofuran, could be used to allow light-activation of 
gene control in deeper tissue and with high spatial resolution.
291, 305
 
New direct-acting antiviral agents have been developed to provide shorter and broader 
HCV therapies with limited side-effects. One such agent, the highly potent daclatasvir, targets 
the HCV nonstructural protein NS5A through a partially unknown mechanism. A biotinylated-
analog of daclatasvir was synthesized to provide a tool compound to decipher the mode of action 
of the inhibitor.
301
 Daclatasvir was hypothesized to directly affect the NS5A–PI4KA interaction. 
However, based on multiple pieces of information complemented with the pull-down experiment 
using the biotinylated-probe of NS5A at similar efficiency in both UHCV and UNS5A cells, a 
model was proposed wherein daclatasvir inhibits conformational changes in the NS5A protein or 
protein complex formations that occur in the context of HCV polyprotein expression.
301
 This 
strategy is applicable to any small molecule drugs, which mechanisms remain to be elucidated, 
as the modification with a biotin group enable the isolation of a target protein through 
streptavidin-biotin affinity purification. This method is also amenable to secondary studies to 
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investigate all of the proteins that show some degree of interaction with the drug of interest, as 
that may help to better understand or predict potential side-effects.  
 
5.4 EXPERIMENTALS 
All reactions were performed in flame-dried glassware under a nitrogen atmosphere and 
stirred magnetically. Reactions were followed by thin layer chromatography (TLC) using glass-
backed silica gel plates (Sorbent technologies, 250 µm thickness). DCM and THF were obtained 
from a delivery solvent system, DMF and pyridine were distilled from calcium hydride and 
stored over 4 Å molecular sieves. DMSO was purchased (Accros), stored under nitrogen and 
used directly without further purification. Yields refer to pure compounds unless otherwise 
stated. Flash chromatography was performed on silica gel (60 Å, 40-63 μm (230 × 400 mesh), 
Sorbtech) as a stationary phase. High resolution mass spectral analysis (HRMS) was performed 
at the University of Pittsburgh on a Q-Exactive (Thermo Scientific) mass spectrometer. The 
1
H 
NMR and 
13
C NMR spectra were recorded on a 300 MHz or a 400 MHz Varian NMR 
spectrometers. Chemical shifts are given in δ units (ppm) for 1H NMR spectra and 13C NMR 
spectra. 
(S)-2-(4-(((2-Amino-4-hydroxypteridin-6-yl)methyl)amino)-benzamido)-5-
((6azidohexyl)amino)-5-oxopentanoic Acid (401). 6-Azidohexan-1-amine (38 mg, 0.26 mmol) 
and DCC (138 mg, 0.67 mmol) were added to a stirred solution of folic acid (118 mg, 0.26 
mmol) and pyridine (0.53 mL) in DMSO (2 mL). The reaction mixture was stirred at rt for 2 
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days. The mixture was then filtered, and the filtrate was slowly poured into Et2O (45 mL) at 0 
°C. The precipitates were collected by centrifugation (at 5,000 x g for 5 min) and washed 3 times 
by centrifugation in MeOH:Et2O (3:30 mL). The solvents were removed, and the precipitate was 
dried to dryness under vacuum to afford 401 as a yellow solid (106 mg, 72%). The compound 
was further purified by reverse phase HPLC (Hewlett-Packard 1100, column Agilent Zorbax 
C18, ACN/H2O 0.1% TFA). 
1
H NMR (400 MHz, DMSO-d6) δ 8.63 (s, 1H), 7.94 (d, J = 7.9 Hz, 
1H), 7.82 (d, J = 5.5 Hz, 1H), 7.64 (d, J = 8.5 Hz, 2H), 6.61 (d, J = 8.5 Hz, 4H), 4.47 (s, 2H), 
4.34 - 4.24 (m, 1H), 3.28 - 3.24 (m, 3H), 3.03 - 2.98 (m, 2H), 2.26 - 2.18 (m, 2H), 1.49 - 1.43 (m, 
2H), 1.37 - 1.31 (m, 2H), 1.29 - 1.17 (m, 5H). The analytical data matched previous report of 
azido folate with C4 azido linker.
306
 LRMS: m/z calcd for C23H31N11O5 [M+H]
+
: 566.3 found 
566.6.  
 
Synthesis of the biotinylated NS5A inhibitor  
 
(S)-1-(2-Phenylacetyl)pyrrolidine-2-carboxylic acid (402). A solution of phenylacetylchloride 
(268 mg, 1.74 mmol) in acetone (1 ml) was added dropwise to a solution of L-proline (200 mg, 
1.74 mmol) in 2 M NaOH (1 ml) and acetone (1 ml) at 0 °C. During the addition the pH was 
monitored and kept at 10 via addition of 2 M NaOH. After completion of the addition, the 
mixture was allowed to warm to rt and stirred for 6 h. The acetone was removed under vacuum, 
the resulting mixture was acidified to pH 2 with concentrated HCl. The aqueous layer was 
saturated with NaCl and extracted with EtOAc (3 x 8 ml). The combined organic layers were 
dried over Na2SO4, filtered, and concentrated to afford 402 as a white solid (334 mg, 82%). 
1
H 
NMR (300 MHz, chloroform-d)  10.98 (s, 1H), 7.35 - 7.25 (m, 5H), 4.60 - 4.58 (m, 1H), 3.74 
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(s, 2H), 3.64 - 3.50 (m, 4H), 2.05 - 1.96 (m, 2H). The data is in agreement with literature 
reports.
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(E)-tert-Butyl (4-(4-aminostyryl)phenyl)carbamate (404). A solution of K2CO3 (293 mg, 2.18 
mmol) in H2O (1 ml) was added to a solution of 4,4-diaminostillbene (400 mg, 1.41 mmol) in 
THF:DMF (1.8 ml:0.6 ml). To this mixture was added di-tert-butyl-dicarbonate (154 mg, 0.71 
mmol). The reaction mixture was then stirred for 6 h at rt. The solution was poured into ice-cold 
H2O (5 ml) and extracted with DCM (3 x 10 ml). The combined organic layers were washed with 
brine (4 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 
chromatography on silica gel, eluting with hexanes/EtOAc (2:1) to deliver 404 as a yellow solid 
(161 mg, 73%). 
1
H NMR (300 MHz, acetone-d6)  8.42 (s, 1H), 7.52 (d, J = 8.5 Hz, 2H), 7.42 
(d, J = 8.7 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.01 - 6.90 (m, 2H), 6.46 (d, J = 8.4 Hz, 2H), 1.48 
(s, 9H).  
(E)-di-tert-Butyl-2,20-(((ethene-1,2-diylbis(4,1-phenylene))bis 
(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (406). K2CO3 (58 mg, 0.42 mmol) 
was added to a solution of 4,4-diaminostilbene (60 mg, 0.21 mmol) in DCM (1 ml), and the 
resulting mixture was stirred at rt for 30 min. Ethyl-2-ethoxyquinoline-1-(2H)-carboxylate (125 
mg, 0.50 mmol) and N-Boc proline (104 mg, 0.48 mmol) were added and the reaction mixture 
was further stirred at rt for 6 h. The solvent was removed under vacuum and the residue was 
triturated in Et2O (12 mL). The product was isolated by filtration, washed with H2O (2 x 5 mL) 
and Et2O (2 x 6 mL), and dried under vacuum to afford 406 as a white solid (120 mg, 95%). 
1
H 
NMR (300 MHz, DMSO-d6) δ 10.08 (s, 2H), 7.61 - 7.48 (m, 4H), 7.07 (s, 2H), 4.21 - 4.09 (m, 
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2H), 3.34 - 3.28 (m, 4H), 2.33 - 2.12 (m, 2H), 1.98 - 1.70 (m, 6H), 1.38 (s, 9H), 1.25 (s, 9H). 
HRMS-ESI (m/z) calcd for C34H45N4O6 [M-H]+: 605.7443, found: 605.3358.  
 
(E)-N,N-(Ethene-1,2-diylbis(4,1-phenylene))bis(pyrrolidine-2-carboxamide) (407). TFA 
(0.15 ml) was slowly added to a solution of 406 (60 mg, 0.01 mmol) in DCM (1.4 ml). The 
reaction mixture was stirred at rt for 4 h. The solvent was removed under vacuum, the residue 
was suspended in EtOAc (4 ml), washed with 1 M NaOH (2 ml) and brine (2 ml), dried over 
Na2SO4, filtered, and concentrated to afford 407 as a yellow solid (39 mg, 99%) which was 
further used without purification. 
1
H NMR (300 MHz, DMSO-d6): δ 9.97 (s, 2H), 7.62 (d, J = 
48.7 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.07 (s, 2H), 3.40 - 3.32 (m, 2H), 2.86 (t, J = 6.6 Hz, 4H), 
2.10 - 1.99 (m, 2H), 1.98 - 1.62 (m, 6H), HRMS-ESI (m/z) calcd for C24H29N4O2 [M-H]
+
: 
404.5127, found: 405.2305.  
 
(E)-1-(2-Phenylacetyl)-N-(4-(4-(pyrrolidine-2-carboxamido)styryl)phenyl)pyrrolidine-2-
carboxamide (408). A solution of phenylacetylchloride (0.07 ml, 0.05 mmol) in DCM (0.1 ml) 
was added to a stirred solution of TEA (0.015 ml, 0.09 mmol) and 407 (30 mg, 0.07 mmol) in 
DCM (0.6 ml) at 0 °C. The reaction mixture was stirred at rt for 4 h, and DCM (5 ml) was added. 
The organic layer was washed with H2O (3 ml), NaHCO3 (3 ml) and brine (3 ml), dried over 
Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography on silica 
gel, eluting with 5% MeOH in DCM to deliver 408 as a white solid (13 mg, 52%). 
1
H NMR (300 
MHz, chloroform-d) δ 7.59 - 7.49 (m, 10 H), 7.31 - 7.28 (m, 3H), 7.06 (d, J = 7.2 Hz, 2H), 4.60 - 
4.56 (m, 1H), 4.04 - 3.99 (m, 1H), 3.78 (s, 2H), 3.76 - 3.58 (m, 4H), 3.28 - 3.12 (m, 2H), 2.07 - 
1.89 (m, 6H), HRMS-ESI (m/z) calcd for C32H35N4O3 [M-H]
+
: 523.6453, found: 523.2736. 
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(S)-1-(5-((3aS,4S,6aR)-2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoyl)-N-(4-
((E)-4-((S)-1-(2-phenylacetyl)pyrrolidine-2-carboxamido)styryl)phenyl)pyrrolidine-2-
carboxamide (409). DIPEA (0.04 ml, 0.21 mmol) and biotin-NHS (14.5 mg, 0.04 mmol) were 
added to a solution of 408 (22 mg, 0.04 mmol) in DMF (0.3ml). The reaction mixture was stirred 
overnight at rt, and slowly poured into vigorously stirred Et2O (6 ml) at 0 °C. The solid was 
isolated by filtration, purified by trituration in cold Et2O (2 x 10 ml), and dried under vacuum to 
afford 409 as a white solid (14 mg, 47%). 
1
H NMR (300 MHz, DMSO-d6) δ 10.04 (s, 2H), 7.94 
(s, 1H), 7.59 - 7.48 (m, 6H), 7.29 - 7.08 (m, 6H), 6.35 (d, J = 8.9 Hz, 2H), 4.45 - 4.06 (m, 4H), 
3.69 (s, 2H), 3.66 - 4.40 (m, 4H), 3.15 - 2.99 (m, 1H), 2.87 - 2.76 (m, 2H), 2.64 - 1.90 (m, 8H), 
1.70 - 1.20 (m, 8H), 1.10 - 1.07 (m, 2H), HRMS-ESI (m/z) calcd for C42H49N6O5S [M-H]
+
: 
749.9407, found: 749.3520. The analytical data are in agreement with literature reports.
304
 
 
 330 
6.0  APPENDIX 
6.1 CELL CULTURE PROTOCOLS 
6.1.1 Cell Culture Maintenance 
The cells were propagated in 10 cm dishes (Greiner) and passaged when they reached 70-
80% confluency. Briefly, the media was removed, the cells were quickly washed with 1 mL PBS 
(pH 7.4, rt), 1 mL of trypsin (Invitrogen) was added, and the plate was shaken on an orbital 
shaker for ~2 min ar rt. The cells were detached by pipetting them up and down, 9 mL of fresh 
media was added, and 1 mL of the cell-containing suspension was transferred to a new 10 cm 
plate containing 10 mL of fresh media. For all experiments the cells were used at a passage 
number <25, after which the cells were discarded and a new vial was thawed.  
6.1.2 Freezing Cells 
The cells were grown in a 15 cm dish (BioExpress) in 25 mL of media until they reached 
80% confluency. The media was removed, the cells were quickly washed with 2 mL of PBS (pH 
7.4, rt), 3 mL of trypsin (Invitrogen)  were added, and the plate was shaken for ~2 min at rt. The 
cells were detached by pipetting them up and down, and 7 mL of media was added. The cells 
were counted using the hemacytometer. Cells need to be frozen at a concentration of 5.10
6
 to 
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2.10
7
 cells/mL. The cells were transferred to a 15 mL conical tube and pelleted by centrifugation 
(10 min, rt, 1,600 x g). The supernatant was carefully removed to not disturb the cell pellet, the 
cells were re-suspended in the appropriate amount of freeze-media, then 1 mL of cells were 
transferred to each cryo cell storage tubes (Fisher). To prepare the freeze-media, DMSO was 
filtered through a 0.5 micron filter, and 0.5 mL of DMSO was added to 9.5 mL fresh media (5% 
final DMSO concentration). The vials were placed at −80 °C for 24 h and then quickly moved to 
the liquid nitrogen dewar. 
6.1.3 Thawing Cells 
The frozen vial containing the desired cell line was quickly moved from the liquid 
nitrogen dewar (the date and initials were properly indicated in the corresponding folder) to a 37 
°C water bath. The vial was incubated at 37 °C for ~2 min, or until thawed, thoroughly sprayed 
with 70% EtOH, and opened inside the cell culture hood. The content was then transferred to a 
plate containing 10 mL of fresh media, the cells were slowly dispersed throughout the plate when 
transferring the liquid, the plate was shaken on an orbital shaker for ~2 min at rt, and placed in 
the CO2 incubator. After an overnight incubation the media was removed, and replaced with 
fresh culture media. 
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6.2 Quantitative Real Time PCR Analysis 
Huh7 cells were seeded at a density of 150,000 cells per well in 6-well plates in 2 mL 
media (DMEM, no antibiotics) and grown overnight. The media was removed, and 1.98 mL 
fresh DMEM was added. The cells were treated with compounds at a 10 μM (20 μL of a 1 mM 
DMSO stock) or with DMSO (1% final DMSO concentration). The cells were incubated at 37 
°C for 48 h (DMEM, antibiotics-free, 5% CO2, 2 mL final volume). The media was removed, 
and the cells were washed with PBS buffer (1 mL, pH 7.4) followed by RNA isolation with the 
miRNeasy mini kit (Qiagen). Briefly, 700 μL of QiaZOL reagent was added to each well and the 
plate was shaken for 6 min. The cells were detached by pipetting them up and down, and were 
transferred to a 1.5 mL microcentrifuge tube. The tubes were vortexed for 1 min, incubated at 
room temperature for 5 min, and 200 μL of chloroform was added. The tubes were quickly 
vortexed and incubated at room temperature for 3 min. The tubes were centrifuged at 4 °C, 
16,250 x g for 20 min. The aqueous top layer (~200 μL) was transferred to a clean 
microcentrifuge tube - this step was very delicate as only the top layer containing RNA needed to 
be collected, if the middle layer was perturbed while transferring the RNA, some DNA will be 
incorporated into the RNA solution and the purity will be low. Ethanol (525 μL) was added, the 
solution was mixed by pipetting up and down several times, and then transferred to an RNA 
wash column (supplied in the miRNeasy kit) and centrifuged at 13,100 x g for 1 min at room 
temperature. The flow-through was discarded. The column was washed twice with 500 μL RPE 
buffer (supplied in the miRNeasy kit). The column was dried by centrifugation at 13,100 x g for 
4 min at room temperature. The RNA was eluted in 30 μL RNAse-free water (supplied in the 
miRNeasy kit), quantified using a Nanodrop ND-1000 spectrophotometer, and each sample was 
diluted to 3 ng/μL in RNAse-free water. The reverse transcription was performed using the 
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TaqMan microRNA Reverse Transcription Kit (Life Technologies) in conjunction with the 
RNU19 (control) or the miR-122 TaqMan RT primer. For each assay (RNU19 and miR-122) a 
mastermix was prepared as follow (per 10 reactions): 1.5 L dNTP, 15 L 10x buffer, 41.6 L 
H20 (nuclease free), 1.9 L RNA inhibitor, and 30 L primer (5x). Everything was combined (on 
ice) and then 10 L reverse transcriptase was added. The mastermix was added to each PCR tube 
(kept on ice, 10 μL), the RNA (5 μL) was added, the tubes were quickly centrifuged (1 min, 4 
°C, 1000 x g), and the reverse transcription was performed on a T100 thermocycler (BioRad, 16 
°C, 30 min; 42 °C, 30 min; 85 °C, 5 min). The quantitative real Time PCR was carried out with a 
TaqMan 2x Universal PCR Master Mix and the appropriate TaqMan miRNA assay (Life 
Technologies). Similarly, two mastermixes were prepared (on ice): (per 10 reactions) combine 
100 L TaqMan 2x mastermix, 77 L H2O (nuclease free), and 10 L probe (20x). The 
mastermix (18.7 L) was added to each well of the PCR plate (BioRad) (kept on ice), the RT-
PCR product (1.3 L) was added (in triplicates), and the plate was quickly centrifuged (1 min, 4 
°C, 1000 x g). The PCR amplification was performed on a BioRad CFX96 RT-PCR 
thermocycler (95 °C, 10 min; followed by 40 cycles of 95 °C, 15 s; 60 °C, 60 s). The triplicate 
threshold cycles (Ct) obtained for each small molecule treatment were used to determine the 
relative levels of miR-122 in small molecule treated cells relative to the DMSO control using the 
 method.
155
 This method is commonly and conveniently used to determine the ‘fold 
change’ in gene expression between different samples.  
 
fold change =  (1) 
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One advantage of this method is that it can be used to normalize the experimental data to 
both an endogenous control (RNU19) and an untreated sample (DMSO). In equation (2), CtX 
corresponds to the Ct value of the gene of interest (miR-21), Ctcnt is the Ct value of the 
endogenous control (RNU19), sampleA corresponds to each inhibitor-treated sample and 
sampleB is the DMSO control sample.
155
  
 (2) 
  
Tips for qRT-PCR experiments: 1) Before performing an RNA isolation, clean up the 
hood and bench spaces with ethanol and spray down some RNAse AWAY (Thermo Scientific). 
Similarly, everything used in the experiments (pipettes, racks, tip boxes, gloves) needs to be 
sprayed with RNAse AWAY to avoid any contamination of the samples. 2) The RNA needs to 
be kept on ice at all times to avoid degradation. 3) It is not recommended to freeze/thaw the 
RNA; for optimal results the RNA needs to be freshly isolated and reverse transcribed the same 
day. The cDNA can be stored at 4 °C (in PCR tubes properly sealed) for up to 2 weeks. 3) In 
addition to the RNA concentration, the NanoDrop calculates the ratios A260/A280 and A260/A230, 
which estimate the purity of the RNA. The A260/A280 accounts for DNA contamination, and 
A260/A230 accounts for the presence of residual EtOH or phenol contaminants from the RNA 
isolation. For optimal RNA quality: A260/A280 >1.9 and  A260/A230 ~2. Additional information 
about qRT-PCR applied to the detection of microRNAs can be found here
308
 and here 
(https://www.genomeweb 
.com/sites/default/files/pdfs/genomeweb/RTPCRmicroRNATechGuide.pdf). 
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6.3 RECIPES 
6.3.1 Click reaction cocktail 
For 200 L (16 L of cocktail was used for 50 g protein) 
140 L PBS 
20 L TCEP (VWR, 50 mM H2O stock)  
20 L CuSO4 (50 mM H2O stock) 
10 L TBTA (10 mM DMSO stock) 
10 L rhodamine-azide (10 mM DMSO stock) 
6.3.2 Huh7-psiCHECK-miR122 media 
For 500 mL, combine: 
5.89 g DMEM (Hyclone) 
1.63 g sodium bicarbonate 
0.145 g L-glutamine 
440 mL milliQ water 
Mix until everything is dissolved. 
Adjust pH to 7.4 with addition of 65% HCl or 2 M NaOH solution. 
Then, in the cell culture hood, add 10 mL FBS (Seradigm premium grade, Lot #093B13) + 5 mL 
Pen/Strep (VWR) + 1.25 mL G418 (VWR, 200 mg/mL H2O stock filtered through a 0.2 micron 
filter and stored at −20 °C).  
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Filter sterilize the media into a plastic 500 mL flask. Store media at 4 °C - for 2 months 
maximum. 
6.3.3 DMEM media 
For 500 mL, combine: 
 5.89 g DMEM (Hyclone) 
1.63 g sodium bicarbonate 
0.145 g L-glutamine 
440 mL milliQ water 
Mix until everything is dissolved. 
Adjust pH to 7.4 with addition of 65% HCl or 2 M NaOH solution. 
Then, in the cell culture hood, add 10 mL FBS (Seradigm premium grade, Lot #093B13) + 5 mL 
Pen/Strep (VWR). 
Filter sterilize the media into a plastic 500 mL flask. Store media at 4 °C - for 2 months 
maximum. 
6.3.4 TBS buffer (10x) 
For 1 L, combine: 
87.6 g NaCl 
12.1 g Tris base (VWR) 
1 L milliQ water 
Mix until everything is dissolved. 
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Adjust pH to 7.6 with addition of 60% HCl. 
6.3.5 TBST buffer (1X) 
For 500 mL, combine: 
50 mL TBS buffer (10x) 
0.5 g Tween 
450 mL milliQ water 
Mix until everything is dissolved 
6.3.6 SDS running buffer (10x) 
For 1 L, combine: 
144 g glycine 
30.2 g Tris base 
10 g SDS 
1 L milliQ water 
Mix until everything is dissolved. 
6.3.7 Staining buffer (coomassie blue) 
For 50 mL, combine: 
50 mL destaining buffer 
15 mg coomassie R250 (brilliant blue) 
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6.3.8 Destaining buffer 
For 1 L, combine: 
100 mL glacial acetic acid 
200 mL methanol 
700 mL milliQ water 
6.3.9 Transfer buffer (10x). 
For 1 L, combine: 
30.3 g Tris 
144 g glycine 
1 L milliQ water 
Mix until everything is dissolved. 
6.3.10 Transfer buffer (1x) 
For 1 L, combine: 
100 mL Transfer buffer (10x) 
200 mL methanol 
0.25 g SDS 
700 mL milliQ water 
 339 
6.3.11 PBS buffer (10x) 
For 500 mL, combine: 
40 g NaCl 
1 g KCl 
7.2 g disodium phosphate 
1.2 g monopotassium phosphate 
500 mL milliQ water 
Mix until everything is dissolved. 
Adjust pH to 7.4 with addition of 60% HCl. 
Autoclave. 
6.3.12 12% SDS-PAGE 
For 1 gel, combine: 
6.45 mL milliQ water 
4.5 mL 40% acrylamide 
3.75 mL 1.5 M Tris buffer (pH 8.9) 
0.15 mL 10% SDS 
0.15 mL 10% APS 
0.009 mL TEMED 
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6.3.13 4% SDS-PAGE stacking gel 
For 1 gel, combine: 
1.458 mL milliQ water 
0.25 mL 40% acrylamide 
0.25 mL 1 M Tris buffer (pH 6.8) 
0.02 mL 10% SDS 
0.02 mL 10% APS 
0.002 mL TEMED 
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LIST OF ABBREVIATIONS 
3′-UTR  3′ untranslated region  
5-Aza-dC  5-aza-2-deoxycytidine  
μL  micro liter  
μM  micromolar  
AcOH  acetic acid  
ACN acetonitrile 
Ago2  Argonaute 2  
AMO anti-miR oligonucleotide 
ASO  antisense agent oligonucleotides 
BBr3  boron tribromide 
BIPDeC  Broad Institute’s probe development center  
Boc  N-tert-butoxycarbonyl  
BSA bovine serum albumin 
tBuOH tert-butanol 
calcd calculated 
CCl4  carbon tetrachloride 
Cs2CO3  cesium carbonate 
CLL  chronic lymphocitic leukemia 
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CuSO45H2O  copper sulfate pentahydrated 
DBU  diazabicycloundecene 
DCC  dicyclohexylcarbodiimide 
DCM  dichloromethane 
DDQ  2,3-dichloro-5,6-dicyanobenzoquinone 
DGCR8  DiGeorge syndrome critical region gene 8 
DIAD  diisopropyl azodicarboxylate 
DIPEA  diisopropylethylamine 
DMA  dimethylacetamide 
DMAP  4-dimethylaminopyridine 
DMF  dimethylformamide 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DOS  diversity oriented synthesis 
EC50 half maximal effective concentration 
EDCI  1-ethyl-3-(3-dimethylaminopropyl) carbodiimide   
Et2O  diethylether 
EtOAc ethylacetate 
EtOH  ethanol 
g gram 
h hour 
H2 hydrogen 
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HATU  2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uranium 
hexafluorophosphate) 
HBV  hepatitis B virus 
HCC  hepatocellular carcinoma 
HCl  hydrochloric acid 
HCV  hepatitis C virus  
HDAC histone deacetylase 
H2NOHHCl  hydroxylamine hydrochloride 
H2O water 
HOBt  hydroxybenzotriazole 
HPLC  high-performance liquid chromatography  
HTS  high-throughput screen 
HRMS high resolution mass spectrometry 
H2SO4  sulfuric acid 
Hz  hertz 
IP  immunopurification  
K2CO3 potassium carbonate 
KOH  potassium hydroxide 
LiOH  lithium hydroxide 
LNA  locked nucleic acids 
M molar 
Me methyl 
MeOH methanol 
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MHz  megahertz 
mg milligram 
MgSO4 magnesium sulfate 
miRNA microRNA 
mL milliliter 
MLPCN  molecular libraries probe production center network library  
mM millimolar 
mmol  millimole 
mol  mole 
mRNA  messenger RNA  
MW microwave 
Na2CO3  sodium carbonate 
NaH sodium hydride 
NIH  National Institute of Health  
NaN3  sodium azide 
NaNO2  sodium nitrite 
NaOH  sodium hydroxide 
NaOMe  sodium methylate 
NMP  N-methylmorpholine 
NMR nuclear magnetic resonance 
OMe methoxy  
PBA  phenylbutyrate  
PBS phosphate buffered saline 
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PCC  pyridinium chlorochromate 
PCR polymerase chain reaction 
PEG polyethylene glycol 
PNA  peptide nucleic acid 
PPh3 triphenylphosphine 
pre-miRNA precursor miRNA 
pri-miRNA  primary miRNA 
PS  phosphorothioate  
PTSA  para-toluenesulfonic acid 
qRT-PCR  quantitative real-time PCR 
RISC  RNA-induced silencing complex  
RNA ribonucleic acid 
rt room temperature 
SAR  structure-activity relationship 
SnCl2   tin(II) chloride 
SOCl2  thionyl chloride 
TBS  tris-buffered saline 
TBTA  tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
TCEP  tris(2-carboxyethyl)phosphine 
TEA  triethylamine 
TFA  trifluoroacetic acid 
TFAA  trifluoroacetic anhydride 
THF tetrahydrofuran 
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TLC thin layer chromatography 
TRBP  TAR RNA binding protein 
TSA  trichostatin A 
UV ultraviolet 
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